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1. Autism Spectrum Disorders (ASD) 
 
1.1 Classification and clinical diagnosis 
Autistic behaviors were independently identified as recognizable syndromes in the early 20
th
 
century by Heller [Heller, 1908] and, subsequently, by Kanner [Kanner, 1943] and Asperger 
[Asperger, 1944]. In particular, Prof. Kanner described autism in 1943 in 11 children manifesting 
withdrawal from human contact as early as age 1 year postulating origins in prenatal life [Kanner, 
1943]. In the Diagnostic and Statistical Manual of Mental Disorders IV-Text Revised (DSM-IV-
TR) [Task Force on DSM-IV, 2000] the autism diagnosis spans a broad continuum of what are 
collectively known as Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorders 
(PDD). ASD include several conditions, namely full-syndrome autism (Autistic Disorder or 
Idiopathic Autism) [MIM 209850], Childhood Disintegrative Disorder, Asperger Syndrome (AS) 
and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) [Task Force on 
DSM-IV, 2000].  
The latest estimates put the population prevalence of ASD at approximately 1 in 110 [Autism and 
Developmental Disabilities Monitoring Network, 2009]. Incidence appears to be independent of 
ancestry and demographics, when similar rates being found on a global scale when the same 
diagnostic tools are used [Fombonne, 2009]. ASD show a 4:1 male to female gender bias, which 
may rise to 11:1 when considering Asperger disorder [Gillberg et al., 2006]. 
Although heterogeneous, ASD are united by a combination of three core behavior symptoms: a) 
impaired language and communication; b) deficiencies in social interaction;  c) restricted interest 
and repetitive stereotypic behavior [Task Force on DSM-IV, 2000]. Symptoms of ASD usually 
begin in early childhood with evidence of delayed development before age 3 years, although 
prospective studies of children at higher risk have shown that deficits in social interaction and 
communication may be starting in the first 6-12 months of life [Pizzarelli and Cherubini, 2011]. 
The fully-autistic patients show impairments in all the three areas of behavior previously described, 
whereas AS patients have deficits in social interaction and behavior but normal cognitive 
development and language skills. A diagnosis of PDD-NOS is instead placed in those patients who 
meet the diagnostic criteria for autism, but with a later onset, or in those patients who show two out 
of the three core behavior symptoms [Task Force on DSM-IV, 2000]. Furthermore, about 50-70% 
of children with autism are identified as intellectually disabled by nonverbal IQ testing and 
approximately 25% develop seizures [Baird et al., 2006; Tuchman and Rapin, 2002]. Autism can 
be considered complex due to the presence of dysmorphic features (25-30%) and/or microcephaly 
(5-15%) or macrocephaly (30%), or essential (i.e., absence of physical abnormalities and 
microcephaly).  
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Other common pathological disturbances may be present including anxiety, sensorial 
abnormalities, gait and motor disturbances, sleep disturbances and comorbidity with psychiatric 
disorders such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder 
(OCD) and mood disorder [Geschwind, 2009]. 
Rating scales helpful in establishing the diagnosis are Autism Diagnostic Interview-Revised (ADI-
R) and the Autism Diagnostic Observation Schedule (ADOS) in combination with clinical 
presentation [Lord et al., 1989, 1994]. 
 
1.2 Etiopathogenesis 
1.2.1 Genetic architecture in Autism Spectrum Disorders  
The etiology of ASD is complex and encompasses the roles of genes, the mitochondria, the 
environment, and the immune system. However, there is strong evidence for the importance of 
complex genetic factors comprised of different form of genetic variations in the etiology of ASD. 
Twin and family studies have, indeed, established the preponderant genetic basis of autism and 
indicate that the heritability of autism is over 90% [Abrahams e Geschwind, 2008; Freitag, 2007; 
Monaco and Bailey 2001; Muhle et al., 2004; Persico e Bourgeron, 2006], which is the highest 
heritability value so far associated with a neuropsychiatric disorder [Schaaf and Zoghbi, 2011]. 
Furthermore, the recurrence risk for ASD varies by gender for the second child to be affected (4% 
if the first child affected is a female and 7% if a male), whereas the recurrence rate increases to 25-
30% if the second child is also diagnosed with ASD [Constantino et al., 2010; Ozonoff et al., 2011; 
Rosenberg et al., 2011].  
The genetic causes of ASD can be classified as follows (Figure 1): 
1) ASD-related monogenic syndromes; 
2) rare chromosomal abnormalities; 
3) rare copy number variations (CNVs); 
4) rare gene mutations; 
5) common genetic variants. 
 
1) Approximately 10% of patients with ASD have an identifiable Mendelian condition or genetic 
syndrome (Fig. 1) [Devlin and Scherer, 2012]. This means that these patients are characterized by a 
complex phenotypic picture, showing autistic traits as well as craniofacial dysmorphism and/or 
congenital malformations. Unlike idiopathic autism, syndromic ASD have a sex ratio M:F of 1:1. 
Among these syndromes the most frequent are Fragile X syndrome (~1-2% of ASD cases), 
Tuberous sclerosis (~1%), PTEN macrocephaly syndrome (1%), and Rett syndrome (~0.5-1%). In 
detail, Fragile X syndrome is caused by expansion of the CGG trinucleotide repeat in the FMR1 
gene to the full mutation size of 200 or more CGG repeats. Molecular studies indicate that FMR1 
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may cause the autism phenotype via two mechanisms: RNA toxicity to the neurons and gene 
silencing that affects neuronal connectivity [Hagerman et al., 2008; Handa et al., 2005; Schenck et 
al., 2003].  
The PTEN (phosphatase and tensin homolog) gene was initially described as a tumor suppressor 
gene associated with a broad group of disorders referred to as PTEN hamartoma tumor syndrome. 
More recently, PTEN mutations have been associated with autism and macrocephaly [Butler et al., 
2005; Buxbaum et al., 2007; Delatycki et al., 2003; Parisi et al., 2001; Zori et al., 1998], and PTEN 
is recognized to play an important role in brain development, neuronal survival and synaptic 
plasticity. 
Rett syndrome was initially classified by the DSM-IV as a pervasive developmental disorder 
(PDD) and it is the only PDD for which a specific genetic etiology has been identified [Amir et al., 
1999]. Ninety-six percent of individuals with classic Rett syndrome have mutations in the X-linked 
MECP2 gene [Moretti and Zoghbi, 2006] and MECP2 mutations have been reported in 
approximately 1% of children diagnosed with autism [Lintas and Persico, 2009; Moretti and 
Zoghbi, 2006]. Evidence of variable expression of MeCP2 in the brains of individuals with both 
autism and Rett syndrome and evidence that MeCP2 deficiency can reduce expression of the genes 
UBE3A and GABRB3, which are implicated in autism, indicate some causal relationship between 
the two disorders [Samaco et al., 2004, 2005]. 
Other rare syndromes associated with ASD (<1%) are, for example, Neurofibromatosis type I, 
Sotos, Timothy, and Joubert syndromes. Moreover, in a recent review over than 103 disease genes 
were identified among subjects with ASD or autistic behavior [Betancur, 2011]. These genes have 
all been previously implicated in ID, thus suggesting that these two neurodevelopmental disorders 
share common genetic basis. 
 
Fig. 1. Genetic architecture in ASD. Four groupings are shown of rare genetic risk factors and their estimated 
contribution to ASD. Genetic contributions to ASD can also arise from direct or indirect effects on genes and 
proteins by environmental influences [Devlin and Scherer, 2012]. 
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2) High resolution karyotyping reveals cytogenetically chromosome rearrangements in ~5% of 
individuals with ASD (Fig. 1). Interestingly, the largest unbalanced chromosomal anomalies were 
found in syndromic-ASD [Devlin and Scherer, 2012; Jacquemont et al., 2006; Miles et al., 2005]. 
Although cytogenetic abnormalities on almost every chromosome have been found in autism, only 
a few occur commonly enough to be possible loci for autism genes [Reddy, 2005; Vorstman et al., 
2006; Wassink et al., 2001]. Among them, the most common cytogenetic abnormality found in 
individuals with ASD (3-5%) is the maternally derived 15q11-q13 duplication of the Prader-
Willi/Angelman syndrome critical region, which is generally the result of a de novo supernumerary 
isodicentric 15q chromosome and less commonly the result of a maternally derived interstitial 15q 
duplication. The maternally derived 15q11-q13 interstitial duplication is a highly penetrant cause of 
autism, whereas the paternally derived duplication has little or no phenotypic effect, indicating the 
significance of genomic imprinting of this region [Hogart et al., 2010].  
Other aneuploidies in ASD include trisomy 21 [Kent et al., 1999], 45,X Turner syndrome [Skuse 
2000], deletions of 2q37, 18q, 22q13.3, Xp22.3, and the sex chromosome aneuploidies 47,XYY, 
47,XXY [Gillberg, 1998; Jha et al., 2007; Manning et al., 2004; Marshall et al., 2008; Vorstman et 
al., 2006; Shinawi et al., 2009a]. 
 
3) Rare de novo and inherited CNVs can also contribute to the genetics of ASD in as many as ~5-
7% of ASD cases reported of unknown cause [Christian et al., 2008; Devlin and Scherer, 2012; 
Gilman et al., 2011; Kumar et al., 2008; Levy et al., 2011; Marshall et al., 2008; Sanders et al., 
2011; Sebat et al., 2007; Weiss et al., 2008]. The yield was higher in those patients identified as 
having “syndromic” autism [Jacquemont et al., 2006]. These CNVs are typically too small to be 
detected by karyotyping and can involve a single gene acting much as a sequence-level mutation, 
or they can encompass several genes as part of a genomic disorder [Lee and Scherer, 2010]. 
Furthermore, larger CNVs often affect recurrent genomic regions leading to well recognizable 
microdeletion/microduplication syndromes. 
Screening for CNVs by using array technologies such as array comparative genomic hybridization 
(aCGH with BAC or oligonucleotide clones) and SNP array, has proven to be a rapid method to 
detect both large and small changes associated with ASD susceptibility. In studies of idiopathic 
ASD, the most common recurrent anomaly is a ~600 kb microdeletion/microduplication of 
chromosome 16p11.2 (0.8%) [Kumar et al., 2008; Marshall et al., 2008; Weiss et al., 2008]. Of 
note, this CNV is also observed in ASD cases with additional dysmorphology [Fernandez et al., 
2010; Shinawi et al., 2010], in a variety of other disorders including schizophrenia (SCZ), bipolar 
disorder (BD), seizures, ADHD, and dyslexia, as well as in apparently unaffected family members; 
thus, interpretation of the significance of this anomaly can be difficult [McCarthy et al., 2009; 
Rosenfeld et al., 2010; Shinawi et al., 2010].  
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The 15q13.3 microdeletion syndrome is characterized by a highly variable phenotype and 
incomplete penetrance, including ID, seizures, subtle facial dysmorphism ad neuropsychiatric 
disorders such as ASD [Ben Shachar et al., 2009; Miller et al., 2009; Pagnamenta et al., 2009; 
Sharp et al., 2008]. The reciprocal duplication have also been reported in association with 
ASD/autistic features [Guilmatre et al., 2009; Miller et al., 2009; Szafranski et al., 2010; van Bon 
et al., 2009]. Both the deletion and duplication span the CHRNA7 gene, a candidate for epilepsy 
[Shinawi et al., 2009b].  
Recently, it has been underlined the importance of the 7q11.23 locus in ASD pathogenesis. Indeed, 
while the deletions of this region cause Williams-Beuren syndrome, a contiguous gene syndrome 
which is comorbid with ASD [Challman et al., 2003; Gillberg and Rasmussen, 1994; Gosch and 
Pankau, 1994; Herguner and Mukaddes, 2006; Klein-Tasman et al., 2009; Lincoln et al., 2007; 
Reiss et al., 1985], the reciprocal duplication is responsible for the 7q11.23 microduplication 
syndrome, which has been reported, among others, in patients with ASD and severe language delay 
[Berg et al., 2007; Depienne et al., 2007; Kirchhoff et al., 2007; Qiao et al., 2009; Stankiewicz and 
Lupski, 2010; Van der Aa et al., 2009].  
The impact of CNV on ASD pathogenesis will be deeply covered in the next chapter. 
 
4) CNV screening and direct sequencing of candidate genes are rapidly identifying genes for 
further characterization in relation to ASD, that overall contribute to a ~5% of the ASD genetic 
architecture (Fig. 1) [Devlin and Scherer, 2012]. These approaches have implicated, among others, 
genes encoding proteins for synaptogenesis such as NRXN1 [Ching et al., 2010; Kim et al., 2008; 
Szatmari et al., 2007], NRXN3 [Vaags et al., 2012], NLGN3 [Jamain et al., 2003], NLGN4 [Jamain 
et al., 2003; Laumonnier et al., 2004], SHANK2 [Berkel et al., 2010, 2012; Leblond et al., 2012], 
and SHANK3 [Durand et al., 2007; Moessner et al., 2007] as affecting ASD risk. Both neurexins 
(NRXN1 and NRXN3), which are located at the pre-synaptic plasma membrane, and neuroligins 
(NLGN3 and NLGN4), that are located at the post-synaptic plasma membrane, are adhesion 
molecules that contribute to synapse formation by directly interaction. The SKANK proteins act, 
instead, as scaffolding proteins at the post-synaptic density. Some rare, highly penetrant mutations 
in these genes appear as sufficient to be monogenic causes of ASD, including cases of syndromic 
autism [Baris et al., 2007; Berkel et al., 2010; Betancur, 2011; Ching et al., 2010; Dhar et al., 
2010; Durand et al., 2007; Gauthier et al., 2009; Glessner et al., 2009; Guilmatre et al., 2009; 
Jamain et al., 2003; Kim et al., 2008; Manning et al., 2004; Marshall et al., 2008; Moessner et al., 
2007; Pinto et al., 2010; Prasad et al., 2000; Szatmari et al., 2007]. 
More than 100 genetic and genomic loci have been reported in subjects with ASD, showing the 
success of ongoing efforts but also underscoring the fact that whole-exome and whole-genome 
sequencing will be critical approaches for identifying ASD genes and loci [Betancur, 2011]. 
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Recently, a few papers reported the utility of whole-exome sequencing in pinpointing the 
contribution of single nucleotide variants (SNVs) to the risk of ASD. Four studies published in the 
current year have looked for de novo mutations and a fifth for recessive mutations. A role for de 
novo mutations in ASD has been, indeed, suggested by previous CNV screenings and smaller-scale 
exome sequencing studies. In 2011 O’Roak et al. [O’Roak et al., 2011] sequenced 20 individuals 
with sporadic ASD and their parents and identified four potentially causative de novo events in 
FOXP1, GRIN2B, SCN1A, and LAMC3, thus showing that family-based exome sequencing was a 
powerful approach for identifying new candidate genes for ASD. 
More recently, Iossifov et al. [Iossifov et al., 2012] sequenced 343 family “quads” (i.e. the parents 
of a single child with ASD and his/her unaffected sibling), Sanders et al. [Sanders et al., 2012] 238 
families, including 200 quads, O’Roak et al. [O’Roak et al., 2012] 189 trios (i.e., a child with ASD 
and his/her parents), and Neale et al. [Neale et al., 2012] 175 trios. Sequencing data from healthy 
parents and siblings allow the de novo point mutation rate to be estimated as 2x10
-8
 per base per 
generation, a value only slightly higher than that previously reported. Interestingly, the mutation 
rate was comparable between patients and unaffected siblings, although a shift in the mutation 
spectrum towards mutations that were predicted to disrupt protein function was found in the 
probands. Furthermore, it has been reported that most de novo mutations have a paternal origin and 
there is an increase in the number of mutations with paternal age [O’Roak et al., 2012].  
In terms of the biology of ASD, a significantly enriched connectivity among the proteins encoded 
by the genes harboring de novo missense or nonsense mutations (~45% of de novo deleterious 
variants affects brain-expressed genes) as well as excess connectivity to either prior ASD genes of 
major effect or genes previously implicated in other neurodevelopmental disorders, has been 
reported, thus indicating that a subset of observed events are relevant to ASD risk. In particular, 
analysis of de novo variations provided evidence in favor of a few genes as genuine autism risk 
genes, namely CHD8 and KATNAL2 [Neale et al., 2012; O’Roak et al., 2012], SCN2A [Sanders et 
al., 2012], and NTNG1 [O’Roak et al., 2012]. Of note, O’Roak et al. [O’Roak et al., 2012] 
identified a network linked to β-catenin and chromatin remodeling whereas Iossifov et al. [Iossifov 
et al., 2012] found out an enrichment of genes regulated by the Fragile-X-syndrome associated 
FMR1 protein. Of note, anomalies in all these pathways have been previously associated with 
ASD. 
Finally, Chahrour et al. [Chahrour et al., 2012] used homozygosity analysis to identify probands 
from nonconsanguineous families that showed evidence of distant shared ancestry, suggesting 
potentially recessive mutations. Whole-exome sequencing of 16 probands revealed validated 
homozygous, potentially pathogenic recessive mutations that segregated perfectly with disease in 
4/16 families. The candidate genes (UBE3B, CLTCL1, NCKAP5L, ZNF18) encode proteins 
involved in proteolysis, GTPase-mediated signaling, cytoskeletal organization, and other pathways 
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already implicated in ASD pathogenesis. Furthermore, it has been reported that neuronal 
depolarization regulated the transcription of these genes [Chahrour et al., 2012]. 
 
5) Although genetic linkage studies performed over the last fifteen years in multiplex families have 
suggested many chromosomal regions as well as single genes as susceptibility loci for ASD [Barret 
et al., 1999; IMGSAC, 1998, 2001; Persico et al., 2001; Philippe et al., 1999, 2002; Yonan et al., 
2003; etc.], current evidences are tenuous for individual common variants that affect risk of ASD. 
Indeed, four large, independent genome-wide association studies (GWAS) have been reported so 
far, two assayed half-million single nucleotide polymorphisms (SNPs) each and detected a 
significant association at two different loci: 5p14.1 [Wang et al., 2009] and 5p15.2 [Weiss et al., 
2009], and two assayed one million SNPs and reported a significant association for a SNP located 
at 20p12.1 [Anney et al., 2010, 2012]. Furthermore, in one recent study, defects in frontal lobe 
circuit connectivity have been associated with a SNP in the CNTNAP2 gene [Scott-Van Zeeland et 
al., 2010], a putative ASD risk gene, subsequently confirmed by Anney et al. [Anney et al., 2012]. 
Thus, the overall data predict that while the existence of common variants affecting the risk of 
ASD is almost assured, their individual effects are modest and their collective effects could be 
smaller than that for rare variations [Anney et al., 2012]. 
 
1.2.2 Mode of inheritance 
Despite the heritability of autistic disorder is now widely recognized, the mode of inheritance is not 
yet fully understood as a single model is likely not applicable in all patients. The most accepted 
model until recently is the polygenic/multigenic model (multiple-hit hypothesis), according to 
which the disease was due to the combined effect of a series of low-penetrance variants (SNPs, 
CNVs, inversions) in genes/susceptibility loci, initially estimated at around 10-20, not necessarily 
shared among different patients and belonging to a very large pool of genes [Folstein and Rosen-
Sheidley, 2001]. Such variations are not to be considered causative per se but may confer an 
increased risk if inherited in particular combinations [Persico and Bourgeron, 2006]. Differences in 
combination and amount of these inherited mutations and/or the different interplay with the 
environment would lead to the onset of a fully-autistic or an ASD phenotype (Fig. 2). 
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Fig. 2. Schematic view of the Polygenic-Multigenic inheritance model. There are several susceptibility loci in the 
genome which can be inherited in different amounts and combinations leading to a more or less severe autistic 
phenotypes, once exceeded the susceptibility threshold. 
 
In 1999 Risch et al. [Risch et al., 1999] performed a genome-wide linkage study using a sample of 
90 families, and, for the first time, proposed a model of heritability based on the existence of at 
least 10 susceptibility loci, which did not exclude a much highly heterogeneous etiology, in some 
cases also of Mendelian type. Recently, the number of loci potentially involved in ASD has grown 
to a few hundreds (130-400) [Gilman et al., 2011; Levy et al., 2011; Sanders et al., 2011]. 
However, there are many exceptions to the polygenic/multigenic model, represented by those 
patients in whom the onset of ASD is due either to a single, highly penetrating gene mutation, as in 
the case of syndromic and not syndromic monogenic ASD that follow a Mendelian genetics, or to a 
chromosomal rearrangement which can be considered causative per se. In addition, CNV screening 
of large ASD cohorts by using high-throughput, high resolution technologies, which have been 
performed during the last few years, highlights the importance of rare de novo and inherited CNVs 
of high penetrance in the etiology of these disorders [Gilman et al., 2011; Levy et al., 2011; 
Sanders et al., 2011], giving rise to a paradigm shift away from common variant model of ASD 
genetic architecture (based on low penetrating variants) to one suggesting a role for multiple rare 
and distinct genetic risk factors (with a higher penetrance), known as oligogenic heterozygosity 
model [Levy et al., 2011], which does not exclude, however, a modulation of the phenotype by 
common susceptibility genetic variants. 
 
1.2.3 Mitochondrial abnormalities in Autism Spectrum Disorders 
Inborn errors of metabolism may contribute to at least 5% of cases with ASD [Manzi et al., 2008]. 
Deficiency of certain enzymes in metabolic disorders leads to an accumulation of substances that 
can cause toxic effects on the developing brain, contributing to ASD. Indeed, a large proportion of 
patients with syndromic-ASD shows signs of dysfunction of mitochondrial energy metabolism 
including (a) high levels of lactate, pyruvate and alanine in the blood, urine and/or cerebrospinal 
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fluid (b) carnitine deficiency in serum (c) increased oxidative stress [Dhillon et al., 2011; Palmieri 
and Persico, 2010]. In the mitochondria ATP production, free oxygen radicals and reactive oxygen 
species (ROS) are produced and then normally removed from the cells by anti-oxidant enzymes. 
When the production of ROS and free radicals exceeds the limit, oxidative stress occurs leading to 
cell death by apoptosis or necrosis [Kannan and Jain, 2000]. Since brain cells have limited 
antioxidant activity, a high lipid content and high requirement for energy, it is more prone to the 
effects of oxidative stress [Juurlink and Paterson, 1998]. 
Coleman and Blass were the first to link to bioenergy metabolism disturbances with ASD. They 
reported lactic acidosis in four children with autism [Coleman and Blass, 1985]. Later, László et al. 
[László et al., 1994] reported increased serotonin, lactic acid and pyruvate levels in children with 
autism. Lombard then proposed that mitochondrial oxidative phosphorylation defects could cause 
abnormal brain metabolism in children with autism, leading to lactic acidosis and decreased serum 
carnitine levels [Lombard, 1998]. Additionally, muscle biopsies studied by Tsao and Mendell 
[Tsao and Mendell, 2007] and Shoffner et al. [Shoffner et al., 2010] in autistic patients showed 
single or combined defects in complex I, II, III, IV, and V. 
These biochemical abnormalities are associated with variable phenotypes, which generally include 
complex neurological clinical features, congenital malformations and/or dysmorphism. In some 
ASD patients mutations or genomic rearrangements involving nuclear or mitochondrial genes, 
which encode mitochondrial enzymes, have been identified [Dhillon et al., 2011]. However, in 
most cases the genetic cause remains unknown although recent evidence emerged from the analysis 
of post-mortem autistic brains suggests that mitochondrial dysfunction represents a downstream 
effect of an immune system deregulation or a wrong calcium signaling [Palmieri and Persico, 
2010]. 
Of note, early screening and treatment of these conditions may have a positive impact in preventing 
disease progress [Dennis et al., 1999; Dhillon et al., 2011]. 
 
Summing up, in most patients with idiopathic ASD (>70%) the genetic cause remains unknown 
(Fig. 3). 
 
Fig. 3. Genetic causes of ASD which have been classified independently from the presence of a syndromic 
phenotypes [Schaaf and Zoghbi, 2011]. 
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1.2.4 Immune dysfunctions in Autism Spectrum Disorders 
Among the large number of ASD candidate genes recently uncovered by using genome-wide 
scanning technologies, several play important roles in immune function. For example, proteins 
encoded by MET, PTEN, TSC1 and TSC2, have a major role in regulating interleukin (IL)-12 
production from myeloid cells [Fukao et al., 2002], whereas the major histocompatibility complex 
type 2 (MHC-II) haplotypes [Lee et al., 2006; Torres et al., 2002], as well as complement 4B 
(C4B) [Odell et al., 2005], and macrophage inhibitory factor (MIF) [Grigorenko et al., 2008] are 
important in directing and controlling immune responses. 
Several evidences suggest that ASD symptoms may be related to immune dysfunction [Careaga et 
al., 2010; Enstrom et al., 2009; Korade and Mirnics, 2011], supporting the importance of all arms 
of the immune system in immune regulation within the central nervous system (CNS) to maintain a 
healthy neuro-immune environment, that may be dysfunctional in ASD (Fig. 4). Indeed, several 
immune proteins function within the nervous system as mediators of normal neurodevelopment 
[Deverman and Patterson, 2009]. Cytokines, such as TNF-a, IL-1b, the TGF-b family of molecules, 
mediate direct effects on neuronal activity. For example, TNF-a inhibits neurogenesis and promotes 
neuron death, and plays an important role in synaptic pruning [Cacci et al., 2005; Stellwagen and 
Malenka, 2006; Widera et al., 2006]. Other neuropoeitic cytokines, such as IL-1b and IL-6, also 
exert varied effects on neuronal survival, proliferation, synapse formation, migration, and 
differentiation, thus suggesting that cytokines are both necessary for normal neurodevelopment and 
behavior and that any perturbation in the cytokine network can impact neurodevelopment (Fig. 4).  
Moreover, microglial cells, that are the resident mononuclear phagocytic cells of the CNS, 
participate in immune surveillance of the CNS as well as in synaptic pruning in normal 
neurodevelopment [Bessis et al., 2007], through the production of inflammatory cytokines and the 
generation of reactive oxygen species (ROS) within the CNS [Garden and Moller, 2006; Hanisch 
and Kettenmann, 2007] (Fig. 4). The phagocytosis of dead or dying neurons by microglia is 
believed to be a normal and relatively non-inflammatory function [Bessis et al., 2007]. 
Furthermore, genetic abnormalities in microglia can result in profound effects on behavior. 
Interesting findings from animal models suggest that neurogenesis is modulated by the interaction 
between T cells and CNS [Ziv et al., 2006; Ziv and Schwartz, 2008]. Altered T cell activation in 
ASD may therefore directly affect the course of neurodevelopment. In addition, increased levels of 
complement proteins can participate in synaptic scaling, opsonizing synapses and targeting them 
for removal by phagocytic microglia (Fig. 4).  
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Fig. 4. Immune dysfunction in ASD involves a network of interactions between several cell types, from the 
innate and adaptive arms of the immune system [Onore et al., 2012].  
 
Numerous immunological anomalies (both in the CNS and in the periphery) involving 
inflammation, cytokines, immunoglobulins, and cellular activation have been noted in individuals 
with autism. In detail: 
- Neuroinflammation. A marked ongoing neuroinflammation, including microglia activation and 
increased inflammatory cytokine and chemokine production (e.g., IL-1b, IL-6, IL-12p40, TNF-a, 
CCL-2), has been reported in postmortem brain specimens from individuals with ASD [Li et al., 
2009; Morgan et al., 2010; Vargas et al., 2005]. Furthermore, expression profiling of postmortem 
brain tissue from ASD individuals revealed increased transcript levels of several immune system 
associated genes, and gene co-expression networks showed abnormalities in cortical patterning 
[Voineagu et al., 2011]. These findings have been associated with changes in microglia and 
immune activation. 
- Altered cytokine/chemokines/complement/adhesion molecule/growth factor protein profiles. 
Increased plasma levels of pro-inflammatory cytokines (IL-1b, IL-6, IL-8 and IL-12p40) as well as 
of chemokines have been reported in ASD [Ashwood et al., 2011b,d; Grigorenko et al., 2008; 
Kajizuka et al., 2010], which positively correlate with worsening in poor communication and social 
interaction behaviors. 
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- Altered immunoglobulin levels and auto-antibodies anti-CNS. Decreased total levels of IgM and 
IgG classes of immunoglobulin have been reported, with lower levels found to correlate with more 
aberrant behaviors [Heuer et al., 2008]. In addition, antibodies reportedly reactive to human and 
non-human primate brain and CNS proteins have also been described in children and adults with 
ASD. They include antibodies against serotonin receptors [Singh et al., 1997a], myelin basic 
protein [Singer et al., 2006; Singh et al., 1993; Vojdani et al., 2002], heat shock proteins [Evers et 
al., 2002], and glial filament proteins [Singh et al., 1997b]. The real role of these auto-antibodies in 
ASD is unknown and it hasn’t been demonstrated yet whether any of these antibodies induce 
cellular damage or have any pathological consequence. However, it has been demonstrated that, 
irrespective of the target epitope, antibodies from ASD subjects bind specifically to cerebellar 
interneurons and Golgi type II cells in tissue obtained from rhesus macaque monkeys [Wills et al., 
2009, 2011], thus leading, alternatively, to decreased or increased cellular activity. Furthermore, 
complement proteins can bind to auto-reactive antibodies, that is another mechanism which may 
lead to cell damage or death [Gasque et al., 2002], and an increase in complement proteins has 
been reported in sera from children with ASD. 
- Anomalies in adaptive cellular response. Atypical adaptive T cell responses are observed in 
individuals with ASD [Ashwood et al., 2011c]. For example, a predominance of IL-4
+
 IFN-γ- T 
cells was observed in the circulating CD4
+
 T cell population [Gupta et al., 1998], with a bias 
towards a TH2 phenotype. An increased production of the pro-inflammatory cytokine TNF-a was 
also found, that is consistent with an activated TH2 immune response in humans. Of note, TNF-a 
production was associated with increased stereotypical behavior, a hallmark symptom of ASD 
[Ashwood et al., 2011c]. Increased T cell activation may also be linked with decreased apoptosis 
leading to the survival of activated cells [Ashwood et al., 2011a], thus supporting a chronic 
inflammation as seen in chronic inflammatory conditions such as Crohn’s disease [Monteleone et 
al., 2006].  
Moreover, anomalies in circulating levels of soluble adhesion molecules P-Selectin, L-Selectin and 
PECAM-1 have been observed in patients with ASD. These proteins control the passage of T cells 
across endothelial barriers, thus mediating T cell/CNS interactions. In high functioning individuals 
with ASD levels of sPECAM-1, sP-Selectin and sL-selectin were decreased compared with 
controls [Iwata et al., 2008; Tsuchiya et al., 2007] and lower levels of P-Selectin were associated 
with more impaired social skills [Iwata et al., 2008], thus suggesting that modulating immune cell 
access to the brain in ASD may influence abnormal social interactions. 
- Anomalies in innate cellular response. Atypical natural killer (NK) cell activity has been 
described in patients with ASD in terms of reduced lytic activity, as well as an increasing number 
of circulating monocytes [Sweeten et al., 2003]. These atypical monocyte responses are intriguing, 
and indicate abnormal myeloid involvement in ASD. Hyperactivation of myeloid cells in ASD is 
17 
 
implicated in both the periphery and CNS, as increased infiltration of monocytes and perivascular 
macrophages are observed in brain specimens from individuals with ASD [Vargas et al., 2005].  
 
Collectively, evidence of atypical cytokine production, altered T cell activation and potential 
impaired apoptotic activity suggest there is a predisposition to chronic inflammation which could 
negatively affect healthy cognitive development in ASD. Furthermore, it is well known the role of 
the blood brain barrier in regulating the interaction between immune cells and CNS, as explained in 
Fig. 5, which can be compromised in autistic patients [Goines and Van de Water, 2010]. 
 
 
Fig. 5. Interactions between the Immune and Central Nervous Systems (CNS) in Autism Spectrum Disorders 
During postnatal life, an intact blood brain barrier (BBB) limits the entry of immune species into the brain 
(left). Lymphocytes, macrophages, various cytokines, and antibodies are generally maintained in the 
periphery. However, the blood brain barrier is permeable during fetal development and can be compromised 
by infections and environmental exposures throughout life, and the absence of a complete barrier allows 
immune components access to the brain. Individuals with autism (right) show alterations in BBB 
permeability which lead to increased pro-inflammatory cytokines in the brain, as well as activation of 
resident immune cells known as microglia. Additionally, antibodies that target brain tissues have been 
described in both children with autism and their mothers [Goines and Van de Water, 2010].  
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1.2.5 Environmental factors 
The absence of a known genetic cause in most ASD cases, and the incomplete penetrance of known 
genetic risk factors, suggests that environmental factors are linked with the causation of ASD. In 
particular, in some individuals with ASD the development of the disorder seems to depend on the 
interactions between a "vulnerable" genome and unfavorable environmental factors (pollutants and 
neurotoxins, viral infections, and maternal factors), which may alter the neurodevelopment 
[Herbert et al., 2006; Newshaffer et al., 2007] (Fig. 6). 
 
 
Fig. 6. Genetic and environmental factors that may influence cerebral development during fetal and early 
postnatal life, potentially implicated in ASD pathogenesis [Pardo and Ebehart, 2007]. 
 
Among these factors there are toxins, such as lead and mercury, that, during CNS development in 
utero, could cause damage to the fetus brain, especially in the early weeks of pregnancy [Bernard et 
al., 2001; Geier et al., 2009]. Indeed, in the United States it was estimated that about 60,000 
children a year are born with neurological problems, including ASD, due to exposure to methyl-
mercury in utero [Mutter et al., 2005], which is thought to alter the chromatin state inducing 
epigenetic modifications [Arai et al., 2011]. It has been hypothesized that children with anomalies 
in the system of detoxification, who were exposed to the adverse effects of mercury, have an 
increased risk to develop ASD compared to healthy controls, since the toxin is retained in the body 
for longer time by failing to be completely eliminated [Holmes et al., 2003]. A treatment with 
chelating has, indeed, demonstrated that these children eliminate much mercury through the urine, 
compared with controls [Bernard et al., 2001; Holmes et al., 2003]. 
Growing research has highlighted maternal immune activation, especially during the first or second 
trimesters of pregnancy, as one potential environmental factor that increases the risk for ASD 
[Patterson, 2009]. It has been reported an increased risk for ASD in association with mothers that 
required hospitalization for a viral infection in the first trimester of pregnancy, or a bacterial 
infection in the second trimester of pregnancy [Atladottir et al., 2010], suggesting that bacterial and 
viral infections may confer different risks depending on gestational age.  
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Furthermore, epidemiological data from large population based studies show increased rates of 
autoimmune disorders (up to 46%) in the families of individuals with ASD [Atladottir et al., 2009; 
Braunschweig et al., 2008; Croen et al., 2005]. Two independent studies have shown that self-
maternal antibodies can recognize and interact with specific protein epitopes of the fetal brain, 
suggesting a potential inflammatory process that leads to the production of antibodies directed to 
the developing brain [Braunschweig et al., 2008; Croen et al., 2008; Singer et al., 2009]. 
Therefore, during the early stages of embryonic life the mother's immune system may act 
negatively against fetal proteins by altering pathways of the CNS neuronal development, thereby 
increasing the risk of developing ASD [Minshew and Williams, 2007; Zimmerman et al., 2007]. In 
experiments using anti-brain protein reactive antibodies from mothers who have children with 
ASD, administration 
of these antibodies mediate behavioral changes and neuro-pathology in the offspring of pregnant 
dams [Singer et al., 2009]. 
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2. Copy number variations (CNVs) in human genome 
With the advent and application of high-resolution, genome wide analyses it has been demonstrated 
that the human genome is a highly dynamic structure that shows significant variations on a large 
scale compared to the current reference genomic sequence and that the human species is much 
more genetically variable than previously appreciated. The genomes of two unrelated individuals 
may, indeed, differ from each other with respect to the number of copies of thousands of loci - 
Copy Number Variations, CNVs [Iafrate et al., 2004; Perry et al., 2008; Redon et al., 2006 ; Sebat 
et al., 2004; Sharp et al., 2005; Wong et al., 2007] - and to the presence of structural 
rearrangements such as polymorphic balanced inversions [Antonacci et al., 2009; Kidd et al., 2008; 
Tuzun et al., 2005]. 
The term CNV refers to a DNA segment of at least 1 kb, for which differences in the number of 
copies have been observed by comparing two or more genomes. These quantitative variations may 
occur as acquisition of genetic material (insertions or duplications) and losses (deletions or null 
genotypes) in relation to the reference genomic sequence. Approximately 11,700 CNVs are known 
so far which involve at least 1,000 genes, and cover 12-15% of the genome, thus significantly 
contributing to the genotypic and phenotypic variability of the population [Carter, 2007; 
Merikangas et al, 2009; Stankiewicz and Lupski, 2010]. CNV size can vary greatly in the order of 
kilobases (kb) or megabases (Mb) and, generally, they are not identified by conventional 
cytogenetics, but through methods that use high-resolution array technology, such as SNP arrays 
(Single Nucleotide Polymorphism arrays) and array-CGH (array-based comparative genomic 
hybridization). 
The best estimates currently available suggest that, considering the genetic difference in terms of 
total number of base pairs between two individuals chosen at random, CNVs contribute about twice 
as much as SNPs [Korbel et al., 2007; Tuzun et al., 2005]. 
Studies performed over the past five years have proven the critical role played by structural genetic 
variants (most of which are in the form of changes in the number of copies) in modulating gene 
expression and the "disease" phenotype. For example, rare CNVs, that affect genes implicated in 
neurodevelopmental pathways, are involved in the onset of schizophrenia [Kirov et al., 2009; 
Stefansson et al., 2008; Vrijenhoek et al., 2008; Walsh et al., 2008], bipolar disorder [Lachman, 
2008], attention deficit hyperactivity disorder [Bateman and Gull; 2011; Elia et al., 2011a and b; 
Jarick et al., 2012; Lionel et al., 2011; Williams et al., 2012], intellectual disability [Shoukier et al., 
2012; Utine et al., 2012], and autism spectrum disorders [Glessner et al., 2009, Marshall et al., 
2008, Sebat et al., 2004; Weiss et al., 2008]. Furthermore, the few available association studies 
have demonstrated the importance of CNVs as common predisposing factors, by identifying 
specific CNVs able to confer a different risk for the development and progression, for example, of 
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HIV infection [Gonzalez et al., 2005], autoimmune diseases [Fanciulli et al., 2007; McKinney et 
al., 2008; Yang et al., 2007] and asthma [Brasch-Andersen et al., 2004; Ivaschenko et al., 2002]. 
 
2.1 Copy number variations in Autism Spectrum Disorders 
Submicroscopic CNVs, de novo and inherited, are emerging as an important category of genetic 
risk for ASD with a different impact depending on the type of CNV identified [Bremer et al., 2011; 
Pinto et al., 2010; Sebat et al., 2007]. Screening for CNVs has proven to be one of the more 
successful strategy for the discovery of ASD candidate loci over the past five years [Cook and 
Scherer, 2008; State, 2010]. Furthermore, the same or overlapping CNVs are being identified as 
risk factors across a few neurodevelopmental disorders, indicating that some ASD loci are likely 
pleiotropic with variable expressivity [Cook and Scherer, 2008; Guillmatre et al., 2009; Lionel et 
al., 2011]. 
The increased resolution of the array-based approaches suggests that the proportion of ASD cases 
(both idiopathic and syndromic) that may be ultimately attributed to a rare structural variant is 
around 10-20%, a percentage higher than that of 6-7% obtained by conventional cytogenetic 
analysis [Abrahams and Geschwind, 2008; Bremer et al., 2011; Cuscò et al., 2009; Marshall et al., 
2008; Pinto et al., 2010]. Furthermore, the de novo CNV rate in ASD is roughly three to seven 
times than that in controls [Levy et al., 2011; Marshall et al., 2008; Pinto et al., 2010; Sanders et 
al., 2011; Sebat et al., 2007] and has been reported to be higher in simplex (low-risk) compared to 
multiplex families (high-risk) [Marshall et al., 2008; Sebat et al., 2007] although this is not always 
the case [Pinto et al., 2010].  
In addition, rare de novo deletions show a higher frequency compared to duplications and an 
increased frequency of rare de novo large CNVs has been observed in ASD female patients 
compared to male patients, findings that allow to speculate on a possible explanation of the sex 
ratio asymmetry observed in ASD [Levy et al., 2011]. It has been suggested, in fact, that due to the 
natural resistance of a female to suffer from genetic forms of ASD, "disruptive" genomic events 
with a high penetrance and involving a great number of genes are needed for ASD onset [Gilman et 
al., 2011; Levy et al., 2011]. 
In some patients multiple de novo variants have been detected presenting with a more complex and 
syndromic form of ASD. Furthermore, the observed rare de novo and inherited variants implicate 
the same genes, indicating that transmitted variants are clearly risk factors in some families and 
may display incomplete penetrance [Fernandez et al., 2010; Vaags et al., 2012]. The evidence of a 
higher frequency of rare inherited CNVs in ASD patients than in general population suggests that 
this type of variations, considered individually, increases the susceptibility to the disease rather 
than being the direct cause [Bremer et al., 2011], thus supporting the existence of an oligogenic 
heterozygosity model of inheritance in multiplex cases, in particular in high-functioning ASD 
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[Schaaf et al., 2011]. In addition, rare inherited duplications have been found more frequently than 
deletions [Levy et al., 2011; Marshall et al., 2008; Pinto et al., 2010; Sanders et al., 2011; Sebat et 
al., 2007; Zhao et al., 2007]. Although many CNVs act in an apparently dominant manner, some 
transmission is clearly recessive (e.g. CNVs affecting PCDH10 and NHE926) in consanguineous 
ASD families with rare homozygous deletions [Chahrour et al., 2012; Morrow et al., 2008]. 
The penetrance of a CNV for ASD depends on the dosage sensitivity and function of the gene(s) 
affected [Cook and Scherer, 2008]. Some CNVs affecting single (e.g., SHANK deletions) or 
multiple (e.g., 16p11.2 deletions) genes are likely sufficient to cause ASD on their own and 
represent highly penetrant forms of the disorder. These CNVs are typically de novo in origin, cause 
a more severe phenotype (some individuals have two or more de novo CNVs and a severe clinical 
presentation), and are more prevalent in sporadic forms of ASD. Recent CNV studies estimate that 
there are as many as 300 de novo risk loci related to ASD across the genome [Anney et al., 2010, 
2012; Levy et al., 2011; Marshall et al., 2008; Pinto et al., 2010; Sanders et al., 2011; Sebat et al., 
2007; Weiss et al., 2009].  
Other CNVs may contribute to the phenotype but in most cases would require other genetic or non-
genetic factors in order to reach the threshold of an ASD diagnosis [Cook and Scherer, 2008]. 
Some of the more highly penetrant ASD CNVs that are transmitted from unaffected parents may be 
explained by a difference in gender expression through parent-of-origin effects (e.g., 15q11–13 
duplications of the maternal allele), or recessive [Morrow et al., 2008] or X-linked transmission in 
males [Jamain et al., 2003; Noor et al., 2010]. However, most of the inherited CNVs (up to 40%) 
have a reduced penetrance as they may be observed in non-ASD family members and in population 
controls, or display pleiotropy in contributing to other neurodevelopmental disorders. In particular, 
common CNVs, that have been found at a frequency significantly higher in ASD patients compared 
to the control population, could act as susceptibility factors for the onset of ASD, modulating the 
“disease” phenotype [Abrahams and Geschwind, 2008, Cuscò et al., 2009, Bremer et al., 2011; 
Pinto et al., 2010].  
 
CNV analysis focused on rare variants, both de novo and inherited, has led to the discovery of 
dozens of ASD susceptibility loci. The involvement of individually rare variants overlapping genes 
important for development and function of neuronal circuits has been reported across multiple 
CNV screening studies. In detail: 
- genes implicated in synaptic complex. At the synaptic membranes neurexins (NRXNs) bind with 
neuroligins (NLGNs) and together act as organizers of excitatory glutamatergic synapses. All the 
three members of NRXN family have been implicated in ASD, as recent CNVs [Vaags et al., 2012] 
and, in particular, rare exonic NXRN1 deletions have been consistently found in ASD CNV screens 
[Reichelt et al., 2011]; 
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- genes expressed at the postsynaptic density. Several CNVs affect genes for scaffolding proteins 
such as SHANK2 [Berkel et al., 2010; 2012; Leblond et al., 2012], SHANK3 [Durand et al., 2007; 
Moessner et al., 2007], and DLGAP2 [Pinto et al., 2010]. The SHANK proteins are crucial 
components of the postsynaptic density and complex with the NLGNs which, in turn, bind with the 
trans-synaptic NRXNs; 
- genes important for axonal growth and guidance. Several CNVs affecting genes encoding cell-
adhesion molecules have been reported, such as CNTN4 (contactin 4) [Cottrell et al., 2011; Roohi 
et al., 2009] and CNTNAP2 (contactin-associated protein) [Nord et al., 2011] as well as a few 
members of the cadherin and protocadherin families, namely CDH8 [Pagnamenta et al., 2011], 
CDH13 [Sanders et al., 2011], PCDH9 [Marshall et al., 2008], and PCDH10 [Morrow et al., 
2008]. 
In addition, pathway analysis shows enrichment of particular gene sets including GTPase/Ras 
[Pinto et al., 2010], ubiquitin degradation genes [Glessner et al., 2009], axon targeting, and neuron 
motility [Gilman et al., 2011], and genes in the TSC/SHANK network [Sakai et al., 2011]. 
 
A crucial point is understanding how a CNV may contribute to the pathogenesis of autism. 
Different mechanisms have been proposed: 
1) changing in gene dosage which may affect the dosage-sensitive genes involved in the CNV. For 
example, the SHANK proteins that participate in the formation of the postsynaptic scaffold are 
particularly sensitive to the dosage whose variations may alter the stoichiometry of SHANK multi-
protein complex (Fig. 7d); 
2) breaking of a gene that maps within the breakpoint region; 
3) physical separation of a gene from its regulatory sequences with consequent alteration of 
transcription (position effect); 
4) in case of deletions, unmasking of point mutations [Toro et al., 2010]. In particular: 
4a) the CNV could reveal the presence of a mutation on the second allele (Fig. 7a), as it has been 
recently demonstrated for the NRXN1 and CNTNAP2 genes, both responsible for the Pitt-Hopkins-
like syndrome. The patients are generally carriers of a CNV that affects one of the disease-genes, 
together with a mutation on the other allele, with a recessive mode of inheritance [Zweier et al., 
2009]. Alternatively, the silencing of the second allele could be due to epigenetic modifications, as 
demonstrated in diseases related to imprinting disorders such as Prader-Willi and Angelman 
syndromes [Schanen, 2006]; 
4b) the second mutation may be present only in certain tissues, for example specific regions of the 
brain (Fig. 7b). This is well known in some familiar neoplasias where a germline mutation together 
with a somatic mutation are required for the development of the disease (“two-hits” model). This 
model has never been reported in ASD; 
24 
 
4c) the allelic exclusion (i.e. the expression of a single allele per cell) may silence the "healthy" 
allele in all cells or in certain cell populations (Fig. 7c). This mechanism is well documented for 
genes encoding immunoglobulins and olfactory receptors [Serizawa et al., 2004]. In the brain, 
allelic exclusion has been reported for adhesion molecules such as cadherins and protocadherins 
[Esumi et al., 2005], which could result in the complete lack of these proteins in neurons. 
 
 
Fig. 7. Potential mechanisms that may perturb neurodevelopment: (a) genetic and epigenetic alterations; (b) 
two-hits model in specific areas of the brain; (c) allelic exclusion which lead to the fully gene silencing or to 
the expression of only one allele; (d) stoichiometric imbalances [Toro et al., 2010]. 
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3. Neurobiology of Autism Spectrum Disorders 
3.1 Neuroanatomical abnormalities in ASD 
The neurobiology of autism has been well documented since the initial description of the disorder 
[Kanner, 1943]. For example, differences in gross brain morphology, such as early brain 
overgrowth, have been well documented [Courchesne et al., 1988, 2001, 2007; Lainhart et al., 
1997]. A large epidemiological study of autism revealed an increased proportion of macrocephaly 
(defined as head circumference greater than the 97th percentile) in patients with autism, up to 
almost 15%. Although macrocephaly is common in children and adults with autism, it is not 
common at birth. Macrocephaly appears to develop after birth in about 80% of cases, as an aberrant 
early postnatal brain overgrowth [Courchesne et al., 1988, 2001, 2007; Lainhart et al., 1997], 
which in autism can occur as the result of three distinct developmental processes: increased 
neurogenesis, decreased neuronal death and/or increased production of non-neuronal brain tissues 
such as glial cells or blood vessels.  
More recent studies investigating the nature of these gross abnormalities have produced 
incongruous results [Stigler et al., 2011]. Frontal lobe volume appears decreased in autism 
[Schmitz et al., 2007], and decreased gray matter volume in orbitofrontal cortex [Hardan et al., 
2006a], as well as abnormally thin frontotemporal cortex [Hadjikhani et al., 2006] has been 
reported. In contrast, others have reported that gray matter volume and thickness is enlarged in 
these cortical regions [Hardan et al., 2006b; Hazlett et al., 2006; Schumann et al., 2010]. Similarly, 
discrepant white matter abnormalities have been reported in autism, including regional increases 
[Amaral et al., 2008; Hazlett et al., 2005; Herbert et al., 2004], as well as decreases in 
crosssectional area and microstructure of the corpus callosum [Alexander et al., 2007; Vidal et al., 
2006]. Concomitant white matter disruptions have been reported in prefrontal, superior temporal, 
temporoparietal cortices, and corpus callosum [Barnea-Goraly et al., 2004], but increases in whole 
brain white matter volume have also been observed [Hazlett et al., 2005; Schumann et al., 2010]. 
Despite some incongruent results, the limitations of small sample sizes, bias in quantification 
techniques and co-morbidity that hamper neuropathological investigation, a few classic 
neuropathological findings from post-mortem studies are rather consistent: 
 an increased cell packing density with limited dendritic arbores and reduced cell size in 
hippocampus, subiculum and amygdalae. This pattern resembles a pattern typical of the earlier 
stages of brain maturation and may therefore reflect features of an immature brain [Bauman 
and Kemper, 1985; Kemper and Bauman, 1993, 1998; Raymond et al., 1996]; 
 a decreased number of Purkinje cells in the cerebellar hemisphere and vermis [Bauman and 
Kemper, 1985; Kemper and Bauman, 1993, 1998; Ritvo et al., 1986]; 
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 cerebral and cerebellar cortical dysgenesis with thickened cortices, high neuronal density, 
presence of neurons in the molecular layer, irregular laminar patterns and poor grey-white 
matter boundaries [Bailey et al., 1998]. These findings are consistent with a reduction in Reelin 
and Bcl-2 proteins in cerebellar cortex, which are involved in neuronal migration and 
programmed cell death, respectively [Fatemi et al., 2001a and b]. 
Moreover, magnetic resonance brain imaging has improved the classification of autistic brain 
anomalies, allowing the in vivo examination of the brain: 
 abnormalities in the neocerebellum were reported, consistent with earlier data from post-
mortem studies (i.e., reduction in the number of Purkinje cells), thus suggesting that these 
anomalies  indirectly could affect, through its connections to the brain stem, hypothalamus and 
thalamus, the development and functioning of cognitive, sensory, autonomic and motor 
activities [Courchesne et al., 1988; Murakami et al., 1989; Stanfield et al., 2007]; 
 the right anterior cingulate area was found in autistic subjects significantly smaller in relative 
volume and also metabolically less active [Haznedar et al., 1997];  
 the corpus callosum is generally reduced in size. This size reduction may diminish 
interhemispheric connectivity and may be involved in pathophysiology of cognitive 
impairments and clinical features of autism [Cody et al., 2002; Stanfield et al., 2007]; 
 at the level of the basal ganglia an enlargement of the caudate nucleus was shown. The caudate 
has connections to the pre-frontal cortex and is known to play an inhibitory role in behaviour. 
A correlation was found between ritualistic and repetitive behaviours and increased volume of 
the caudate nucleus [Brambilla et al., 2003]. 
Recently, the development of new quantitative structural imaging studies like voxel-based whole 
brain analysis, led to more standardized methods for data analysis. Localized grey matter 
reductions within the fronto-striatal and parietal networks were reported and additional decreases 
were described in the ventral and superior temporal grey matter [Boddaert et al., 2004; McAlonan 
et al., 2005].  
Morphometric differences were also shown in key language regions. In normal individuals there 
exists a bias towards larger cortical language regions in the left hemisphere, whereas boys with 
autism showed a significant asymmetry reversal in the inferior lateral frontal language cortex, 
which was 27% larger on the right side. Thus, it was hypothesized that semantic encoding, 
normally performed by the inferior frontal gyrus, in autistic patients is performed via alternative 
pathways [Herbert et al., 2002, 2005; Just et al., 2004], and a PET study seemed to confirm these 
findings with less percentual change in blood flow in the dorsolateral pre-frontal area while 
listening to, repeating, and generating sentences [Muller et al., 1998]. 
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3.2 ASDs represent a “synaptopathy” 
In healthy brains, a balance of excitation and inhibition is essentially for nearly all functions, 
including representation of sensory information, cognitive processes such as decision making, sleep 
and motor control. At the cellular level, the number and distribution of excitatory and inhibitory 
inputs onto single neurons has significant impact on the integration of synaptic inputs and the 
output from neurons [Gulledge et al., 2005]. This in turn affects circuit function and plasticity, for 
instance by affecting long-term potentiation or the stereotypic output from central pattern 
generators [Alford et al., 2003]. 
Moreover, during development the balance between excitation and inhibition governs the 
establishment of sensory system projections, including the onset of the critical period for visual 
system plasticity [Fagiolini et al., 2004]. 
Currently, more than 100 genes are susceptibility candidates for ASD, indicating that ASD 
represents a collection of conditions with heterogeneous causation [Betancur, 2011]. These genes 
can be divided into two groups on the basis of the penetrance of the mutation in relation to the risk 
of developing the disease. Table 1 lists the major genes whose mutations show a high penetrance; 
variants are usually point mutations or rare CNVs, de novo or inherited, and duplications/deletions 
detectable by conventional cytogenetics [Toro et al., 2010]. 
 
Table 1. Genes associated with high risk for ASD. ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum 
disorder; CNV, copy number variation; MR, mental retardation; SCZ, schizophrenia; SNP, single nucleotide polymorphism; TS, 
Tourette syndrome. 
a
The pathogenetic role of these rare variants have not yet be confirmed [Toro et al., 2010]. 
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Most of genes that are affected by variants at low penetrance, such as SNPs or inherited common 
CNVs, are listed in Table 2 [Toro et al., 2010]. These variations, which seem to be responsible for 
increased susceptibility to the development of ASD, may be considered with caution because they 
have not always been replicated in the genome-wide association studies [Anney et al., 2010, 2012; 
Weiss et al., 2009]. 
 
 Table 2. Proposed susceptibility genes for ASD. ADHD, attention-deficit hyperactivity disorder; AHC, alternating hemiplegia 
of childhood; ASD, autism spectrum disorder; BP, bipolar disorder; CNV, copy number variation; FHM2, familial hemiplegic 
migraine 2; MR, mental retardation; OCD, obsessive-compulsive disorder; PD, Parkinson disease; SCZ, schizophrenia; SNP, 
single nucleotide polymorphism; TS, Tourette syndrome [Toro et al., 2010]. 
Recent evidences have unveiled a remarkable convergence of several of these genes on common 
cellular pathways that intersect at neuronal synapses [Peça and Feng, 2012]. Indeed, the notion that 
some ASD and ID represent “synaptophaties” is supported by the preponderance of penetrant 
mutations in genes associated with synaptic structure and function. ASD and ID appear to be 
common consequences of disruptive mutations that cause synaptic pathophysiology at both ends of 
a spectrum as both “gain of function” and “loss of function” mutations can manifest in similar ways 
(Fig. 8). Furthermore, the interdependence among proteins that work as a biochemical complex 
suggest that even single gene disorders may perturb the full complex and the related pathways and 
networks [Zoghbi and Bear, 2012].  
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Fig. 8. Gain or loss of function of individual genes often yields an overlapping behavioral phenotype in 
humans 
that includes ASD and ID. Optimal synaptic function may occur within a limited dynamic range, and the 
pathophysiology at both ends of this range can cause autistic behavior and intellectual disability [Zoghbi and 
Bear, 2012]. 
 
Synaptic scaffolding disorders 
For ASD, the trans-synaptic complex composed of Neurexin/Neuroligin/PSD-95/SAPAP/Shank 
pathway is a good examples of a set of genes converging on both function, location and associated 
disorders. From these, Neurexin-1 [Feng et al., 2006; Kim et al., 2008; Wisniowiecka-Kowalnik et 
al., 2010; Yan et al., 2008], Neuroligin-3 and Neuroligin-4 [Jamain et al., 2003], PSD-95 [Feyder 
et al., 2010], SAP97 [Willatt et al., 2005], SAPAP2 [Pinto et al., 2010], Shank1, Shank2 and 
Shank3 [Berkel et al., 2010, 2012; Durand et al., 2007; Leblond et al., 2012; Pinto et al., 2010] 
have all been implicated in ASD and validated across multiple studies (Fig. 9).  
All Shank proteins are expressed in the brain, especially in cortical and hippocampal neurons, and 
localized to the post-synaptic density (PSD) of dendritic spines. The PSD is key for organizing and 
maintaining proper synaptic communication, and within this structure Skanks have been 
hypothesized to function as master scaffolds. Shanks stabilize PSD-95/SAPAP/Shank/Homer 
complexes, which form a platform for the anchoring of ionotropic and metabotropic glutamate 
receptors at synapses [Baron et al., 2006; Hayashi et al., 2009]. In addition, they recruit inositol 
1,4,5-triphosphate (IP3) and F-actin to the synapse, thereby enlarging dendritic spine heads and 
stabilizing them [Sala et al., 2001; Tu et al., 1998, 1999] (Fig. 9). For example, overexpression of 
Shank1 in hippocampal neurons leads to increased maturation and size of dendritic spines, whereas 
deletion of Shank1 in mice leads to smaller spines and weakened synaptic transmission. 
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Furthermore, knockdown of Shank3 in hippocampal neurons cultured in vitro leads to reduced 
number and increased length of dendritic spines, whereas overexpression of Shank3 in aspiny 
cerebellar granule neurons is sufficient to induce functional dendritic spines [Roussignol et al., 
2005]. 
Interestingly, the four different lines of Shank3 mutant mice characterized so far show neuronal 
deficits that all lead to decreased glutamatergic signaling, loss of synaptic strength and, at the 
behavioral level, to deficiencies pertaining social interactions and other ASD-related behavior.  
Neurexins (NRXNs) and Neuroligins (NLGNs) are synaptic cell adhesion molecules whose critical 
role in synaptic function has been well established. Both NRXNs and NLGNs have single 
transmembrane domains and short cytoplasmic domains containing PDZ-binding motifs at the 
carboxyl terminus [Hata et al., 1996; Irie et al., 1997]. They form a trans-synaptic complex 
believed to organize the presynaptic and postsynaptic compartments through various interactions 
with proteins like CASK, MAGUK, and PSD-95 [Sudhof, 2008] (Fig. 9). Mice lacking Nlgn1, 2, 
and 3 have normal synapse number and ultrastructures, but die perinatally from respiratory failure. 
Neurophysiologically studies revealed that glutamatergic and GABAergic synaptic transmission is 
impaired in the respiratory center of the triple null animals [Varoqueaux et al., 2006]. Interestingly, 
mice carrying a single deletion or double knockout of these genes are viable, that is consistent with 
the finding, for example, that Nlgn1 deficiency impairs N-methyl-D-aspartate (NMDA) receptor 
signaling, whereas Nlgn2 deficiency impairs inhibitory synaptic transmission [Chubykin et al., 
2007]. Furthermore, a deletion of an NLGN4 ortholog in mice caused impaired social interactions 
consistent with the loss-of-function mutation in humans that cause ASD and ID [Jamain et al., 
2008]. 
In the different individual Nrxn knockout mice synaptic function is impaired, as evident by 
decrease spontaneous as well as evoked neurotransmitter release in both the neocortex and brain 
stem of α-NRXN deficient mice. Moreover, Ca2+ channel function is also compromised based on 
decreased presynaptic Ca
2+ 
currents [Missler et al., 2003]. 
Synaptic signaling disorders 
It is noteworthy that pathogenesis of Fragile X syndrome (FXS), Angelman syndrome (AS), and 
Tuberous Sclerosis syndrome (TSC), which all show comorbidity with ASD, involves regulation of 
synaptic protein abundance and turnover (Fig. 9). In FXS this is due to derepression of translation 
of FMRP-target mRNAs. Indeed FMRP, which is enriched in neuronal soma and dendrites, serves 
as negative regulator of translation of many mRNA transcripts [O’Donnell and Warren, 2002], and 
an increased rate of basal protein synthesis is observed in the hippocampus of Fmr1 null mice 
[Osterweil et al., 2010; Qin et al., 2005]. Another consistent finding in animal models of fragile X 
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is evidence of impaired GABAergic inhibition [Levenga et al., 2010], which could be a 
consequence of excessive protein synthesis during development. 
Reduced proteolysis of UBE3a-target proteins is the AS underlying pathogenic mechanism. Several 
synaptic deficits have been described in the UBE3a knockout mouse model of AS, including 
reduced density and strength of excitatory synapses and, at a later developmental stage, reduced 
functional inhibition [Philpot et al., 2010]. In addition to UBE3A, other proteins involved in CNVs 
affecting other ubiquitin genes have been collected in patients with ASD, such as PARK2, RFWD2, 
and FBXO40 [Glessner et al., 2009]. Interestingly, changing neuronal activity levels produces a 
rapid bidirectional change in the composition of PSD proteins, an effect that is mediated by the 
proteasome system [Ehlers, 2003], thus supporting the importance of ubiquitin ligases to the 
regulation of excitatory synapses (Fig. 9) [Peça and Feng, 2012]. 
The proteins encoded by TSC1 and TSC2, harmartin (TSC1) and tuberin (TSC2), form a 
heterodimeric complex that responds to numerous intracellular signals to negatively regulate the 
protein kinase mTOR (mammalian target of rapamycin) residing in the protein complex mTORC1. 
Relief from TSC1/2 repression of mTOR by upstream signaling (e.g., PI3 kinase acting through 
PDK1 and AKT) stimulates cell growth and proliferation (Fig. 9). Homozygous silencing 
mutations of either TSC1 or TSC2 are embryonic lethal. Humans born with the disease typically 
have heterozygous truncating germline mutations in either TSC1 or TSC2 [Han and Sahin 2011; 
Orlova and Crino 2010]. Heterozygous null mutations of TSC1 or TSC2 were both shown to cause 
cognitive and synaptic impairments in the absence of gross neuropathology or seizures [Ehninger et 
al., 2008; Goorden et al., 2007; Nie et al., 2010; von der Brelie et al., 2006]. One particularly 
interesting phenotype reported in the Tsc2+/- mouse is an enhancement of late-phase LTP 
[Ehninger et al., 2008]. Persistent LTP requires synthesis of synaptic proteins that might be 
increased in abundance owing to excess mTOR activity. 
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Fig. 9. Shank proteins at the center of an ASD disease-module. Neurexin and Neuroligins are trans-synaptic 
partners which in the postsynaptic density bind to the SAPAP family of proteins, PSD-95, SAP97, Shank2 
and Shank3. Shank dimers are thought to organize a molecular platform in concert with Homer tetramers to 
stabilize the larger PSD, connecting AMPAR, NMDAR and mGluR into one protein hub. In the deeper 
synaptic compartment the control of PSD protein levels may be tightly controlled by independent complexes 
such as TSC1/2 through mTOR, or via FMRP regulation of synaptic transcripts, and most likely also through 
synaptic ubiquitin ligases [Peça and Feng, 2012]. 
 
Synaptic transcriptional dysregulation 
MeCP2, whose mutations cause Rett syndrome (RTT), is a nuclear protein that binds to methylated 
cytosines [Lewis et al., 1992] and is a member of a methyl-CpG-binding protein family [Hendrich 
and Bird, 1998]. MeCP2 interacts with histone deacetylase–containing complexes and represses 
transcription [Jones et al., 1998; Nan et al., 1998]. Surprisingly, in mouse models of RTT several 
genes are down-regulated upon loss of MeCP2 but are increased upon its overexpression, 
suggesting that this protein is not a classical transcriptional repressor [Chahrour et al., 2008; Jordan 
et al., 2007; Nuber et al., 2005; Tudor et al., 2002]. Among these genes there are brain-derived 
neurotrophic factor (BDNF) and several other neuronal genes [Chahrour et al., 2008; Chen et al., 
2003; Martinowich et al., 2003; Yasui et al., 2007]. 
MeCP2 is abundant in neurons, and its levels increase postnatally as neurons mature [Balmer et al., 
2003; Kishi and Macklis 2004; Shahbazian et al., 2002b]. Recent studies revealed that MeCP2 is 
also expressed in glia, albeit at lower levels than neurons, and that glia lacking MeCP2 fail to 
support dendritic morphology of either wild-type or Mecp2-null neurons [Ballas et al., 2009; 
Kifayathullah et al., 2010; Maezawa and Jin 2010; Maezawa et al., 2009]. Mice lacking functional 
MeCP2 reproduce features of RTT [Chen et al., 2001; Guy et al., 2001; Pelka et al., 2006; 
Shahbazian et al., 2002a]. Despite the devastating neurological phenotypes, the brain appears 
normal, with the exception of microcephaly, decrease in dendritic spine density, and dendritic 
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swelling [Belichenko et al., 2009]. Furthermore, deletion of MeCP2 from various neuronal types 
revealed that this protein is critical for the functional integrity of a diverse set of neurons. Loss of 
Mecp2 from forebrain glutamatergic neurons causes motor abnormalities, anxiety-like behavior, 
social abnormalities, and impaired learning [Gemelli et al., 2006]. A more recent study revealed 
that deletion of Mecp2 in GABAergic neurons reproduced most of the features of RTT (including 
the stereotyped behavior and premature lethality) and resulted in reduced GABA signaling [Chao et 
al., 2010]. Interestingly, the RTT model shows a decrease in AKT/mTOR signaling in contrast with 
models of TSC and fragile X, in which AKT/mTOR activity is increased [Zoghbi and Bear, 2012]. 
 
To date, the role of neurotransmitters transporters and synaptic glutamatergic receptors in 
susceptibility to ASD must be still clarified. Since abnormal levels of serotonin have been found in 
patients with ASD [Cook and Leventhal, 1996], the SLC6A4 gene encoding the serotonin 
transporter has been extensively studied, although only a weak association with ASD has been 
highlighted as in the case of the GRIK gene, which encodes a receptor for glutamate [Jamain et al., 
2002]. 
Moreover, it is likely that many proteins involved in axonal growth and synaptic identity have a 
role in the pathogenesis of ASD. The semaphorins, for example, are involved in axonal growth and 
maturation of dendritic spines and SNPs in the SEMA5A gene have been associated with ASD in a 
large cohort of patients [Weiss et al., 2009]. In addition, deletions in the genes encoding the 
contactins proteins (CNTN3 and CNTN4), which are also involved in axonal growth and in the 
mediation of the connections between axon and glial cells, have been identified in patients with 
ASD [Morrow et al., 2008]. 
Finally, many pathways are involved in the intracellular signaling from the synapse to the neuronal 
soma, whose perturbation may be potentially related to ASD development (Fig. 10).  
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Fig. 10. Schematic view of the synaptic genes that are involved in the pre-postsynaptic connection and in the 
signal transduction from the synapse to the neuronal soma, most of which have been already implicated in 
ASD.  
 
In detail, genes working in the same network are depicted in yellow, genes potentially perturbed by rare de 
novo CNVs reported by Levy et al. [Levy et al., 2011] in blue, and genes associated with ASD in previous 
studies in red [Gilman et al., 2011]. 
 
In detail: 
- remodeling of actin cytoskeleton. The information for the regulation of the morphology of 
dendritic spine are transmitted through the GTPase Rho family of proteins, such as RhoA/B, 
Cdc42, and Rac1 [Linseman and Loucks, 2008] to downstream targets, for example LIMK1 and 
PAK1/2/3, that are linked to proteins which are able to modify the morphology of the actin 
cytoskeleton (cofilin and Arp2/3) [Blanchoin et al., 2000]. The GTPase activity is regulated pre- 
and post-synaptically by different GEF (guanine nucleotide exchange factor), GDI (GDP 
dissociaton inhibitors) and GAP (GTP-activating proteins) proteins (Fig. 10); 
- Wnt/β-catenin pathway, that plays a crucial role in the formation of neuronal circuits [Salinas and 
Zou, 2008] and is directly involved in the reorganization of actin filaments (Fig. 10) [Rosso et al., 
2005; Salinas et al., 1994]; 
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- reelin-mediated signaling. Reelin is secreted at the synaptic space and regulates the mTOR 
pathway acting on TSC1/TSC2 by the AKT-mediated signaling (Fig. 10) [Fatemi et al., 2005; 
Jossin and Goffinet, 2007; Kumar et al., 2005; Niu et al., 2008; Shaw and Cantley, 2006]; 
- MAPK3/ERK1 signaling pathway, that is activated by both NF1 and Ras and represents another 
way of regulation of mTOR. Indeed, mTOR is able to integrate the stimuli that arrive from the 
upstream pathways involved in the regulation of cell growth and to mediate the morphogenesis of 
the dendrite (Fig. 10) [Tavazoie et al., 2005]. 
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PATIENTS AND METHODS 
37 
 
4.1 Patients 
We collected a series of 115 patients (92 males and 23 females, M:F sex ratio 4:1) who were 
diagnosed with ASD as a result of evaluation by geneticists and psychiatrics in agreement with the 
international criteria of DSM-IV Text Revised [Task Force on DSM-IV, 2000]. The overall 
phenotypic picture was therefore characterized as: idiopathic Autism (AU), which always involves 
intellectual disability (ID); Pervasive Development Disorder Not Otherwise Specified (PDD-NOS), 
which may or may not involve ID; High-Functioning Autism (HF-AU); Asperger syndrome (AS); 
and Syndromic Autism (S-AU), where the autistic phenotype is part of a syndromic picture 
characterized by dysmorphism and/or major malformations. One patient with S-AU suffered from 
Tourette syndrome. Four of the 115 patients demonstrated epilepsy (~3.5%).  
The detailed clinical diagnoses were as follows (Fig. 11): 
 46 patients with PDD-NOS; 
 41 with AU-ID (notably, only one female patient suffered from a severe ID); 
 15 with S-AU;  
 8 with HF-AU; 
 5 with AS. 
 
Fig. 11. Distribution of the sample by sex (left) and phenotype (right). The number and percentage of patients 
are shown for each category.  
Genomic DNA from all patients, which was extracted from peripheral blood samples collected in 
tubes containing EDTA, was used to perform array CGH analysis (Agilent Technology) in order to 
detect copy number variants (CNVs). Three kits with different resolutions were used, specifically: 
- 6 patients were analyzed with the 60K SurePrint G3 Human CGH Microarray, which includes 
approximately 55,077 oligonucleotide probes at an average spatial resolution of 41 kb (33 kb in 
gene-enriched genomic regions);  
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- 12 patients with 44K Human Genome CGH Microarray, which includes approximately l42,494 
probes at an average spatial resolution of 43 kb (24 kb in gene-enriched genomic regions); 
- 97 patients with 244K Human Genome CGH Microarray, which includes approximately 236,381 
probes at an average spatial resolution of 8.9 kb (7.4 kb in gene-enriched genomic regions). 
In the event of detection of rare CNVs, if possible, patients’ parents were analyzed to characterize 
the origin of the unbalanced microrearrangement (de novo or inherited). 
39 
 
4.2 Molecular karyotyping by means of array-based Comparative Genomic 
Hybridization (array CGH) analysis 
4.2.1 Extraction of genomic DNA (gDNA) from peripheral blood 
For gDNA extraction from fresh or frozen (-80°C) peripheral blood collected in anticoagulant 
(EDTA) tubes, the GenElute Blood Genomic DNA Kit (Sigma) was used following the 
manufacturer’s instructions. Briefly: 
- add 500 µl of whole blood to a 2 ml tube containing 50 µl of proteinase K and 40 µl of RNAseA; 
- add 550 µl of Lysis Buffer C Solution, then vortex thoroughly for 15 seconds and incubate at 55 
°C for 10 minutes; 
- add 550 µl of 100% ethanol and vortex the sample again for 15 seconds; 
- in the meantime, for gDNA recovery moisturize the pre-assembled GenElute Miniprep Binding 
Columns by washing them with 500 µl of the Column Preparation Solution, then centrifuge at 7000 
rpm for 1 minute and discard the flow-through liquid; 
- load 500 µl of the sample into the column, centrifuge at 7000 rpm for 1 minute and discard the 
collection tube containing the flow-through liquid; 
- repeat this step until the entire sample was loaded into the column and place the binding column 
to a new 2 ml tube; 
- add 500 µl of Prewash Solution, centrifuge at 7000 rpm for 1 minute and discard the collection 
tube containing the flow-through liquid. Place the binding column to a new 2 ml tube; 
- add 500 µl of Wash Buffer, centrifuge at 13000 rpm for 3 minutes and discard the collection tube 
containing the flow-through liquid; 
- place the binding column to a new 2 ml tube and let it dry under a safety hood for 10 minutes; 
- add 50 µl of Elution Buffer directly into the centre of the binding column and wait for 5 minutes, 
then centrifuge at 7000 rpm for 2 minutes; 
- the concentration and quality of the gDNA (it should be free of contaminants such as 
carbohydrates, proteins, and traces of organic solvents) are determined by a spectrophotometric 
analysis by using the NanoDrop ND-1000 UV-VIS Spectrophotometer. Moreover, by means of 
agarose gel electrophoresis  it could be verified if the gDNA is intact or degradated.  
 
4.2.2 gDNA enzymatic restriction digestion 
Test and reference DNAs must be processed separately. The amount of DNA required, which must 
necessarily be the same for test and reference, depends on the slide used as indicated in the table 
below. 
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 44K array  60K array  array 244K  
DNA (μg) 0.5-1.5 μg 0.2-0.5μg 0.5-3 μg 
 
For 44K and 244K arrays: 
- add to DNA Nuclease-free water up to volume 20.2 µl;  
- preparation of Digestion Master Mix, component per reaction: 
2 µl of nuclease-free water 
2.6 µl of Buffer C 
0.2 µl of BSA (10 µg/µl) 
0.5 µl of AluI (10 U/µl) 
0.5 µl of RsaI (10 U/µl) 
5.8 µl final volume 
- add 5.8 μl of Digestion Master Mix to the genomic DNA; 
- make a total volume of 26 μl; 
- mix well by pipetting up and down; 
- incubate at 37°C for 2 hours; 
- incubate at 65°C for 20 minutes to inactivate the enzymes; 
- move the sample tubes to ice; 
- verify the digestion reaction by means of agarose gel electrophoresis run (Agarose 0.8% in TAE 
buffer; ethidium bromide 0.01 mg/ml) of 2 µl of digested DNA. 
 
For 60K array: 
- add to DNA Nuclease-free water up to volume 10.1 µl;  
- preparation of Digestion Master Mix, component per reaction: 
1 µl of nuclease-free water 
1.3 µl of Buffer C 
0.1 µl of BSA (10 µg/µl) 
0.25 µl of AluI (10 U/µl) 
0.25 µl of RsaI (10 U/µl) 
2.9 µl final volume 
- add 2.9 μl of Digestion Master Mix to the genomic DNA; 
- make a total volume of 13 μl; 
- mix well by pipetting up and down; 
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- incubate at 37°C for 2 hours; 
- incubate at 65°C for 20 minutes to inactivate the enzymes; 
- move the sample tubes to ice; 
- verify the digestion reaction by means of agarose gel electrophoresis run (Agarose 0.8% in TAE 
buffer; ethidium bromide 0.01 mg/ml) of 2 µl of digested DNA. 
 
4.2.3 Fluorescent Labeling of DNA by Agilent Genomic DNA Labeling Kit PLUS 
For labeling reaction fluorescent cyanines (CY3 and CY5) are used so the reaction must be 
performed in the dark. 
 
For 44K and 244K arrays: 
- add 5 μl of Random Primers to each reaction tube containing 24 μl of digested gDNA to make a 
total volume of 29 μl; 
- mix well by pipetting up and down gently; 
- incubate at 95-100°C for 5 minutes; 
- move to ice and incubate on ice for 5 minutes; 
- preparation of Labeling Master Mix, component per reaction: 
2 µl of Nuclease-free water 
10 µl of 5X Buffer  
5 µl of 10X dNTP 
3 µl of Cyanine 3-dUTP (1.0 mM) or Cyanine 5-dUTP (1.0 mM) 
1 µl of Exo-Klenov fragment 
21 µl final volume 
- add 21 μl of Labeling Master Mix to 29 μl of digested gDNA; 
- make a total volume of 50 μl;  
- mix well by gently pipetting up and down; 
- incubate at 37°C for 2 hours; 
- incubate at 65°C for 10 minutes to inactivate the enzyme, then move to ice. 
 
For 60K array: 
- add 2.5 μl of Random Primers to each reaction tube containing 11 μl of digested gDNA to make a 
total volume of 13.5 μl; 
- mix well by pipetting up and down gently; 
- incubate at 95-100°C for 5 minutes; 
- move to ice and incubate on ice for 5 minutes; 
- preparation of Labeling Master Mix, component per reaction: 
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2 µl of Nuclease-free water 
5 µl of 5X Buffer 
2.5 µl of 10X dNTP 
1.5 µl of Cyanine 3-dUTP (1.0 mM) or Cyanine 5-dUTP (1.0 mM) 
0.5 µl of Exo-Klenov fragment 
11.5 µl final volume 
- add 11.5 μl of Labeling Master Mix to 13.5 μl of digested gDNA; 
- make a total volume of 25 μl;  
- mix well by gently pipetting up and down; 
- incubate at 37°C for 2 hours; 
- incubate at 65°C for 10 minutes to inactivate the enzyme, then move to ice.  
 
4.2.4 Clean-up of Labeled Genomic DNA 
- Add 430 μL of 1X TE (pH 8.0, Promega) to a Microcon YM30 (Millipore) filter (the filter is into 
a 1.5-ml microfuge tube); 
- load each labeled gDNA into the filter, mix well; 
- spin 10 minutes at 14,000 × g in a microcentrifuge at room temperature. Discard the flow-
through; 
- add 480μl of 1X TE (pH 8.0) to each filter. Spin for 10 minutes at 14,000 × g in a microcentrifuge 
at room temperature. Discard the flow-through; 
- invert the filter into a fresh 1.5-mL microfuge tube; 
- spin for 1minute at 1,000 × g in a microcentrifuge at room temperature to collect purified sample; 
- measure and record volume (μl) of each eluate and repeat the last steps until the volume is <9.5 µl 
(60K), 21 µl (44K), or 80.5 µl (244K). Bring total sample volume to the final volume with 1X TE 
Buffer (pH 8.0); 
-Take 1.5μl of each sample to determine the yield and specific activity by using the NanoDrop ND-
1000 UV-VIS Spectrophotometer. 
-Labeled DNA can be stored overnight at -20°C in the dark. 
 
4.2.5 Preparation of Labeled Genomic DNA for Hybridization 
The hybridization reaction must be performed in the dark: 
- mix the labeled reference and test DNAs; 
- add the reagents as described in the table below: 
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 60K 44K 244K 
Labeled DNAs  16 µl 39 µl 158 µl 
Human Cot-1 DNA (1mg/ml) 2 µl 5 µl 50 µl 
Agilent 10X Blocking agent 4.5 µl 11 µl 52 µl 
Agilent 2X Hybridization buffer 22.5 µl 55 µl 260 µl 
Finale volume 45 µl 110 µl 520 
 
- mix the sample by pipetting up and down, then quickly spin in a microcentrifuge to drive contents 
to the bottom of the reaction tube; 
- incubate at 95°C for 5 minutes; 
- immediately incubate at 37°C for 30 minutes; 
- spin 1 minute at 13000 rpm in a microcentrifuge to collect the sample at the bottom of the tube; 
- put the full volume on the cover-slip using the Agilent microarray 8/slide gasket for 60K array, 
the Agilent microarray 4/slide gasket for 44K arrays and the Agilent microarray 1/slide gasket for 
244K array, previously lying on the bottom of the Agilent Microarray Hybridization Chamber; 
- place the slide with the up-face toward the sample and close the Agilent Hybridization Chamber; 
- place the slide into a preheated oven at 65°C and leave for 24-48 hours. 
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4.3 Copy Number Variant analysis 
The evaluation of the possible pathogenicity of all the identified CNVs was performed based on 
international guidelines, such as those described by Miller in 2010 [Miller et al., 2010] and 
Marshall et al. in 2012, who focused on the prioritization criteria [Marshall et al., 2012] (Fig. 12).  
 
Fig. 12. General analysis and prioritization workflow (pink boxes) for discovery of rare CNVs 
associated with ASD. 
Once a CNV was detected, the first target was to understand whether it was a rare variant or a CNV 
already reported in healthy controls according to the Database of Genomic Variants 
(http://projects.tcag.ca/variation/). In the case of rare CNVs, array CGH analysis was performed on 
the parents’ DNA to determine whether the rearrangement is de novo or inherited. Although in 
terms of follow-up the de novo CNVs have the highest priority (Fig. 12, pink boxes), parameters 
such as recurrence in ASD cases and overlap with other neurodevelopmental disorders, together 
with a precise analysis of the CNV gene content, may be of help in identifying possible ASD 
candidate loci (Fig. 12, light pink box) affected by both de novo and inherited CNVs.  
We performed ad hoc analysis of the identified CNV gene content using public databases, 
specifically: 
- the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) and NCBI Entrez Gene 
(http://www.ncbi.nlm.nih.gov/gene), which are both useful to collect information about the genes 
involved in the imbalance (i.e. gene function, molecular structure, presence of different isoforms, 
etc.), their expression in different tissues, and the pathways in which they are involved; 
- the Decipher database (http://decipher.sanger.ac.uk/), which collects all pathogenetic CNVs 
reported to date as well as the clinical description of the related patients; 
45 
 
- the OMIM database (Online Mendelian Inheritance in Man) 
(http://www.ncbi.nlm.nih.gov/omim), which collects information about all Mendelian disorders 
described to date, focusing particularly on genotype-phenotype correlation; 
- PubMed (http://www.ncbi.nlm.nih.gov/pubmed), which provides updated international medical 
literature. 
Furthermore, two databases specific for ASD were consulted, namely the Autism Database 
(http://www.mindspec.org/autdb.html) and the SFARI Database (Simmons Foundation Autism 
Research Initiative) (http://sfari.org/resources/sfari-gene), which collect the genes previously 
reported as mutated or affected by CNVs in ASD patients, as well as genes associated with ASD by 
association studies.  
A possible replication of the findings in other cohorts, as well as gene sequencing in the case of 
CNV affecting single genes, may be good approaches to validate the collected data (Fig. 11, blue 
box). 
Of note, considering the autism disease, which shows an oligo-/polygenic genetic aetiology, it 
cannot be assumed a priori that an inherited CNV is benign per se. Indeed, the combination of 
several variants in different loci, both de novo and/or inherited, often leads to the manifestation of 
the disease, which is not present in the parents as they do not share the same combination of 
variants identified in the children. Although we cannot exclude the possibility that any of the 
“common” CNVs detected in our series may have contributed to ASD susceptibility, the 
assessment of this susceptibility would have required a time-expensive association study that did 
not fit appropriately with the goals of the present work. 
.
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RESULTS 
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5.1 Identification and classification of rare CNVs 
A cohort of 115 patients with ASD was analyzed by high-resolution array CGH analysis to identify 
CNVs possibly implicated in ASD pathogenesis. In 63 of 115 patients (55%), rare CNVs (one or 
more) were detected that were not already reported in healthy subjects according to the DGV. This 
group comprised: 
 52 males and 11 females; 
 51 sporadic and 12 familial cases;  
 49 patients analyzed by the Agilent 244K Human Genome CGH Microarray Kit and 14 by the 
44K or the 60K Kits. 
The phenotype distribution of the 63 patients is shown in Fig. 13. 
 
 
Fig. 13. Distribution of the group of 63 patients with at least one rare CNV by sex (left) and phenotype 
(right). For each subgroup, the number and percentage of patients are shown. 
 
The detection rate for rare CNVs using the high-resolution array CGH analysis was approximately 
50.5% (49 of 97 patients analyzed by means of the Agilent 244K Kit) vs. 77.8% using the array 
CGH analysis at a lower resolution (14 of 18 patients analyzed by means of the Agilent 44K or 
60K Kits). Of note, 6 of 97 patients analyzed with the Agilent 244K Kit were negative using a 
previous array CGH analysis at a lower resolution, and in 4 of these patients, at least one rare CNV 
was subsequently identified. Overall, 120 rare CNVs were detected, 73 gains (60.8%) and 47 losses 
(39.2%), ranging from 10 kb to 11 Mb in size (Fig. 14). Furthermore, inheritance is unknown for 
13 CNVs (10.8%). Twenty of the remaining 107 CNVs were de novo (16.7%), and 87 were 
inherited (72.5%), 50 from the mother (57.5%) and 37 from the father (42.5%). All these data are 
summarized in Fig. 14. 
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Fig. 14. Schematic view of the 120 rare CNVs identified, which have been subdivided based on the type of 
rearrangement (left), origin (middle) and parental inheritance (right). For each subgroup the number of 
patients and the percentage are shown. 
 
Exclusively rare de novo CNVs (one or more) were found in only 10 of 63 patients (15.9%), 
whereas in 15 of 63 patients (23.8%), only one inherited CNV was detected. In the remaining 38 
patients, more than one CNV was identified (60.3%), in different combinations. Specifically: 
- in 7 of 63 patients (11.1%), a single rare de novo CNV together with one or more inherited 
CNV were detected (7 CNVs were inherited from the mother and one from the father), with 
only one patient who inherited the CNVs from both parents; 
- in 25 of 63 patients (39.7%), more than one rare inherited CNV was detected, 18 of whom 
inherited the CNVs from both parents, 7 from the same parent;  
- in a single patient (1.6%), two CNVs were found, one inherited and one with an unknown 
origin; 
- 5 of 63 patients (7.9%) were found to carry rare CNVs with an unknown origin (Fig. 15). 
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Fig. 15. Schematic view of the 63 patients who were found to be carriers of rare CNVs, based on the origin 
of the identified CNVs. For each subgroup the number of patients and the percentage are shown. 
 
A detailed list of the identified rare CNVs is shown in Table 3. Furthermore, high-resolution array 
CGH analysis allowed the identification of a few CNVs already reported in the DGV in a subset of 
the ASD cohort. These variations were very heterogeneous in terms of size and physical 
localization, spread throughout the genome, and usually recurrent in our cohort. Among these 
“common” CNVs, which have been selected for their possible role as susceptibility loci for ASD 
pathogenesis, two variants appeared to be more significant. They both involve genes highly 
expressed in the CNS and affect the Protocadherin gene cluster and the KIAA1267 gene, 
respectively (data not shown). 
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Tab. 3. Rare CNVs (de novo or inherited) identified in the ASD cohort by means of array CGH analysis. 
 
ID Sex Phenotype 
Chromosome 
band 
Gain/ 
Loss 
Size Genes Total Physical position
#
 Inheritance 
           Array CGH 244K 
1 F 
AU, severe ID, 
EP 
Xp22.11 Gain 99 kb EIF2S3, ZFX  2 chrX:24091852-24190826 pat 
           2  M AU, ID 1p34.1 Loss 108 kb JMJD2A 3 chr1:44149337-44257788 pat 
   5q23.1 Loss 222 kb  / chr5:119532516-119755412 pat 
           3  M HF-AU 3p21.31 Gain 173 kb CSPG5, SMARCC1 2 chr3:47578922-47752329 pat 
   20p12.1 Loss 85 kb MACROD2 1 chr20:15055853-15140973 mat 
           4  M AU, ID 10p12.31 Gain 106 kb  / chr10:22394622-22500888 pat 
           5  F PDD-NOS 18q21.1 Gain 51 kb  1 chr18:47902251-47953250 mat 
   21q21.3 Gain 52 kb  PDE9A 1 chr21:44168808-44220396 mat 
           6  M AU, ID 4q23 Gain 81 kb TSPAN5 1 chr4:99393391-99474056 de novo 
           7  M PDD-NOS 2p23.1 Loss 34 kb LCLAT1 1 chr2:30814684-30848349 mat 
   8q12.1 Gain 45.5 kb PLAG1 1 chr8:57052812-57098333 pat 
           8  M HF-AU 4p15.2 Loss 54 kb  / chr4:28107488-28161143 mat 
   7q11.23 Gain 51 kb  1 chr7:72745047-72795632 mat 
   18q22.1 Gain 139 kb  / chr18:61838447-61977366 mat 
           9 M AU, ID, EP, 
BM 
5q14.3 Loss 25 kb GPR98 1 chr5:90287474-90312790 mat 
  5q23.1 Gain 23 kb PRR16 1 chr5:119982811-120005757 pat 
           
10 M AU, ID 2q14.2q14.3 Gain 3.9 Mb 
CLASP1, C1QL2, DBI, EN1, 
EPB41L5, GLI2, MARCO, 
PCDP1, PTPN4, RALB, 
RNU4ATAC, SCTR 
20 chr2:119130298-123004562 pat 
   3q26.1 Gain 185 kb  / chr3:165221892-165406558 mat 
11  M PDD-NOS 4q23 Gain 35 kb RAP1GDS1 1 chr4:99227050-99262338 pat 
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Tab 3. Continued. 
12 M AU, ID 11q14.2 Gain 36 kb ME3 1 chr11:86370779-86407258 mat 
          13 M HF-AU 13q21.1 Loss 218 kb  / chr13:56137534-56355454 pat 
   13q31.1 Loss 77 kb   / chr13:84541850-84619100 mat 
          14  M S-AU 9q34.3 Gain 442.5 kb CACNA1B, EHMT1 2 chr9:140527202-140969676 de novo 
   Xq22.3 Gain 24 kb IL1RAPL2 1 chrX:104155507-104179536 mat 
           15  M AU, ID 15q26.2 Loss 38 kb  MCTP2 1 chr15:94783059-94819771 mat 
           16  M PDD-NOS 17q23.1 Gain 44 kb CA4 1 chr17:58206236-58249853 de novo 
           17 M PDD-NOS 12p13.1 Gain  69 kb   / chr12:14400276-14468981 pat 
   12p12.2p12.1 Loss 387 kb  3 chr12:21017576-21404166 mat 
   14q13.1 Gain 131 kb CFL2, SNX6  2 chr14:35062258-35193276 pat 
           18 M PDD-NOS 6q21 Loss 47 kb PREP 1 chr6:105824080-105871245 de novo 
           19 M AS Yq11.21 Gain 449 kb USP9Y 1 chrY:14492654-14941561 pat 
           20§* M HF-AU 8q12.1 Gain 45.5 kb PLAG1 1 chr8:57052812-57098274 mat 
           21  M HF-AU 5q31.3 Gain 76 kb ARHGAP26 1 chr5:142148254-142224066 mat 
           22  M AU, ID 3p14.1 Gain 94 kb ADAMTS9 1 chr3:64408148-64502388 mat 
   6q25.2 Loss 15 kb IPCEF1 2 chr6:154614264-154628947 pat 
           23 M PDD-NOS 17q21.31 Loss 748 kb  ACBD4, CRHR1, FMNL1 10 chr17:43193251-43941693 de novo 
   17q24.2 Loss 93 kb  PRKCA 1 chr17:64341093-64433941 mat 
           24 M AU, ID 9p24.2 Loss 191 kb RFX3 1 chr9:3454648-3645936 de novo 
   13q12.11 Gain 363 kb MPHOSPH8, PSPC1, ZMYM5  4 chr13:20181070-20544241 mat 
           25 M HF-AU 10p11.21 Gain 61 kb PARD3 1 chr10:35044586-35105887 mat 
   10p11.21 Gain 223 kb CCNY, CREM 2 chr10:35485580-35708979 mat 
   15q13.3 Gain 377 kb CHRNA7 2 chr15:32085731-32462701 mat 
   16p11.2 Gain 538 kb 
ALDOA, ASPHD1, CDIPT, 
C16orf53, DOC2A, FAM57B, 
GDPD3, HIRIP3, INO80E, 
KCTD13, KIF22, MAPK3, MAZ, 
MVP, QPRT, PPP4C, PRRT2, 
SEZ6L2, SPN, TAOK2, YPEL3 
27 chr16:29652999-30190568 pat 
   17q21.31 Loss 8 kb VAT1 2 chr17:41159926-41167557 pat 
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Tab 3. Continued. 
26 F 
PDD-NOS, 
severe ID 
6p22.3 Loss 67 kb  / chr6:22696464-22763720 de novo 
   11q14.1 Loss 46 kb DLG2 1 chr11:84239601-84285477 mat 
           27 M AU, ID 1q44 Loss 242 kb SMYD3 1 chr1:246143162-246385329 pat 
   2p11.2 Gain 217 kb POLR1A, REEP1 5 chr2:86289130-86506034 mat 
          
   22q11.21 Gain 2.6 Mb 
AIFM3, ARVCF, CDC45, 
CLDN5, CLTCL1, COMT, 
CRKL, DGCR2, DGCR6, 
DGCR6L, DGCR8, DGCR14, 
GNB1L, GP1BB, GSC2, HIRA, 
KLHL22, LZTR1, MED15, 
MRPL40, PI4KA, PRODH, 
RANBP1, RTN4R, SEPT5, 
SLC7A4, SLC25A1, SNAP29, 
TBX1, TRMT2A, TXNRD2, 
UFD1L, ZDHHC8, ZNF74 
44 chr22:18894835-21505417 de novo 
           28 M AU, ID 21q22.3 Gain 40 kb DIP2A, PCNT 2 chr21:47864658-47904775 mat 
           29 M AU, ID 4p15.1 Gain 1.1 Mb PCDH7 1 chr4:30096956-31196169 mat 
          
   15q11.1q13.1 Gain 8.0 Mb 
ATP10A, C15orf2, CYFIP1, 
GABRA5, GABRB3, GABRG3, 
MAGEL2, MKRN3, NDN, 
NIPA1, NIPA2, SNRPN, 
SNURF, TUBGCP5, cluster 
snoRNAs, UBE3A 
~80 a chr15:20575646-28535051 de novo 
           30§ M AU, ID 3p35.3-p25.2 Gain 145 kb  2 chr3:11732027-11876792 no mat 
   7q11.23 Gain 95 kb PTPN12 1 chr7:77126596-77221182 no mat 
   16p13.11 Gain 800 kb NDE1 8 chr16:15492317-16292235 no mat 
   22q11.22 Loss 200 kb  1 chr22:23046186-23245888 mat 
           31§ F PDD-NOS 7q22.1 Loss 260 kb CUX1 1 chr7:101463620-101723676 NA 
   22q11.22 Loss 524 kb ZNF280A 5 chr22:22721907-23245888 NA 
           32 F AU, ID 10p14 Gain 349 kb  / chr10:10587763-10936503 mat 
   10p12.31 Gain 22 kb  / chr10:20790681-20812664 pat 
   22q11.21 Loss 120 kb DGCR6, PRODH 2 chr22:18890271-19010508 mat 
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Tab 3. Continued. 
33 M AU, ID 2p23.1 Loss 34 kb LCLAT1 1 chr2:30814684-30848349 mat 
   9p24.3 Gain 107 kb DOCK8 1 chr9:254654-361777 pat 
   9p24.3 Gain 78 kb KANK1 1 chr9:509521-587418 pat 
   20p12.1 Loss 103 kb MACROD2 1 chr20:14653662-14756452 pat 
           34§ M S-PDD 13q14.3 Loss 68 kb RNASEH2B 2 chr13:51530516-51598396 mat 
                     35§ M PDD-NOS, 
language delay 
12q24.31 Loss 93 kb MPHOSPH9 2 chr12:123585931-123678954 pat 
  Xp22.31 Gain 414 kb NLGN4X 1 chrX:6,031,746-6,445,321 mat 
           36 M AU, ID 7q11.23 Loss 26 kb HSPB1 2 chr7:75913642-75939538 de novo 
   10q22.2 Loss 24 kb CAMK2G, NDST2 3 chr10:75559706-75583870 de novo 
   15q22.2 Loss 48 kb  1 chr15:59776382-59824713 de novo 
           37  M AU, ID 6q12 Loss 260 kb  1 chr6:66158720-66418279 pat 
   8q24.3 Loss 33 kb MAPK15 3 chr8:144766624-144799957 mat 
           38§ M PDD-NOS 9p24.1 Gain 102 kb GLDC, JMJD2C 2 chr9:6641759-6743452 mat 
   12p13.33 Gain 262 kb CACNA1C 1 chr12:2205044-2467239 pat 
   12p13.33p13.32 Gain 489 kb PRMT8  2 chr12:3169239-3658542 pat 
   16p11.2 Gain 659 kb 
ALDOA, ASPHD1, CDIPT, 
CORO1A, C16orf53, DOC2A, 
FAM57B, GDPD3, HIRIP3, 
INO80E, KCTD13, KIF22, 
MAPK3, MAZ, MVP, QPRT, 
PPP4C, PRRT2, SEZ6L2, 
SULT1A3, SPN, TAOK2, YPEL3 
31 chr16:29673954-30332581 mat 
           39§ F PDD-NOS 9p24.1 Gain 102 kb GLDC, JMJD2C 2 chr9:6641759-6743452 mat 
   12p13.33 Gain 262 kb CACNA1C 1 chr12:2205044-2467239 pat 
   12p13.33p13.32 Gain 489 kb PRMT8 2 chr12:3169239-3658542 pat 
   16p11.2 Gain 659 kb 
ALDOA, ASPHD1, CDIPT, 
CORO1A, C16orf53, DOC2A, 
FAM57B, GDPD3, HIRIP3, 
INO80E, KCTD13, KIF22, 
MAPK3, MAZ, MVP, QPRT, 
PPP4C, PRRT2, SEZ6L2, 
SULT1A3, SPN, TAOK2, YPEL3 
31 chr16:29673954-30332581 mat 
                    
54 
 
Tab 3. Continued. 
40
§ M AS 9p22.3p22.2 Loss 119 kb  1 chr9:16591045-16710334 mat 
   20p12.1 Loss 78 kb MACROD2 1 chr20:14685390-14763042 pat 
           41§ M TS 6p12.1 Gain 31 kb  1 chr6:56917608-56948694 pat 
   18q23 Loss 28 kb PARD6G 1 chr18:77982067-78010032 mat 
   20p12.1 Loss 78 kb MACROD2 1 chr20:14685390-14763042 pat 
           42 M AU, ID 4q22.1 Loss 25 kb GRID2 1 chr4:93565167-93590451 NA 
   18q23 Gain 55 kb MBP, ZNF236 2 chr18:74671482-74726694 NA 
43 M AS 3p22.3 Gain 63 kb ARPP21 1 chr3:35807767-35870363 pat 
   3q23 Gain 245 kb XRN1 3 chr3:141839309-142083916 pat 
   16q23.1 Loss 78 kb CFDP1 1 chr16:75343357-75421614 mat 
           44 M AU, ID 3p26.1 Gain 287 kb GRM7 1 chr3:7474361-7761159 mat 
   18q22.1 Gain 139 kb  / chr18:61838447-61977366 mat 
           45§ M AU, ID 17q23.3 Loss 23 kb CSH1, GH2  2 chr17:61954172-61977250 mat 
           46 F AU, ID 1q43 Loss 78 kb PLD5 1 chr1:242364270-242442157 pat 
           47 M AS 4p15.31 Gain 139 kb  / chr4:19301430-19440122 mat 
   7q11.21 Loss 74 kb ZNF138 1 chr7:64204753-64278830 pat 
           48 M AU, ID 3q27.1 Gain 46 kb AP2M1, DVL3 3 chr3:183872255-183917986 pat 
           49 M AU, ID 5q12.1 Gain 242 kb KIF2A, IPO11 3 chr5:61618444-61860338  pat 
   18q22.1 Gain 127 kb  / chr18:62131257-62258013  mat 
           Array CGH 44K 
50 M PDD-NOS 15q11.2 Loss 211 kb 
CYFIP1, NIPA1, NIPA2, 
TUBGCP5 
4 chr15:22873688-23085096 de novo 
           
51 F PDD-NOS 2q14.3q21.3 Loss 8.8 Mb 
ACMSD, ARHGEF4, BIN1, 
CCDC115, ERCC3, FAM123C, 
FAM168B, GPR17, GPR39, 
GPR148, HS6ST1, LYPD1, 
MAP3K2, MGAT5, NCKAP5, 
PLEKHB2, RAB6C, 
RAB3GAP1, TUBA3D, TUBA3E 
50 chr2:127083045-135910585 de novo 
           
52
§* F PDD-NOS 7q11.23 Gain 1.4 Mb 
BAZ1B, BCL7B, CLDN3, 
CLDN4, CLIP2, EIF4H, FZD9, 
GTF2I, GTF2IRD1, LAT2, 
LIMK1, STX1A, TRIM50 
24 chr7:72726578-74139390 de novo 
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Tab 3. Continued. 
53 M PDD-NOS 2q31.3q32.3 Loss 11.1 Mb 
FRZB, GLS, GULP1, HIBCH, 
INPP1, ITGA4, NAB1, NCKAP1, 
NEUROD1, ORMDL1, PDE1A, 
STAT1, STAT4, TMEFF2, 
UBE2E3, ZNF804A  
54 chr2:181882353-193007633 de novo 
   Xp11.4 Gain 103 kb  2 chrX:37850095-37953580 mat 
           54 M AU, ID 1p36.32 Gain 304 kb  2 chr1:2857518-3161082 pat 
           55 F S-AU, ID 1q24.2 Gain 399 kb SELE, SELL  8 chr1:169413880-169812887 mat 
          
   15q11.2 Gain 203 kb 
CYFIP1, NIPA1, NIPA2, 
TUBGCP5 
4 chr15:22873688-23076420 mat 
           56 M PDD-NOS 16p11.2 Loss 162 kb SH2B1 9 chr16:28837450-28998957 de novo 
           
57 F PDD-NOS 5q31.1q31.2 Gain 3.8 Mb 
CAMLG, C5orf20, CDC23, 
CDC25C, CXCL14, DDX46, 
FAM13B, FAM53C, FBXL21, 
H2AFY, IL9, KIF20A, KLHL3, 
LECT2, NEUROG1, PITX1, 
SAR1B, SEC24A, SLC25A48, 
SPOCK1, WNT8A 
31 chr5:133871536-137708167 de novo 
           58 M PDD-NOS 15q23 Loss 85 kb  2 chr15:69192894-69277766 mat 
           59 M AU, ID 8p23.3 Gain 654 kb ARHGEF10, DLGAP2  5  chr8:1434838-2088785 mat 
   19q13.2 Gain 94 kb B9D2, BCKDHA 5 chr19:41836441-41930226 NA 
           
60 M AU, ID 5p15.33p15.31 Loss 7.8 Mb 
ADCY2, AHRR, CEP72, 
C5orf38, EXOC3, IRX1, IRX2, 
IRX4, LPCAT1, NSUN2, 
PDCD6, SDHA, SLC6A3, 
SRD5A1, TPPP, ZDHHC11 
36 chr5:95243-7859564 de novo 
          
   18p11.32p11.22 Gain 9.1 Mb 
ADCYAP1, ARHGAP28, 
DLGAP1, EPB41L3, LAMA1, 
NDUFV2, PTPRM, RAB12, 
TGIF1, THOC1, USP14 
34 chr18:180229-9281969 de novo 
             Xq22.2 Gain 175 kb TMSB15B 2 chrX:103094005-103269195 NA 
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 Array CGH 8x60K        
61 M PDD-NOS Xq28 Gain 246 kb 
ATP6AP1, FLNA, IKBKG, 
PLXNA3, RPL10 
16 chrX:153576890-153822717 NA 
           62§* M S-AU Xp22.31 Gain 1.5 Mb STS, PNPLA4  4 chrX:6551155-8032120 NA 
           63 M PDD-NOS Xp22.31 Gain 551 kb STS  2 chrX:7269569-7820659 NA 
   Yp11.2 Gain 878.5 kb   / chrY:8028838-8907306 NA 
           #Physical position of the identified CNVs based on UCGC Genome Browser, hg19, released February 2009; §familiar cases: patients 30 and 31, son and mother, patients 34 and 35 first cousins, patients 38-39 and 40-41 siblings, the 
mother of patient 45 shows autistic traits but she has not been included in the analyzed ASD cohort; 
§*
sibling with a similar phenotype who does not carry the same genetic anomaly.  
AS, Asperger syndrome; AU, full autism; BM, brain malformations; EP, epilepsy; HF-AU, high-functioning autism; ID, intellectual disability; NA, not available; PDD-NOS, pervasive developmental disorder not otherwise specified; 
S-AU, syndromic autism; S-PDD-NOS, syndromic PDD-NOS; TS, Tourette syndrome.  
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5.2. Analysis of the gene content of the identified rare CNVs 
The ad hoc analysis of the rare CNV gene content using databases revealed a total of 276 genes that 
were considered good candidates for ASD. A detailed list of the selected genes is shown in Table 4, 
which reports the genes affected by rare CNVs localized to genomic regions that are not involved in 
recurrent genomic rearrangements, and in Table 4.1, which conversely reports those genes affected by 
rare CNVs localized to genomic regions that are either involved in recurrent rearrangements 
responsible for some microdeletion/microduplication syndromes that are comorbid with ASD or have 
been proposed by linkage studies as candidate loci for ASD or other neuropsychiatric disorders.  
A small percentage of the selected genes (~11%) (depicted in red in Tabs. 4 and 4.1) have been 
previously reported as causative genes based on mutations and/or CNVs, often de novo, that have been 
described in autistic patients. Moreover, SNPs in a very few genes (~5%) (depicted in purple in Tabs. 
4 and 4.1) have been significantly associated with ASD. However, most of the proposed candidate 
genes (54%) have not been previously reported in association with ASD, and a significant percentage 
(30.5%) have been involved in some microdeletion/microduplication syndromes that are comorbid 
with ASD (depicted in dark red in Tabs. 4 and 4.1) (Fig. 16). 
 
 
Fig. 16. Schematic view of the classification of the collected genes, based on their previous implication in ASD. 
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On the basis of gene expression data, function, and pathway of action, all the selected genes contribute 
to CNS neurodevelopment and maintenance, acting during embryonic and foetal development as well 
as in the early postnatal period and, in some cases, in adult life. Sixty-six of the 276 selected genes are 
implicated in neurogenesis and neurodevelopment (24%), 27 in CNS metabolism (10%), 29 in 
synaptogenesis and synaptic plasticity (10.5%), 19 in CNS development, homeostasis, and 
immunosurveillance mediated by the immune system (7%), 81 in intracellular signaling and 
trafficking (29%), and 51 in transcriptional and translational regulation and chromatin remodeling 
(18.5s%), as shown in Fig. 17. For 3 of the 276 genes, the function is still unknown (1%). 
 
Fig. 17. Schematic view of the different pathways of action that contribute to neurodevelopment and 
maintenance. CNS, central nervous system; IS, immune system. 
 
A detailed analysis of the 276 selected genes is reported in Tabs. 4 and 4.1, where each gene box is 
depicted with a different color to indicate the specific gene function. Of note, 89 of 276 selected genes, 
which are indicated in the following tables with light blue boxes or with a star shape, contribute to 
CNS development and maintenance acting in concert with the immune system.  
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Tab. 4. Detailed list of the genes potentially perturbed by the identified rare CNVs and possible implicated in ASD pathogenesis
 
(UCSC Genome 
Browser, hg19, release February 2009)
§
. 
 
Gene name Function and expression Interactors and possible role in brain 
Findings in ASDs o rin  other neuropsychiatric 
disorders 
References 
      
ADAMTS9(-)* 
 
Organogenesis 
This gene encodes the ADAM metallopeptidase 9 with 
thrombospondin type 1 motif protein. 
Members of the ADAMTS family have been implicated in 
the cleavage of proteoglycans and the control of organ shape 
during development. 
 
Expression detected in all fetal tissues. 
The ADAM and the related ADAMTS metalloproteinases are 
membrane-anchored and secreted proteins exhibiting key roles 
in mediating cell adhesion, proteolytic shedding, and cell 
signaling. Dysregulation of these proteins has been observed in 
some pathologic states, including cancers. Indeed, ADAMTS9 
was aberrantly expressed by primary malignant pl ma cells. 
During mouse development ADAMTS9 expression in the CNS 
is limited to the floor plate of the diencephalon, to the 
ventricular zone of the cerebral cortex and to the choroid plexus. 
Mutations and/or CNVs affecting ADAMTS9 have never 
been reported in patients with ASD. 
Bret et al., 2011 
Jungers et al., 2005 
      
AP2M1(+) 
 
Intracellular membrane 
trafficking: clathrin-
mediated endocytosis 
This gene encodes the adaptor-related protein complex 2, mu 
1 subunit, which is a subunit of the heterotetrameric coat 
assembly protein complex 2 (AP2). The encoded protein is 
required for the activity of a vacuolar ATPase, which is 
responsible for proton pumping occurring in the acidification 
of endosomes and lysosomes. The encoded protein may also 
play an important role in regulating the intracellular 
trafficking and function of CTLA-4 protein.  
 
Moderate expression in fetal brain and good expression in 
postnatal CNS. 
It is well known that clathrin-mediated endocytosis is crucial for 
the normal functioning and integrity of neurons in the CNS.  
Recently, it has been demonstrated that expression of coat 
proteins changes during postnatal development in selected areas 
of the rat brain. This finding supports the hypothesis that  
proteins that conform the intracellular transport machinery in 
the brain cells seems to accompany development, according to 
the maturation of the different brain areas. 
Mutations and/or CNVs affecting AP2M1 have never 
been reported in patients with ASD. 
 
Mutations in the AP1S2 gene, encoding the sigma1B 
subunit of the clathrin-associated adaptor protein complex 
(AP)-1, are responsible for a clinically recognizable 
XLMR and autism syndrome associating hypotonia, 
delayed walking, speech delay, aggressive behavior, brain 
calcifications, and elevated CSF protein levels.  
Borck et al., 2008 
Borgonovo et al., 2012 
      
 
ARHGAP26(-)* 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the Rho GTPase activating protein 26 
which binds to focal adhesion kinase and mediates the 
activity of the GTP binding proteins RhoA and Cdc42. 
Focal adhesion kinase is one of the protein involved in the 
signaling cascades that regulate the organization of the actin-
cytoskeleton which mediate the interaction of a cell with the 
extracellular matrix. 
 
Quite high expression in postnatal parietal and occipital 
lobes, cerebellum peduncles, and hypothalamus. 
Moderate expression in immune cell types. 
The Rho GTPases, RhoA and Cdc42, are involved in neuronal 
morphogenesis, axonal guidance and synaptic plasticity by 
modulating the organization of actin cytoskeleton. 
The same pathway is involved in T-cells activation, migration, 
and cell-cell adhesion. 
Mutations and/or CNVs affecting ARHGAP26 have never 
been reported in patients with ASD.  
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both the TSC1 and TSC2 proteins 
activate RhoA whereas TSC2 activates CdC42, thus 
regulating cell adhesion and migration. 
Fombonne et al., 1997 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Wiznitzer, 2004 
Wong, 2006 
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ARHGEF10(+) 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the Rho guanine nucleotide exchange 
factor (GEF) 10 protein.  
Rho GTPases play a fundamental role in numerous cellular 
processes that are initiated by extracellular stimuli that work 
through G protein coupled receptors. The encoded protein 
may form complex with G proteins and stimulate Rho-
dependent signals.  
 
Moderate expression in fetal brain and good expression in 
postnatal brain, in particolar in prefrontal cotex, amygdalaee 
and hypothalamus. 
High expression in immune cell types. 
RhoGTPases play a pivotal role in regulating the actin 
cytoskeleton and influence cell polarity, microtubule dynamics, 
membrane-transport pathways, and transcription-factor activity. 
Numerous evidence has implicated RhoGTPases in neuronal 
morphogenesis, including cell migration, axonal growth 
and guidance, dendrite elaboration and plasticity, and 
synapse formation.  
RhoGEFs activate RhoGTPases by catalyzing the exchange of 
bound GDP for GTP, which induces a conformational change in 
the GTP-bound GTPase that allows its interaction with 
downstream effector proteins, thus playing a central role in 
defining the temporal and spatial activation of the corresponding 
GTPase within neuronal cells. 
In particular, ARHGEF10 is mostly involved in peripheral nerve 
development. 
Mutations and/or CNVs affecting ARHGEF10 have never 
been reported in patients with ASD. However, mutations 
in ARHGEF10 have been aasociated to slowed nerve-
conduction velocities, a biological endophenotype in the 
majority of the hereditary motor and sensory 
neuropathies. In addition, a weak association of SNPs in 
ARHGEF10 with SCZ has been reported. 
 
RhoGEFs have been previously implicated in human 
genetic disorders: 
- a mutation in the DH domain of FGD1 
GEF cosegregates with faciogenital dysplasia, a 
developmental disorder;  
- mutations in ARHGEF6 are associated with 
X-linked nonsyndromic MR; 
- aberrant EphB/Ephexin5 signaling during the 
development of synapses may contribute to the abnormal 
cognitive function that occurs in AS and, possibly, ASD. 
Boguski and McCormick 
1993 
Bourne et al., 1990 
Etienne-Manneville and Hall 
2002 
Hart et al., 1994 
Kutsche et al., 2000  
Margolis et al., 2010 
Pasteris et al., 1994 
Verhoeven et al., 2003 
      
ARPP21(-)* 
 
Intracellular signaling: 
regulation of CaM-
dependent signaling 
This gene encodes the cAMP-regulated phosphoprotein, 
21kDa. The encoded protein is enriched in the caudate 
nucleus and cerebellar cortex.  
 
Very high expression in fetal brain and in postnatal CNS.  
ARPP21 may act as a competitive inhibitor of calmodulin-
dependent enzymes such as calcineurin in neurons. Indeed, 
ARPP21, also known as regulator of calmodulin (CaM) 
signaling (RCS), when phosphorylated by protein kinase A 
binds to CaM and inhibits CaM-dependent signaling. RCS 
expression is high in the dorsal striatum, nucleus accumbens and 
amygdalaee, suggesting that the protein is involved in limbic-
striatal function. 
In mouse a similar protein is enriched in the central extended 
amygdalaee. Moreover, it may be involved in regulating the 
effects of dopamine in the basal ganglia.  
Recently, it has been demonstrated that the regulator of 
calmodulin signaling knockout mice display anxiety-like 
behavior and motivational deficits. 
Mutations and/or CNVs affecting ARPP21 have never 
been reported in patients with ASD.  
Becker et al., 2008 
Davis et al., 2012 
      
ATP6AP1(+) 
 
Intracellular membrane 
trafficking: 
neurotransmitter uptake 
This gene encodes the ATPase, H+ transporting, lysosomal 
accessory protein 1, which is a component of a multisubunit 
enzyme that mediates acidification of eukaryotic intracellular 
organelles. The encoded protein is approximately 45 kD and 
may assist in the V-ATPase-mediated acidification of 
neuroendocrine secretory granules. 
 
Good-high expression in fetal brain and in postnatal CNS. 
The vacuolar (H+)-ATPase (V-ATPase) is a universal proton 
pump and its activity is required for a variety of cell-biological 
processes such as membrane trafficking, receptor-mediated 
endocytosis, lysosomal protein degradation, osteoclastic bone 
resorption and maintenance of acid-base homeostasis by renal 
intercalated cells. In neuronal and neuroendocrine cells, the V-
ATPase is the major regulator of intragranular acidification 
which is indispensable for correct prohormone processing and 
neurotransmitter uptake. 
Mutations and/or CNVs affecting ATP6AP1 have never 
been reported in patients with ASD.  
 
Recurrent Copy Number gains at Xq28 including 
ATP6AP1 have been reported in mentally retarded 
patients. 
Jansen and Martens, 2012 
Vandewalle et al., 2009 
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Tab. 4. Continued. 
BCKDHA(-)* 
 
Branched-chain amino 
acid catabolism 
This nuclear gene encodes the branched chain keto acid 
dehydrogenase E1, alpha polypeptide, which is a subunit of 
an innter mitochondrial enzyme complex that catalyzes the 
second major step in the catabolism of the branched-chain 
amino acids leucine, isoleucine, and valine.  
 
Moderate expression in postnatal whole brain. 
In the brain, metabolism of the essential branched chain 
aminoacids (BCAAs) leucine, isoleucine, and valine, is 
regulated in part by protein synthesis requirements. Excess 
BCAAs are catabolized or excreted. The first step in BCAA 
catabolism is catalyzed by the branched chain aminotransferase 
(BCAT) isozymes. A product of this reaction, glutamate, is the 
major excitatory neurotransmitter and precursor of the major 
inhibitory neurotransmitter GABA. The BCATs are thought to 
participate in a α-keto-acid nitrogen shuttle that provides 
nitrogen for synthesis of glutamate from α-ketoglutarate. 
The branched-chain α-ketoacid dehydrogenase enzyme complex 
(BCKDC) catalyzes the second, irreversible step in BCAA 
metabolism, which is oxidative decarboxylation of the 
branched-chain α-ketoacid (BCKA) products of the BCAT 
reaction.  
 
Defects in BCKDHA are a cause of maple syrup urine disease 
type IA. MSUD is an autosomal recessive disorder 
characterized by mental and physical retardation, feeding 
problems, and a maple syrup odor to the urine. 
In individuals with MSUD, the oxidation of BCAAs is inhibited 
and, therefore, intake of BCAAs above the daily requirement for 
protein synthesis causes accumulation of BCAAs and their 
BCKAs to toxic level. If left untreated, most patients experience 
seizures, changes in muscletone, and coma due to brain 
swelling. Analysis of MSUD brains by magnetic resonance 
diffusion imaging spectroscopy suggests impaired brain energy 
metabolism. Neurological disorders frequently involve 
disruption of the proper balance of these excitatory (glutamate) 
and inhibitory (GABA) neurotransmitters, which result in 
altered excitability. 
Mutations or CNVs affecting BCKDHA have never been 
reported in patients with ASD.  
 
Inactivating mutations affecting BCKDK (Branched 
Chain Ketoacid Dehydrogenase Kinase) have been 
reported in consanguineous families with autism, EP, and 
ID. The encoded protein is responsible for 
phosphorylation-mediated inactivation of the E1-α 
subunit of branched chain ketoacid dehydrogenase 
(BCKDH). 
Cole et al., 2012 
Novarino et al., 2012 
      
B9D2(+) 
 
Ciliogenesis: regulation 
of microtubule 
cytoskeleton dynamics 
This gene encodes the B9 protein domain 2, which is 
exclusively found in ciliated organisms. The gene is 
upregulated during mucociliary differentiation, and the 
encoded protein localizes to basal bodies and cilia. 
Disrupting expression of this gene results in ciliogenesis 
defects.  
 
Good expression in fetal brain and moderate expression in 
postnatal parietal and temporal lobes, and in thalamus.  
B9D2, as well as KIF2A, belongs to kinetochore and is involved 
in the microtubule-bound to the kinetochore. KIF2A, the kinesin 
heavy chain member 2A protein, may regulate microtubule 
dynamics during axonal growth. By analogy, also B9D2 is 
probably involved in brain development. 
Mutations and/or CNVs affecting B9D2 have never been 
reported in patients with ASD.  
 
Mutations in human genes encoding the B9 domain-
containing proteins (MKS1, B9D1, and B9D2) cause 
Meckel syndrome, a severe ciliopathy characterized by 
occipital encephalocele, liver ductal plate malformations, 
polydactyly, and kidney cysts.  
Dowdle et al., 2011 
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Tab. 4. Continued. 
CA4(+) 
de novo 
 
Ecitatory synaptic 
plasticity  
This gene encodes the carbonic anhydrase IV, which belongs 
to a large family of zinc metalloenzymes that catalyze the 
reversible hydration of carbon dioxide. They participate in a 
variety of biological processes, including respiration, 
calcification, acid-base balance, bone resorption, and the 
formation of aqueous humor, cerebrospinal fluid, saliva, and 
gastric acid. 
The protein CA4 has been found in the endothelium of the 
choriocapillaris in eyes and no detectable levels are found in 
renal capillaries. 
 
Good expression in postnatal brain and cerebellum. 
The presence of extracellular carbonic anhydrases in the CNS 
was detected in physiological studies of rat hippocampal slices. 
The enzymes are indirectly implicated in regulation of 
excitatory synaptic transmission, because the curtailment of 
extracellular alkaline shifts by extracellular carbonic anhydrases 
was shown to limit postsynaptic NMDA receptor activation 
during synchronous neural activity.  
The principal isoforms of carbonic anhydrases in the brain are 
CA4 and CA14, and both enzymes catalyze the buffering of 
activity-dependent pHe transients.  
 
Defects in CA4 are the cause of retinitis pigmentosa type 17.  
Mutations and/or CNVs affecting CA4 have never been 
reported in patients with ASD.  
 
Carbonic anhydrase II (CA II) deficiency in man is an 
autosomal recessive disorder manifest by osteopetrosis, 
renal tubular acidosis, cerebral calcification, growth 
retardation and MR. 
 
Rare single gene mutations affecting CA6 has been 
reported in a few autistic patients. 
Bucan et al., 2009 
Fedirko et al., 2007 
Parkkila et al., 2001 
Shah et al., 2005 
Sly et al., 1991 
Tong et al., 2000 
      
CACNA1C(-)* 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the calcium channel, voltage-dependent, L 
type, alpha 1C subunit. Calcium channels mediate the influx 
of calcium ions into the cell upon membrane polarization, 
and they are involved in a variety of calcium-dependent 
processes, including muscle contraction, hormone or 
neurotransmitter release, gene expression, cell motility, cell 
division and cell death. 
 
Good-high expression in fetal brain and in postnatal temporal 
lobe, prefrontal and cingulate cortex, and amygdalaee. 
CACNA1C is most frequently implicated in coupling of cell 
membrane depolarization to transient increase of the membrane 
permeability for calcium, leading to activation and, potentially, 
changes in intracellular signaling pathway activity, gene 
transcription, and synaptic plasticity. It is involved in the proper 
function of numerous neurological circuits including those 
involving the hippocampus, amygdalaee, and mesolimbic 
reward system, which are strongly implicated in psychiatric 
disease pathophysiology.  
In particular, it has been reported that a gain of function 
mutation in CACNA1C may result in an inappropriate activation 
of the ERK cascade as seen in a subset of autistic patients. 
Defects in CACNA1C are the cause of Timothy 
syndrome, which is comorbid with ASD.  
Moreover, mutations in CACNA1C have been associated 
to depression and SCZ. 
 
Mutations affecting different CACNA genes, such as 
CACNA1F and CACNA1H, have been previously reported 
in idiopathic or syndromic patients with ASD. 
Bhat et al., 2012 
Hemara-Wahanui et al., 2005 
Kalkman, 2012 
Splawski et al., 2004, 2006 
      
CAMK2G(-) 
de novo 
 
Intracellular Wnt/Ca
2+
 
signaling pathway  
This gene encodes the calcium/calmodulin-dependent protein 
kinase II gamma, which is one of the four subunits of an 
enzyme which belongs to the serine/threonine protein kinase 
family, and to the Ca(2+)/calmodulin-dependent protein 
kinase subfamily. Calcium signaling is crucial for several 
aspects of plasticity at glutamatergic synapses.  
 
High expression in fetal brain and in postnatal CNS.  
Calcium/calmodulin-dependent protein kinase type II (CaMKII) 
is a highly abundant serine/threonine kinase comprising a 
significant fraction of total protein in mammalian forebrain and 
forming a major component of the postsynaptic density. 
CaMKII is essential for certain forms of synaptic plasticity and 
memory consolidation and this is mediated through substrate 
binding and intramolecular phosphorylation of holoenzyme 
subunits. It has been suggested that cellular specific pattern of 
the different isoforms of the holoenzyme subunits might play a 
role in propagating the type of recurrent neuronal activity 
associated with disorders such as temporal lobe EP. 
 
CAMK2G is involved in the Wnt/Ca2+ signaling which is 
mediated through G proteins and phospholipases and leads to 
transient increases in cytoplasmic free calcium that 
subsequently activate the kinase PKC (protein kinase C) and 
CAMKII (calcium calmodulin mediated kinase II) and the 
phosphatase calcineurin. 
Mutations and/or CNVs affecting CAMK2G have never 
been reported in patients with ASD. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Liu and Murray, 2012 
Okerlund and Cheyette, 2011 
Wang et al., 2010  
Zhang et al., 2012 
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CCNY(-)* 
 
Intracellular Wnt 
signaling pathway  
This gene encodes the cyclin Y protein. Cyclins, such as 
CCNY, control cell division cycles and regulate cyclin-
dependent kinases (e.g., CDC2). CCNY acts as a cell-cycle 
regulator of Wnt signaling pathway during G2/M phase by 
recruiting CDK14/PFTK1 to the plasma membrane and 
promoting phosphorylation of LRP6, leading to the 
activation of the Wnt signaling pathway. 
 
Moderate expression in postnatal CNS.  
CCNY directly interacts with CDK14, the cyclin-dependent 
kinase 14, which plays a role in neuron differentiation and/or 
function.  
CDK14/cyclin Y complex promotes Wnt signaling through 
phosphorylation of the LRP6 co-receptor, a key regulatory 
nexus in the Wnt/beta-catenin pathway, thus suggesting that this 
pathway might orchestrate mitotic processes. 
Mutations and/or CNVs affecting CCNY have never been 
reported in patients with ASD. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
Davidson and Niehrs, 2010 
De Ferrari and Moon, 2006 
Jiang et al., 2009 
Okerlund and Cheyette, 2011 
Wang et al., 2010  
Zhang et al., 2012 
       
CFDP1(-) 
 
Embryonal development 
This gene encodes the craniofacial development protein 1, 
which may play a role during embryogenesis. 
 
Good expressione in fetal brain and in postnatal CNS, in 
particolar in temporal lobe, prefrontal cortex, amygdalaee, 
thalamus, and hypothalamus. 
Good expression in immune cell types. 
It has been suggested that CP27, a mouse homologous of human 
CFDP1, has a role in organogenesis.  
CFDP1 is a substrate of CSNK2A1, the casein-kinase 2 alpha 
which is ubiquitously expressed in different brain regions and 
phosphorylates several proteins with a known role in brain 
development (e.g. STX1A, L1CAM). 
Mutations and/or CNVs affecting CFDP1 have never 
been reported in patients with ASD.  
 
SNPs in STX1A showed nominal associations with HF-
AU.  
A missense mutation in L1CAM has been reported in an 
adult male patient with L1 disease and autism. 
Iwashita et al, 1999 
Luan and Diehwisch, 2002 
Nakamura et al., 2008, 2011 
Risinger and Bennett, 1999 
Simonati et al., 2006 
Wong et al., 1996 
      
CFL2(+) 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encode the cofilin 2 protein, an intracellular 
protein that is involved in the regulation of actin-filament 
dynamics in a pH-sensitive manner.  
 
Low expression in fetal brain and high expression in 
postnatal CNS.  
The activity of CFL2 is directly regulated by the opposite 
functions of LIMK1, a protein kinase, and SSH1 (slingshot 
homolog 1 of Drosophila), a protein phosphatase, both involved 
in brain development. Indeed, the activity of cofilin is repressed 
by phosphorilation by LIM kinase and is reactived by 
dephosphorilation by SSH1. LIMKs are activated by Rho family 
GTPases via actions of their downstream effectors, such as Rho-
associated kinase (ROCK) and p21-activated kinase (PAK). 
Thus, LIMKs seem to play a critical role in stimulus-induced 
actin cytoskeletal remodeling by linking the signal from Rho 
family GTPases to the change in cofilin activity. This regulation 
is essential in controlling growth cone motility and morphology 
and neurite extension.  
 
Mutations in CFL2 cause nemaline myopathy type 7, a form of 
congenital myopathy. 
Mutations and/or CNVs affecting CFL2 have never been 
reported in patients with ASD. 
 
Rho GTPases, RhoA and Cdc42, are involved in neuronal 
morphogenesis, axonal guidance and synaptic plasticity 
by modulating the organization of actin cytoskeleton. 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA whereas TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
Agrawal et al., 2007 
Endo et al., 2003 
Fombonne et al., 1997 
Galkin et al., 2011 
Lewis et al., 2004 
Meyer and Feldman, 2002 
Muzykewicz et al., 2007 
Samiere and Bamburg, 2004 
Wiznitzer, 2004 
Wong, 2006 
       
 
CREM(-)* 
 
Trascriptional regulation  
This gene encodes the cAMP responsive element modulator 
protein, which is a transcription factor that binds to the 
cAMP responsive element found in many viral and cellular 
promoters. It is an important component of cAMP-mediated 
signal transduction during the spermatogenetic cycle, as well 
as other complex processes. Alternative promoter and 
translation initiation site usage allows this gene to exert 
spatial and temporal specificity to cAMP responsiveness.  
 
Moderate expression in postnatal whole brain and good 
expression in amygdalaee. 
The family of CREB (cAMP response element-binding protein) 
transcription factors are involved in a variety of biological 
processes including the development and plasticity of the 
nervous system. In the maturing and adult brain, CREB genes 
are required for activity-dependent processes, including 
synaptogenesis, refinement of connections and long-term 
potentiation. 
By examining CREB1-CREM(-/-) mouse mutants, it has been 
demonstrated that the lack of CREB/CREM genes, specifically 
in neural and glial progenitors, leads to migration abnormalities 
during brain development and that CREB/CREM transcription 
factors negatively regulate early synaptogenesis and 
spontaneous network activity. 
A rare inherited CNV involving CREM has been reported 
in a patient with ASD and ID. 
Aguado et al., 2009 
Diaz-Ruiz et al., 2008 
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CSH1(-) 
 
Organogenesis, 
intrauterine growth 
This gene encodes the chorionic somatomammotropin 
hormone 1, which is a member of the somatotropin/prolactin 
family of hormones and plays an important role in growth 
control. The gene is located at the growth hormone locus on 
chromosome 17 along with four other related genes. 
It is produced only during pregnancy and is involved in 
stimulating lactation, fetal growth and metabolism. 
 
Good expression in fetal brain and in postnatal temporal, 
parietal and occipital lobes, and cerebellum. 
Pituitary GH1/IGF-I axis may play an important role in CNS 
functions, including those associated with neuronal growth, 
development, and protection. Furthermore, the GH1/IGF axis 
may play a role in influencing aspects of mood and cognition. 
GH-binding sites have been identified in several areas of the 
brain, including the choroid plexus, putamen, thalamus, 
pituitary, hippocampus, and cortex.. It has been demonstrated 
that GH modulates synaptic efficacy of hippocampal neurons 
and itself is regulated during memory formation, learning 
processes, and emotional experiences. 
 
Somatotropin/prolactin hormonedeficiency may cause 
intrauterine growth restriction (IUGR), which has an effect on 
the hippocampus structure that correlates with behavioural 
problems in preterm infants. 
Mutations and/or CNVs affecting CSH1 have never been 
reported in patients with ASD. 
 
A few autistic patients showing growth hormone 
deficiency have been reported. 
Devillard et al., 2010 
Donahue et al., 2006 
Gingell et al., 1996 
Lodygensky et al., 2008 
Ragusa et al., 1993 
Zearfoss et al., 2008 
     
CSPG5(+) 
 
Neuronal growth 
This gene encodes the chondroitin sulfate proteoglycan 5, 
also known as neuroglycan C, which is a proteoglycan that 
functions as a neural growth and differentiation factor.  
 
Very high and specific expression in fetal brain and in 
postnatal CNS.  
Neuroglycan C (NGC) is a transmembrane-type chondroitin 
sulfate proteoglycan that is exclusively expressed in the CNS. 
Both protein kinase C (PKC) inhibitors and phosphatidylinositol 
3-kinase (PI3K) inhibitors attenuated the NGC-mediated neurite 
outgrowth in a dose-dependent manner, suggesting that NGC 
promotes neurite outgrowth via PI3K and PKC pathways. 
 
NGC directly interacts with GOLPH3, the golgi phosphoprotein 
3, which is involved in modulation of mTOR signaling, that is 
in turn regulated by both TSC1 and TSC2. 
Mutations and/or CNVs affecting CSPG5 have never 
been reported in patients with ASD. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2.  
Fombonne et al., 1997 
Hassel et al., 2003 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Nakanishi et al., 2006 
Wiznitzer, 2004 
Wong, 2006 
      
 
CUX1(-) 
 
Transcriptional 
regulation  
This gene encodes the cut-like homeobox 1 protein, which is 
a member of the homeodomain family of DNA binding 
proteins. It may regulate gene expression, morphogenesis, 
and differentiation and it also has a role in the cell cycle 
progession. 
 
Low expression in fetal brain, moderate expression in 
postnatal CNS, in particolar in prefrontal cortex, cerebellum 
and cerebellum peduncles.  
Good-high expression in immune cell types. 
CUX1 is a regulator of brain development. It is co-expressed 
with EN2 during CNS development and throughout the 
postnatalhood. Mouse Cux1 regulates dendritic branching, spine 
morphology and synapse formation in cerebral cortex, which 
contributes to cognitive circuitry. 
 
CUX1 mediates changes in the chromatin conformation and 
influences V(D)J recombination in B-cells. 
Mutations and/or CNVs affecting CUX1 have never been 
reported in patients with ASD. 
 
SNPs in EN2 have previously been associated with ASD.  
Benayed et al., 2005 
Choi et al., 2012 
Cubelos et al., 2010  
Gharani et al., 2004  
Goebel et al., 2002 
Hulea and Nepveu, 2012 
Li et al., 2010 
       
DIP2A(-)* 
 
Neurogenesis: axon 
patterning 
This gene encodes the DIP2 disco-interacting protein 2, 
homolog A (Drosophila), which is involved in axon 
patterning in the CNS.  
 
Low expression in fetal brain, and in postnatal CNS, escept 
for prefrontal cortex and hypothalamus where expression is 
good.  
High expression in immune cell types. 
DIP2A is the plasma membrane receptor for follistatin-like 1 
protein, FSTL1, which has been implicated in diverse disease 
processes as a regulator of inflammatory cytokine expression. 
Mutations and/or CNVs affecting DIP2A have never been 
reported in patients with ASD.  
 
DIP2A has been proposed as a candidate gene for 
dyslexia. 
Adams et al., 2010 
Poelmans et al., 2009 
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DLGAP2(SAPAP2) 
(+) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the discs, large (Drosophila) homolog-
associated protein 2, which is one of the membrane-
associated guanylate kinases localized at postsynaptic density 
in neuronal cells. This protein is an adapter protein linking 
ion channel to the subsynaptic cytoskeleton and plays a role 
in the molecular organization of synapses and in neuronal 
cell signaling.  
 
High expression in fetal brain and in postnatal CNS, in 
particolar in thalamus and amygdalaee. 
NMDA neurotransmitter receptors and SAPAP2 (DLGAP2) are 
integral components of post-synaptic macromolecular signaling 
complexes that serve to propagate glutamate responses 
intracellularly. Recently, NMDA receptor subtype-specific 
binding sites, that mediate direct interactions with scaffold 
protein SAPAP2, have been identified. 
Furthermore, DLGAP2 binds to SHANK2, which acts as a link 
between the post-synaptic receptor on the plasma membrane and 
the cytoskeleton, and directly interacts with NLGN4X. 
A de novo CNV involving DLGAP2 has been reported in 
a patient with ASD. 
 
Mutations and/or CNVs affecting SHANK2 and NLGN4X 
have been previously reported in autistic patients. 
Baris et al., 2007 
Berkel et al., 2010, 2012 
Bolliger et al., 2001 
Cousins and Stephenson, 
2012 
Jamain et al., 2003 
Kent et al., 2008b 
Laumonnier et al., 2004  
Lawson-Yuen et al., 2008 
Leblond et al., 2012 
Marshall et al., 2008  
Pinto et al., 2010 
      
DLG2(-) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the discs, large homolog 2 (Drosophila) 
protein, which is a member of the membrane-associated 
guanylate kinase (MAGUK) family. The encoded protein 
forms a heterodimer with a related family member that may 
interact at postsynaptic sites to form a multimeric scaffold for 
the clustering of receptors, ion channels, and associated 
signaling proteins.  
 
Good expression in fetal brain, very high expression in 
postnatal CNS. 
DLG2 is part of the postsynaptic protein scaffold of excitatory 
synapses; it is required for perception of chronic pain through 
NMDA receptor signaling and is involved in regulation of 
synaptic stability at cholinergic synapses.  
 
DLG2 interacts with NMDA glutamate receptors GRIN2A and 
GRIN2B, as well as with other proteins of the postsynaptic 
scaffold such as DLGAP1 and DLGAP4 and cytoskeleton 
proteins such as MAP1A. 
Mutations and/or CNVs affecting DLG2 have never been 
reported in patients with ASD. 
 
DLG2 is deleted in SCZ in a study of Genome-Wide 
Copy Number Variation and shows a reduction in protein 
expression in post-mortem brain samples from 
schizophrenics. Moreover, mouse knockouts of DLG2 
show hypofunction of NMDA receptor signaling, a 
process implicated in SCZ. 
 
It has been reported that DLG4 gene disruption in mice 
produces a complex range of behavioral and molecular 
abnormalities relevant to autism spectrum disorders and 
Williams' syndrome. 
 
A SNP in GRIN2B has been associated with ASD in 
Korean patients. A de novo GRIN2B mutation has been 
reported in an autistic patient. 
 
SNPs in GRIN2A have been associated with SCZ. Two de 
novo GRIN2A mutations has been reported in SCZ 
patients. 
Barnby et al., 2005 
Feyder et al., 2010 
MacLaren et al., 2011 
Tarabeux et al., 2011 
Walsh et al., 2008 
Yoo et al., 2012 
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DOCK8(-)* 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the dedicator of cytokinesis 8 protein, 
which is a member of the DOCK180 family of guanine 
nucleotide exchange factors. GEFs proteins interact with Rho 
GTPases and are components of intracellular signaling 
networks.  
 
It is expressed at low levels in brain tissue. 
In mammalian cells, the DOCK family of proteins have roles in 
regulating cytoskeletal reorganization, which is important for 
neuronal and immune function.  
DOCK8 is involved in the reorganization of the actin filament 
system through its direct interaction with CDC42, RhoJ, and 
RhoK.  
The interaction between DOCK8 and Cdc42-is critical for 
interstitial dendritic cell migration through the interstitium and 
for the polarity changes necessary for T-cell activation and 
function. Indeed, both B and T-cells from DOCK8 mutant mice 
form defective immunological synapses and have abnormal 
functions, in addition to impaired immune memory 
development.  
 
In humans, mutations in DOCK8 result in the autosomal 
recessive form of the hyper-IgE syndrome. It is a rare disorder 
of immunity characterized by immunodeficiency, recurrent 
infections, eczema, increased serum IgE, eosinophilia and lack 
of connective tissue and skeletal involvement.  
Two de novo 9p24 terminal deletion including DOCK8 
and ANKRD15 have been reported in a female and a male 
patient with ASD. The male patient presented also a 
gonadal dysgenesia. 
DOCK8 disrupton has been reported in two patients with 
MR and developmental disabilities. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2.  
Both TSC1 and TSC2 proteins activate RhoA whereas 
TSC2 activates CdC42, thus regulating cell adhesion and 
migration. 
Fombonne et al., 1997 
Griggs et al., 2008 
Harada et al., 2012 
Jabara et al., 2012 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Ounap et al., 2004 
Ruusala and Aspenstrom, 
2004 
Vinci et al., 2007 
Wiznitzer, 2004 
Wong, 2006 
      
DVL3(+) 
 
Intracellular Wnt 
signaling pathway  
This gene encodes the dishevelled, dsh homolog 3 protein, 
which is a member of a multi-gene family that shares strong 
similarity with the Drosophila dishevelled gene, dsh. The 
Drosophila dishevelled gene encodes a cytoplasmic 
phosphoprotein that regulates cell proliferation.  
 
Moderate expression in fetal brain and in postnatal CNS. 
DVL3 plays a role in the signal transduction pathway mediated 
by multiple Wnt genes.  
In a recent genome-wide analysis of repressive histone 
methylation in nucleus accumbens of mice subjected to chronic 
social defeat stress, numerous genes were identified where 
stress induced changes in histone methylation in susceptible but 
not resilient mice. A prominent gene was dishevelled (DVL)-2, 
a key step in the WNT-Frizzled signaling cascade. Indeed, 
under basal conditions, DVL is maintained in the cytoplasm in 
an inactive, depolymerized form. WNT, secreted from afferent 
cells, activates Frizzled, a plasma membrane receptor, which 
then triggers the binding and polymerization of DVL. DVL 
activation leads to its binding of Axin, phosphorylation and 
inhibition of glycogen synthase kinase-3β (GSK3β), and the 
regulation of several downstream targets, including β-catenin.  
 
More recently, a concerted regulation of multiple proteins in this 
pathway, including all three isoforms of DVL (DVL1–3) and 
GSK3β, has been demonstrated in susceptible but not resilient 
mice, and provide direct, causal evidence that such regulation 
represents a prodepression-like maladaptation that promotes 
susceptibility to chronic stress.  
Mutations and/or CNVs affecting DVL3 have never been 
reported in patients with ASD. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Gao and Chen, 2010 
Okerlund and Cheyette, 2011 
Wang et al., 2010  
Wilkinson et al., 2009, 2011 
Zhang et al., 2012 
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EIF2S3(-)* 
 
Translational regulation  
This gene encodes the eukaryotic translation initiation factor 
2 protein, which functions in the early steps of protein 
synthesis by forming a ternary complex with GTP and 
initiator tRNA. 
 
Moderate expression in fetal brain and in postnatal 
amygdalaee and hypothalamus.  
Another member of the eukaryotic translation initiation factor 
proteins, EIF4E, plays a key role in learning and memory 
through its control of translation within the synapse. EIF4E 
mediated translation is the final common process modulated by 
mTOR (upstream regulator of EIF4E), PTEN and FRMP 
pathways, which are implicated in autism.  
Mutations and/or CNVs affecting EIF2S3 have never 
been reported in patients with ASD. 
 
A chromosome translocation t(4;5) which likely 
interrupted an alternative transcript of EIF4E, has been 
identified in a boy with a classical autism. 
Mutations in EIF4E promoter harboured by two autistic 
siblings and one of the parents have been reported in two 
unrelated autism families. 
Neves-Pereira et al., 2009 
       
 
FLNA(-)* 
 
Neurodevelopment: actin 
cytoskeleton organization 
This gene encodes filamin A, alpha protein which is an actin-
binding protein that crosslinks actin filaments and links actin 
filaments to membrane glycoproteins. FLNA is involved in 
remodeling the cytoskeleton to effect changes in cell shape 
and migration.  
 
Expressed at moderate levels in brain. 
Very high expression in immune cell types. 
FLNA is associated with a broad range of congenital disorders 
affecting multiple organs. Loss-of-function mutations, although 
lethal in males, result in defective neuronal migration leading to 
periventricular nodular heterotopia (PVNH) in females. On the 
contrary, clustered missense mutations are associated with a 
diverse spectrum of congenital malformations in males and 
females, referred to as otopalatodigital spectrum disorders.  
 
It has recently been reported a direct interaction between FLNA 
and SHANK3 (whose mutations cause syndromic ASD) in 
mouse brain extracts. 
One patient with ASD, carrying a duplication at Xq28 
which encompasses the entire FLNA gene, has been 
recently reported.  
 
Recurrent Copy Number gains at Xq28 including FLNA 
have been reported in mentally retarded patients. 
Lian et al., 2012 
Robertson, 2005 
Sakai et al., 2011 
Vandewalle et al., 2009 
      
GH2(-) 
 
Organogenesis, 
intrauterine growth 
This gene encodes the growth hormone 2, which is a member 
of the somatotropin/prolactin family of hormones that play 
an important role in growth control. The gene, along with 
four other related genes, is located at the growth hormone 
locus on chromosome 17 where they are interspersed in the 
same transcriptional orientation; an arrangement which is 
thought to have evolved by a series of gene duplications. The 
five genes share a remarkably high degree of sequence 
identity. 
 
Good expression in fetal brain and low expression in 
postnatal CNS. 
Pituitary GH1/IGF-I axis may play an important role in CNS 
functions, including those associated with neuronal growth, 
development, and protection. Furthermore, the GH1/IGF axis 
may play a role in influencing aspects of mood and cognition. 
GH-binding sites have been identified in several areas of the 
brain, including the choroid plexus, putamen, thalamus, 
pituitary, hippocampus, and cortex.. It has been demonstrated 
that GH modulates synaptic efficacy of hippocampal neurons 
and itself is regulated during memory formation, learning 
processes, and emotional experiences. 
 
Somatotropin/prolactin hormonedeficiency may cause 
intrauterine growth restriction (IUGR), which has an effect on 
the hippocampus structure that correlates with behavioural 
problems in preterm infants.  
Mutations and/or CNVs affecting GH2 have never been 
reported in patients with ASD. 
 
A few autistic patients showing growth hormone 
deficiency have been reported. 
Devillard et al., 2010 
Donahue et al., 2006 
Gingell et al., 1996 
Lodygensky et al., 2008 
Ragusa et al., 1993 
Zearfoss et al., 2008 
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Tab. 4. Continued. 
GLDC(+)* 
 
Glycine metabolism 
This nuclear gene encodes the mitochondrial glycine 
dehydrogenase protein. Degradation of glycine is brought 
about by the glycine cleavage system, which is composed of 
four mitochondrial protein components: P protein (a 
pyridoxal phosphate-dependent glycine decarboxylase), H 
protein (a lipoic acid-containing protein), T protein (a 
tetrahydrofolate-requiring enzyme), and L protein (a 
lipoamide dehydrogenase). The protein encoded by this gene 
is the P protein, which binds to glycine and enables the 
methylamine group from glycine to be transferred to the T 
protein.  
 
Good-high expression in fetal brain and in postnatal whole 
brain, in particular in prefrontal cortex, cerebellum, 
amygdalaee and hypothalamus. 
Defects in GLDC are a cause of non-ketotic hyperglycinemia 
(NKH), also known as glycine encephalopathy (GCE). NKH is 
an autosomal recessive disease characterized by accumulation 
of a large amount of glycine in body fluid and by severe 
neurological symptoms.  
The majority of glycine encephalopathy presents in the neonatal 
period. The neonatal form manifests in the first hours to days of 
life with progressive lethargy, hypotonia, and myoclonic jerks 
leading to apnea and often death. Surviving infants have 
profound ID and intractable seizures.  
The infantile form is characterized by hypotonia, developmental 
delay, and seizures. The atypical forms range from milder 
disease, with onset from late infancy to adulthood, to rapidly 
progressing and severe disease with late onset. 
Mutations and/or CNVs affecting GLDC have never been 
reported in patients with ASD. 
Hamosh et al., 2009 
      
GPR98(-) 
 
CNS development 
This gene encodes the G protein-coupled receptor 98, which 
contains a 7-transmembrane receptor domain and binds 
calcium.  
 
Good expression in fetal brain, and generally low expression 
in postnatal tissues except for postnatal CNS, where the 
expression is .good 
In situ hybridization studies with mouse embryo sections have 
shown that high level expression of GPR98 is restricted to the 
developing CNS and eye and strong expression in the 
ventricular zone, home of neural progenitor cells during 
embryonal neurogenesis, have suggested a fundamental role for 
GPR98 in the development of the CNS. 
 
Mutations in GPR98 are associated with Usher syndrome 2 and 
familial febrile seizures. Indeed, GPR98 is one of the disease-
causing genes for EP, which include SCN1A. 
Mutations and/or CNVs affecting GPR98 have never 
been reported in patients with ASD. 
 
Rare point mutations affecting SCN1A were found in 
sporadic and familial cases of ASD. 
McMillan et al., 2002 
Munoz-Yunta et al., 2008 
O’Roak et al., 2011  
Wang et al., 2005 
Weiss et al., 2003 
      
GRID2(-) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the ionotropic glutamate receptor delta 2, 
a relatively new member of the family of ionotropic 
glutamate receptors which are the predominant excitatory 
neurotransmitter receptors in the mammalian brain. GRID2 is 
selectively expressed in cerebellar Purkinje cells.  
 
Good expression in postnatal cerebellum and cerebellum 
peduncles. 
GRID2 directly interacts with DLG2 and SHANK2 which act as 
adapter proteins in the postsynaptic density of excitatory 
synapses, interconnecting receptors of the postsynaptic 
membrane and the actin-based cytoskeleton.  
Rare single gene mutations affecting GRID2 has been 
reported in two autistic patients. Moreover, a de novo 
CNV at 4q22.2 including GRID2 has recently been 
reported in an autistic patient. 
 
Mutations and CNVs (de novo and inherited) affecting 
SHANK2 have been reported in patients with ASD. 
Berkel et al., 2010, 2012 
He et al., 2012 
Leblond et al., 2012 
Pinto et al., 2010 
Schaaf et al., 2011 
Uemura et al., 2004 
y       
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Tab. 4. Continued. 
GRM7(-)* 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the glutamate receptor, metabotropic 7. 
The metabotropic glutamate receptors are a family of G 
protein-coupled receptors that have been divided into three 
groups on the basis of sequence homology, putative signal 
transduction mechanisms, and pharmacologic properties. 
Group I includes GRM1 and GRM5, and these receptors 
have been shown to activate phospholipase C. Group II 
includes GRM2 and GRM3, while Group III includes 
GRM4, GRM6, GRM7 and GRM8. Group II and III 
receptors are linked to the inhibition of the cyclic AMP 
cascade but differ in their agonist selectivities. 
 
It is expressed at a very high level in fetal brain and in many 
areas of the postnatal brain, especially in cerebral cortex, 
hippocampus, and cerebellum.  
L-glutamate is the major excitatory neurotransmitter in the 
central nervous system, and it activates both ionotropic and 
metabotropic glutamate receptors. Glutamatergic 
neurotransmission is involved in most aspects of normal brain 
function and can be perturbed in many neuropathologic 
conditions, including SCZ, alcohol and drug addiction. 
De novo CNVs affecting GRM7 have been recently 
reported in patients with ASD. 
 
Mutations and CNVs affecting GRM5 and GRM8, 
respectively, have been reported in a few autistic patients. 
Choi et al., 2009 
He et al., 2012 
Iossifov et al., 2012 
Serajee et al., 2003 
Vadasz et al., 2007 
      
HSPB1(-) 
de novo 
 
Intracellular signaling: 
neuropreotection 
during stress response 
mediated by activation of 
mTOR pathway 
This gene encodes the heat shock 27kDa protein 1, which is 
induced by environmental stress and developmental changes. 
The encoded protein is involved in stress resistance and actin 
organization and translocates from the cytoplasm to the 
nucleus upon stress induction.  
 
Low expression in fetal brain and in postnatal CNS, except 
for cortex, thalamus and hypoyhalamus where the expression 
is good. 
The stress response involving up-regulation of heat shock 
proteins (Hsps) is a powerful mechanism of cells to deal with 
harmful conditions to which they are exposed throughout life, 
such as hyperthermia, hypoxia, or oxidative stress.  
A direct interaction of HSPB1 with Akt1 (mTOR pathway) 
during stress response has been reported, which results in the 
activation of Akt signal transduction pathway during various 
forms of stress. 
In cultured murine hippocampal neurons it has been 
demonstrated that stress-induced phosphorylation of HspB1 and 
B5 may lead to the translocation from the nucleus to neuronal 
processes and to the binding of these Hsps to their targets at 
synapses and neuronal processes which might provide one 
important mechanism of how they exert their neuroprotective 
effect. 
 
Defects in HSPB1 are a cause of Charcot-Marie-Tooth disease 
type 2F and distal hereditary motor neuropathy.  
Mutations and/or CNVs affecting HSPB1 have never 
been reported in patients with ASD. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
(mTOR pathway) have been reported in patients with 
ASD and Tuberous Sclerosis 1 or 2.  
Capponi et al., 2011 
Fombonne et al., 1997 
Kirbach and Golenhofen, 
2011 
Konishi et al., 1997 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Schmidt et al., 2012 
Wiznitzer, 2004 
Wong, 2006 
      
IKBKG(+) 
 
CNS development: 
myelin formation 
This gene encodes the inhibitor of kappa light polypeptide, 
which is the regulatory subunit of the inhibitor of kappaB 
kinase (IKK) complex, which activates NF-kappaB resulting 
in activation of genes involved in inflammation, immunity, 
cell survival, and other pathways.  
 
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in amygdalaee and thalamus.  
Very high expression in immune cell types. 
Mutations in IKBKG result in incontinentia pigmenti, 
hypohidrotic ectodermal dysplasia, and several other types of 
immunodeficiencies.  
 
Recently, it has been reported that brain abnormalities correlate 
with additional copies of the IKBKG. Indeed, IKBKG 
overexpression causes impaired NF-κB signaling in skin 
fibroblasts derived from patients with white matter anomalies, 
thus further supporting the role of NF-κB signaling in astroglial 
cells for normal myelin formation of the CNS. 
Mutations and/or CNVs affecting IKBKG have never 
been reported in patients with ASD. However, IKBKG 
maps in the genomic region involved in Xq28 duplication 
syndrome (MECP2), which is comorbid with ASD.  
 
NF-κB is an important gene transcriptional factor that 
mediates cellular responses in inflammation, immunity, 
development, cell proliferation and apoptosis. Elevated 
levels of NF-κB have been reported in autistic patients vs. 
controls. 
Malik et al., 2011 
Naik et al., 2011 
Philippe et al., 2012  
Ramocki et al., 2009, 2010 
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Tab. 4. Continued. 
IL1RAPL2(-)* 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the interleukin 1 receptor accessory 
protein-like 2, which is a member of the interleukin 1 
receptor family.  
 
Expressed at low levels in fetal and postnatal brain, in 
particular in frontal and temporal lobes and cerebellum.  
A member of the same family, IL1RAPL1, encodes a 
transmembrane protein that does not seem to be involved in 
interleukin-1 pathway. It interacts with the neuronal calcium 
sensor 1 protein, thus playing a role in the down-regulation of 
voltage-dependent calcium channels activity, in calcium-
dependent exocytosis in excitatory synapses and NGF-induced 
neurite outgrowth. 
 
Both IL1RAPL1 and IL1RAPL2 are located at a genomic region 
on chromosome X previously associated with X-linked non-
syndromic MR. Recently, it has been reported that both 
IL1RAPL1 and IL1RAPL2 can induce excitatory pre-synapse 
differentiation and dendritic spine formation. 
SNPs affecting IL1RAPL2 have been recently associated 
with ASD.  
 
Mutations, CNVs and chromosomal rearrangements 
involving IL1RAPL1 have been reported in patients with 
ASD associated or not with XLMR. 
Bhat et al., 2008 
Chung et al., 2011 
Kantojärvi et al., 2011 
Piton et al., 2008 
Pinto et al., 2010 
Valnegri et al., 2011 
Yoshida et al., 2011 
       
 
 
 
IPCEF1(-) 
 
Intracellular ARF6 
signaling: regulation of 
cytoskeleton dynamics 
and membrane 
trafficking 
This gene encodes the interaction protein for cytohesin 
exchange factors 1. 
 
High expression in fetal brain and very high expression in 
postnatal CNS. 
Very high expression in immune cell types. 
IPCEF1 has been reported to interact with the low weight ARF 
GEF (ADP-ribosylation factor GTP exchange factors) proteins 
of the cytohesin family (in particular cytohesin 2/ARNO) and 
function by modulating the cytohesin activity by stimulating the 
formation of ARFGTP (including ARF6GTP which is particularly 
active in brain). The interaction of cytohesin 2 and IPCEF1 in 
mammalian cells was demonstrated by immunoprecipitation.  
A regulatory role for cytohesin 2 in dendritic branching and 
axonal elongation and branching during neuritogenesis, 
particularly with respect to cytoskeletal dynamics, has been 
demonstrated as well as a role in endosomal dynamics during 
neurite elongation in hippocampal neurons has been recently 
reported. 
 
Cytohesin regulates the activation of RhoA in primary dendritic 
cells (DCs). Cytohesin-1 and RhoA are both required for the 
induction of chemokine-dependent conformational changes of 
the integrin beta-2 subunit of DCs during adhesion. 
Mutations and/or CNVs affecting IPCEF1 have never 
been reported in patients with ASD. 
Hernández-Deviez et al., 
2004, 2007 
Hernández-Deviez and 
Wilson, 2005 
Jaworski, 2007 
Quast et al., 2009 
Venkateswarlu, 2003 
     
IPO11(-)* 
 
Synapto-nuclear 
trafficking 
This gene encodes the importin 11 protein. Importins, 
including IPO11, are a members of the karyopherin/importin-
beta family of transport receptors that mediate 
nucleocytoplasmic transport of protein and RNA cargoes. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in prefrontal and cingulated cortex. 
It is known that retrograde axonal injury signaling stimulates 
cell body responses in lesioned peripheral neurons and that 
importins are involved in retrograde transport. Recently, it has 
been reported that multiple transcription factors are found in 
axons and associate with dynein in axoplasm from injured 
nerve. For example, axonal STAT3 is locally translated and 
activated upon injury, and is transported retrogradely with 
dynein and importin α5 to modulate survival of peripheral 
sensory neurons after injury.  
Mutations and/or CNVs affecting IPO11 have never been 
reported in patients with ASD. 
Ben-Yaakov et al., 2012 
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Tab. 4. Continued. 
JMJD2A(-) 
(KDM4A) 
 
Chromatin remodeling 
This gene encodes the lysine (K)-specific demethylase 4A 
protein, which functions as a trimethylation-specific 
demethylase, converting specific trimethylated histone 
residues to the dimethylated form, and acts as a 
transcriptional repressor. 
 
Good expression in fetal cerebellum, postnatal cortex and 
cerebellum. 
JMJD2A interacts with NCOR1, the nuclear receptor co-
repressor 1, which mediates transcriptional repression by certain 
nuclear receptors. Together with SIN3A and MECP2, it is part 
of a complex which promotes histone deacetylation and the 
formation of repressive chromatin structures which may impede 
the access of basal transcription. 
Mutations and/or CNVs affecting JMJD2A have never 
been reported in patients with ASD. 
 
A SNP in JMJD2C has been associated with ASD in 
Finnish samples. 
 
MECP2 mutations or deletions cause Rett syndrome 
(comorbidity with autism) in female, and congenital 
encephalopathy or non syndromic ID in males. 
Abdul-Rahman and Hudgins, 
2006 
Auger et al., 2011 
Carney et al., 2003 
Kantojärvi et al., 2010 
Mount et al., 2003 
Schaefer and Lutz, 2006 
Zappella et al., 2003 
Zhang et al., 2005 
      
JMJD2C(-)* 
(KDM4C) 
 
Chromatin remodeling 
This gene encodes the lysine (K)-specific demethylase 4C 
protein, which is a member of the Jumonji domain 2 
(JMJD2) family. This nuclear protein functions as a 
trimethylation-specific demethylase, converting specific 
trimethylated histone residues to the dimethylated form. 
 
Good-high expression in fetal brain and in postnatal 
prefrontal cortex, cerebellum, cerebellum peduncles, and 
amygdalaee. 
JMJD2C interacts with androgen receptor in vitro and in vivo. 
Assembly of ligand-bound androgen receptor and JMJD2C on 
androgen receptor-target genes results in demethylation of 
trimethyl H3K9 and in stimulation of androgen receptor-
dependent transcription. 
A SNP in JMJD2C has been associated with ASD in 
Finnish samples. 
 
The GGN polymorphism in exon 1 of the AR (androgen 
receptor) gene has been associated with ASD 
susceptibility with gender specificity: the rare 20-repeat 
allele has been reported undertransmitted to male cases 
and the 23-repeat allele overtransmitted to female cases. 
Henningsson et al., 2009 
Kantojärvi et al., 2010 
Wissmann et al., 2007 
     
KANK1(-)* 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the KN motif and ankyrin repeat domains 
1 protein, which belongs to the Kank family of proteins that 
contain multiple ankyrin repeat domains.  
KANK1 functions in cytoskeleton formation in a RhoA-
dipendent manner by regulating actin polymerization and is a 
candidate tumor suppressor for renal cell carcinoma.  
 
Mild expression in fetal brain, good expression in postnatal 
CNS, in particolar in prefrontal cortex, amygdalaee, thalamus 
and hypothalamus.   
Defects in KANK1 (ANKRD15) are the cause of cerebral palsy 
spastic quadriplegic type 2 which is a non-progressive disorder 
of movement and/or posture resulting from defects in the 
developing CNS. Affected individuals manifest congenital 
hypotonia evolving over the first year to spastic quadriplegia 
with accompanying transient nystagmus and varying degrees of 
MR. Neuroimaging shows brain atrophy and ventriculomegaly. 
 
Recently, it has been demonstrated that nucleo-cytoplasmic 
shuttling of human Kank protein accompanies intracellular 
translocation of beta-catenin and, therefore, beta-catenin-
dependent transcription. 
Two de novo 9p24 terminal deletion including DOCK8 
and ANKRD15 have been reported in a female and a male 
patient with ASD. The male patient presented also a 
gonadal dysgenesia. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA whereas TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Fombonne et al., 1997 
Kakinuma et al., 2008 
Lewis et al., 2004 
Lerer et al., 2005 
Muzykewicz et al., 2007  
Okerlund and Cheyette, 2011 
Ounap et al., 2004,  
Vinci et al., 2007 
Wang et al., 2006 
Wang et al., 2010  
Wiznitzer, 2004 
Wong, 2006 
Zhang et al., 2012 
      
 
 
KIF2A(-)* 
 
Intracellular trafficking: 
regulation of microtubule 
cytoskeleton dynamics 
This gene encodes the kinesin heavy chain member 2A, 
which is a plus end-directed motor required for normal 
mitotic progression. The encoded protein is required for 
normal spindle activity during mitosis and is necessary for 
normal brain development.  
 
High expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
Kinesin superfamily proteins (KIFs) are motor proteins that 
transport membranous organelles and macromolecules 
fundamental for cellular functions along microtubules. Their 
roles in transport in axons and dendrites have been studied 
extensively, but KIFs are also used in intracellular transport in 
general.  
KIFs play important roles in higher order neuronal activity; 
transgenic mice overexpressing KIF17, which transports N-
methyl-d-asp (NMDA) receptors to dendrites, show enhanced 
memory and learning. KIFs also play significant roles in 
neuronal development and brain wiring: KIF2A suppresses 
elongation of axon collaterals by its unique microtubule-
depolymerizing activity. 
Mutations and/or CNVs affecting KIF2A have never been 
reported in patients with ASD. 
 
A recurrent 5q12.1 deletion, encompassing KIF2A, has 
been recently reported in four patients in association with 
a phenotype including MR and ocular defects. 
 
A de novo mutation affecting KIF5C has been reported in 
a patient with ASD. 
Awadalla et al., 2010 
Hirokawa and Takemura, 
2004 
Jaillard et al., 2011 
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LCLAT1(-) 
 
Phospholipid metabolism 
This gene encodes the lysocardiolipin acyltransferase 1, 
which has a role in phospholipid metabolism, in particular in 
cardiolipin metabolism. It is required for establishment of the 
hematopoietic and endothelial lineages. 
 
Good expression in fetal brain and postnatal hypothalamus.  
Recently it has been demonstrated that LCLAT1 controls 
mitochondrial DNA fidelity and biogenesis through cardiolipin 
remodeling in response to oxidative stress. 
 
LCLAT1 interacts with LPPR4, the lipid phosphate 
phosphatase-related protein type 4, a protein specifically 
expressed in neurons. It is located in the membranes of 
outgrowing axons and has been shown to be important for 
axonal outgrowth during development and regenerative 
sprouting.  
Mutations and/or CNVs affecting LCLAT1 have never 
been reported in patients with ASD although it is well 
known the involvement of mithocondrial oxidative stress 
response dysfunctions in ASD pathogenesis.  
 
Anti-cardiolipin antibodies have been associated to 
psychiatric disorders such as SCZ, developmental delay 
and autism. 
 
LPPR4 haploinsufficiency has been found in patients 
affected by severe MR and psychomotor development 
delay.  
Chang et al., 2011 
Christie et al., 2011 
Dhillon et al., 2011 
Lehtimaki et al., 2011 
Li et al., 2012 
Mekinian et al., 2012 
van Kuilenburg et al., 2009 
      
MACROD2(-) 
 
CNS development? 
This gene encodes the MACRO domain containing 2 protein, 
which has an unknown function.   
 
Good expression in postnatal parietal and occipital lobes, 
cingulate cortex, subthalamic nucleus, globus pallidus, ciliary 
ganglion and spinal cord. 
The MACROD2 haploinsuffciency may be the cause of Kabuki 
syndrome in a minority of patients. 
A MACROD2 SNP has been associated with ASD (datum 
not replicated in two independent studies). 
 
A de novo CNV affecting MACROD2 has been reported 
in a patient with ADHD. 
Anney et al., 2010 
Curran et al., 2011 
Lionel et al., 2011 
Maas et al., 2007 
Prandini et al., 2012 
      
MAPK15-ERK8(-) 
 
Intracellular MAPK 
signaling: regulation of 
cell growth and 
differentiation  
This gene encodes the mitogen-activated protein kinase 15 
(ERK8), which is involved in cell growth and differentiation. 
 
The protein is ubiquitously expressed. 
Different findings support a role for ERK8 in mainting genomic 
integrity through DNA repair. Moreover, it has been reported by 
an in vitro assay a direct interaction between ERK8 and MBP, 
the myelin basic protein, one of the most abundant protein 
components of the myelin membrane in the CNS, with a role in 
both its formation and stabilization.The major residue in MBP 
phosphorylated by ERK8 (Ser-126) is distinct from that 
phosphorylated by ERK2 (Thr-97), demonstrating that, although 
ERK8 is a proline-directed protein kinase, its specificity is 
distinct from ERK1/ERK2. 
Mutations and/or CNVs affecting MAPK15 have never 
been reported in patients with ASD. 
Abe et al., 2002 
Groehler and Lannigan, 2010 
Klevernic et al., 2006, 2009 
      
 
 
MBP(-)* 
 
Intracellular 
Ras/Raf/ERK1/2 
signaling 
This gene encodes the myelin basic protein, which is a major 
constituent of the myelin sheath of oligodendrocytes and 
Schwann cells in the nervous system. However, MBP-related 
transcripts are also present in bone marrow and immune cell 
types.  
 
Good expression in fetal brain and very high expression in 
postnatal CNS. 
MBP directly interacts with ERK1 (extracellular signal-
regulated kinase 1) and ERK2, which encode the mitogen-
activated protein kinases 3 and 1, respectively.  
It is known that the Ras/Raf/ERK1/2 signaling pathway plays 
important roles in the genesis of neural progenitors, learning and 
memory as well as in death-promoting apoptotic roles in neural 
cells. 
Mutations and/or CNVs affecting MBP have never been 
reported in patients with ASD. 
 
Auto-antibodies anti-MBP were found enriched in ASD 
patient sera, thus implicating an autoimmune reaction in 
ASD pathogenesis. More recently, this datum has not 
been replicated. 
 
Up-regulation of the Ras/Raf/ERK1/2 signaling pathway 
has been found in the brain of autistic subjects and mouse 
animal model. In addition, two studies reported that a 
recurrent deletion on chromosome 16p11.2, which 
includes the MAPK3 (ERK1) gene, is associated with 
autism. 
Libbey et al., 2008 
Mostafa and Al-Ayadhi, 2011 
Singh, 2009 
Stephenson et al., 2011 
Vojdani et al., 2002 
Yang et al., 2011, 2012 
Zimmerman et al., 2007 
Zou et al., 2011 
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MCTP2(-) 
 
Intracellular membrane 
trafficking 
This gene encodes the multiple C2 domains, transmembrane 
2 protein. 
 
Mild expression in postnatal temporal lobe and amygdalaee. 
MCTP2 may be involved in intercellular signal transduction and 
synapse function. 
 
A possible involvement of MCTP2 as a potential novel 
susceptibility gene for SCZ has been reported in genotyping 
studies (37 SNPs across MCTP2) in three independent 
Scandinavian samples. 
 
 
Mutations and/or CNVs affecting MCTP2 have never 
been reported in patients with ASD. 
Djurovic et al., 2009 
Shin et al., 2005 
     
ME3(-)* 
 
Pyruvate metabolism-
glycolysis 
This nuclear gene encodes the mitochondrial protein malic 
enzyme 3, NADP(+)-dependent. Malic enzyme catalyzes the 
oxidative decarboxylation of malate to pyruvate using either 
NAD+ or NADP+ as a cofactor.  
 
High expression in fetal brain and in postnatal CNS, in 
particular in prefrontal cortex, thalamus, hypothalamus, 
amygdalaee, caudate nucleus, and amygdalaee.  
ME3 is involved in the metabolic pathway of glycolysis. Energy 
metabolism is essential for neuronal growth and function.  
 
Proteome analysis of the thalamus and cerebrospinal fluid 
performed post-mortem in patients affected by SCZ reveals 
glycolysis dysfunction. 
Mutations and/or CNVs affecting ME3 have never been 
reported in patients with ASD. 
Martins-de-Souza et al., 2010 
      
MPHOSPH8(+) 
 
Transcriptional 
regulation  
This gene encodes the M-phase phosphoprotein 8, which has 
a role in negative regulation of transcription through 
methylated DNA binding and in cell cycle regulation. 
 
Good-high expression in fetal brain and in postnatal CNS, in 
particular in occipital and parietal lobes, prefrontal cortex, 
amygdalaee, thalamus and hypothalamus. 
High expression in immune cell types. 
 
Mutations and/or CNVs affecting MPHOSPH8 have 
never been reported in patients with ASD. 
Matsumoto-Taniura et al., 
1996 
      
MPHOSPH9(-) 
 
Cell cycle regulation 
This gene encodes the M-phase phosphoprotein 9, which is 
involved in cell cycle regulation.  
 
High expression in fetal brain and in postnatal CNS, in 
particular in cortex, parietal lobe, thalamus and 
hyphotalamus.  
Very high expression in immune cell types.  
A SNP in the MPHOSPH9 locus has recently been associated to 
multiple sclerosis. Indeed, it has been demonstrated that the risk 
allele correlate with diminished MPHOSPH9 RNA expression 
in both lymphoblastic cell lines and in peripheral blood 
mononuclear cells from subjects with multiple sclerosis. Thus, 
MPHOSPH9 might represent a novel inflammatory disease 
locus that could affect autoreactive cell proliferation. 
Mutations and/or CNVs affecting MPHOSPH9 have 
never been reported in patients with ASD. 
IMSGC, 2010 
      
NDST2(-) 
de novo 
 
Heparan sulfate and 
heparin biosynthesis 
This gene encodes the N-deacetylase/N-sulfotransferase 2 
protein, which is a member of the N-deacetylase/N-
sulfotransferase subfamily of the sulfotransferase 1 proteins. 
The encoded enzyme has dual functions in processing 
glucosamine and heparin polymers, including N-
deacetylation and N-sulfation.  
 
Moderate expression in fetal brain and good expression in 
postnatal cortex and thalamus. 
High expression in immune cell types. 
Roles of heparan sulfate (HS) in neural development have been 
well established by using animal models that carry mutations in 
genes encoding enzymes involved in HS synthesis, thus 
revealing that HS is necessary for the specification of certain 
brain structures, such as the cerebellum and the olfactory bulbs, 
cortical neurogenesis, and a variety of axon path-finding 
processes. However, a key unresolved issue concerning is the 
role of HS in the adult brain and its possible relevance to human 
neurological and mental disorders. Several pieces of evidence 
suggest a role for HS in synaptic function as well as in higher 
cognitive function. For example, in adult neurons HS is 
enriched in synapses, especially in the postsynaptic membrane 
of dendritic spines. 
Mutations and/or CNVs affecting NDST2 have never 
been reported in patients with ASD. 
 
The association of autism and other symptoms of mental 
impairment with multiple exostoses in patients carrying 
mutations in HS/HSPG genes has been reported.  
More recently, genetic association has been found 
between autism and the HS3ST5 gene encoding one of the 
HS 3-O sulfotransferases in two large cohorts of 
European ancestry. Furthermore, a genome-wide scan for 
rare CNVs in 996 autism cases has identified four 
independent CNVs in the GPC5/GPC6 gene cluster, 
which encodes the glypican-5 and glypican-6 HSPGs in 
tandem array, on chromosome 13q22. 
Bolton et al.,1995 
Conway et al., 2011 
Ethell and Yamaguchi, 1999  
Hsueh and Sheng 1999 
Inatani et al., 2003  
Irie et al., 2012 
Ishikawa-Brush et al., 1997  
Kantor et al., 2004  
Li et al., 2002  
Matsumoto et al., 2007 
Pinto et al., 2010 
Pratt et al., 2006  
Swarr et al., 2010 
Wang et al., 2009  
Wuyts et al., 2002 
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NLGN4X(-)* 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the neuroligin 4, X-linked protein, which 
is a member of a family of neuronal cell surface proteins. 
Members of this family act as splice site-specific ligands for 
beta-neurexins and are involved in the formation and 
remodeling of the CNS synapses.  
 
Very high expression in the fetal brain and postnatal CNS.  
NLGNX4 directly interacts with neurexinn-1β through Ca2+ to 
form trans-synaptic associations which are required for the 
maturation of glutamatergic excitatory and GABAergic 
inhibitory synapses. 
Mutations and/or CNVs affecting NLGN4X have been 
reported in patients affected by non syndromic ASD, ID, 
Asperger and Tourette syndromes. 
Baris et al., 2007  
Jamain et al., 2003 
Kent et al., 2008b 
Laumonnier et al., 2004  
Lawson-Yuen et al., 2008 
Marshall et al., 2008 
Pampanos et al., 2009 
Zhang et al., 2009 
      
PARD3(-)* 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
for asymmetric cell 
division and polarized 
neuronal growth 
This gene encodes the par-3 partitioning defective 3, 
homolog (C. elegans) protein, which is a member of the 
PARD protein family. PARD family members affect 
asymmetrical cell division and direct polarized cell growth.  
 
Good expression in fetal brain and in postnatal CNS, in 
particular in prefrontal cortex, thalamus and hypothalamus. 
It has been demonstrated that PARD3, a key cell polarity 
determinant, exhibits dynamic distribution in radial glial 
progenitors, thus contributing in asymmetrically dividing of 
these cells which is essential for embryonic neocortex 
development. Indeed, radial glial cells constitute a major 
population of neural progenitor cells in mammals. The division 
of radial glial progenitors can be either symmetrical or 
asymmetrical, which is reflected by the fate of the two daughter 
cells. During the peak phase of neurogenesis, they 
predominantly divide asymmetrically to both self-renew, and to 
produce either a neuron or an intermediate progenitor cell.  
Furthermore, Par3 was shown to play a role in Schwann cell 
myelination. It is recruited by the brain-derived neurotrophic 
factor (BDNF) to the axon-glial interface and regulates Rac1 
activation. During development, active Rac1 signaling is 
localized to the axon-glial interface in Schwann cells by a Par3-
dependent polarization mechanism. 
Mutations and/or CNVs affecting PARD3 have never 
been reported in patients with ASD. 
 
Recently, SNPs in PARD3 have been associated to SCZ 
in Korean patients and to neural tube defects in a Chinese 
Han population. 
 
SNPs in PARD3B have been associated to ASD. 
Anney et al., 2012 
Bultje et al., 2009 
Gao et al., 2012 
Kim et al., 2012 
Tep et al., 2012 
      
 
PARD6G(-) 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
for asymmetric cell 
division and polarized 
neuronal growth 
This gene encodes the par-6 partitioning defective 6 gamma 
protein, which is an adapter protein involved in asymmetrical 
cell division and cell polarization processes through the 
formation of tight junction. The PARD6-PARD3 complex 
links GTP-bound Rho small GTPases to atypical protein 
kinase C proteins. 
  
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in prefrontal cortex, thalamus, 
hypothalamus, caudate nucleus and spinal corde.  
Good expression in immune cell types. 
PARD6G directly interacts with CDC42 and is involved in cell-
cell adhesion process and polarization through the formation of 
tight junction, which are important processes during 
neuritogenesis.  
Moreover, PARD6G is involved in T cell polarity, motility, and 
ability to scan dendritic cells. 
Mutations and/or CNVs affecting PARD6G have never 
been reported in patients with ASD. 
 
SNPs in PARD3B have been associated to ASD. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA whereas TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
Anney et al., 2012 
Da Silva et al., 2003 
Fombonne et al., 1997 
Lewis et al., 2004 
Lisik et al., 2010 
Muzykewicz et al., 2007 
Pertz et al., 2008 
Wiznitzer, 2004 
Wong, 2006 
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PCDH7(+) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the protocadherin 7 protein. It belongs to 
the protocadherin gene family, a subfamily of the cadherin 
superfamily. PCDH7 is an integral membrane protein that is 
thought to function in cell-cell recognition and adhesion.  
 
Moderate expression in fetal brain and good expression in 
postnatal whole brain, in particular in occipital and parietal 
lobes, and in prefrontal cortex.  
In rat brain using in situ hybridization the spatiotemporal 
distribution of mRNAs for 12 non-clustered PCDHs has been 
examined. Some of them (PCDH1, PCDH7, PCDH9, PCDH10, 
PCDH11, PCDH17, and PCDH20) exhibited region-dependent 
expression pattern in the cerebral cortex during the early 
postnatal stage (P3), which is a critical period for the 
establishment of specific synaptic connections, and were also 
expressed in the specific regions of the connecting thalamic 
nuclei. In particular, PCDH7 and PCDH20 mRNAs were 
predominantly expressed in the somatosensory (parietal) and 
visual (occipital) cortices. 
 
PCDH7 binds to PPP1CA, the protein phosphatase 1, catalytic 
subunit, alpha isoform, which is involved in regulation of ionic 
conductances and long-term synaptic plasticity. PPP1CA may 
play an important role in dephosphorylating substrates such as 
the postsynaptic density-associated Ca(2+)/calmodulin 
dependent protein kinase II. 
Mutations and/or CNVs affecting PCDH7 have never 
been reported in patients with ASD. 
 
Homozygous deletion within a protocadherin cluster 
proximal to PCDH10 has been shown to be associated 
significantly with the pathophysiology of cognitive 
impairment such as autism, and recurrent and overlapping 
CNVs, including PCDH9 loci, have been identified in 
autism patients.  
Another delta protocadherin PCDH17 is involved in the 
pathogenesis of SCZ. 
Dean et al., 2007 
Kim et al., 2007, 2011 
Marshall et al 2008  
Morrow et al., 2008  
Yoshida et al., 1999 
       
 
PCNT(-)* 
 
Neurogenesis: regulation 
of microtubule 
cytoskeleton dynamics  
This gene encodes the pericentrin protein, which binds to 
calmodulin and is expressed in the centrosome.  
PCNT is an integral component of the filamentous matrix of 
the centrosome involved in the initial establishment of 
organized microtubule arrays in both mitosis and meiosis. It 
plays a role, together with DISC1, in the microtubule 
network formation, and prevents premature centrosome 
splitting during interphase by inhibiting NEK2 kinase 
activity at the centrosome. 
 
High expression in fetal brain and in postnatal prefrontal 
cortex, moderate expression in amygdalaee and thalamus.  
High expression in immune cell types. 
PCNT binds to DCTN2, the dynactin 2 protein, which 
modulates cytoplasmic dynein binding to an organelle, and 
plays a role in prometaphase chromosome alignment and 
spindle organization during mitosis. It is involved in anchoring 
microtubules to centrosomes and may play a role in synapse 
formation during brain development. 
Moreover, DISC1 localizes to the centrosome by binding to 
PCNT, and PCNT anchors the γ-tubulin complex to the 
centrosome, providing microtubule nucleation sites. Thus 
DISC1–PCNT interaction might be involved in the 
pathophysiology of mental disorders owing to their putative 
effect on centrosomal function. 
Mutations and/or CNVs affecting PCNT have never been 
reported in patients with ASD. 
 
Mutations affecting PCNT cause Seckel syndrome-4 and 
microcephalic osteodysplastic primordial dwarfism type 
II, both characterized by severe microcephaly, thus 
involving the gene in modulating brain size.  
 
Three SNPs in PCNT have been associated with MDD in 
the Japanese population. 
Griffith et al., 2008 
Numata et al., 2009 
Purohit et al., 1999 
Rauch et al., 2008 
      
PDE9A(-)* 
 
Intracellular cAMP and 
cGMP signaling 
This gene encodes the phosphodiesterase 9A protein, which 
catalyzes the hydrolysis of cAMP and cGMP to their 
corresponding monophosphates and plays a role in signal 
transduction by regulating the intracellular concentration of 
these cyclic nucleotides.  
 
Vey high expression in fetal brain, postnatal cerebellum and 
spinal cord. Good expression in postnatal whole brain. 
In rodent CNS PDE9A activity regulates neuronal cGMP 
signaling downstream of multiple neurotransmitter systems 
(dopaminergic, cholinergic, and serotonergic 
neurotransmission), with a possible role in sensory processing 
and memory. Thus, inhibition of PDE9A may provide 
therapeutic benefits in psychiatric and neurodegenerative 
diseases promoted by the dysfunction of these diverse 
neurotransmitter systems. 
Mutations and/or CNVs affecting PDE9A have never 
been reported in patients with ASD. 
 
SNPs in PDE9A have been associated with a 
susceptibility to MDD. 
 
A lower expression of PDE4A and PDE4B in the 
cerebella of subjects with autism compared with matched 
controls has been reported.  
Braun et al., 2007 
Fisher et al., 1998 
Kleiman et al., 2012 
Wong et al., 2006 
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PLAG1(-)* 
 
Transcriptional 
regulation: control of cell 
fate and proliferation  
This gene encodes the pleomorphic adenoma gene 1 protein, 
which is a developmentally regulated zinc finger protein, 
consistently rearranged in pleomorphic adenomas of the 
salivary glands. PLAG1 acts as a transcription factor whose 
activation results in up- regulation of target genes, such as 
IGFII, leading to uncontrolled cell proliferation and, 
possibly, transformation. 
 
Mild expression in postnatal thalamus and hypoyhalamus. 
PLAG1 activation in salivary gland tumors induces a 
transcriptional up-regulation of IGF2 (murine and human 
protein) and beta-catenin (murine protein). 
Moreover, it has been demonstrated in mice that Plag1 controls 
cell fate and proliferation decisions in the developing nervous 
system.  
Mutations and/or CNVs affecting PlAG1 have never been 
reported in patients with ASD. 
 
Aberrant imprinting of IGF2 is associated with BWS and 
SRS, characterized by growth anomalies. Both disorder 
have been reported in patients with ASD. 
Alam et al., 2005 
Kent et al., 2008 
Zhao et al., 2006 
      PLD5(-) 
 
Neurodevelopment 
This gene encodes the phospholipase D family, member 5 
protein. 
 
Good expression in fetal brain. 
PLDs are known to play a key role in neurite outgrowth, 
especially axon outgrowth, in neuronal cells. In particular, 
PLD2 has been shown to regulate metabotropic glutamate 
receptor signaling. 
SNPs affecting PLD5 and PLD2 have been associated 
with a higher risk to develop ASD.   
Anney et al., 2010 
Dhami and Ferguson, 2006 
Kanaho et al., 2009 
     
PLXNA3(+) 
 
Intracellular semaphorin 
signaling: regulation of 
actin cytoskeleton 
dynamics 
This gene encodes the plexin A3 protein, which is a member 
of the plexin class of proteins. It is a coreceptor for SEMA3A 
and SEMA3F and is necessary for signaling by class 3 
semaphorins and subsequent remodeling of the cytoskeleton. 
PLXNA3 plays a role in axon guidance in the developing 
nervous system and it is required for normal dendrite spine 
morphology in pyramidal neurons.  
 
Moderate-good expression in fetal brain and in postnatal 
prefrontal cortex, cerebellum, amygdalaee, thalamus, and 
hypothalamus.  
PLXNA3 directly binds to SEMA3A, a candidate for SCZ, and 
SEMA3F, thus having a role in semaphoring signaling whose 
alterations may have important implications for autism 
pathogenesis.  
SEMA3F is expressed during development along the 
cortical/hippocampal GABAergic neuron migratory pathway. 
Further, its ectopic expression can alter GABAergic neuron 
migration. 
Genetic lesioning studies knocking out different components of 
this signaling system (NPN2, Sema3F, or plexin A3) have 
resulted in animals with extended infrapyramidal mossy fiber 
axonal pathways and spontaneous seizures, suggesting that 
semaphorin signaling is normally associated with experience-
dependent neuronal activity and that experimental 
manipulations decreasing this signaling pathway function are 
closely allied with hyperexcitability and abnormal neuritic 
outgrowth in the hippocampus. 
Mutations and/or CNVs affecting PLXNA3 have never 
been reported in patients with ASD. 
 
Recently, it has been reported a decreased expression of 
axon-guidance receptors suc as PLXNA4 in the anterior 
cingulate cortex in autism. 
Gant et al., 2009 
Giger et al., 2000 
Sahay et al., 2005 
Suda et al., 2011 
Tamamaki et al., 2003 
Tran et al., 2009 
     
POLR1A(-)* 
 
Transcriptional 
regulation 
This gene encodes the RNA polymerase I polypeptide A, 
which is the largest and catalytic core component of RNA 
polymerase I that synthesizes ribosomal RNA precursors. 
 
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in prefrontal cortex and 
cerebellum. 
POLR1A is involved in cell growth and cell cycle progression. 
A duplication involving REEP1-POLR1A has been 
recently detected in three autistic subjects. 
Donati et al., 2011 
Holt et al., 2012 
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PREP(-) 
de novo 
 
CNS metabolism: 
neuropeptide maturation 
and degradation 
This gene encodes the prolyl endopeptidase protein, which is 
a cytosolic prolyl endopeptidase that cleaves peptide bonds 
on the C-terminal side of prolyl residues within peptides that 
are up to approximately 30 amino acids long. Prolyl 
endopeptidases have been reported to be involved in the 
maturation and degradation of peptide hormones and 
neuropeptides. 
 
Good expression in fetal brain and in postnatal whole brain, 
in particular in cortex, cerebellum, amygdalaee and thalamus. 
The prolyl endopeptidase is a phylogenetically conserved serine 
protease and, in humans and rodents, is highly expressed in the 
brain. Several neuropeptides associated with learning and 
memory and neurodegenerative disorders have been proposed to 
be the substrates for PREP, suggesting a possible role for PREP 
in these processes. Indeed, PREP genetrap mice have decreased 
synaptic spine density in the hippocampus, reduced 
hippocampal long-term potentiation, and impaired hippocampal-
mediated learning and memory, thus revealing a possible role 
for PREP in mediating hippocampal plasticity and spatial 
memory formation. 
 
PREP directly binds to TAC1, the tachykinin, precursor 1. 
Tachykinins are active peptides which excite neurons and evoke 
behavioral responses. 
Mutations and/or CNVs affecting PREP have never been 
reported in patients with ASD. 
 
Recently, elevated serum levels of a pro-inflammatory 
neuropeptide, the neurokinin A, which is a member of the 
tachykinin family, have been reported in some autistic 
children. Interestingly, levels of neurokinin A correlated 
to the severity of autism and to serum levels of anti-
ribosomal P protein antibodies, thus supporting the 
pathogenic role of neurokinin A and its possible link to 
autoimmunity in autism.  
D’Agostino et al., 2012 
Mostafa and AL-Ayadhi, 
2011 
       
 
 
PRKCA(-) 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics  
This gene encoder the protein kinase C-alpha, which is a 
member of serine- and threonine-specific protein kinases that 
can be activated by calcium and the second messenger 
diacylglycerol. PKC proteins phosphorylate a wide variety of 
protein targets and are known to be involved in diverse 
cellular signaling pathways. 
 
Moderate expression in postnatal parietal lobe, thalamus, 
subtalamic nucleus, and spinal cord.  
Moderate expression in immune cell types. 
PKCα directly interacts with RhoA and Cdc42 and is involved 
in different pathways such as focal adhesion, the formation of 
tight junctions, the Wnt signaling pathway, and leukocyte 
transendothelial migration, which are known to be involved in 
neurogenesis as well as in immune response. 
  
Recently, it has been demonstrated that Erk1/PKCα pathway in 
mice hippocampal neurons is involved in the signaling activity 
mediated by the brain serotonin 1A receptor (5–HT1A-R), 
which has been implicated in a large number of behavioural 
abnormalities. Indeed, both decreased as well as increased 5–
HT1A-R signaling in the brain have been linked to a number of 
affective disorders.  
Moreover, PKCα has an important role in T-cell function. 
Mutations and/or CNVs affecting PRKCA have never 
been reported in patients with ASD. 
 
SNPs in PRKCB1 have been strongly associated with 
autism. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA, thus regulating cell adhesion and migration. 
Astrinidis et al., 2002 
Fombonne et al., 1997 
Gillberg et al., 1994 
Lewis et al., 2004 
Mogha et al., 2012 
Muzykewicz et al., 2007 
Pfeifhofer-Obermair et al., 
2012 
Philippi et al., 2005 
Slater et al., 2001 
Wiznitzer, 2004 
Wong, 2006 
      
PRMT8(-)* 
 
Post-translation 
modifications: arginine 
methylation 
This gene encodes the protein arginine methyltransferase 8. 
Arginine methylation is a widespread post-translational 
modification mediated by arginine methyltransferases, such 
as PRMT8. Arginine methylation is involved in a number of 
cellular processes, including DNA repair, RNA transcription, 
signal transduction, protein compartmentalization, and 
possibly protein translation  
 
High expression in fetal brain and in postnatal CNS.  
PRMT8 expression was firstly studied in mouse CNS where it 
was demonstrated a broadly distribution in the CNS neurons 
with markedly intense signals in the cerebellum, hippocampal 
formation, and cortex. More recently, a high PRMT8 expression 
was identified in human brain cortex where PRMT8 is a marker 
of post-mitotic neurons. 
Mutations and/or CNVs affecting PRMT8 have never 
been reported in patients with ASD. 
Kousaka et al., 2009 
Lee et al., 2005 
Weng et al., 2012 
      
PRR16(-)* 
 
Unknown function 
This gene encodes for the proline rich 16 protein with 
unknown function. 
 
High expression in fetal and postnatal brain, particularly in 
postnatal parietal lobe, cerebellum, thalamus, and caudate 
nucleus. 
No interacting proteins have been reported. 
Mutations and/or CNVs affecting PRR16 have never been 
reported in patients with ASD. 
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PSPC1(+) 
 
Transcriptional 
regulation 
This gene encodes the paraspeckle component 1 protein, a 
nucleolar protein which localizes to punctate subnuclear 
structures that occur close to splicing speckles, known as 
paraspeckles. Paraspeckles may function in the control of 
gene expression via an RNA nuclear retention mechanism.  
 
Moderate-good expression in fetal brain, prefrontal cortex 
and hypothalamus.  
PSPC1 directly interacts with TLE3, the transducin-like 
enhancer of split 3 protein, a transcriptional co-repressor that 
inhibits the transcriptional activation mediated by CTNNB1 and 
TCF family members in Wnt signaling.  
 
A role of the repressor TLE1 in neurogenic switching from 
transcription repression to activation, which is needed for brain 
development, has been reported. 
Mutations and/or CNVs affecting PSPC1 have never been 
reported in patients with ASD.  
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Ju et al., 2004 
Okerlund and Cheyette, 2011 
Wang et al., 2010  
Zhang et al., 2012 
       
 
 
 
PTPN12(-)* 
 
Intracellular FAK 
signaling: regulation of 
actin cytoskeleton 
dynamics 
This gene encodes the protein tyrosine phosphatase, non-
receptor type 12, which is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are signaling molecules that 
regulate a variety of cellular processes including cell growth, 
differentiation, mitotic cycle, and oncogenic transformation. 
It may also have a regulatory role in controlling cell shape 
and mobility. 
 
Moderate expression in fetal brain and in postnatal CNS, in 
particolar in prefrontal cortex, amygdalaee, and 
hypothalamus. 
High expression in immune cell types. 
It has been reported that the focal adhesion kinase (FAK) 
functions in regulating tyrosine phosphorylation of several of 
focal adhesion proteins, including paxillin, which may be 
involved in the regulation of the cytoskeleton and in the control 
of signals for growth and survival. Protein tyrosine 
phosphatases, such as PTPN12, the counterparts of protein-
tyrosine kinases, also presumably regulate phosphorylation 
of these proteins. 
The association of both FAK and PTPN12 with paxillin 
suggests that these protein may play a critical role in the 
regulation of the phosphotyrosine content of proteins in focal 
adhesions. 
 
Recent studies suggest that one of the major pathways to the 
pathogenesis of autism is reduced cell migration due to an 
abnormal FAK signaling. Indeed, FAK has an important role in 
neural migration, dendritic morphological characteristics, 
axonal branching, and synapse formation. 
Mutations and/or CNVs affecting PTPN12 have never 
been reported in patients with ASD.  
 
Using B lymphoblasts as a model, it has been 
demonstrated that FAK-Src signaling is abnormally 
regulated in autism, due to a reduced expression of the 
paxillin gene and that FAK-Src signaling leads to defects 
in B-lymphoblast adhesion, migration, proliferation, and 
IgG production. 
Shen et al., 1998 
Wei et al., 2011 
       
 
RAP1GDS1(-)* 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the RAP1, GTP-GDP dissociation 
stimulator 1 protein, which stimulates GDP/GTP exchange 
reaction of a group of small GTP-binding proteins (G 
proteins) including Rap1a/Rap1b, RhoA, RhoB and KRas, by 
stimulating the dissociation of GDP and the subsequent 
binding of GTP to each small G protein. RAP1GDS1 is 
involved in signal transduction. 
 
Very high expression in fetal brain and postnatal CNS. 
Very high expression in immune cell types. 
One of the main interacting protein is RhoA which is involved 
in different pathways such as endocytosis, Wnt signaling 
pathway, TGF-beta signaling pathway, axon guidance, focal 
adhesion, regulation of actin cytoskeleton, chemokine signaling 
pathway, T cell receptor signaling pathway, leukocyte 
transendothelial migration. 
Mutations and/or CNVs affecting RAP1GDS1 have never 
been reported in patients with ASD. 
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD with Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA whereas TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Fombonne et al., 1997 
Ghandour et al., 2007 
Hamel et al., 2011 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Okerlund and Cheyette, 2011 
Wang et al., 2010  
Wiznitzer, 2004 
Wong, 2006 
Zhang et al., 2012 
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REEP1(-)* 
 
Intracellular membrane 
trafficking : ER-shaping 
This gene encodes the receptor accessory protein 1, which 
encodes a mitochondrial protein that functions to enhance the 
cell surface expression of odorant receptors.  
 
High expression in fetal brain and in postnatal CNS.  
Mutations in REEP1 cause spastic paraplegia autosomal 
dominant type 31, a neurodegenerative disorder. 
Pathological mechanisms for hereditary spastic paraplegias 
(HSPs) include mitochondrial dysfunction, abnormalities in 
axonal pathfinding or myelination, and intracellular trafficking 
defects.  
A majority of HSP gene products have been implicated 
generally in intracellular membrane and protein trafficking. 
In particular, REEP1 is an ER-shaping proteins and localizes to 
the ER in cultured rat cerebral cortical neurons, where it 
colocalizes with other two HSP proteins, spastin and atlastin-1. 
REEP proteins are required for ER network formation in vitro, 
and REEP1 also bound microtubules and promoted ER 
alignment along the microtubule cytoskeleton. 
CNVs affecting REEP1 have recently been reported in 
patients with ASD. 
Holt et al., 2012 
Park et al., 2010 
      
RFX3(-) 
de novo 
 
Transcriptional 
regulation in ciliogenesis 
This gene encodes the regulatory factor X 3, which is a 
member of the regulatory factor X gene family that encodes 
transcription factors. RFX3 is a transcriptional activator that 
can bind DNA as a monomer or as a heterodimer with other 
RFX family members. 
 
Moderate expression in fetal brain and in postnatal parietal 
and temporal lobes, and thalamus. 
RFX3 acts as a transcription factor required for ciliogenesis and 
islet cell differentiation during endocrine pancreas development. 
It regulates the expression of genes involved in ciliary assembly 
(DYNC2LI1, FOXJ1 and BBS4) and genes involved in ciliary 
motility (DNAH11, DNAH9 and DNAH5).  
 
It has been reported that in mouse RFX3 is expressed strongly 
in the ciliated ependymal cells of the subcommissural organ, 
choroid plexuses and ventricular walls during embryonic and 
postnatal development. Rfx3-/-deficient mice show several 
hallmarks of ciliopathies including left–right asymmetry defects 
and hydrocephalus. Moreover, these mice suffer from corpus 
callosum agenesis associated with a marked disorganisation of 
guidepost neurons required for axon pathfinding across the 
midline. 
Mutations and/or CNVs affecting RFX3 have never been 
reported in patients with ASD. 
Baas et al., 2006 
Benadiba et al., 2012 
El-Zein et al., 2009 
       
 
RNASEH2B(-) 
 
DNA replication 
This gene encodes the ribonuclease H2, subunit B, protein. 
RNase H2 is composed of a single catalytic subunit (A) and 
two non-catalytic subunits (B and C) and specifically 
degrades the RNA of RNA:DNA hybrids.  
 
Moderate expression in fetal brain and amygdalaee. 
High expression in immune cell types. 
Defects in RNASEH2B are a cause of Aicardi-Goutieres 
syndrome type 2 (autosomal recessive inheritance and, rarely, 
autosomal dominant) which is a genetically heterogeneous 
disease characterized by cerebral atrophy, leukoencephalopathy, 
intracranial calcifications, chronic cerebrospinal fluid (CSF) 
lymphocytosis, increased CSF alpha-interferon, and negative 
serologic investigations for common prenatal infection. Severe 
neurological dysfunctions manifest in infancy as progressive 
microcephaly, spasticity, dystonic posturing and profound 
psychomotor retardation.  
Mutations and/or CNVs affecting RNASEHB have never 
been reported in patients with ASD. 
 
Crow and Livingston, 2008 
     
RPL10(+) 
 
Protein synthesis 
This gene encodes the ribosomal protein L10 that is a 
component of the ribosomal 60S subunit.  
 
High expression in brain, in particular in hippocampus.  
High expression of RPL10 has been detected by RNA in situ 
hybridization in mouse hippocampus, a constituent of the brain 
limbic system known to be afflicted in autism.  
Two missense mutations affecting RPL10 have been 
reported in two autistic patients. 
 
Recurrent Copy Number gains at Xq28 including RPL10 
have been reported in mentally retarded patients. 
Klauck et al., 2006 
Vandewalle et al., 2009 
Chiocchetti et al., 2011 
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SELE(+) 
 
CNS 
immunosurveillance 
This gene encodes the selectin E protein, which is found in 
cytokine-stimulated endothelial cells and is thought to be 
responsible for the accumulation of blood leukocytes at sites 
of inflammation by mediating the adhesion of cells to the 
vascular lining. It is part of the selectin family of cell 
adhesion molecules.  
 
Good expression in fetal brain and low expression in 
postnatal CNS. 
Good expression in whole blood, in particular in monocytes. 
P-selectin, L-selectin and E-selectin are involved in the capture 
and rolling of lymphocytes along the endothelial cell surface at 
the first step of lymphocyte migration. 
In lupus-prone mice it has been recently demonstrated an up-
regulation of the adhesion molecule expression, such as ICAM-
1 and E-selectin, that precedes brain damages of and correlates 
with kidney pathology. Immunofluorescence studies revealed 
that ICAM-1 and E-selectin upregulation localizes to blood 
vessel walls, astrocytes related to the blood-brain barrier, and 
microglial cells. The collected data indicated that brain 
involvement, even subclinical, should be presumed when 
peripheral organs are inflamed. 
Mutations and/or CNVs affecting SELE have never been 
reported in patients with ASD.  
 
No differences between serum levels of E-selectin in 
autistic or SCZ patients vs. controls have been so far 
reported. 
Engelhardt and Ransohoff , 
2005 
Iwata et al., 2007, 2008 
Onore et al., 2012 
Stielke et al., 2012 
     
SELL(+) 
 
CNS 
immunosurveillance 
This gene encodes the selectin L protein, which is a cell 
surface adhesion molecule that belongs to a family of 
adhesion/homing receptors. The encoded protein contains a 
C-type lectin-like domain, a calcium-binding epidermal 
growth factor-like domain, and two short complement-like 
repeats. It is required for binding and subsequent rolling of 
leucocytes on endothelial cells, facilitating their migration 
into secondary lymphoid organs and inflammation sites.  
 
Low expresiion in fetal brain and in postnatal CNS, except 
for corpus callosum where the expression is moderate. 
Very high expression in immune cell types, in particular in B 
and T lymphocytes. 
As known, P-selectin is expressed on the endothelium 
of the blood–CNS barrier and soluble L-selectin has been found 
in cerebrospinal fluid. Moreover, both P and L-selectin play 
important roles in the entry of circulating T-lymphocytes into 
the CNS.  
It is possible that molecules not expressed in the brain may alter 
CNS function. Indeed, aberrant immune activity during brain 
development might play a role in the neural basis of 
neurodevelopment disorders such as ASD. Diminished 
expression of P-selectin has been associated with delayed 
neutrophil transmigration in neonatal rats. Therefore, 
decreased expression of P-selectin in individuals early in life 
may contribute to delayed leukocyte transmigration and 
increased susceptibility to infection, which may in turn damage 
neural tissues during CNS development. In fact, there is 
evidence that maternal viral infection in the first trimester can 
increase the risk of offspring developing an autistic-spectrum 
disorder. 
Mutations and/or CNVs affecting SELL have never been 
reported in patients with ASD.  
 
A decreased serum level of P- and L-selectin has been 
recently observed in a group of autistic subjects vs. 
controls, confirming a previous finding in a cohort of HF-
AU patients, thus indicating an involvement of 
hypoactivity of T-lymphocytes in the pathophysiology of 
autistic-spectrum disorders. 
 
Conversely, it has been found that the serum level of L-
selectin in patients with SCZ was significantly higher 
than that in controls, whereas the level of P-selectin was 
not altered, suggesting distinct patterns of alterations for 
the two disorders. 
Engelhardt and Ransohoff , 
2005 
Iwata et al., 2007, 2008 
Onore et al., 2012 
       
 
SH2B1(-) 
de novo 
 
Intracellular signaling 
This gene encodes the SH2B adaptor protein 1,which is a 
member of the SH2-domain containing mediators family. 
The encoded protein mediates activation of various kinases 
and may function in cytokine and growth factor receptor 
signaling and cellular transformation.  
SH2B adaptor protein family members (SH2B1-3) regulate 
various physiological responses through affecting signaling, 
gene expression, and cell adhesion. For example, SH2B1 and 
SH2B2 were reported to enhance nerve growth factor (NGF)-
induced neuronal differentiation in PC12 cells, a well-
established neuronal model system. 
An autism multiplex family with 16p12.2p11.2 
microduplication syndrome in monozygotic twins and 
distal 16p11.2 deletion in their brother, both 
encompassing SH2B1, has been recently reported. 
 
Recurrent 200-kb deletions (de novo or inherited) of 
16p11.2 that include the SH2B1 gene, have been 
associated with developmental delay and obesity. 
Bachmann-Gagescu et al., 
2010 
Tabet et al., 2012 
Wang et al., 2011 
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SMARCC1(-)* 
 
Chromatin remodeling 
This gene encodes the SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin protein, which is a 
member of the SWI/SNF family of proteins, that display 
helicase and ATPase activities and which are thought to 
regulate transcription of certain genes by altering the 
chromatin structure around those genes.  
 
Moderate expression in fetal brain and in postnatal prefrontal 
cortex.  
Very high expression in immune cell types. 
SMARCC1 belongs to the neural progenitors-specific chromatin 
remodeling complex (npBAF complex) and the neuron-specific 
chromatin remodeling complex (nBAF complex). During neural 
development a switch from a stem/progenitor to a post-mitotic 
chromatin remodeling mechanism occurs as neurons exit the 
cell cycle and become committed to their adult state. 
Furthermore, in mouse embryonic stem cells (mESCs) it has 
been demonstrated that Smarcc1 is necessary for 
heterochromatin formation and chromatin compaction during 
differentiation, and that it plays important roles in facilitating 
mESCs differentiation by coupling gene repression with global 
and local changes in chromatin structure. 
 
SMARCC1 is also implicated in B and T-cell development. 
Mutations and/or CNVs affecting SMARCC1 have never 
been reported in patients with ASD. 
Choi et al., 2012 
Marei et al., 2012  
Schaniel et al., 2009  
      
SMYD3(-) 
 
Chromatin remodeling 
This gene encodes the SET and MYND domain containing 3 
protein, which is a histone methyltransferase that functions in 
RNA polymerase II complexes by an interaction with a 
specific RNA helicase.  
 
Moderate expression in fetal brain and good expression in 
postnatal whole brain, in particolar in hypothalamus.  
Members of the SET and MYND domain containing (Smyd) 
family of proteins possess SET-dependent methyltransferase 
capacity and have been shown to be involved in the 
transcriptional control of cell differentiation and cell 
proliferation. With the exception of Smyd1, little is known 
about the distinct functional relevance of Smyd family proteins 
during vertebrate development, although it has been proposed a 
role of Smyd1 and 2 in cardiac development and in brain 
development for the only Smyd2, which is similar to Smyd3. 
Mutations and/or CNVs affecting SMYD3 have never 
been reported in patients with ASD. 
Brown et al., 2006 
Diehl et al., 2010 
Hamamoto et al., 2004 
Kwon et al., 2009 
      
SNX6(-)* 
 
Intracellular membrane 
trafficking 
This gene encodes the sorting nexin 6 protein, a member of 
the sorting nexin family which is involved in intracellular 
trafficking. This protein may form oligomeric complexes 
with family member proteins through interactions of both the 
PX domain and the coiled coil regions of the molecules. It 
plays a role in retrograde protein transport from endosomes 
to the trans-Golgi network. 
 
SNX6 has been detected in fetal brain and shows moderate-
good expression in postnatal prefrontal cortex and 
hypoyhalamus.  
SNX6 is expressed in fetal brain and, recently, it has been 
demonstrated a role in olygodendrocyte differentation. 
Mutations and/or CNVs affecting SNX6 have never beeen 
reported in patients with ASD. 
 
SNX6 is a candidate locus for holoprosencephaly. 
Kamnasaran et al., 2005 
Schimdt et al., 2012 
      
TMSB15B(+) 
 
Neurodevelopment: 
cytoskeleton organization 
This gene encodes the thymosin beta 15B protein, which 
plays an important role in the organization of the 
cytoskeleton. It binds to and sequesters actin monomers (G 
actin) and therefore inhibits actin polymerization. 
 
Good expression in fetal brain. 
Thymosin beta15 (Tbeta15) is a pleiotropic factor which exerts 
multiple roles in the development of nervous system and brain 
diseases. It has been demonstrated that the expressions of 
Tbeta15 mRNA and protein were increased in several brain 
regions including hippocampal formation and cerebral cortex, 
following kainic acid (KA)-evoked seizures in rat.  
Mutations and/or CNVs affecting TMSB15B have never 
been reported in patients with ASD. 
Kim et al., 2008 
      
 
 
 
82 
 
Tab. 4. Continued. 
TSPAN5(-)* 
de novo 
 
Neurodevelopment and 
IS development 
This gene encodes the tetraspanin 5 protein, which mediates 
signal transduction events that play a role in the regulation of 
cell development, activation, growth and motility.  
 
Very high expression in fetal brain and in postnatal CNS. 
One of the first interacting protein is NOTCH2 which is 
involved in differentiation, proliferation and apoptotic 
programs, and shows a well-known role in IS development. 
NOTCH2 interacts with CNTN1, contactin 1, involved in brain  
development, specifically in synapse formation.  
 
In mouse brain development a specific pattern of TSPAN5 
expression has been observed, particularly in cerebellar Purkinje 
cells. 
Mutations and/or CNVs affecting TSPAN5 have never 
been reported in patients with ASD. 
 
Rare single gene mutations affecting TSPAN7 have been 
reported in a few autistic patients. 
 
Expression profiling of the superior temporal gyrus of six 
autistic subjects and matched controls revealed increased 
transcript levels of many immune system related genes 
such as NOTCH2. These expression patterns appear to be 
more associated with the late recovery phase of 
autoimmune brain disorders, than with the innate immune 
response characteristic of neurodegenerative diseases.  
 
CNVs affecting CNTN4 have been observed in patients 
with ASD. 
Cottrell et al., 2011 
Fernandez et al., 2008 
Garbett et al., 2008 
Glessner et al., 2009 
Juenger et al., 2005 
Lamprianou et al., 2011 
Morrow et al., 2008 
Piton et al., 2011 
Roohi et al., 2009 
      
USP9Y(-)* 
 
Intracellular signaling: 
protein deubiquitination 
pathway 
This gene encodes an ubiquitin specific peptidase 9, Y-
linked, which is a member of the peptidase C19 family that is 
similar to ubiquitin-specific proteases, which cleave the 
ubiquitin moiety from ubiquitin-fused precursors and 
ubiquitinylated proteins. It may therefore play an important 
regulatory role at the level of protein turnover by preventing 
degradation of proteins through the removal of conjugated 
ubiquitin. Essential component of TGF-beta/BMP signaling 
cascade. 
 
Quite high expression in fetal brain and postnatal CNS, in 
particular in parietal and temporal lobes, amygdalaee and 
thalamus.  
It has been reported that USP9Y, previously considered as testis-
specific, is highly expressed in developing mouse brain whereas 
expression in adult brain is low and probably inhibited by 
androgens. Furthermore, a distinctive pattern of cerebral 
expression of different sex chromosome genes, including 
USP9Y, has been reported in mouse and human brain in specific 
neuronal subpopulations, that may possibly contribute to gender 
differences in prevalence noted for some neuropsychiatric 
disorders. 
A significant association of SNPs in USP9Y with 
susceptibility to ASD has been reported 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Glessner et al., 2009 
Kishino et al., 1997 
Matsuura et al., 1997 
Vawter et al., 2004  
Wang et al., 2009 
Xu et al., 2002 
      
VAT1(-) 
 
Synaptic plasticity: 
cholinergic system 
This gene encodes the vesicle amine transport protein 1 
homolog (T. californica). Synaptic vesicles are responsible 
for regulating the storage and release of neurotransmitters in 
the nerve terminal. The protein encoded by this gene is an 
abundant integral membrane protein of cholinergic synaptic 
vesicles and is thought to be involved in vesicular transport.  
 
Moderate expression in fetal brain and in postnatal CNS. 
In the CNS the cholinergic system, that uses acetylcholine 
(ACh) as neurotransmitter, has a variety of neuromodulation 
effects upon plasticity, arousal and reward. ACh has an 
important role in sustaining attention, learning and short-term 
memory.  
Damage to the cholinergic system in the brain has been shown 
to be plausibly associated with the memory deficits associated 
with Alzheimer's disease.  
Mutations and/or CNVs affecting VAT1 have never been 
reported in patients with ASD. 
 
The cholinergic system is known to regulate the function 
of the visual pathway, including the fusiform gyrus which 
is the key structure in face perception. In adults with 
ASD, showing deficiencies in face perception, a deficit in 
cholinergic innervations of the fusiform gyrus has been 
observed. 
Furthermore, the cholinergic system has been implicated 
in the development of autism on the basis of neuronal 
nicotinic acetylcholine receptor losses in cerebral and 
cerebellar cortex, and in thalamus, thus contributing to 
sensory or attentional deficits. 
Himmelheber et al., 2000 
Ray et al., 2005 
Suzuki et al., 2011 
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XRN1(-)* 
 
RNA degradation 
This gene encodes the 5'-3' exoribonuclease 1, which 
localizes to cytoplasmic foci containing a complex of 
mRNA-degrading enzymes. It is involved in mRNA decay. 
 
Moderate expression in fetal brain and postnatal prefrontal 
cortex, amygdalaee and hypothalamus.  
High expression in immune cell types. 
It has been reported that XRN1, which is a glial cell line-derived 
neurotrophic factor-inducible protein, forms together with 
FMRP and other proteins a multiprotein complex that is 
localized in the GW bodies in astrocytes and astrocytoma cells. 
GWBs are unique cytoplasmic structures that contain the 
mRNA binding protein GW182 and other proteins involved in 
mRNA processing pathways.  
Mutations and/or CNVs affecting XRN1 have never been 
reported in patients with ASD. 
 
Mutation in FMR1, which encodes the FMRP protein, is 
responsible for Fragile X syndrome, that is comorbidity 
with ASD. 
Clifford et al., 2007 
Kielinen et al., 2004 
Moser et al., 2007 
Shimoyama et al., 2003 
Wang et al., 2010 
      
ZFX(-)* 
 
Chromatin remodeling 
This gene encodes the Zinc finger protein, X-linked, which is 
a member of the krueppel C2H2-type zinc-finger protein 
family and probable plays a role as transcriptional activator.  
 
Good expression in postnatal temporal lobe, prefrontal 
cortex, thalamus and amygdalaee.  
High expression in immune cell types. 
ZFX interacts with JARID1C (KDM5C), a lysine (K)-specific 
demethylase 5C that specifically demethylates Lys- 4 of histone 
H3, thereby playing a central role in histone code. It participates 
in transcriptional repression of neuronal genes by recruiting 
histone deacetylases and REST at neuron-restrictive silencer 
elements. 
 
ZFX is an essential transcriptional regulator of hematopoietic 
stem cell function. Furthermore, ZFX is required for pro-B to 
pre–B-cell transition and maintenance of mature recirculating B 
cells and B-1 cells.  
Mutations and/or CNVs affecting ZFX have never been 
reported in patients with ASD. 
 
A JARID1C missense mutation affecting a highly 
conserved amino acid has been reported in a little boy 
diagnosed with idiopathic autism.  
A few JARID1C-regulated genes SCN2A, CACNA1H, 
BDNF, and SLC18A1 have been associated with autism 
and cognitive dysfunction. 
Adegbola et al., 2008 
Akbarian and Huang, 2009 
Arenzana et al., 2009 
      
ZMYM5 or 
ZNF237(+) 
 
Transcriptional 
regulation 
This gene encoder the zinc finger MYM-type 5 protein. 
 
Moderate expression in postnatal parietal lobe, cerebellum 
and cerebellum peduncles. 
It has been reported that ZMYM5 may inhibit Presenilin1 (PS1) 
transcription by forming an inhibitory complex with ERM, a 
member of the Ets transcription factors, which directly binds 
PS1 promoter. 
 
Mutations in PS1 are responsible of sporadic juvenile and 
familial cases of Alzheimer’s disease. Besides the involvement 
of Presenilins in amyloid plaques formation, PSs regulate 
the cleavage of other signaling receptors and transducers such as 
Notch-1, ErbB4, DC44, and LDL-receptor-related proteins and 
cadherins. PSs also affect different other signaling molecules, 
such as Wnt signal transduction pathway, which regulates 
morphology, proliferation, and motility of the cell. 
Mutations and/or CNVs affecting ZNF237 have never 
been reported in patients with ASD. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Baulac et al., 2003 
De Ferrari and Moon, 2006 
De Strooper, 2003 
Kopan and Goate, 2000 
Nizzari et al., 2012 
Okerlund and Cheyette, 2011 
Pastoric and Das, 2007 
Schroeter et al., 1998 
Wang et al., 2010  
Zhang et al., 2012 
      ZNF138(-) 
 
Transcriptional 
regulation 
This gene encodes the zinc finger protein 138 which is 
involved in transcriptional regulation. 
 
Moderate expression in fetal brain and in postnatal CNS, 
high expression in cerebellum.  
ZNF138 is probably involved in development. 
Mutations and/or CNVs affecting ZNF138 have never 
been reported in patients with ASD. 
Tommerup and Vissing, 1995 
     ZNF236(-)* 
 
Transcriptional 
regulation 
This gene encodes the zinc finger protein 236 which is 
involved in transcriptional regulation. 
 
It is ubiquitous expressed with the highest levels in skeletal 
muscle and brain. 
 
Mutations and/or CNVs affecting ZNF236 have never 
been reported in patients with ASD. 
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ZNF280A(-) 
 
Transcriptional 
regulation 
This genes encoder the zinc finger protein 280A which acts 
as a transcription factor. 
 
Good expression in fetal brain and moderate expression in 
postnatal whole brain, in particular in amygdalaee. 
 
Mutations and/or CNVs affecting ZNF280A have never 
been reported in patients with ASD. 
 
§
In this table only the genes included in rare CNVs which do not localize in recurrent genomic regions have been analyzed. (-), deleted or disrupted gene due to a rare deletion; (-)*, possible disrupted gene due to a rare duplication; (+), duplicated gene due to a rare 
duplication. The genes already implicated in ASD, due to mutations and/or CNVs or SNPs, are depicted in red and purple, respectively. 
 
      Genes implicated in CNS metabolism. 
      Genes implicated in synaptogenesis and synaptic plasticity. 
      Genes implicated in CNS-IS network.     
      Genes implicated in intracellular signaling and membrane trafficking. 
      Genes implicated in neurogenesis and neurodevelopment. 
      Genes implicated in transcriptional and translational regulation, and chromatin remodeling. 
       
          Genes whose function may be related to the IS development and function, within and outside the CNS. 
 
ADHD, attention deficit hyperactivity disorder; AS, Angelman syndrome; BD, bipolar disorder; BWS, Beckwith-Wiedemann syndrome; CNS, central nervous system; CNV, copy number variation; CSF, cerebrospinal fluid; EP, epilepsy; ER, endoplasmic reticulon; HF-AU, 
high functioning autism; ID, intellectual disability; IS, immune system; MDD, major depressive disorder; MR, mental retardation; SCZ, schizophrenia; SNP, single nucleotide polymorphism; SRS, Siver-Russell syndrome; XLMR, X-linked mental retardation. 
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Tab. 4.1. Detailed list of the genes potentially perturbed by the identified rare CNVs and possible implicated in ASD pathogenesis (UCSC 
Genome Browser, hg19, February 2009)
§
. 
Gene name Function and expression Interactors and possible role in brain 
Findings in ASDs or in other neuropsychiatric 
disorders 
References 
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 Patient 10, gain of 3.9 Mb at 2q14.2q14.3 (chr2:119130298-123004562) 
 
 
CLASP1(+) 
 
Intracellular membrane 
trafficking: regulation of 
microtubule cytoskeleton 
dynamics 
This gene encodes the cytoplasmic linker associated protein 
1. CLASPs, such as CLASP1, are nonmotor microtubule-
associated proteins. CLASP1 is involved in the regulation of 
microtubule dynamics at the kinetochore and throughout the 
spindle. 
 
High expression in fetal brain and in postnatal CNS.  
High expression in immune cell types. 
It has been recently reported that CLASP protein (CLASP1 and 
CLASP2) function to both promote and restrict axon growth, 
thus suggesting that the opposing roles of CLASP are rooted in 
its unique microtubule (MT)-binding activities: CLASP 
supports axon extension when it binds to MT plus ends, whereas 
it restricts axon growth when bound along MT lattices. 
 
It directly interacts with CLIP2, the CAP-GLY domain 
containing linker protein 2, which seems to link microtubules to 
dendritic lamellar body (DLB), a membranous organelle 
predominantly present in bulbous dendritic appendages of 
neurons linked by dendrodendritic gap junctions. It may operate 
in the control of brain-specific organelle translocations. 
Mutations and/or CNVs affecting CLASP1 have never 
been reported in patients with ASD.  
Akhmanova et al., 2001 
Al-Bassam et al., 2010 
Hur et al. 2011 
Maiato et al., 2003 
Neukirchen and Bradke, 2011 
Watanabe et al., 2009  
Wittmann and Waterman-Storer, 
2005 
   
 
  
C1QL2(+) 
 
CNS development 
This gene encodes the complement component 1, q 
subcomponent-like 2. 
 
Highly expressed in the CNS. 
Many member of the C1q family are secreted and play a crucial 
role in intercellular signaling.  
The gene expression of the C1ql subfamily in adult and 
developing mouse brain has been recently investigated. In adult 
brain the C1ql1-C1ql3 mRNAs were mainly expressed in 
neurons and weak expression was found in glia-like structures. 
Moreover, although the C1ql1-C1ql3 mRNAs were detectable 
as early as embryonic day 13, the C1ql2 mRNA was observed at 
later embryonic stages.  
 
Another member of the C1q family of proteins, Cbln, is highly 
expressed in the CNS and plays two fundamental roles in 
cerebellum synapses: the formation and stabilization of synaptic 
contact, and the control of functional synaptic plasticity by 
regulating the postsynaptic endocytotic pathway. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving C1QL2, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
Devillard et al., 2010 
Iijima et al., 2010 
Yuzaki, 2010 
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DBI(+) 
 
Synaptic plasticity 
(GABA receptor 
modulation) 
This gene encodes the diazepam binding inhibitor (GABA 
receptor modulator, acyl-CoA binding protein), which is a 
protein that binds medium- and long-chain acyl-CoA esters 
with very high affinity and may function as an intracellular 
carrier of acyl-CoA esters. It is also able to displace 
diazepam from the benzodiazepine (BZD) recognition site 
located on the GABA type A receptor. It is therefore possible 
that this protein also acts as a neuropeptide to modulate the 
action of the GABA receptor located in brain synapses. 
 
Moderate expression in fetal brain, good expression in 
postnatal cerebellum, thalamus, amygdalae, corpus callosum 
and spinal cord. 
A potential imbalance between excitatory and inhibitory 
interneurons in the cortex may contribute to altered information 
processing in autism. Furthermore, reduced numbers of GABA 
and benzodiazepine receptors have been reported in the autistic 
brain, particularly in posterior cingulate cortex. 
A CNV (loss) including DBI has recently been reported in 
an autistic patient. 
 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving DBI, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
 
A SNP in DBI has been associated with anxiety disorders 
with panic attacks.  
Devillard et al., 2010 
Griswold et al., 2012 
Oblak et al., 2011 
Thoeringer et al., 2007 
     
EN1(+) 
 
Intracellular Wnt 
signaling 
This gene encodes the engrailed homeobox 1 protein, which 
is a transcription factor that has been implicated in the 
control of pattern formation during CNS development.  
 
Low expression in fetal brain and moderate expression in 
postnatal occipital and temporal lobes, cerebellum, 
hypothalamus, and cervical ganglion. 
En1 and En2 are important transcription factors whose role in 
CNS development is well known. They are involved in Wnt 
signaling pathway and, in particular, En1 togheter with β-
catenin regulates transcription of β-catenin target genes in 
neuronal cells. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving EN1, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
 
A single study reported no SNPs affecting EN1 in 247 
patients with SCZ, 98 patients with autism, and 56 
patients with idiopathic MR. Conversely, a SNP in EN2 
has been associated with autism. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Alves dos Santos and Smidt, 2011 
Benayed et al., 2009 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Devillard et al., 2010 
Laroche et al., 2008 
Okerlund and Cheyette, 2011 
Sen et al., 2010 
Wang et al., 2010  
Yang et al., 2010  
Zhang et al., 2012 
     
EPB41L5(+) 
 
Neurodevelopment 
This gene encodes the erythrocyte membrane protein band 
4.1 like 5. 
 
Moderate expression in fetal brain and in postnatal CNS. 
EPB41L5 belongs to the family of the FERM proteins, which 
contain a FERM domain and are ubiquitous components of the 
cytocortex of animal cells where they are engaged in structural, 
transport, and signaling functions, thus contributing to animal 
morphogenesis. 
It has been demonstrated that the murine ortholog protein of the 
human Epb4.1L5, Lulu, helps anchor the actin-myosin 
contractile machinery to the cell membrane to allow the 
dynamic rearrangements of epithelia that mediate embryonic 
morphogenesis. In particular, this process is necessary for the 
organization of the neural plate (neuroepithelium polarity). 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving EPB41L5, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
Devillard et al., 2010 
Lee et al., 2007 
Tepass, 2009 
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GLI2(+) 
 
Transcriptional 
regulation 
This gene encodes the GLI family zinc finger 2 protein, 
which belongs to the C2H2-type zinc finger protein subclass 
of the Gli family. Members of this subclass are characterized 
as transcription factors which bind DNA through zinc finger 
motifs. It is thought to play a role during embryogenesis.  
 
High expression in fetal brain and low expression in 
postnatal CNS, except for cerebellum where the expression is 
good. 
In mouse embryo Gli2 shows an essential role in the 
establishment of dorsoventral polarity in the vertebrate CNS. In 
addition, in mouse brain the Gli transcription factor are essential 
for thalamic development acting downstream the 
Sonichedgehog (Shh) signaling. In particular, Gli2 is the major 
activator, while Gli3 acts primarily as a repressor. Moreover, the 
expression of sox2 gene, which is essential for the maintenance 
of neuronal stem cells (NSCs), is regulated by Gli2, by its 
binding to an enhancer that is vital for sox2 expression in 
telencephalic neuroepithelial cells, which consist of NSCs and 
neural precursor cells. 
Mutations and/or CNVs affecting GLI2 have never been 
reported in patients with ASD. 
 
Defects in GLI2 are the cause of holoprosencephaly type 
9 (HPE9) also called pituitary anomalies with 
holoprosencephaly-like features. The primary features of 
this disease include defective anterior pituitary formation 
and pan-hypopituitarism, with or without overt forebrain 
cleavage abnormalities, and holoprosencephaly-like  
midfacial hypoplasia.  
 
A SNP in GLI2 has been associated with tardive 
diskinesia in patients with chronic SCZ. 
Greenbaum et al., 2010 
Haddad-Tovolli et al., 2012 
Matise et al., 1998 
Roessler et al., 2003 
Takanaga et al., 2009 
     
MARCO(+) 
 
Microglial cells 
maturation 
This gene encodes the macrophage receptor with collagenous 
structure, which is a member of class A scavenger receptor 
family and it is part of the innate antimicrobial immune 
system. The protein MARCO acts as a homotrimer and binds 
both Gram.negative and Gram-positive bacteria.  
 
Low-moderate expression in fetal brain and in postnatal 
CNS. 
High expression in lymph nodes and monocytes. 
Microglial cells originate from bone marrow and migrate in the 
brain when they finish their differentiation under the influence 
of growth factors and cytokines release by resident cells, such as 
granulocyte-macrophage colony stimulated factor (GM-CSF). 
GM-CSF treated microglial cells show enhanced ability to 
process antigens and enhanced antigen-presentation capacity. 
It has been demonstrated a strong up-regulation of MARCO 
mRNA in maturing microglial cells. Furthermore, during 
microglia maturation, MARCO induces a profound actin 
cytoskeleton rearrangement and a down-regulation of antigen-
uptake function. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving MARCO, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
Devillard et al., 2010 
Gehrmann, 1996 
Granucci et al., 2003 
Ling and Wong, 1993 
Matyszak et al., 1999 
Ulvestad et al., 1994 
     PCDP1(+) 
 
Ciliogenesis and ciliary 
motility 
This gene encodes the primary ciliary dyskinesia protein 1, 
which is required for ciliary motility. 
 
It is specifically expressed in brain ependymal cells. 
PCDP1 plays an important role in ciliary and flagellar 
biogenesis and motility. Homozygous mice for mutations 
affecting PCDP1 show the primary ciliary dyskinesia, which 
results from ciliary dysfunction and is commonly characterized 
by sinusitis, male infertility, hydrocephalus, and situs inversus.  
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving PCDP1, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
Devillard et al., 2010 
Lee et al., 2008 
      
 
 
PTPN4(+) 
 
Intracellular signaling 
This gene encodes the protein tyrosine phosphatase, non-
receptor type 4, which is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be signaling 
molecules that regulate a variety of cellular processes 
including cell growth, differentiation, mitotic cycle, and 
oncogenic transformation. This PTP has been shown to 
interact with glutamate receptor delta 2 and epsilon subunits, 
and is thought to play a role in signaling downstream of the 
glutamate receptors through tyrosine dephosphorylation.  
 
High expression in fetal brain and in postnatal whole brain, 
in particolar in thalamus and amygdalae.  
High expression in immune cell types. 
PTPN4 associates directly with GRID2 and plays a role in 
signaling downstream of the GRID2 and/or in regulation of their 
activities through tyrosine dephosphorylation.  
GRID2 is selectively expressed in cerebellar Purkinje cells. It 
directly interacts with DLG2 and SHANK2 which act as adapter 
proteins in the postsynaptic density of excitatory synapses, 
interconnecting receptors of the postsynaptic membrane and the 
actin-based cytoskeleton. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving PTPN4, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
 
A de novo CNV at 4q22.2 including GRID2 has recently 
been reported in an autistic patient. 
 
Mutations and CNVs (de novo and inherited) affecting 
SHANK2 have been reported in ASD patients. 
Berkel et al., 2010, 2012 
Devillard et al., 2010 
He et al., 2012 
Hironaka et al., 2000 
Leblond et al., 2012 
Pinto et al., 2010 
Uemura et al., 2004 
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Tab. 4.1. Continued. 
 
 
 
RALB(+) 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the v-ral simian leukemia viral oncogene 
homolog B protein, which is a GTP-binding protein that 
belongs to the small GTPase superfamily and Ras family of 
proteins. It is a multifuntional GTPase involved in a variety 
of cellular processes including gene expression, cell 
migration, cell proliferation, oncogenic transformation and 
membrane trafficking.  
 
Moderate expression in fetal brain and good expression in 
postnatal whole brain, in particular in cortex, amygdalae, and 
thalamus. 
High expression in immune cell types. 
The Ras-like small GTPases, RalA and RalB, regulate a large 
variety of cellular processes including transcription, translation, 
cytoskeletal organization, membrane trafficking, cytokinesis, 
cell migration, cell proliferation, and cell survival.  
 
Recently, it has been demonstrated an involvement of RalA/B in 
projection neuron migration from the ventricular zone to the 
neocortical plate during mouse brain development. This process 
implies that the neurons become multipolar and move non-
radially in the intermediate zone. Both Reelin, the Rap1 
GTPase, and N-cadherin are important for multipolar neurons to 
polarize their migration towards the cortical plate. Indeed, 
Reelin regulates migration through Rap1 and Akt, and Rap1-
regulated GTPases, RalA/B, Rac1 and Cdc42, are also involved. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving RALB, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
 
The Rho GTPase Cdc42 is involved in neuronal 
morphogenesis, axonal guidance and synaptic plasticity 
by modulating the organization of actin cytoskeleton. 
The same pathway is involved in T-cell activation, 
migration, cell-cell adhesion.  
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
Devillard et al., 2010 
Fombonne et al., 1997 
Jossin and Cooper, 2011 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Shirakawa et al., 2009 
Wiznitzer, 2004 
Wong, 2006 
     
RNU4ATAC(+) 
 
Neurodevelopment 
This gene encodes the RNA, U4atac, small nuclear RNA, 
which is part of the U12-dependent minor spliceosome 
complex.  
 
No expression data are available at UCSC Genome Browser, 
release February 2009. 
Homozygous defects in RNU4ATAC are a cause of 
microcephalic osteodysplastic primordial dwarfism type 1 
(MOPD). 
Mutations and/or CNVs affecting RNU4ATAC have never 
been reported in patients with ASD. 
Abdel-Salam et al., 2011 
     
SCTR(+) 
 
Synaptic plasticity:  
secretin receptor 
This gene encodes the secretin receptor, which is a G protein-
coupled receptor and belongs to the glucagon-VIP-secretin 
receptor family. It binds secretin which is the most potent 
regulator of pancreatic bicarbonate, electrolyte and volume 
secretion.  
 
Moderate expression in postnatal parietal lobe, prefrontal 
cortex, amygdalae, and hypothalamus. 
Secretin is a peptide hormone released from the duodenum to 
stimulate the secretion of digestive juice by the pancreas. It also 
functions as a neuropeptide hormone in the brain. Secretin 
receptor-deficient mice show an impaired synaptic plasticity in 
the hippocampus, and abnormal social and cognitive 
behaviours, thus suggesting that the secretin receptor system has 
an important role in the CNS relating to social behaviour such 
as autism. 
A de novo duplication of 4.2 Mb at 2q14.1q14.2, 
involving SCTR, has been detected in an autistic boy 
carrying the paracentric inversion inv(2)(q14.2q37.3), 
that was inherited from the healthy mother, and a terminal 
deletion at 2q37.3. 
 
Improved behavioral and language skills in autistic 
children who received porcine secretin have been firstly 
described in 1998. Subsequent controlled studies have 
either failed to confirm these results or have shown some 
behavioral improvements among a subset of children with 
autism. Secretin has also been described as being 
potentially therapeutic for other behavioral 
disorders such as SCZ. 
Alamy et al., 2004 
Devillard et al., 2010 
Esch and Carr, 2004 
Horvath et al., 1998 
Kern et al., 2002 
Nishijima et al., 2006 
Sheitman et al., 2004 
Tay et al., 2004  
Yung et al., 2001 
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Tab. 4.1. Continued. 
 Patient 14, gain of 442.5 kb at 9q34.3 (chr9:140527202-140969676) 
CACNA1B(-)* 
de novo 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the calcium channel, voltage-dependent, 
N type, alpha 1B subunit. The protein encoded by this gene is 
the pore-forming subunit of an N-type voltage-dependent 
calcium channel, which controls neurotransmitter release 
from neurons.  
 
Good expression in fetal brain and moderate expression in 
postnatal CNS, in particular in cerebellum and thalamus. 
Calcium channels mediate the influx of calcium ions into the 
cell upon membrane polarization, and they are involved in a 
variety of calcium-dependent processes, including muscle 
contraction, hormone or neurotransmitter release, gene 
expression, cell motility, cell division and cell death. 
Clear function in presynaptic neurotransmitter release. 
CACNA1B maps in the chromosomal region which is 
implicated in the 9q subtelomeric deletion syndrome 
(Kleefstra syndrome), which is comorbidi with ASD. 
In addition, GWAS have previously associated 
CACNA1B with SCZ and BD and a few CNVs (both 
gains and losses) affecting CACNA1B have been found in 
SCZ patients. 
 
Mutations affecting different CACNA genes, such as 
CACNA1C, CACNA1F, and CACNA1H have been 
reported in idiopathic or syndromic patients with ASD.  
Anderlid et al., 2002 
Bhat et al., 2012 
Dawson et al., 2002 
Glessner et al., 2010 
Hemara-Wahanui et al., 2005 
Iwakoshi et al., 2004 
Kleefstra et al., 2005, 2009  
McMullan et al., 2009 
Moskvina et al., 2009 
Sahoo et al., 2006 
Splawski et al., 2004, 2006 
 
EHMT1(-)* 
de novo 
 
Chromatin remodeling 
This gene encodes the euchromatic histone-lysine N-
methyltransferase 1. The protein is a histone 
methyltransferase that is part of the E2F6 complex, which 
represses transcription, methylating the Lys-9 position of 
histone H3, which tags it for transcriptional repression. It 
could play a role in the G0/G1 cell cycle transition.  
 
Low expression in fetal brain and in postnatal CNS. 
Alterations in RNA levels are frequently reported in brain of 
subjects diagnosed with autism, SCZ, depression and other 
psychiatric diseases. Recently it has been demonstrated that 
different epigenetic regulation, through histone lysine 
methylation, is present in post-morten human brain of patients 
affected by neuropsychiatric disorders vs. controls.  
EHMT1 point mutations and deletions of different size 
includine EHMT1 cause the 9q subtelomeric deletion 
syndrome (Kleefstra syndrome), which is comorbidi with 
ASD. 
 
Balanced chromosomal abnormalities affecting EHMT1 
have been found in autistic patients.  
Akbarian and Huang, 2009 
Anderlid et al., 2002 
Dawson et al., 2002 
Iwakoshi et al., 2004 
Kleefstra et al., 2005, 2009  
McMullan et al., 2009 
Sahoo et al., 2006 
Talkowski et al., 2012 
  
 Patient 23, loss of 748 kb, at 17q21.31 (chr17:43193251-43941693)  
ACBD4(-) 
de novo 
 
Lipid metabolism 
This gene encodes the acyl-CoA binding domain containing 
4 protein, which is a member of the acyl-coenzyme A 
binding domain containing protein family. They are thought 
to play roles in acyl-CoA dependent lipid metabolism. 
 
Moderate expression in fetal brain and in postnatal CNS, in 
particular in prefrontal cortex, thalamus and hypothalamus. 
Recently, brain transcriptome variation among behaviorally 
distinct strains of zebrafish has been reported including acbd3 
and acbd4 genes.  
 
No data about the role in human brain are so far available. 
Mutations and/or CNVs affecting ACBD4 have never 
been reported in patients with ASD. 
 
ACBD4 maps in the proximity of the genomic region 
involved in the 17q21.31 microdeletion/microduplication 
syndrome, which shows comorbidity with ASD. One 
ASD deleted patient and several ASD duplicated patients 
have so far been reported. 
Betancur et al., 2008 
Drew et al., 2012 
Grisart et al., 2009 
Koolen et al., 2008 
       
 
CRHR1(-) 
de novo 
 
Synaptic plasticity: stress 
response modulation 
This gene encodes the corticotropin releasing hormone 
receptor 1, a G-protein coupled receptor that binds 
neuropeptides of the corticotropin releasing hormone family 
that are major regulators of the hypothalamic-pituitary-
adrenal pathway. The encoded protein is essential for the 
activation of signal transduction pathways that regulate 
diverse physiological processes including stress, 
reproduction, immune response and obesity. 
 
Good expression in fetal brain and postnatal CNS, in 
particular in cerebellum, amygdalae, and thalamus. 
It has been demonstrated that CRHR1 critically controls 
behavioral adaptation to stress and is causally linked to 
emotional disorders. In particular, the lack of CRHR1 in murine 
forebrain glutamatergic circuits reduces anxiety and impairs 
neurotransmission in the amygdalae and hippocampus whereas 
selective deletion of CRHR1 in midbrain dopaminergic neurons 
increases anxiety-like behavior and reduces dopamine release in 
the prefrontal cortex. Moreover, CRHR1 is involved in CRH-
induced hippocampal neuron apoptosis. 
CRHR1 maps within the genomic region involved in the 
17q21.31 microdeletion/microduplication syndrome, 
which shows comorbidity with ASD. One ASD deleted 
patient and several ASD duplicated patients have so far 
been reported. 
Amath et al., 2012 
Betancur et al., 2008 
Grisart et al., 2009 
Hsu et al., 2012 
Koolen et al., 2008 
Refojo et al., 2011 
Zhang et al., 2012 
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Tab. 4.1. Continued. 
 
FMNL1(-) 
de novo 
 
Neurodevelopment and 
macrophages motility 
and survival: actin 
cytoskeleton dynamics 
This gene encodes the formin-like 1 protein, which is a 
formin-related protein. Formin-related proteins have been 
implicated in morphogenesis, cytokinesis, and cell polarity. 
FMNL1 may play a role in the control of cell motility and 
survival of macrophages. 
 
Low expression in fetal brain and moderate-good expression 
in postnatal whole brain, in particular in parietal and occipital 
lobe, amygdalae and hypothalamus. 
Very high expression in bone marrow and immune cell types. 
FMNL1 is responsible for modifying actin at the macrophage 
podosome and may be involved in actin cytoskeleton dynamics 
during adhesion and migration within tissues. 
By analogies with other members of the same family, it may 
also have a role in neurogenesis. Indeed, recently it has been 
reported that Formin1 mediates the induction of dendritogenesis 
and synaptogenesis by neurogenin3 in mouse hippocampal 
neurons through a direct role in cytoskeleton dynamics. 
Mutations and/or CNVs affecting FMNL1 have never 
been reported in patients with ASD. 
 
FMNL1 maps in the proximityof  the genomic region 
involved in the 17q21.31 microdeletion/microduplication 
syndrome, which shows comorbidity with ASD. One 
ASD deleted patient and several ASD duplicated patients 
have so far been reported. 
Betancur et al., 2008 
Grisart et al., 2009 
Koolen et al., 2008 
Mersich et al., 2010 
Simon-Arceres et al., 2011 
Yu et al., 2011 
 
 Patient 25, gain of 377 kb at 15q13.3 (chr15:32085731-32462701) 
 
CHRNA7(+) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the cholinergic nicotinic receptor alpha 7. 
The nicotinic acetylcholine receptors (nAChRs) are members 
of a superfamily of ligand-gated ion channels that mediate 
fast signal transmission at synapses. The nAChRs are thought 
to be hetero-pentamers composed of homologous subunits. 
The protein encoded by this gene forms a homo-oligomeric 
channel, displays marked permeability to calcium ions and is 
a major component of brain nicotinic receptors that are 
blocked by, and highly sensitive to, alpha-bungarotoxin. 
Once this receptor binds acetylcholine, it undergoes an 
extensive change in conformation that affects all subunits 
and leads to opening of an ion-conducting channel across the 
plasma membrane.  
 
High expression in fetal brain and in postnatal CNS, in 
particular in cortex, amygdalae and thalamus.  
In human fetal brain high levels of CHRNA7 gene expression 
have been found in nuclei that receive sensory information, such 
as those of the neocortex and hippocampus, the thalamic nuclei, 
the reticular thalamic nucleus, the pontine nuclei and the 
superior olive complex, thus supporting a possible regulatory 
function for alpha 7-containing receptors in CNS development 
and in sensory processing, which may be involved in the 
pathological physiology of SCZ and autism.  
CHRNA7 maps within the genomic region involved in the 
15q13.3 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD. 
 
SNPs in the CHRNA7 promoter have been associated 
with SCZ. 
CNVs sncompassing CHRNA7 have been found in 
patients with ADHD, DD, and ID. 
Ben-Shachar et al., 2009 
Guilmatre et al., 2009  
Hoppman-Chaney et al., 2012 
Leonard et al., 2002 
Masurel-Paulet et al., 2010 
Mikhail et al., 2011 
Miller et al., 2009 
Pagnamenta et al., 2009 
Pinto et al., 2010 
Sharp et al., 2008 
Szafranski et al., 2010 
van Bon et al., 2009 
Williams et al., 2012 
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Tab. 4.1. Continued. 
 Patient 25, gain of 538 kb at 16p11.2 (chr16:29652999-30190568)  
 Patient 38, gain 659 kb at 16p11.2 (chr16:29673954-30332581) 
 Patient 39, gain 659 kb at 16p11.2 (chr16:29673954-30332581) 
     
ALDOA(+) 
 
Brain metabolism: 
glycolysis 
This gene encodes the aldolase A, fructose-bisphosphate 
protein, which is a glycolytic enzyme that catalyzes the 
reversible conversion of fructose-1,6-bisphosphate to 
glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate. Three aldolase isozymes (A, B, and C), encoded 
by three different genes, are differentially expressed during 
development. Aldolase A is found in the developing embryo 
and is produced in even greater amounts in adult muscle, 
whereas is repressed in adult liver, kidney and intestine. 
Aldolase A shows levels similar to aldolase C in brain and 
other nervous tissue.  
 
Low expression in fetal brain and good expression in 
postnatal CNS. 
Defects in ALDOA are the cause of glycogen storage disease 
type 12, also known as red cell aldolase deficiency, a metabolic 
disorder associated with increased hepatic glycogen and 
hemolytic anemia. It may lead to myopathy with exercise 
intolerance and rhabdomyolysis. 
 
Using the zebrafish as a tool, a set of 16p11.2 homologs has 
been recently identified. This set of genes is highly active 
during the first 5 days of development, and most genes in this 
region are required for nervous system development (including 
aldoa) – impacting brain morphology, eye development, axonal 
density or organization, and motor response.  
Screening for 16p11.2 genes whose function is sensitive to 
hemizygosity, the aldoaa and kinesin family member 22 genes 
were identified as giving clear phenotypes when RNA levels 
were reduced by ~50%, suggesting that these genes are deletion 
dosage sensors.  
ALDOA maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
ASPHD1(+) 
 
Neurodevelopment 
This gene encodes the aspartate beta-hydroxylase domain 
containing 1 protein. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in cerebellum. 
The zebrafish loss of function model for the ASPHD1 gene 
shows a weak phenotype with defective in brain morphology. 
ASPHD1 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
CDIPT(+) 
 
Intracellular signaling: 
phosphatidylinositol 
signaling system 
This gene encodes the CDP-diacylglycerol-inositol 3-
phosphatidyltransferase protein. Phosphatidylinositol 
breakdown products are ubiquitous second messengers that 
function downstream of many G protein-coupled receptors 
and tyrosine kinases regulating cell growth, calcium 
metabolism, and protein kinase C activity.  
 
Moderate expression in fetal brain and in postnatal CNS. 
In mice, CDIPT mRNA had already expressed on the prenatal 
day 15 throughout the neuroaxis including the spinal cord. 
During the postnatal stages, CDIPT gene expression has been 
detected widely in the gray matters throughout the entire brain. 
The highest levels have bee reported in the olfactory mitral 
cells, the cerebral cortex, the hippocampal and dentate neuronal 
layer and the cerebellar Purkinje and granule cells. 
 
The zebrafish loss of function model for the CDIPT gene shows 
defective in brain morphology. 
CDIPT maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Saito et al., 1998 
Shinawi et al., 2010 
Weiss et al., 2008 
          
92 
 
Tab. 4.1. Continued. 
CORO1A(+) 
 
CNS 
immunosurveillance, 
neurodevelopment: actin 
cytoskeleton dynamics 
This gene encodes the coronin actin binding protein 1A, 
which is a member of the WD repeat protein family. 
Members of this family are involved in a variety of cellular 
processes, including cell cycle progression, signal 
transduction, apoptosis, and gene regulation. It is a crucial 
component of the cytoskeleton of highly motile cells, 
functioning both in the invagination of large pieces of plasma 
membrane, as well as in forming protrusions of the plasma 
membrane involved in cell locomotion. 
 
Good expression in fetal brain and very high expression in 
postnatal whole brain, in particular in cerebellum and 
amygdalae. 
Very high expression in thymus, bone marrow and immune 
cell types. 
Coronins are a highly conserved family of actin regulatory 
genes. They regulate the actin cytoskeleton through 
antagonizing actin polymerization and promoting actin severing. 
Mice with mutations in Coronin-1A, expressed predominantly in 
hematopoeitic cells, are T-lymphocytopenic in part due to 
inability of mature T cells to be released from the thymus into 
the peripheral circulation, suggesting the role of actin 
cytoskeleton regulation in T cell homeostasis. 
In the CNS coronin 1A is predominantly expressed in microglial 
cells. The zebrafish loss of function model for the CORO1A 
gene shows defective in the neural tube formation. 
 
Recently, a patient carrying a heterozygous microdeletion at 
16p11.2, affected by ADHD and a severe combined 
immunodeficiency, has been reported. The deletion 
encompassed the CORO1A gene and, in addition, a deletion of 
2bp on the CORO1A allele, inherited from the healthy father, 
was found. 
CORO1A maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Foger et al., 2006 
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Shiow et al., 2008, 2009 
Uetrecht and Bear, 2006 
Weiss et al., 2008 
     
C16orf53(+) 
 
Chromatin remodeling 
This gene encodes the chromosome 16 open reading frame 
53, which is a component of a Set1-like multiprotein histone 
methyltransferase complex. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in amygdalae and cerebellum. 
The zebrafish loss of function model for C16orf53 shows 
defective in brain morphology. 
C16orf53 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Cho et al., 2007 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
DOC2A(+) 
 
Synaptic function and 
plasticity 
This gene encodes the double C2-like domains, alpha 
protein. DOC2A is mainly expressed in brain and is 
suggested to be involved in Ca2+-dependent neurotransmitter 
release through the interaction with UNC13B. It most 
probably regulates fusion of vesicles with membranes.  
 
Very high expression in fetal brain and in postnatal CNS, in 
particular in cortex, amygdalae, and cerebellum. 
It has been reported that DOC2A-UNC13B interaction in vitro 
plays a role in a step before the final fusion of synaptic vesicles 
with the presynaptic plasma membrane in the evoked 
neurotransmitter release process. 
Furthermore, DOC2A binds to STXBP1, the syntaxin (STX) 
binding protein 1, thus regulating the interaction STXBP1-STX 
which is essential for the activity of the synaptic vesicle fusion 
machinery. 
 
Doc2a knockout mice exhibit defects in excitatory synaptic 
transmission and long-term potentiation, whereas knockdown of 
doc2a in zebrafish resulted in defective brain morphology, but 
apparently normal motor responses and axon tracts. Because the 
mice were studied at later stages, similar phenotypes could 
develop in older fish. 
DOC2A maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010 
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Sakaguchi et al., 1999 
Shinawi et al., 2010  
Weiss et al., 2008 
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FAM57B(+) 
 
Neurodevelopment 
This gene encodes the family with sequence similarity 57 
protein. 
 
Good expression in fetal brain and in postnatal CNS. 
The zebrafish loss of function model for FAM57B shows 
defective in brain morphology. 
FAM57BA maps within the genomic region involved in 
the 16p11.2 microdeletion/microduplication syndrome, 
which shows comorbidity with ASD, EP, SCZ, ID and 
ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
GDPD3(+) 
 
Neurodevelopment 
This gene encodes the glycerophosphodiester 
phosphodiesterase domain containing 3 protein. 
 
Moderate expression in postnatal CNS. 
The zebrafish loss of function model for GDPD3 shows 
defective in brain morphology. 
GDPD3 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
HIRIP3(+) 
 
Neurodevelopment: 
histone metabolism 
This gene encodes the HIRA interacting protein 3, which 
shares sequence similarity with Hir1p and Hir2p, the two 
corepressors of histone gene transcription characterized in 
the yeast, Saccharomyces cerevisiae. The structural features 
of the HIRA protein suggest that it may function as part of a 
multiprotein complex, probably involved in some aspects of 
chromatin and histone metabolism. 
 
Low expression in fetal brain and in postnatal CNS, except 
for amygdalae, cerebellum and thalamus where good levels 
of expression have been detected.  
The zebrafish loss of function model for HIRIP3 shows 
defective in brain morphology. 
HIRIP3maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
INO80E(+) 
 
Chromatin remodeling, 
transcriptional regulation 
This gene encodes the INO80 complex subunit E protein, 
which is a putative regulatory component of the chromatin 
remodeling INO80 complex that is involved in 
transcriptional regulation, DNA replication and probably 
DNA repair. 
 
Moderate expression in fetal brain and in postnatal whole 
brain. 
The zebrafish loss of function model for INO80E shows very 
strong phenotype, suggesting early embryonic defects. In 
particular, it shows abnormal body length and defective neural 
tubes, resulting in anomalies in brain morphology. 
INO80E maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
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Tab. 4.1. Continued. 
 
 
KCTD13(+) 
 
Neurodevelopment: actin 
cytoskeleton dynamics 
This gene encodes the potassium channel tetramerisation 
domain containing 13 protein, which is the substrate-specific 
adapter of a BCR E3 ubiquitin-protein ligase complex 
involved in regulation of cytoskeleton structure. The BCRE3 
ubiquitin ligase complex mediates the ubiquitination of 
RHOA, leading to its degradation by the proteasome, thereby 
regulating the actin cytoskeleton and cell migration. 
 
High expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
Overexpression of 16p11.2 human transcript in zebrafish 
embryos identified KCTD13 as the sole message capable of 
inducing the microcephaly phenotype associated with the 
16p11.2 duplication, whereas suppression of the same locus 
yielded the macrocephalic phenotype associated with the 
16p11.2 deletion. 
Analyses of zebrafish and mouse embryos suggest that 
microcephaly is caused by decreased proliferation of neuronal 
progenitors with concomitant increase in apoptosis in the 
developing brain, whereas macrocephaly arises by increased 
proliferation and no changes in apoptosis.  
KCTD13 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD.  
 
A role for KCTD13 dosage changes is consistent with 
autism in both a recently reported family with a reduced 
16p11.2 deletion, encompassing five genes such as MVP, 
CDIPT, SEZ6L2, ASPHD1 and KCTD13, and a subject 
with a complex 16p11.2 rearrangement involving de novo 
structural alteration of KCTD13. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Crepel et al., 2011 
Fernandez et al., 2010  
Golzio et al., 2012 
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
KIF22(+) 
 
Intracellular membrane 
trafficking: regulation of 
microtubule cytoskeleton 
dynamics 
This gene encodes the kinesin family member 22 protein, 
which is a member of the kinesin-like protein family. They 
are microtubule-dependent molecular motors that transport 
organelles within cells and move chromosomes during cell 
division. Studies with the Xenopus homolog suggest its 
essential role in metaphase chromosome alignment and 
maintenance. 
 
Moderate expression in fetal brain and in postnatal CNS.  
In zebrafish loss of function model KIF22 is required for 
nervous system development, impacting brain morphology, eye 
development, axonal density or organization, and motor 
response. KIF22 was identified as giving a clear phenotype 
when RNA level was reduced by ~50%, suggesting that this 
gene is a deletion dosage sensor. 
KIF22 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
MAPK3-ERK1(+) 
 
Intracellular MAP kinase 
signaling 
This gene encodes the mitogen-activated protein kinase 3 
(ERK1), which is a member of the MAP kinase family. MAP 
kinases, also known as extracellular signal-regulated kinases 
(ERKs), act in a signaling cascade that regulates various 
cellular processes such as proliferation, differentiation, and 
cell cycle progression in response to a variety of extracellular 
signals.  
 
Good expression in fetal brain and in postnatal CNS. 
MAPK3 interacts with PTPN11, the protein tyrosine 
phosphatase, non-receptor type 11, which has a role in signal 
transduction.  
 
The zebrafish loss of function model for MAPK3 shows very 
strong phenotype, suggesting early embryonic defects. In 
particular, it shows abnormal body length and defective neural 
tubes, resulting in anomalies in brain morphology. 
MAPK3 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
 
Rare single missense mutations affecting MAPK3 have 
been reported in a few HF-AU patients. 
 
Up-regulation of the Ras/Raf/ERK1/2 signaling pathway 
has been found in the brain of autistic subjects and mouse 
animal model.  
 
Mutations affecting PTPN11 cause Noonan syndrome 
which is comorbid with ASD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Ghaziuddin et al., 1994 
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Paul et al., 1983 
Pierpont et al., 2009  
Pinto et al., 2010 
Rosenfeld et al., 2010  
Schaaf et al., 2011 
Shinawi et al., 2010 
Swillen et al., 1996 
Weiss et al., 2008  
Yang et al., 2011, 2012 
Zou et al., 2011 
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Tab. 4.1. Continued. 
MAZ(+) 
 
Neurodevelopment 
This gene encodes the MYC-associated zinc finger protein, a 
purine-binding transcription factor. 
 
Moderate expression in fetal brain and in postnatal CNS. 
It has been demonstrated that MAZ mediates enhancement of 
NMDA receptor subunit type 1 (NR1) promoter activity during 
neuronal differentiation. Furthermore, MAZ binds to DDC 
(deleted in colorectal carcinoma), which is a receptor for netrin 
required for axon guidance. DDC mediates axon attraction of 
neuronal growth cones in the developing nervous system upon 
ligand binding.  
 
In zebrafish loss of function model MAZ is required for brain 
development. 
MAZ maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
 
Significantly differential MAZ gene expression in relation 
to age between a group of patients with SCZ and controls 
has been reported in peripheral blood lymphocytes.  
Bataller et al., 2003 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Bowden et al., 2006 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Okamoto et al., 2002 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
MVP(+) 
 
Intracellular signaling: 
regulation of MAP 
kinase signaling 
This gene encodes the major vault protein, which is the major 
component of the vault complex. Vaults are multi-subunit 
ribonucleoprotein structures that may be involved in nucleo-
cytoplasmic transport. The encoded protein may play a role 
in multiple cellular processes by regulating the MAP kinase, 
JAK/STAT and phosphoinositide 3-kinase/Akt signaling 
pathways.  
 
Low expression in fetal brain and in postnatal CNS. 
Recently, the cellular and subcellular expression of MVP in 
primate and rodent cerebral cortex, and in cortical neurons in 
vitro has been described. In prefrontal, somatosensory and 
hippocampal cortices, MVP was predominantly expressed in 
pyramidal neurons.  
Axons and particularly principal dendrites expressed MVP 
along individual microtubules, and in pre- and postsynaptic 
structures. Colocalization with microtubule-associated protein-
2, tubulin, tau, and phalloidin has been observed in neurites and 
growth cones in culture. Immunoprecipitation coupled with 
reverse transcription PCR showed that MVP associates with 
mRNAs that are known to be translated in response to synaptic 
activity.  
 
In zebrafish loss of function model MVP is required for brain 
development. 
MVP maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Paspalas et al., 2009 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
      
 
 
QPRT(+) 
 
Tryptophan metabolism 
This gene encodes the quinolinate phosphoribosyltransferase, 
which is a key enzyme in catabolism of quinolinate, an 
intermediate in the tryptophan-nicotinamide adenine 
dinucleotide pathway. Quinolinate acts as a most potent 
endogenous exitotoxin to neurons.  
 
Low expression in postnatal CNS, in particular in amygdalae 
and thalamus. 
High expression in dendritic cells, NK-cells and monocytes. 
QPRT converts quinolic acid (QUIN) to nicotinic acid 
ribonucleotide, a precursor in the synthesis of NAD+, and 
carbon dioxide in the presence of Mg2+ and 5-phosphoribosyl- 
1-pyrophosphate. In the brain, QPRT is one 
of the rate-limiting enzymes of NAD+ synthesis from 
Tryptophane, and therefore likely to influence QUIN levels 
in the CNS. Thus, QPRT activity is essential for the 
maintenance of cellular energy metabolism and DNA repair. A 
reduction in QPRT activity can be envisioned to lead to an 
accumulation of QUIN, and likely to induce a cytotoxic 
cascade within astrocytes and neurons. 
 
The zebrafish homolog of human QPRT is not known. 
QPRT maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
 
One possible explanation for ASD pathogenesis is the 
modern theory of immunoexcitotoxicity (see the ACMSD 
gene). 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Braidy et al., 2011 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Schwarcz et al., 2012 
Shinawi et al., 2010 
Weiss et al., 2008 
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Tab. 4.1. Continued. 
 
 
PPP4C(+) 
 
Neurodevelopment: 
microtubule cytoskeleton 
dynamics 
This gene encodes the protein phosphatase 4, which is 
involved in many processes such as microtubule organization 
at centrosomes, maturation of spliceosomal snRNPs, 
apoptosis, DNA repair, tumor necrosis factor (TNF)-alpha 
signaling, activation of c-Jun N-terminal kinase MAPK8, 
regulation of histone acetylation, DNA damage checkpoint 
signaling, NF-kappa-B activation and cell migration.  
 
Moderate expression in fetal brain and in postnatal CNS. 
Very high expression in immune cell types. 
It has been recently reported that PPP4R2, a regulatory subunit 
of the protein phosphatase 4 (PPP4C), displays a very dynamic 
intracellular localization in mouse and rat neuronal cell lines 
and in rat primary hippocampal neurons, strongly correlating 
with differentiation. 
Furthermore, in zebrafish loss of function model PPP4C is 
required for brain development. 
PPP4C maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
 
NF-κB is an important gene transcriptional factor that 
mediates cellular responses in inflammation, immunity, 
development, cell proliferation and apoptosis. Elevated 
levels of NF-κB have been reported in autistic patients vs. 
controls. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Bosio et al., 2012 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Naik et al., 2011 
Philippe et al., 2012  
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
PRRT2(+) 
 
Neurodevelopment 
This gene encodes the proline-rich transmembrane protein 2, 
which contains a proline-rich domain in its N-terminal half. 
Studies in mice suggest that it is predominantly expressed in 
brain and spinal cord in embryonic and postnatal stages.  
 
Good expression in fetal brain and in postnatal CNS. High 
expression in cerebellum. 
Mutations in PRRT2 are associated with paroxysmal kinesigenic 
dyskinesia (PKD), infantile convulsions with choreoathetosis 
(PKD with infantile seizures), and benign familial infantile 
seizures. 
There is a limited amount of research regarding the function of 
PRRT2; however, some indirect evidence suggested its role in 
the pathogenesis of PKD. First, PRRT2 was found to be mainly 
expressed in the basal ganglia, a brain area possibly involved in 
the PKD pathogenesis. Secondly, SNAP25, an interactive 
protein of PRRT2, is also expressed in the brain, especially 
the basal ganglia, participates in the regulation of 
neurotransmitter release and is involved in ADHD onset. 
 
No phenotype has been observed in the zebrafish loss of 
function model for PRRT2 which is not expressed until the 48 
hours of life. 
PRRT2 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Graham et al., 2002 
Hamano et al.,.1995 
Hanson et al., 2010 
Hayashi et al., 1997 
Iwasaki et al., 2004  
Ko et al., 2001  
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Shirane et al., 2001 
Stelzl et al., 2005  
Volonte et al., 2001 
Wang et al., 2011 
Weiss et al., 2008 
     
SEZ6L2(+) 
 
Neurodevelopment 
This gene encodes the seizure related 6 homolog (mouse)-
like 2 protein, which is localized on the cell surface. 
Increased expression of this gene has been found in lung 
cancers, and the protein is therefore considered to be a novel 
prognostic marker for lung cancer.  
 
Very high expression in fetal brain and in postnatal CNS. 
In situ analyses in whole mouse embryos have demonstrate that 
Sez6l2 mRNA is expressed in the developing brain and spinal 
cord whereas in human fetal brain sections SEZ6L2 is enriched 
in the cortical plate in the post mitotic neuron, in the ventricular 
zone, in the hippocampus, thalamus, ganglionic eminence, 
basal ganglia, and amygdalae and at lower levels in the pons and 
the putamen.  
 
The zebrafish loss of function model for the SEZ6L2 gene 
shows a weak phenotype with defective in brain morphology. 
SEZ6L2 maps in the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity ASD, EP, SCZ, ID and ADHD. 
 
A coding variant in SEZ6L2 has been significantly 
associated with ASD (datum not replicated). 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Konyukh et al., 2011 
Kumar et al., 2008, 2009 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
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Tab. 4.1. Continued. 
SPN(+) 
 
T-cell activation 
This gene encodes the sialophorin protein, which is a major 
sialoglycoprotein found on the surface of thymocytes, T 
lymphocytes, monocytes, granulocytes, and some B 
lymphocytes.  
 
Moderate expression in fetal brain and low expression in 
postnatale CNS, except for amygdalae and hypothalamus 
where expression is moderate. 
High expression in immune cell types. 
SPN is part of a physiologic ligand-receptor complex involved 
in T-cell activation. During T-cell activation, this protein is 
actively removed from the T-cell-APC (antigen-presenting cell) 
contact site, suggesting a negative role in adaptive immune 
response. 
SPN maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
      
 
SULT1A3(+) 
 
CNS metabolism 
This gene encodes the sulfotransferase family cytosolic 1A, 
phenol-preferring member 3 protein. 
Sulfotransferase enzymes catalyze the sulfate conjugation of 
many hormones, neurotransmitters, drugs, and xenobiotic 
compounds.  
 
Good expression in fetal brain and moderate expression in 
postnatal CNS. 
High expression in immune cell types. 
SULT1A3 sulfates catecholamine neurotransmitters and its 
expression is highest in cytosol from superior temporal gyrus, 
hippocampus, and temporal lobe.  
SULT1A3 has been found in both neurons and glial cells. 
SULT1A3 maps within the genomic region involved in 
the 16p11.2 microdeletion/microduplication syndrome, 
which shows comorbidity with ASD, EP, SCZ, ID and 
ADHD. 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Salman et al., 2009 
Shinawi et al., 2010 
Weiss et al., 2008 
     
TAOK2(+) 
 
Intracellular signaling: 
dendrite morphogenesis 
This gene encodes the TAO kinase 2, which is a 
serine/threonine protein kinase that is involved in many 
different processes, including cell signaling, microtubule 
organization and stability, and apoptosis. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Very recently, it has been demonstrated that TAOK2 is essential 
for dendrite morphogenesis. TAOK2 downregulation impairs 
basal dendrite formation in vivo without affecting apical 
dendrites. Moreover, TAOK2 interacts with Neuropilin 1, a 
receptor protein that binds the secreted guidance cue 
Semaphorin 3A. Finally, Sema3A and TAOK2 modulate the 
formation of basal dendrites through the activation of the c-Jun 
N-terminal kinase (JNK).  
 
In zebrafish loss of function model TAOK2 is required for brain 
development. 
TAOK2 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
de Anda et al., 2012 
Fernandez et al., 2010  
Hanson et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
     
YPEL3(+) 
 
Neurodevelopment 
This gene encoder the yippee-like 3 protein. 
 
Good expression in fetal brain and in postnatal CNS. 
YPEL3, a member of a recently discovered family of putative 
zinc finger motif coding genes consisting of YPEL1-5, is a p53-
regulated gene. YPEL3 expression induced by DNA damage 
leads to p53 recruitment to a cis-acting DNA response element 
located near the human YPEL3 promoter. Physiologic induction 
of YPEL3 results in a substantial decrease in cell viability 
associated with an increase in cellular senescence. 
 
In zebrafish loss of function model YPEL3 is required for brain 
development. 
YPEL3 maps within the genomic region involved in the 
16p11.2 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, EP, SCZ, ID and ADHD. 
Blaker-Lee et al., 2012 
Bijlsma et al., 2009 
Christian et al., 2008 
Fernandez et al., 2010  
Hanson et al., 2010 
Kelley et al., 2010 
Kumar et al., 2008 
Marshall et al., 2008 
Mochida et al., 1998 
Pinto et al., 2010 
Rosenfeld et al., 2010  
Shinawi et al., 2010 
Weiss et al., 2008 
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Tab. 4.1. Continued. 
 Patient 27, gain of 2.6 Mb at 22q11.21 (chr22:18894835-21505417)  
 Patient 32, loss of 120 kb at 22q11.21 (chr22:18890271-19010508) 
AIFM3(+) 
de novo 
 
Neurodevelopment 
This nuclear gene encodes the apoptosis-inducing factor, 
mitochondrion-associated 3 protein. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Apoptosis-inducing factor (AIF) is implicated in caspase-
independent apoptotic-like death. AIF released from 
mitochondria translocates to the nucleus, where it mediates 
some apoptotic events such as chromatin condensation and 
DNA degradation.  
During cerebellar development, a significant increase in the 
number of neurons with nuclear AIF localization has been 
reported in an age-dependent manner, suggesting the idea that 
AIF could be involved in apoptotic-like death of cerebellar 
granule neurons and that it could be an alternative mechanism of 
neuronal death during cerebellar development. 
AIFM3 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Blancas and Moran, 2011 
Bucan et al., 2009 
Fine et al., 2005 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
ARVCF(+) 
de novo 
 
Neurodevelopment 
This gene encodes the armadillo repeat gene deleted in 
velocardiofacial syndrome, which is a member of the catenin 
family. This family plays an important role in the formation 
of adherens junction complexes, which are thought to 
facilitate communication between the inside and outside 
environments of a cell. ARVCF belongs to the beta-catenin 
family. 
 
Good expression in fetal brain and in postnatal CNS. 
It has been demonstrated by haplotype analyses performed on a 
22q11.2 region including the TXNRD2, COMT and ARVCF 
genes, that a particular set of SNPs are over-transmitted in 
individuals with SCZ, a disorder characterized by specific 
cognitive impairments. 
Furthermore, the developmental impact of over-expression of an 
~190 kb segment of human 22q11.2, which includes TXNRD2, 
COMT and ARVCF, on behaviors in bacterial artificial 
chromosome transgenic mice vs. wild-type mice has been 
determined. The collected data suggest that over-expression of 
this 22q11.2 segment enhances incentive learning and impairs 
the prolonged maintenance of working memory, but has no 
apparent effect on working memory per se, affect- and 
stress-related behaviors or motor capacity. 
ARVCF maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Antshel et al., 2007 
Bucan et al., 2009 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Fine et al., 2005 
Liu and Murray, 2012 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mas et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Okerlund and Cheyette, 2011 
Pinto et al., 2010 
Ramelli et al., 2008 
Sanders et al., 2005 
Sim et al., 2012 
Suzuki et al., 2009 
Szatmari et al., 2007  
Vorstman et al., 2006 
Wang et al., 2010  
Zhang et al., 2012 
     
CDC45(+) 
de novo 
 
DNA replication 
This gene encodes the cell division cycle 45 homolog (S. 
cerevisiae), which is an essential protein required to the 
initiation of DNA replication. Cdc45 is a member of the 
highly conserved multiprotein complex including 
Cdc6/Cdc18, the minichromosome maintenance proteins 
(MCMs) and DNA polymerase, which is important for early 
steps of DNA replication in eukaryotes.  
 
Expressed during neurogenesis. 
It has been demonstrated that diminished dosage of the genes 
deleted in the 1.5 Mb 22q11 minimal critical deleted region, 
including CDC45, in a mouse model of 22q11 DiGeorge 
syndrome specifically compromises neurogenesis and 
subsequent differentiation in the cerebral cortex. In particular, 
CDC45 is expressed in the cortical ventricular and 
subventricular zones with highest level of expression during 
neurogenesis. 
CDC45 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Meechan et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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Tab. 4.1. Continued. 
 
CLDN5(+) 
de novo 
 
CNS 
immunosurveillance: 
brain blood barrier 
permeability 
This gene encodes the claudin 5 protein. Claudins are 
integral membrane proteins and components of tight junction 
strands. Tight junction strands serve as a physical barrier to 
prevent solutes and water from passing freely through the 
paracellular space between epithelial or endothelial cell 
sheets. 
 
Moderate expression in fetal brain and good expression in 
postnatal CNS. 
Claudin-5 is a key tight junction protein whose expression in the 
brain endothelial cells is critical to the function of brain blood 
barrier. In mouse model it has been recently demonstrated a 
regulation of CLDN5 expression by Tnf-.  
 
Diminished levels of CLDN5 with tight junction structure 
alterations have been found in nueroinflammatory disease 
model. 
 
Mutations in this gene have been found in patients with 
velocardiofacial syndrome. 
CLDN5 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A SNP in CLDN5 has been associated with SCZ. 
Antshel et al., 2007 
Aslam et al., 2012 
Bucan et al., 2009 
Fine et al., 2005 
Ishiguro et al., 2008 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Sun et al., 2004 
Szatmari et al., 2007  
Vorstman et al., 2006 
Wu et al., 2010 
CLTCL1(+) 
de novo 
 
Intracellular trafficking 
This gene encodes the clathrin, heavy chain-like 1 protein, 
which is a member of the clathrin heavy chain family and 
encodes a major protein of the polyhedral coat of coated pits 
and vesicles.  
 
Moderate expression in fetal brain and in postnatal CNS. 
Good expression in amygdalae and thalamus. 
CLTCL1 encodes a member of the clathrin heavy chain 
family, which is involved in intracellular trafficking, that are 
important to glutamate receptor turnover. 
 
Chromosomal aberrations involving this gene are associated 
with meningioma, DiGeorge syndrome (DGS), and velo-cardio-
facial syndrome (VCFS). In particular, a patient with features of 
DGS/VCFS, who carry a balanced (21;22)(p12;q11) 
translocation that interrupts only the CLTCL1 gene, has been 
reported. 
CLTCL1 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
Recently, whole-exome sequencing of 16 autistic 
probands revealed validated homozygous, potentially 
pathogenic recessive mutations affecting candidate genes 
such as UBE3B, CLTCL1, NCKAP5L, and ZNF18, that 
segregated perfectly with the disease in 4/16 families. 
Moreover, it has been demonstrated that the mouse 
homologs of these four genes are upregulated in response 
to neuronal activity. 
Antshel et al., 2007 
Bucan et al., 2009 
Chahrour et al., 2012 
Fine et al., 2005 
Holmes et al., 1997 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
COMT(+) 
de novo 
 
Catecholamine 
metabolism 
This gene encodes the catechol-O-methyltransferase protein, 
which catalyzes the transfer of a methyl group from S-
adenosylmethionine to catecholamines, including the 
neurotransmitters dopamine, epinephrine, and 
norepinephrine. This O-methylation results in one of the 
major degradative pathways of the catecholamine 
transmitters. 
 
Low expression in fetal brain and moderate expression in 
postnatal whole brain, in particular in caudate nucleus, 
corpus callosum, thalamus, and hypothalamus. 
The methylation of dopamine by COMT is an important 
mechanism for dopamine inactivation and dopaminergic tone in 
the CNS. Although COMT is expressed widely throughout the 
brain, it appears to play a particularly important role in 
dopamine flux in the prefrontal cortex. In the cortex, the 
dopamine transporter, which has a 1,000-fold higher affinity for 
dopamine than does COMT, is expressed at very low levels and 
does not appear to affect extracellular dopamine levels. Thus, 
inactivation of dopamine in the prefrontal cortex appears to rely 
preferentially on catabolic enzymes, including COMT. 
 
Different polymorphisms of COMT have been associated over 
the years with many neuropsychiatric disorders such as BD, 
anorexia nervosa, obsessive-compulsive disorders, and 
aggressive behaviour in SCZ. 
COMT maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A SNP affecting COMT has been associated with ASD 
and probably correlates with a more aggressive 
phenotype. 
Antshel et al., 2007 
Bucan et al., 2009 
Chen et al., 2004 
Fine et al., 2005 
Frisch et al., 2001 
Garris et al., 1993 
James et al., 2006 
Jones et al., 2001 
Li et al., 1997 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Nieoullon, 2002 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Schindler et al., 2000 
Suzuki et al., 2009 
Szatmari et al., 2007  
Tunbridge et al., 2006 
Vorstman et al., 2006 
      
 
100 
 
Tab. 4.1. Continued. 
CRKL(+) 
de novo 
 
Intracellular signaling 
This gene encodes the v-crk sarcoma virus CT10 oncogene 
homolog (avian)-like, which is a protein kinase containing 
SH2 and SH3 domains that activates the RAS and JUN 
kinase signaling pathways and transforms fibroblasts in a 
RAS-dependent fashion. It is a substrate of the BCR-ABL 
tyrosine kinase, plays a role in fibroblast transformation by 
BCR-ABL, and may be oncogenic. 
 
Moderate expression in fetal brain and in postnatal 
cerebellum and thalamus. 
The Crk and Crk-like (CrkL) adaptor proteins play important 
roles in numerous signaling pathways, bridging tyrosine kinase 
substrates to downstream signaling effectors by virtue of their 
phosphotyrosine-binding SH2 domains and their effector-
binding SH3 domains.  
Crk and CrkL are known biochemically and genetically to be 
essential mediators of Reelin/Disabled-1 (Dab1) signaling, 
which governs proper mammalian brain development. 
Multimeric Reelin clusters its receptors as well as the receptor-
bound intracellular scaffolding protein Dab1.  
Recently, 101 CrkL-SH3 binding proteins have been identified 
from embryonic murine brain. The identified proteins are 
enriched in the Crk/CrkL-SH3 binding motif and signaling 
activities regulating cell adhesion and motility.  
 
An atypical 0.8 Mb inherited duplication of 22q11.2, which 
encompasses 14 genes including CRKL, ZNF74, PIK4CA, 
SNAP29 and PCQAP known to contribute to several aspects of 
the DGS/VCFS phenotype, has been recently described in a 
patient with psychomotor impairment, suggesting a role for 
these genes in neurodevelopment. 
CRKL maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Cheerathodi and Ballif, 2011 
Fine et al., 2005 
Holmes et al., 1997 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pebrel-Richard et al., 2012 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
DGCR2(+) 
de novo 
 
Neurodevelopment 
This gene encodes the DiGeorge syndrome critical region 
gene 2 protein, which is a novel putative adhesion receptor 
protein that could play a role in neural crest cell 
differentiation and migration. 
 
Moderate expression in fetal brain and in postnatal CNS. 
DGCR2 could be involved in cell-cell or cell-matrix interactions 
required for normal cell differentiation and migration. 
DGCR2 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
The association between DGCR2 and SCZ has been 
demonstrated through individual genotyping of 1,400 
subjects. In a subsequnt gene expression analysis the risk 
allele of a coding SNP associated with SCZ was found to 
be associated with a reduced expression of DGCR2. 
This datum was not later replicated in a German sample. 
 
A de novo potentially disruptive mutation in DGCR2 has 
been recently detected by exome sequencing analysis in a 
cohort of SCZ patient. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005 
Georgi et al., 2009 
Ishiguro et al., 2008 
Liu et al., 2007 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
Xu et al., 2011 
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DGCR6(-)*de novo 
DGCR6(-) 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the DiGeorge syndrome critical region 
protein 6, which shares homology with the Drosophila 
melanogaster gonadal protein that participates in gonadal and 
germ cell development, and with the gamma-1 subunit of 
human laminin. This gene is a candidate for involvement in 
DiGeorge syndrome pathology and in SCZ. 
DGCR6 may play a role in neural crest cell migration into 
the third and fourth pharyngeal pouches. 
 
Low expression in fetal brain and high expression in 
postnatal CNS.  
Recently, it has been demonstrated a role for DGCR6 in 
GABAB-receptor localization, which mediate slow inhibitory 
effects of the neurotransmitter gamma-aminobutyric acid 
(GABA) on synaptic transmission in the CNS.  
DGCR6 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
CNVs (loss) exclusively affecting PRODH and DGCR6 
and parentally inherited have been significantly 
associated with ASD.  
 
A significant relationship between the increased 
frequency of anxiety disorders and low DGCR6 and 
DGCR6L expression has been recently reported in 
children with 22q11 DiGeorge syndrome. 
Antshel et al., 2007 
Bucan et al., 2009 
Das Chakraborty et al., 2012 
Fine et al., 2005 
Guilmatre et al., 2009 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Meechan et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
Zunner et al., 2010 
     
DGCR6L(+) 
de novo 
 
Synaptogenesis and 
synaptic plasticity? 
This gene encodes the DiGeorge syndrome critical region 
gene 6-like protein. 
This gene, the result of a duplication at this locus, is one of 
two functional genes encoding nearly identical proteins that 
have similar expression patterns. The product of this gene is 
a protein that shares homology with the Drosophila gonadal 
protein, expressed in gonadal tissues and germ cells, and with 
the human laminin gamma-1 chain that functions in cell 
attachment and migration. 
DGCR6L may play a role in neural crest cell migration into 
the third and fourth pharyngeal pouches. 
 
Low expression in fetal brain and high expression in 
postnatal CNS, except for corpus callosum and spinal cord 
where the expression is low. 
 
DGCR6L maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A significant relationship between the increased 
frequency of anxiety disorders and low DGCR6 and 
DGCR6L expression has been recently reported in 
children with 22q11 DiGeorge syndrome. 
Antshel et al., 2007 
Bucan et al., 2009 
Das Chakraborty et al., 2012 
Fine et al., 2005 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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DGCR8(+) 
de novo 
 
MicroRNA biogenesis 
This gene encodes the DiGeorge syndrome critical region 
gene 8 protein, which is a subunit of the microprocessor 
complex which mediates the biogenesis of microRNAs from 
the primary microRNA transcript. This protein is required for 
binding the double-stranded RNA substrate and facilitates 
cleavage of the RNA by the ribonuclease III protein, Drosha. 
 
Good expression in fetal brain and moderate expression in 
postnatal CNS. 
Good expression in immune cell types. 
It has been reported that Dgcr8+/- mice display reduced 
expression of a subset of microRNAs in the prefrontal cortex, a 
deficit that emerges over postnatal development. Layer V 
pyramidal neurons in the medial prefrontal cortex of Dgcr8+/- 
mice have altered electrical properties, decreased complexity of 
basal dendrites, and reduced excitatory synaptic transmission. 
These findings demonstrate that precise microRNA expression 
is critical for the postnatal development of prefrontal cortical 
circuitry. Similar defects in neuronal maturation resulting from 
microRNA deficiency could represent endophenotypes of 
certain neuropsychiatric diseases of developmental onset. 
 
Furthermore, mouse model of 22q11DS displays an age-
dependent increase in hippocampal long-term potentiation 
(LTP), a form of synaptic plasticity underlying learning and 
memory. The sarco(endo)plasmic reticulum Ca(2+) ATPase 
(SERCA2), which is responsible for loading Ca(2+) into the 
endoplasmic reticulum (ER), is elevated in this mouse model. 
Screening of multiple mutant mouse lines revealed that 
haploinsufficiency of Dgcr8 causes age-dependent, synaptic 
SERCA2 overexpression and increased LTP. Finally, SERCA2 
is elevated in the brains of patients with SCZ, providing a link 
between mouse model findings and the human disease.  
DGCR8 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Earls et al., 2012 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Schofield et al., 2011 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
DGCR14(+) 
de novo 
 
Transcript maturation 
This gene encodes the DiGeorge syndrome critical region 
gene 14 (DGCR14) protein, which may be a component of C 
complex spliceosomes. The orthologous protein in the mouse 
localizes to the nucleus. 
 
Moderate expression in fetal brain and in postnatal CNS, in 
particular in cortex, caudate nucleus and cerebellum. 
DGCR14 is possibly involved pre-mRNA splicing. 
 
It has been demonstrated that the Df(16)A+/− mice which carry 
a microdeletion including the Gscl and Dgcr14 genes, both 
located within the DiGeroge critical region, showed reduced 
synchrony of hippocampal theta with the neuronal activity of 
the prefrontal cortex. Moreover, it has been recently reported 
that loss of Gscl and Dgcr14 affects the regulation of 
hippocampal theta and REM sleep, possibly contributing to the 
psychiatric symptoms frequently seen in patients who have 
22q11 syndrome. 
DGCR14 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
Evidence of association between promoter 
polymorphisms in 22q11 gene DGCR14 and SCZ have 
been detected by transmission disequilibrium test. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Funato et al., 2010 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Sigurdsson et al., 2010 
Szatmari et al., 2007  
Vorstman et al., 2006 
Wang et al., 2006 
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GNB1L(+) 
de novo 
 
Intracellular signaling 
This gene encodes the guanine nucleotide binding protein (G 
protein), beta polypeptide 1-like, which is a member of the 
WD repeat protein family. WD repeats are minimally 
conserved regions of approximately 40 amino acids typically 
bracketed by gly-his and trp-asp (GH-WD), which may 
facilitate formation of heterotrimeric or multiprotein 
complexes. Members of this family are involved in a variety 
of cellular processes, including cell cycle progression, signal 
transduction, apoptosis, and gene regulation.  
 
Detected at high levels in fetal brain and at low levels in 
postnatal CNS. 
GNB1L shows homology to the human guanine nucleotide–
binding protein b subunit (GNB1). GNB1 functions in G-
protein–coupled receptor protein signaling pathways and 
intracellular signaling cascade. 
 
Recently, significant evidence for association between 
SCZ and GNB1L have been reported in a case–control 
association study. This observation, combined with the findings 
of reduced expression of GNB1L in postmortem brains of 
schizophrenics and the effect of heterozygous deletion of Gnbl1 
on prepulse inhibition, a SCZ endophenotype, in a mouse 
model, suggest that GNB1L is associated with SCZ phenotype 
observed in del22q11.2. 
GNB1L maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A patient with ASD and SCZ, who carry a balanced 
translocation involving the 22q11.2 region and 
interrupting GNB1L, has been recently reported. 
Furthermore, private GNB1L missense variants in 
conserved residues, that affect residues in the WD40 
repeat domains and are predicted to have deleterious 
effects on the protein, have been identified in three 
autistic families, thus supporting involvement of GNB1L 
in autism spectrum disorders as well. 
Antshel et al., 2007 
Bucan et al., 2009 
Chen et al., 2012 
Fine et al., 2005 
Ishiguro et al., 2010  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Meechan et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Paylor et al., 2006 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
Williams et al., 2008  
      
 
 
GP1BB(+) 
de novo 
 
Neurodevelopment 
This gene encodes the glycoprotein Ib (platelet), beta 
polypeptide, which is a heterodimeric transmembrane protein 
consisting of a disulfide-linked 140 kD alpha chain and 22 
kD beta chain. It is part of the GPIb-V-IX system that 
constitutes the receptor for von Willebrand factor (VWF), 
and mediates platelet adhesion in the arterial circulation. 
GPIb alpha chain provides the VWF binding site, and GPIb 
beta contributes to surface expression of the receptor and 
participates in transmembrane signaling through 
phosphorylation of its intracellular domain.  
 
Very high expression in fetal brain and in postnatal CNS. 
Very high expression in whole blood, dendritic cells and 
monocytes. 
Mutations in the GPIBB gene have been associated with 
Bernard-Soulier syndrome (BSS), velocardiofacial syndrome 
and giant platelet disorder. 
In particular, it has been recently reported on a four-year-old 
boy with a homozygous deletion comprising the GP1BB and 
SEPT5 genes, located 5' to GP1BB. He presented with BSS, 
cortical dysplasia (polymicrogyria), developmental delay, and 
platelet secretion defect, thus supporting the possible effect of 
defect of these two genes in neurodevelopment. 
GP1BB maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
Both GP1BB and SEPT5 have been previously suggested 
as autism candidate genes by molecular cytogenetic 
analysis and in silico studies. 
Antshel et al., 2007 
Bartsch et al., 2011 
Bucan et al., 2009 
Fine et al., 2005  
Iurov et al., 2010 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
GSC2(GSCL)(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the goosecoid homeobox 2 protein. 
Goosecoidlike (GSCL), a homeodomain-containing gene, 
resides in the critical region for VCFS/DGS on 22q11 and 
the encoded protein has a possible role in embryonic 
development as transcriptional regulator. 
 
Expressed in a limited number of adult tissues, including 
cerebral temporal and parietal lobes, as well as in early 
human development. 
It has been demonstrated that the Df(16)A+/− mice which carry 
a microdeletion including the Gscl and Dgcr14 genes, both 
located within the DiGeroge critical region, showed reduced 
synchrony of hippocampal theta with the neuronal activity of 
the prefrontal cortex. Moreover, it has been recently reported 
that loss of Gscl and Dgcr14 affects the regulation of 
hippocampal theta and REM sleep, possibly contributing to the 
psychiatric symptoms frequently seen in patients who have 
22q11 syndrome. 
GSCL maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Funato et al., 2010 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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HIRA(+) 
de novo 
 
Embryonic development 
This gene encodes the HIR histone cell cycle regulation 
defective homolog A (S. cerevisiae), which is a histone 
chaperone that preferentially places the variant histone H3.3 
in nucleosomes. Orthologs of this gene in yeast, flies, and 
plants are necessary for the formation of transcriptionally 
silent heterochomatin. This gene plays an important role in 
the formation of the senescence-associated heterochromatin 
foci. These foci likely mediate the irreversible cell cycle 
changes that occur in senescent cells. It is considered the 
primary candidate gene in some haploinsufficiency 
syndromes such as DiGeorge syndrome, and insufficient 
production of the gene may disrupt normal embryonic 
development. 
 
Good expression in fetal brain and in postnatal caudate 
nucleus, amygdalae, and thalamus. 
High expression in immune cell types.  
HIR/HIRA, one of the histone chaperones, was initially 
identified in yeast as negative regulators of histone gene 
expression. It has been confirmed that HIRA contains a 
conserved family of proteins found in various species including 
low eukaryotes, invertebrates and vertebrates. It is essential for 
proper development. Mutations of Hir/Hira genes result in very 
serious defects in normal development not only in yeast but also 
in advanced eukaryotes.  
HIRA maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
Wang and Du, 2005 
     
KLHL22(+) 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway  
This gene encodes the kelch-like 22 (Drosophila) protein 
which is a substrate-specific adapter of a BCR (BTB-CUL3-
RBX1) E3 ubiquitin ligase complex required for cell 
division.  
 
Good expression in fetal brain and in postnatal CNS, in 
particular in prefrontal cortex, cerebellum, amygdalae and 
hypothalamus.  
The ubiquitin-proteasome system plays crucial roles in various 
aspects of neuronal development, such as axon formation, 
elongation and pruning, and synapse formation and 
elimination.  
The Cullin3 (Cul3)-based ubiquitin E3 ligases use BTB 
domain–containing proteins as substrate adaptors and, recently, 
KLHL20, a protein possessing a BTB domain and six kelch 
repeats, has been identified as such an adaptor. KLHL20 mRNA 
is abundantly expressed in the brain of an embryonic day 14.5 
(E14.5) mouse embryo, implying its role in neural development. 
In the adult mouse brain KLHL20 mRNA is highly expressed in 
the hippocampus, especially in the dentate gyrus, where a 
lifelong neurogenesis occurs. 
 
By analogy, it is possible that also KLHL22 may be involved in 
neurodevelopment.  
KLHL22 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lee et al., 2010 
Lin et al., 2011 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Segref and Hoppe, 2009  
Szatmari et al., 2007  
Tai and Schuman, 2008 
Vorstman et al., 2006 
Yi and Ehlers, 2007 
     
LZTR1(+) 
de novo 
 
Neurodevelopment: 
Golgi complex 
stabilizator 
This gene encodes the leucine-zipper-like transcription 
regulator 1 protein, which is a member of the BTB-kelch 
superfamily. Initially described as a putative transcriptional 
regulator based on weak homology to members of the basic 
leucine zipper-like family, the encoded protein subsequently 
has been shown to localize exclusively to the Golgi network 
where it may help stabilize the Golgi complex.  
 
Good expression in fetal brain and in postnatal CNS. In 
particular, high expression in the cortex. 
It is a probable transcriptional regulator that may play a crucial 
role in embryogenesis. 
 
LZTR1 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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MED15(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the mediator complex subunit 15, which is 
a subunit of the multiprotein complexes PC2 and ARC/DRIP 
and may function as a transcriptional coactivator in RNA 
polymerase II transcription.  
 
Moderate expression in fetal brain and in postnatal CNS.  
Good expression in immune cell types. 
Mediator is recruited to promoters by direct interactions with 
regulatory proteins and serves as a scaffold for the assembly of 
a functional preinitiation complex with RNA polymerase II and 
the general transcription factors.  
 
A possible involvement of the multiprotein complex MED15 in 
SCZ susceptibility was supported by the detection of an 
association in patients with SCZ vs. controls for an intragenic 
coding trinucleotide polymorphism. This datum was not later 
replicated. 
Recently, it has been reported that the mediator complex is used 
as a host RNA polymerase coactivator by herpes simplex, which 
diverts the polymerase activity toward viral RNA synthesis, thus 
suggesting a role of this protein in supporting cerebral infections 
which might be implicated in the onset of neurodevelopmental 
disorder. 
MED15 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
SNPs in MED12 have been associated with ASD. 
Antshel et al., 2007 
Beyer et al., 2012 
Bucan et al., 2009 
Carter, 2009 
De Luca et al., 2003 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Sandhu et al., 2004 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
MRPL40(+) 
de novo 
 
Neurodevelopment and 
maintainance: 
mitochondrial protein 
synthesis 
This nuclear gene encodes the mitochondrial ribosomal 
protein L40. Mammalian mitochondrial ribosomal proteins 
are encoded by nuclear genes and help in protein synthesis 
within the mitochondrion. Mitochondrial ribosomes 
(mitoribosomes) consist of a small 28S subunit and a large 
39S subunit.  
 
Moderate expression in fetal brain and in postnatal CNS. 
MRPL40 appears more selectively, but not exclusively, 
associated with projecton neurons in the bulb, cortex and 
cerebellum. Expression was also detected in adult brain and 
enriched in brain synapses. 
MRPL40 facilitates expression from the mitochondrial genes. 
MRPL40 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Accardi et al., 2004 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Maynard et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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PI4KA(+) 
de novo 
 
Phosphatidylinositol 
signaling system 
This gene encodes the phosphatidylinositol 4-kinase, 
catalytic, alpha protein, which catalyzes the first committed 
step in the biosynthesis of phosphatidylinositol 4,5-
bisphosphate. 
 
Good expression in fetal brain and in postnatal CNS. 
Good expression in immune cell types. 
Recently, it has been demonstrated that reduced expression of 
individual phosphatidylinositol 4-kinase isozymes is associated 
with impaired survival of specific neuronal populations within 
the CNS. Furthermore, alterations to the concentrations of 
different phosphoinositide lipid species in the brain can have 
deleterious effects on clathrin-dependent membrane trafficking 
both in the Golgi-endosomal pathway and at the plasma 
membrane. 
Therefore, the four mammalian phosphatidylinositol 4-kinases 
modulate neuronal pools of phosphoinositide lipid and regulate 
intracellular membrane trafficking in the endocytic and 
secretory pathways. Dysfunctions in these enzymes have been 
associated with a broad spectrum of disorders including SCZ, 
BD, Lowe syndrome, age-related neurodegeneration, 
Alzheimer's disease and Down syndrome.  
 
An atypical 0.8 Mb inherited duplication of 22q11.2, which 
encompasses 14 genes including CRKL, ZNF74, PIK4CA, 
SNAP29 and PCQAP known to contribute to several aspects of 
the DGS/VCFS phenotype, has been recently described in a 
patient with psychomotor impairment, suggesting a role for 
these genes in neurodevelopment. 
PI4KA maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
PI4KA has been previously suggested as autism candidate 
genes by molecular cytogenetic analysis and in silico 
studies. 
Antshel et al., 2007 
Bucan et al., 2009 
Clayton et al., 2012 
Fine et al., 2005  
Iurov et al., 2010 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pebrel-Richard et al., 2012 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
PRODH(+)de novo 
PRODH(-) 
 
Proline metabolism 
This nuclear gene encodes the proline dehydrogenase 
(oxidase) 1, which is a mitochondrial protein that catalyzes 
the first step in proline degradation.  
 
High expression in the fetal brain and in postnatal CNS. 
Mutations in PRODH are associated with hyperprolinemia type 
1 and susceptibility to schizophrenia 4 (SCZD4), which is a 
complex, multifactorial psychotic disorder or group of disorders 
characterized by disturbances in the form and content of 
thought, in mood (e.g. inappropriate affect), in sense of self and 
relationship to the external world (e.g. loss of ego boundaries, 
withdrawal), and in behavior (e.g bizarre or apparently 
purposeless behavior). There may be mild impairment of 
cognitive function 
 
PRODH is known to be dosage-sensitive in mouse 
neurodevelopment. 
PRODH maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
CNVs (loss) exclusively affecting PRODH and DGCR6 
and parentally inherited have been significantly 
associated with ASD.  
 
De novo CNVs (loss) affecting PRODH (demonstrated 
haploinsufficiency) have been reported in patients with 
ASD. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Guilmatre et al., 2009 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Meechan et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Nord et al., 2011 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
RANBP1(+) 
de novo 
 
Intracellular RAN-GTP 
signaling  
This gene encodes the RAN binding protein 1, which 
interacts specifically with GTP-charged RAN. RANBP1 does 
not activate GTPase activity of RAN but does markedly 
increase GTP hydrolysis by the RanGTPase-activating 
protein (RanGAP1).  
RANBP1 may act in an intracellular signaling pathway 
which may control the progression through the cell cycle by 
regulating the transport of protein and nucleic acids across 
the nuclear membrane. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Changes of hippocampal signaling protein levels, including the 
GTP-binding nuclear protein RAN, during postnatal brain 
development in the rat have been reported, thus supporting a 
developmental regulation of individual signaling proteins in the 
brain. 
RANBP1 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Weitzdörfer et al., 2008 
Vorstman et al., 2006 
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RTN4R(+) 
de novo 
 
Regulation of 
synaptogenesis during 
neurodevelopment 
This gene encodes the reticulon 4 receptor precursor, an 
oligodendrocyte myelin glycoprotein and myelin-associated 
glycoprotein. This receptor mediates axonal growth 
inhibition and may play a role in regulating axonal 
regeneration and plasticity in the adult CNS.  
 
It is widespread expressed in the brain but highest levels are 
found in the gray matter. 
It has been recently reported that RTN4R, also known as NgR1, 
inhibits the formation of new synapses in the postsynaptic 
neuron by signaling through the coreceptor TROY and RhoA, 
and functions in the dendrite as a barrier that limits excitatory 
synapse number during brain development, in particular in 
hippocampus. 
RTN4R maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005 
Guilmatre et al., 2009 
Lo-Castro et al., 2009  
Marshall et al., 2008  
Mukaddes and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010; 
Ramelli et al., 2008 
Szatmari et al., 2007 
Wills et al., 2012 
Vorstman et al., 2006 
     
SEPT5(+) 
de novo  
 
Intracellular vescicle 
trafficking: 
cytoskeleton dynamics 
This gene encodes the septin 5 protein, which is is a 
nucleotide binding protein, originally described in yeast as 
cell division cycle regulatory proteins. Septins are highly 
conserved in yeast, Drosophila, and mouse and appear to 
regulate cytoskeletal organization. Disruption of septin 
function disturbs cytokinesis and results in large 
multinucleate or polyploid cells. 
 
Very high expression in fetal brain and in postnatal CNS. 
SEPT5 acts as a filament-forming cytoskeletal GTPase and may 
play a role in cytokinesis and platelet secretion. Indeed, septins 
polymerize into heterooligomeric protein complexes that form 
filaments, and can associate with cellular membranes, actin 
filaments and microtubules.  
SEPT5 is important for active membrane movement such as 
vesicle trafficking and exocytosis in non-dividing cells (i.e. 
platelets, neurons). In a heterologous system, SEPT5 
overexpression has been shown to exert dopamine-dependent 
neurotoxicity. 
 
It has been recently reported on a four-year-old boy with a 
homozygous deletion comprising the GP1BB and SEPT5 genes, 
located 5' to GP1BB. He presented with Bernard-Soulier 
syndrome, cortical dysplasia (polymicrogyria), developmental 
delay, and platelet secretion defect, thus supporting the possible 
effect of defect of these two genes in neurodevelopment. 
SEPT5 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
Both GP1BB and SEPT5 have been previously suggested 
as autism candidate genes by molecular cytogenetic 
analysis and in silico studies. 
Antshel et al., 2007 
Bartsch et al., 2011 
Bucan et al., 2009 
Fine et al., 2005  
Iurov et al., 2010 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
SLC7A4(+) 
de novo 
 
Cellular trafficking: 
cationic amino acid 
transport 
This gene encodes the solute carrier family 7 (orphan 
transporter), member 4, which is involved in the transport of 
the cationic amino acids (arginine, lysine and ornithine). 
 
Moderate expression in fetal brain and in postnatal CNS. 
Cationic amino acid transporters (CAT) have important roles for 
normal brain functioning and various brain diseases.  
Recently, human cationic amino acid transporters 1, 2 and 3 
(hCAT1, 2, and 3) have been mapped immunohistochemically 
throughout five adult human brains. All three hCAT1s were 
mainly localized in neurons, but were also found in numerous 
astrocytes, oligodendrocytes, plexus choroideus epithelial cells, 
and small blood vessels. The highest density of hCAT 
expressing neurons was observed in the hypothalamus, in some 
areas of the cerebral cortex, the thalamic reticular nucleus and 
the caudate nucleus, whereas weak to moderate expression was 
detected in the hippocampus, the prefrontal cortex (hCAT1 
only), pons, brain stem and cerebellum. 
SLC7A4 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Jäger et al., 2012 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
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SLC25A1(+) 
de novo 
 
Cerebral mitochondrial 
metabolism 
This gene encodes the solute carrier family 25 (mitochondrial 
carrier; citrate transporter), member 1 (CTP), which is 
responsible for the movement of citrate across the 
mitochondrial inner membrane. 
In mouse models, the citrate transporter Slc25a1 is expressed 
minimally, but apparently ubiquitously, throughout the brain. In 
addition, Slc25a1 is highly expressed in a subset of large cells in 
the globus pallidus. It is essential for mithochondrial 
metabolism. 
SLC25A1 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Kaplan et al., 1995 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Maynard et al., 2009 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
      
 
 
 
 
 
SNAP29(+) 
de novo  
 
Synaptic plasticity 
This gene encodes the synaptosomal-associated protein, 
29kDa, which is a member of the SNAP25 gene family and 
is involved in multiple membrane trafficking steps. Two 
other members of this gene family, SNAP23 and SNAP25, 
encode proteins that bind a syntaxin protein and mediate 
synaptic vesicle membrane docking and fusion to the plasma 
membrane. The protein encoded by this gene binds tightly to 
multiple syntaxins and is localized to intracellular membrane 
structures rather than to the plasma membrane.  
 
Moderate expression in fetal brain and postnatal CNS.  
High expression in immune cell types. 
In vitro studies in cultured hyppocampal neurons have recently 
reported SNAP-29 as a candidate molecule regulating the 
disassembly of the SNARE complex. Indeed, SNAP-29 is 
present at synapses and regulates recycling of the SNARE 
complexes by competing with α-SNAP for binding to the 
SNAREs and consequently inhibiting disassembly of the 
SNARE complex. These findings suggest that SNAP-29 acts as 
a negative modulator for neurotransmitter release, probably by 
slowing recycling of the SNARE-based fusion machinery and 
synaptic vesicle turnover. 
In presynaptic neurons SNAP-29 binds to STX1A, which is also 
involved in docking of synaptic vesicles at presynaptic active 
zones. Moreover, SNAP-29 promoter is one of the targets of β-
catenin. 
 
Defects in SNAP29 are the cause of CEDNIK syndrome, which 
is a neurocutaneous syndrome characterized by cerebral 
dysgenesis, neuropathy, ichthyosis and palmoplantar 
keratoderma. 
 
An atypical 0.8 Mb inherited duplication of 22q11.2, which 
encompasses 14 genes including CRKL, ZNF74, PIK4CA, 
SNAP29 and PCQAP known to contribute to several aspects of 
the DGS/VCFS phenotype, has been recently described in a 
patient with psychomotor impairment, suggesting a role for 
these genes in neurodevelopment. 
SNAP29 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A polymorphism in the SNAP29 gene promoter has been 
associated to SCZ. 
 
SNPs in STX1A have been associated with ASD and HF-
AU. Moreover, in the postmortem anterior cingulate 
gyrus region of autistic patients, STX1A expression was 
found to be significantly lower than that of the control 
group. 
Antshel et al., 2007 
Bucan et al., 2009 
de Queiroz Soares et al., 2012 
Fine et al., 2005  
Guilmatre et al., 2009 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Nakamura et al. 2008, 2011 
Niklasson et al., 2009 
Pedrosa et al., 2010 
Pan et al., 2005 
Pebrel-Richard et al., 2012 
Pinto et al., 2010 
Ramelli et al., 2008 
Saito et al., 2001 
Sprecher et al., 2005  
Su et al., 2001 
Szatmari et al., 2007  
Vorstman et al., 2006 
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TBX1(+) 
de novo  
 
Transcriptional 
regulation  
This gene encodes the T-box 1 (TBX1), transcript variant B 
protein, which belongs to a family of conserved transcription 
factors involved in the regulation of developmental 
processes.  
 
Moderate expression in fetal brain and in postnatal CNS. 
Studies using mouse models of DiGeorge syndrome suggest a 
major role for TBX1 in the molecular etiology of DGS/VCFS, 
which are characterized by neural-crest-related developmental 
defects. 
 
It has been reported that Tbx1 heterozygous mice are impaired 
in social interaction, ultrasonic vocalization, memory-based 
behavioral alternation, working memory and thigmotaxis, 
compared with wild-type mice. Furthermore, Tbx1 mRNA and 
protein are ubiquitously expressed throughout the brain, but 
protein expression is enriched in regions that postnatally retain 
the capacity of neurogenesis. In postnatally derived 
hippocampal culture cells, Tbx1 levels are higher during 
proliferation than during differentiation, and expressed in neural 
progenitor cells, immature and matured neurons and glial cells.  
TBX1 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
An inactivating mutation of TBX1 has been previously 
reported in a patient with Asperger syndrome. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Hiramoto et al., 2011 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Paylor et al., 2006 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
TRMT2A 
(HTF9C)(+) 
de novo  
 
Neurodevelopment? 
This gene encodes the TRM2 tRNA methyltransferase 2 
homolog A (S. cerevisiae) protein, which has an unknown 
function. However, it is orthologous to the mouse Trmt2a 
gene and contains an RNA methyltransferase domain. 
Expression of this gene varies during the cell cycle, with 
aberrant expression being a possible biomarker in certain 
breast cancers. 
 
Low expression in fetal brain and moderate expression in 
postnatal CNS. 
TRMT2A probably functions as a regulator of cell cycle. 
TRMT2A maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
A SNP of the HTF9C gene has been previously 
associated with a deficit in sustained attention within SCZ 
in a Taiwanese cohort that might be an endophenotype of 
SCZ. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Liu et al., 2007 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
TXNRD2(+) 
de novo  
 
Mitochondrial neuronal 
metabolism  
This nuclear gene encodes the thioredoxin reductase 2, a 
mitochondrial dimeric NADPH-dependent FAD containing 
enzyme that catalyzes the reduction of the active site 
disulfide of thioredoxin and other substrates. TR is a member 
of a family of pyridine nucleotide-disulfide oxidoreductases 
and is a key enzyme in the regulation of the intracellular 
redox environment. Three thioredoxin reductase genes have 
been found that encode selenocysteine containing proteins. 
This gene partially overlaps the COMT gene on chromosome 
22. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Expression was also detected in adult brain and enriched in 
brain synapses. 
TXNRD2 has been analyzed in mammalian cells and it has been 
demonstrated that its role in reducing thioredoxin appears to be 
essential for preventing cell death. 
 
The developmental impact of over-expression of an ~190 kb 
segment of human 22q11.2, which includes TXNRD2, COMT 
and ARVCF, on behaviors in bacterial artificial chromosome 
transgenic mice vs. wild-type mice has been determined. The 
collected data suggest that over-expression of this 22q11.2 
segment enhances incentive learning and impairs the prolonged 
maintenance of working memory, but has no apparent effect on 
working memory per se, affect- and stress-related behaviors or 
motor capacity. 
TXNRD2 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
TXNRD2 polymorphisms in the shared upstream 
promoter with COMT have been associated with SCZ. 
Moreover, TXNRD2 is apparently elevated in 
schizophrenic brain samples. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Maynard et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Prabakaran et al., 2004 
Ramelli et al., 2008 
Sanders et al., 2005 
Suzuki et al., 2009 
Szatmari et al., 2007  
Vorstman et al., 2006 
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UFD1L(+) 
de novo  
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the ubiquitin fusion degradation 1 like 
(yeast) protein, which forms a complex with two other 
proteins, nuclear protein localization-4 and valosin-
containing protein, and this complex is necessary for the 
degradation of ubiquitinated proteins. In addition, this 
complex controls the disassembly of the mitotic spindle and 
the formation of a closed nuclear envelope after mitosis.  
 
Moderate expression in fetal brain and in postnatal CNS. 
Mutations in this gene have been associated with Catch 22 
syndrome as well as cardiac and craniofacial defects. 
 
UFD1L encodes for the ubiquitin fusion degradation 1 protein, 
which is expressed in the medial telencephalon during mouse 
development.  
An association between SCZ and a single nucleotide functional 
polymorphism, located within the noncoding region upstream 
the first exon of the UFD1L gene, has been reported. 
UFD1L maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Antshel et al., 2007 
Bucan et al., 2009 
De Luca et al., 2001 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
     
ZDHHC8(+) 
de novo  
 
Synaptic transmission: 
post-translational 
modification 
(palmytoilation) 
This gene encodes the zinc finger, DHHC-type containing 8 
protein, which is a member of the zinc finger DHHC domain-
containing protein family. The encoded protein may function 
as a palmitoyltransferase and is localized in mitochondria. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Expression was also detected in adult brain and enriched in 
brain synapses. 
Post-translational modification of proteins by the lipid palmitate 
is critical for protein localization and function. Palmitoylation is 
regulated by the opposing enzymes palmitoyl acyltransferases 
(PATs) and acyl protein thioesterases, which add and remove 
palmitate from proteins, respectively. Palmitoylation is 
particularly important for a number of processes including 
neuronal development and synaptic activity in the central 
nervous system.  
Dysregulated palmitoylation contributes to neuropsychiatric 
disease. Indeed, in total six PATs (HIP14, HIP14L, ZDHHC8, 
ZDHHC9, ZDHHC12, and ZDHHC15) have been implicated in 
Huntington disease, Alzheimer disease, SCZ, MR, and infantile 
and adult onset forms of neuronal ceroid lipofuscinosis. 
 
Zdhhc8 is found primarily in apparent presynaptic processes, 
with an apparent preference for Zdhhc8 in glutmatergic versus 
GABAergic processes indicates an enhanced role for Zdhhc8 in 
excitatory synaptic transmission.  
ZDHHC8 overexpression studies demonstrated an increased 
level of the corresponding protein and a subsequent increase in 
apoptotic cell death, perhaps leading to disrupted mitochondrial 
function. 
ZDHHC8 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder.  
 
SNPs affecting ZDHHC8 have been robustly associated 
to SCZ. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Liu et al., 2002a and b 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Maynard et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Vorstman et al., 2006 
Young et al., 2012 
     
ZNF74(+) 
de novo  
 
Transcriptional 
regulation 
This gene encoder the zinc finger protein 74. 
 
High expression in fetal brain and good expression in 
postnatal CNS. 
A speciific ZNF74 genotype has been associated with age-at-
onset of SCZ. 
An atypical 0.8 Mb inherited duplication of 22q11.2, which 
encompasses 14 genes including CRKL, ZNF74, PIK4CA, 
SNAP29 and PCQAP known to contribute to several aspects of 
the DGS/VCFS phenotype, has been recently described in a 
patient with psychomotor impairment, suggesting a role for 
these genes in neurodevelopment. 
ZNF74 maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
Antshel et al., 2007 
Bucan et al., 2009 
Fine et al., 2005  
Lo-Castro et al., 2009 
Marshall et al., 2008 
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pebrel-Richard et al., 2012 
Pinto et al., 2010 
Ramelli et al., 2008 
Szatmari et al., 2007  
Takase et al., 2001 
Vorstman et al., 2006 
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 Patient 29, gain of 8.0 Mb at 15q11.1q13.1 (chr15:20575646-28535051) 
 Patient 50, loss of 211 kb at 15q11.2 (chr15:22873688-23085096) 
 Patient 55, gain of 203 kb at 15q11.2 (chr15:22873688-23076420) 
     
ATP10A(+) 
de novo 
 
Neurodevelopment? 
This gene encodes the ATPase class V, type 10A protein, 
which belongs to the family of P-type cation transport 
ATPases, and to the subfamily of aminophospholipid-
transporting ATPases. The aminophospholipid translocases 
transport phosphatidylserine and phosphatidylethanolamine 
from one side of a bilayer to another. This gene is maternally 
expressed.  
 
Good expression in fetal brain and in postnatal whole brain. 
Defects in ATP10A contribute, in addition to mutations in 
UBE3A, to the onset of Angelman syndrome (AS). 
 
Allelic expression of ATP10A transcript in 16 human control 
brain samples has been recently examined: 10/16 exhibited 
biallelic expression while only 6/16 showed monoallelic 
expression. Contrary to the expectation for a maternally 
expressed imprinted gene, quantitative RT-PCR revealed 
significantly reduced ATP10A transcript in Prader-Willi 
syndrome brains with two maternal chromosomes due to 
uniparental disomy (PWS UPD). Investigation of factors that 
may influence allelic ATP10A expression status revealed that 
gender has a major affect, as females were significantly more 
likely to have monoallelic ATP10A expression than males. 
Moreover, a promoter polymorphism that disrupts binding of 
the transcription factor Sp1 also potentially contributes to allelic 
expression differences in females, thus supporting that 
monoallelic expression of human ATP10A is variable in the 
population and is influenced by both gender and common 
genetic variation. 
In mouse brain ATP10A is not imprinted. 
ATP10A maps within the genomic region which is deleted 
in PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11.2-q13.1 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
SNPs in ATPA10 have been previously associated with 
ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006 
DuBose et al., 2010 
Hogart et al., 2008, 2010 
Nurmi et al., 2003 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
     
C15orf2(+) 
de novo 
 
Neurodevelopment?  
This gene encodes the chromosome 15 open reading frame 2 
protein. This gene is biallelically expressed in adult testis and 
brain but is paternally imprinted in fetal brain. Defects in this 
gene may be associated with Prader-Willi syndrome. 
 
Moderate expression in fetal brain and in postnatal CNS. 
C15orf2 has no ortholog in rodents, but appears to be under 
strong positive selection in primates. C15orf2 encodes a 1156 
amino acid protein with six nuclear localisation sequences. 
Recently, it has been predicted a sequence similarity of C15orf2 
to the nuclear pore complex (NPC) protein POM121 and it has 
been demonstrated that C15orf2 is located at the inner face of 
the nuclear envelope where it strongly associates with the NPC  
C15orf2 maps within the genomic region which is deleted 
in PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11.2-q13.1 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Neumann et al., 2012 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
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CYFIP1(+)de novo 
CYFIP1(-)de novo 
CYFIP1(+) 
 
Translational repression  
This gene encodes the cytoplasmic FMR1 interacting protein 
1, which is a component of the CYFIP1-EIF4E-FMR1 
complex that binds to the mRNA cap and mediates 
translational repression. CYFIP1 promotes the translation 
repression activity of FMR1 in brain probably by mediating 
its association with EIF4E and mRNA. Moreover, it regulates 
formation of membrane ruffles and lamellipodia, plays a role 
in axon outgrowth throught its actin remodeling activity. 
 
Moderate expression in fetal brain and in postnatal CNS, 
particularly in amygdalae. 
CYFIP1 is particularly enriched at synapses. 
CNVs (de novo and inherited) between BP1 and BP2 
encompassing CYFIP1, NIPA1, NIPA2, and TUBGCP5, 
are responsible for the 15q11.2 
microdeletion/microduplication syndrome, which is 
comorbid with ASD and shows incomplete penetrance. 
 
A few rare deletions and common SNPs at 15q11.2, 
including CYFIP1, have been recently associated with 
SCZ in a Chinese Han population. 
 
Mutation affecting FMR1 are responsible for the Fragile 
X syndrome which is comorbid with ASD. 
Clifford et al., 2007 
Doornbos et al., 2009 
Kielinen et al., 2004 
Schenck et al., 2003 
Sempere Perez et al., 2011 
Wang et al., 2010 
van der Zwaag et al., 2010 
Zhao et al., 2012 
     
GABRA5(+) 
de novo 
 
Synaptic function and 
plasticity 
This gene encodes the gamma-aminobutyric acid (GABA) A 
receptor, alpha 5. GABA is the major inhibitory 
neurotransmitter in the mammalian brain where it acts at 
GABA-A receptors, which are ligand-gated chloride 
channels. Chloride conductance of these channels can be 
modulated by agents such as benzodiazepines that bind to the 
GABA-A receptor. It is located at postsynaptic cell 
membrane. 
 
Very high expression in fetal brain and in postnatal CNS. 
An altered expression of gamma-aminobutyric acid A 
(GABAA) and gammaaminobutyric acid B (GABAB) receptors 
has been reported in the brains of subjects with autism. 
GABRA5 maps within the genomic region which is 
deleted in PWS and AS, that both are comorbid with 
ASD. Moreover, this gene is involved in the 15q11.2-
q13.1 duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
GABRA5 polymorphisms have been associated with BD, 
major depression and SCZ of a later-age onset. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Fatemi et al., 2010 
Hogart et al., 2010 
Oruc et al., 1997 
Papadimitriou et al., 1998, 2001 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
      
GABRB3(+) 
de novo 
 
Synaptic function and 
plasticity 
This gene encoder the gamma-aminobutyric acid (GABA) A 
receptor, beta 3 (GABRB3), which is a member of the ligand-
gated ionic channel family. The encoded protein is one of at 
least 13 distinct subunits of a multisubunit chloride channel 
that serves as the receptor for gamma-aminobutyric acid, the 
major inhibitory transmitter of the nervous system.  
 
Very high expression in fetal brain and in postnatal CNS, in 
particular in amygdalae.  
An altered expression of gamma-aminobutyric acid A 
(GABAA) and gammaaminobutyric acid B (GABAB) receptors 
has been reported in the brains of subjects with autism. 
GABRB3 maps within the genomic region which is 
deleted in PWS and AS, that both are comorbid with 
ASD. Moreover, this gene is involved in the 15q11.2-
q13.1 duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
Polymorphisms in GABRB3 have been reported in 
patients with ASD. 
 
Defects in GABRB3 are associated with absence epilepsy 
type 5 (ECA5), which is a subtype of idiopathic 
generalized EP characterized by an onset at age 6-7 years, 
frequent absence seizures (several per day) and bilateral, 
synchronous, symmetric 3-Hz spike waves on EEG. 
Bolton, 2004 
Bonati et al., 2007 
Buxbaum et al., 2002 
Cook et al., 1997, 1998 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Fatemi et al., 2010 
Hogart et al., 2010 
Kim et al., 2006 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Tanaka et al., 2008 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
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Tab. 4.1. Continued. 
GABRG3(+) 
de novo 
 
Synaptic function and 
plasticity 
This gene encodes the gamma-aminobutyric acid (GABA) A 
receptor, gamma 3 (GABRG3). GABA-A receptors are 
pentameric, consisting of proteins from several subunit 
classes: alpha, beta, gamma, delta and rho. The protein 
encoded by this gene is a gamma subunit, which contains the 
benzodiazepine binding site. GABA is the major inhibitory 
transmitter of the nervous system.  
 
Moderate expression in fetal brain and in postnatal CNS, in 
particolar in the cortex.  
An altered expression of gamma-aminobutyric acid A 
(GABAA) and gammaaminobutyric acid B (GABAB) receptors 
has been reported in the brains of subjects with autism. 
GABRG3 maps within the genomic region which is 
deleted in PWS and AS, that both are comorbid with 
ASD. Moreover, this gene is involved in the 15q11.2-
q13.1 duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
Two SNPs in GABRG3 have been associated with ASD.  
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Menold et al., 2001 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
     
MAGEL2(+) 
de novo 
 
Neurodevelopment  
This gene encodes the MAGE-like protein 2. This gene is 
structurally similar to NDN, is also localized to the PWS 
chromosomal region, and is paternally imprinted, suggesting 
a possible role for it in PWS. MAGEL2 belongs to the 
MAGE/necdin family of proteins, which have roles in cell 
cycle, differentiation, and apoptosis. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in amygdalae, thalamus and hypothalamus. 
MAGEL2 is expressed in various brain regions, most notably the 
hypothalamus. Mice with a targeted deletion of Magel2 display 
hypoactivity, blunted circadian rhythm, decreased fertility, and 
increased adiposity.  
It has been reported that in Magel2-null mice brain volume was 
reduced in specific regions, particularly in the parieto-temporal 
lobe of the cerebral cortex, the amygdalae, the hippocampus, 
and the nucleus accumbens, as measured by quantitative 
magnetic resonance imaging. Abnormal neurochemistry was 
detected in brain samples from adult mice, consisting of 
decreased serotonin and 5-hydroxyindoleacetic acid in the 
cortex and the hypothalamus, and decreased dopamine in the 
hypothalamus. Magel2-null mice displayed relatively normal 
motor and learning abilities, but exhibited abnormal behavior in 
novel environments.  
MAGEL2 maps within the genomic region which is 
deleted in PWS and AS, that both are comorbid with 
ASD. Moreover, this gene is involved in the 15q11.2-
q13.1 duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006 
Hogart et al., 2010 
Mercer et al., 2009 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
     
MKRN3(+) 
de novo 
 
Probabably involved in 
protein ubiquitination 
pathway 
This gene encodes the makorin ring finger protein 3, which 
contains a RING (C3HC4) zinc finger motif and several C3H 
zinc finger motifs. This gene is intronless and imprinted, with 
expression only from the paternal allele. Disruption of the 
imprinting at this locus may contribute to Prader-Willi 
syndrome. An antisense RNA of unknown function has been 
found overlapping this gene. 
 
Low expression in fetal brain and good expression in 
postnatal amygdalae, thalamus and hypothalamus. 
MKRN3 encodes the zing finger protein 127 (ZNF127) which 
possibly function as a ribonucleoprotein. The intronless ZNF127 
gene is expressed ubiquitously and allele-specific analysis 
shows that ZNF127 is expressed only from the paternal allele. 
Consistent with this expression pattern, in the brain the ZNF127 
5' CpG island is completely unmethylated on the paternal allele 
but methylated on the maternal allele. 
ZNF127 probably belongs to the E3 ubiquitin ligase complex. 
 
Defects at this locus are not sufficient to cause PWS. 
MKRN3 maps within the genomic region which is deleted 
in PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11.2-q13.1 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006 
Hogart et al., 2010 
Jong et al., 1999 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
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Tab. 4.1. Continued. 
NDN(+) 
de novo 
 
Transcriptional 
regulation 
This intronless gene encodes the necdin homolog (mouse) 
protein, and is located in the Prader-Willi syndrome deletion 
region. It is an imprinted gene and is expressed exclusively 
from the paternal allele. Studies in mouse suggest that the 
protein encoded by this gene may suppress growth in 
postmitotic neurons, facilitating the entry of the cell into the 
cycle arrest. 
 
High expression in fetal brain and in postnatal CNS. 
NDN directly interacts with the transcription factor E2F1 via its 
transactivation domain and represses E2F1-dependent 
transcription. In addition, necdin interacts with NGFR, the nerve 
growth factor receptor, via its distinct intracellular domains. 
NDN maps within the genomic region which is deleted in 
PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11.2-q13.1 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
     
NIPA1(+) de novo 
NIPA1(-) de novo 
NIPA1(-)* 
 
Neurodevelopment and 
maintenance 
This gene encodes the non imprinted in Prader-
Willi/Angelman syndrome 1 protein, which is a magnesium 
transporter that associates with early endosomes and the cell 
surface in a variety of neuronal and epithelial cells. This 
protein may play a role in nervous system development and 
maintenance.  
 
Widely expressed with highest levels in neuronal tissues. 
Two non imprinted genes in the 15q11.2 region, CYFIP1 and 
NIPA1, are widely expressed during mouse brain development 
and are known to be implicated in axonal growth, neuronal 
connectivity, and neuronal morphology, thus being good 
candidates for ASD pathogenesis. 
Moreover, defects in NIPA1 are the cause of spastic paraplegia 
autosomal dominant type 6 (SPG6). Spastic paraplegia is a 
degenerative spinal cord disorder characterized by a slow, 
gradual, progressive weakness and spasticity of the lower limbs. 
CNVs (de novo and inherited) between BP1 and BP2 
encompassing CYFIP1, NIPA1, NIPA2, and TUBGCP5, 
are responsible for the 15q11.2 
microdeletion/microduplication syndrome, which is 
comorbid with ASD and shows incomplete penetrance. 
 
A few rare deletions and common SNPs at 15q11.2, 
including NIPA1, have been recently associated with SCZ 
in a Chinese Han population. 
Doornbos et al., 2009 
Sempere Perez et al., 2011 
van der Zwaag et al., 2010 
Zhao et al., 2012 
     
NIPA2(+) de novo 
NIPA2(-) de novo 
NIPA2(+) 
 
Neurodevelopment 
This gene encodes the non imprinted in Prader-
Willi/Angelman syndrome 2 protein, which is a possible 
magnesium transporter. This gene is located adjacent to the 
imprinted domain in the Prader-Willi syndrome deletion 
region of chromosome 15. 
 
Low expression in fetal brain and high expression in postnatal 
amygdalae. 
NIPA2 plays a role in magnesium metabolism and regulation of 
renal magnesium conservation. 
 
NIPA2 heterozygous muutations cause the Childhood Absence 
Epilepsy in Chinese populations. 
CNVs (de novo and inherited) between BP1 and BP2 
encompassing CYFIP1, NIPA1, NIPA2, and TUBGCP5, 
are responsible for the 15q11.2 
microdeletion/microduplication syndrome, which is 
comorbid with ASD and shows incomplete penetrance. 
 
A few rare deletions and common SNPs at 15q11.2, 
including NIPA2, have been recently associated with SCZ 
in a Chinese Han population. 
Doornbos et al., 2009 
Goytan et al., 2008 
Jiang et al., 2012 
Sempere Perez et al., 2011 
van der Zwaag et al., 2010 
Zhao et al., 2012 
      
 
SNRPN(+) 
de novo 
 
Tissue-specific mRNA 
splicing regulation 
This gene encodes the small nuclear ribonucleoprotein 
polypeptide N, which belongs to the snRNP SMB/SMN 
family. The protein plays a role in pre-mRNA processing, 
possibly tissue-specific alternative splicing events. Multiple 
transcription initiation sites have been identified and 
extensive alternative splicing occurs in the 5' untranslated 
region.  
 
Good expression in fetal brain and high expression in 
postnatal CNS. 
Good-high expression in immune cell types. 
Defects in SNURF-SNRPN methylation cause Prader-Willy 
syndrome. 
 
Patients with the autoimmune disease systemic lupus 
erythematosus (SLE) have autoantibodies directed against some 
of the individual snRNP polypeptides. The most common 
autoantigen is called Sm. A wide range of non-specific 
symptoms can reveal neurolupus such as psychiatric disorders 
(mood disorders and schizoid personality)clear role of anti-
Sm autoantibodies in brain. 
SNRPN maps in the genomic region which is deleted in 
PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11-q13 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
Recently, a rare CNV disrupting the SNRPN-SNURF 
genes has been reported in an autistic boy without clinical 
signs of PWS/AS. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Simonin et al., 2004 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Talkowski et al., 2012 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
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SNURF(+)de novo 
 
Neurodevelopment? 
This gene encodes the SNRPN upstream reading frame 
protein, which is a highly basic protein localized to the 
nucleus. The evolutionarily constrained open reading frame is 
found on a bicistronic transcript which has a downstream 
ORF encoding the small nuclear ribonucleoprotein 
polypeptide N. The upstream coding region utilizes the first 
three exons of the transcript, a region that has been identified 
as an imprinting center. Multiple transcription initiation sites 
have been identified and extensive alternative splicing occurs 
in the 5' untranslated region but the full-length nature of these 
transcripts has not been determined. 
 
Moderate expression in fetal brain and very high expression 
in postnatal CNS. 
High expression in B- and T-cells. 
Defects in SNURF-SNRPN methylation cause Prader-Willy 
syndrome. 
SNURF maps in the genomic region which is deleted in 
PWS and AS, that both are comorbid with ASD. 
Moreover, this gene is involved in the 15q11-q13 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
Recently, a rare CNV disrupting the SNRPN-SNURF 
genes has been reported in an autistic boy without clinical 
signs of PWS/AS. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Talkowski et al., 2012 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
      
 
TUBGCP5(+) 
de novo 
TUBGCP5(-) 
de novo 
TUBGCP5(+)* 
 
Intracellular signaling: 
regulation of 
microtubule cytoskeleton 
dynamics 
This gene encodes the tubulin gamma complex associated 
protein 5. 
 
Low expression in fetal brain and good expression in 
postnatal parietal lobe, prefrontal cortex, and hypothalamus. 
High expression in T-cells. 
The gamma-tubulin complex is a large multiprotein complex, 
conserved among different species, that is required for 
microtubule nucleation at the centrosome. GCP5 and GCP6, like 
other components of the gamma-tubulin complex, localize to the 
centrosome and associate with microtubules, suggesting that the 
entire gamma-tubulin complex takes part in both of these 
interactions. Stoichiometry experiments revealed that there is a 
single copy of GCP5 and multiple copies of gamma-tubulin, 
GCP2, GCP3, and GCP4 within the gamma-tubulin complex. 
Thus, the gamma-tubulin complex is conserved in structure and 
function, suggesting that the mechanism of microtubule 
nucleation is conserved. 
Glycogen synthase kinase-3beta (GSK-3beta) is involved in the 
regulation of the dynamics of microtubule networks in cells. 
GSK-3beta interacts with GCP5 and both proteins partecipate in 
the proper formation of the mitotic spindles. 
CNVs (de novo and inherited) between BP1 and BP2 
encompassing CYFIP1, NIPA1, NIPA2, and TUBGCP5, 
are responsible for the 15q11.2 
microdeletion/microduplication syndrome, which is 
comorbid with ASD and shows incomplete penetrance. 
 
A few rare deletions and common SNPs at 15q11.2, 
including TUBGCP5, have been recently associated with 
SCZ in a Chinese Han population. 
Doornbos et al., 2009 
Izumi et al., 2008 
Murphy et al., 2001 
Sempere Perez et al., 2011 
van der Zwaag et al., 2010 
Zhao et al., 2012 
     
cluster 
snoRNAs(+) 
de novo 
 
Neurodevelopment 
These genes encode different classes of small nucleolar 
RNAs. 
 
High expression in the CNS. 
A few small deletions of different class of snoRNA genes  
The cluster of snoRNA genes map in the genomic region 
which is deleted in PWS and AS, that both are comorbid 
with ASD. Moreover, these genes are involved in the 
15q11-q13 duplication syndrome, which is the most 
frequently chromosomal anomaly associated with ASD. 
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Hogart et al., 2010 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
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UBE3A(+) 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This genen encodes the ubiquitin protein ligase E3A, which is 
part of the ubiquitin protein degradation system. This 
imprinted gene is maternally expressed in brain and 
biallelically expressed in other tissues.  
 
Good-high expression in fetal brain and moderate expression 
in postnatal CNS. 
Increased UBE3A gene dosage produce autism-related 
behavioral traits both in humans and mice that share the same 
conserved imprinting pattern. In particular, autism behavioral 
traits are weakly penetrant in individuals with mat dup15 
(double dose of UBE3A), but highly penetrant in mat idic15 
(triple dose of UBE3A). 
Indeed, UBE3A triple dosage reconstitute the three core autism 
traits in mice: defective social interaction, impaired 
communication, and increased repetitive stereotypic behavior. 
Moreover, in animals with increased UBE3A gene dosage, 
glutamatergic, but not GABAergic, synaptic transmission is 
suppressed as a result of reduced presynaptic release 
probability, synaptic glutamate concentration, and post-synaptic 
action potential coupling. 
Maternally inherited deletion of this gene causes 
Angelman Syndrome (AS), which is an imprinting 
disorder characterized by severe motor and intellectual 
retardation, ataxia, hypotonia, EP, absence of speech, and 
characteristic facies. AS is caused by maternal deletion of 
chromosome 15, paternal uniparental disomy, imprinting 
defect, or UBE3A mutation. Over one-half of the patients 
with Angelman syndrome have ASD. 
Moreover, UBE3A is involved in the 15q11.2-q13.1 
duplication syndrome, which is the most frequently 
chromosomal anomaly associated with ASD. 
 
CNVs involving other E3 ligase genes have been 
previously reported in patients with ASD.  
Bolton, 2004 
Bonati et al., 2007 
Cook et al., 1997 
Depienne et al., 2009 
Descheemaeker et al., 2006  
Glessner et al., 2009 
Hogart et al., 2010 
Kishino et al., 1997 
Matsuura et al., 1997 
Pinto et al., 2010 
Sahoo et al., 2006 
Schroer et al., 1998 
Scheuerle and Wilson, 2011 
Smith et al., 2011 
Steffenburg et al., 1996 
Szatmari et al., 2007 
Trillingsgaaard and Østergaard, 
2004 
Veltman et al., 2005 
 
 Patinet 30, gain of 800 kb at 16p13.11 (chr16:15492317-16292235) 
      
NDE1(+) 
 
Neurogenesis and 
neuronal migration: 
regulation of microtubule 
cytoskeleton dynamics 
This gene encodes the nudE nuclear distribution gene E 
homolog 1 protein, which is a member of the nuclear 
distribution E family of proteins. This protein is localized at 
the centrosome and interacts with other centrosome 
components as part of a multiprotein complex that regulates 
dynein function. Moreover, it plays an essential role in 
microtubule organization, mitosis and neuronal migration.  
 
Moderate expression in postnatal prefrontal cortex, occipital 
lobe, thalamus, and hypothalamus.  
High expression in immune cell types. 
NDE1 is known to interact with DISC1 (disrupted in 
schizophrenia, which has a role in neurogenesis and neuronal 
migration) and LIS1 (causing lissencephaly 1).  
Deficiency of the LIS1–NDE1 complex impairs cortical 
neurogenesis and neuronal migration frequently leading to EP, 
whereas DISC1-NDE1 deficiency appears to play a role in 
neuropsychiatric disorders, including SCZ and BD. 
  
Moreover, mutations in NDE1 cause lissencephaly 4, a disorder 
characterized by lissencephaly, severe brain atrophy, 
microcephaly, and severe MR.  
NDE1 mapswithin the genomic region involved in 
the16p13.11 microdeletion/microduplication syndrome, 
which shows comorbidity with ASD, EP, ID, and SCZ.  
 
Inherited CNV (loss) involving DISC1 has been reported 
in patients with ASD and SCZ. 
SNPs in DISC1 in Chinese-Han populations have been 
associated with autism. 
Barkicioglu et al., 2011 
de Kovel et al., 2010 
Hennah et al., 2009 
Hennah and Porteus, 2009 
Pawlisz et al., 2008 
Pinto et al., 2010 
Ullmann et al., 2007 
Williams et al., 2009 
Zheng et al., 2011 
                Patient 51, loss of 8.8 Mb at 2q14.3q21.3 (chr2:127083045-135910585) 
      
 
 
ACMSD(-) 
de novo 
 
Tryptophan metabolism 
This gene encoder the aminocarboxymuconate semialdehyde 
decarboxylase. 
Quinolinate is derived from alpha-amino-beta-carboxy-
muconate-epsilon-semialdehyde (ACMS). ACMSD can 
divert ACMS to a benign catabolite and thus prevent the 
accumulation of quinolinate from ACMS. 
 
Moderate expression in postnatal temporal lobe, occipital 
lobe, parietal lobe, prefrontal cortex, and cerebellum 
peduncles. Good expression in thalamus.  
Good expression in monocytes, NK-, T-, and B-cells. 
The essential amino acid tryptophan is not only a precursor of 
serotonin but is also degraded to several other neuroactive 
compounds, including kynurenic acid, 3-hydroxykynurenine 
and quinolinic acid. In particulare, the quinolinate induce a 
neuronal excitotoxin due to its role as a NMDA receptor 
agonist.  
The synthesis of these metabolites is regulated by an enzymatic 
cascade, known as the kynurenine pathway, that is tightly 
controlled by the immune system. Dysregulation of this 
pathway, resulting in hyper-or hypofunction of active 
metabolites, is associated with neurodegenerative and other 
neurological disorders, such as Huntington’s disease, 
Parkinson’s disease and Alzheimer’s disease, as well as with 
psychiatric diseases such as depression and SCZ. 
Mutations and/or CNVs affecting ACMSD have never 
been reported in patients with ASD. 
 
One possible explanation for ASD pathogenesis is the 
modern theory of immunoexcitotoxicity. Indeed, chronic 
microglial activation is present in autistic brains from age 
5 years to age 44 years, which result in an outpouring of 
neurotoxic levels of the excitotoxins, glutamate and 
quinolinic acid. Careful control of brain glutamate levels 
is essential to brain pathway development and excesses 
can result in arrest of neural migration, as well as 
dendritic and synaptic loss. In addition, certain cytokines, 
such as TNF-alpha, can, via its receptor, interact with 
glutamate receptors to enhance the neurotoxic reaction. 
Blaylock, 2008 
Schwarcz et al., 2012 
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ARHGEF4(-) 
de novo 
 
Intracellular signaling: 
RhoA signaling 
implicated in regulation 
of actin cytoskeleton 
dynamics  
This gene encodes the Rho guanine nucleotide exchange 
factor 4.  
Rho GTPases play a fundamental role in numerous cellular 
processes that are initiated by extracellular stimuli that work 
through G protein coupled receptors. ARHGEF4 acts as 
guanine nucleotide exchange factor for RHOA, RAC1 and 
CDC42 GTPases. The APC-ARHGEF4 complex seems to be 
involved in cell migration as well as in E-cadherin-mediated 
cell-cell adhesion.  
 
Very high expression in fetal brain and in postnatal CNS. 
RhoGTPases play a pivotal role in regulating the actin 
cytoskeleton and influence cell polarity, microtubule dynamics, 
membrane-transport pathways, and transcription-factor activity. 
Numerous evidence has implicated RhoGTPases in neuronal 
morphogenesis, including cell migration, axonal growth and 
guidance, dendrite elaboration and plasticity, and synapse 
formation.  
RhoGEFs activate RhoGTPases by catalyzing the exchange of 
bound GDP for GTP, which induces a conformational change in 
the GTP-bound GTPase that allows its interaction with 
downstream effector proteins, thus playing a central role in 
defining the temporal and spatial activation of the corresponding 
GTPase within neuronal cells. 
Recently, a rare small (~450 kb unique sequence) 
recurrent deletion in a previously linked attention-deficit 
hyperactivity disorder (ADHD) locus at 2q21.1 has been 
identified in five unrelated families with developmental 
delay/ID, ADHD, EP and other neurobehavioral 
abnormalities. Moreover, the reciprocal duplications have 
been identified in five unrelated families with autism, 
developmental delay, seizures and ADHD. The 
rearranged segment harbors five genes: GPR148, 
FAM123C, ARHGEF4, FAM168B and PLEKHB2. 
 
RhoGEFs have been previously implicated in human 
genetic disorders: 
- a mutation in the DH domain of FGD1 
GEF cosegregates with faciogenital dysplasia, a 
developmental disorder;  
- mutations in ARHGEF6 are associated with 
X-linked nonsyndromic MR; 
- aberrant EphB/Ephexin5 signaling during the 
development of synapses may contribute to the abnormal 
cognitive function that occurs in Angelman syndrome 
and, possibly, ASD. 
Boguski and McCormick, 1993 
Bourne et al., 1990 
Dharmadhikari et al., 2012 
Etienne-Manneville and Hall, 
2002 
Hart et al., 1994 
Kutsche et al., 2000  
Margolis et al., 2010 
Pasteris et al., 1994 
Verhoeven et al., 2003 
      
 
 
 
 
 
BIN1(-) 
de novo 
 
Synaptic function and 
plasticity  
This gene encodes the bridging integrator 1 protein 
(amphiphysin 2), which is a nucleocytoplasmic adaptor 
protein. Isoforms that are expressed in the CNS may be 
involved in synaptic vesicle endocytosis and may interact 
with dynamin, synaptojanin, endophilin, and clathrin. 
Isoforms that are expressed in muscle and ubiquitously 
expressed isoforms localize to the cytoplasm and nucleus and 
activate a caspase-independent apoptotic process. Studies in 
mouse suggest that this gene plays an important role in 
cardiac muscle development. 
 
High expression in fetal brain and in postnatal CNS. 
Amphiphysin is an intracellular protein involved in the synaptic 
vesicle cycle that promotes cleavage of clathrin-coated vesicles 
via binding of its Src homology 3 (SH3)—domain to dynamin. 
Acute blocking of the function of amphiphysin impairs synaptic 
vesicle endocytosis in vitro, leading to alteration of the 
presynaptic architecture with an increased number of clathrin 
coat intermediates and a decrease in the releasable vesicle pool. 
This results in a functionally relevant synaptic transmission 
failure, particularly at higher frequencies. In knockout mice with 
amphiphysin deficiency, stimulus-dependent vesicle recycling is 
reduced, resulting in learning deficits and an increased 
susceptibility to seizures, consistent with reduced CNS 
inhibition. 
In humans, paraneoplastic stiff person syndrome (SPS) is an 
autoimmune disease associated with autoantibodies to 
amphiphysin. One of the symptoms is anxiety and a reduced 
function of GABAergic synapses in amygdalae of stiff patients 
has been recently reported, thus supporting the link between the 
presence of auto-Ab against BIN1 and the perturbation of 
GABAergic signaling.  
 
Defects in BIN1 are the cause of centronuclear myopathy 
autosomal recessive, also known as autosomal recessive 
myotubular myopathy.  
Mutations and/or CNVs affecting BIN1 have never been 
reported in patients with ASD. 
Folli et al., 1993 
Geis et al., 2010 
Wigge and McMahon, 1998 
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CCDC115(-) 
de novo 
 
Neurogenesis 
This gene encodes the coiled-coil domain containing 115 
protein. 
 
Expressed throughout the brain. 
The CCDC115 (or CCP1) gene has been recently identified 
downstream of Fibroblast Growth Factor 2 (FGF2) by 
microarray analysis. The CCP1 transcript is 
up-regulated upon FGF2 stimulation in primary cortical 
neuron culture derived from mouse embryonic telencephalon at 
embryonic day 14.5 (E14.5) and in neuroblastoma cell line, SK-
N-SH. In situ hybridizations revealed that CCP1 is expressed in 
the ventricular zone (VZ), a region of the developing cerebral 
cortex known to be composed of progenitor cells undergoing 
proliferation. 
It has been demonstrated that forced CCP1 expression in mouse 
embryonic fibroblast and neuroblastoma SK-N-SH cell line 
increased cell proliferation, whereas down-regulation of CCP1 
expression by siRNA reduced it, thus suggesting that CCP1 
regulates cell number by promoting proliferation and 
suppressing cell death. 
Mutations and/or CNVs affecting CCDC115 have never 
been reported in patients with ASD. 
McConnell and Kaznowski,  
1991 
Pellicano et al., 2006, 2010 
     
ERCC3(-)  
de novo 
 
DNA repair and 
transcription 
This gene encodes the excision repair cross-complementing 
rodent repair deficiency, complementation group 3 protein. 
ERCC3 is an ATP-dependent DNA helicase that functions in 
nucleotide excision repair and complements xeroderma 
pigmentosum group B mutations. It also is the 89 kDa 
subunit of basal transcription factor 2 (TFIIH) and thus 
functions in class II transcription. 
 
Moderate expression in fetal brain and in postnatal CNS, in 
particular in amygdalae, thalamus and hypothalamus. 
Defects in ERCC3 are the cause of xeroderma pigmentosum 
complementation group B, also known as xeroderma 
pigmentosum group B combined with Cockayne syndrome 
(XP/CS), an autosomal recessive pigmentary skin disorder 
characterized by solar hypersensitivity of the skin, high 
predisposition for developing cancers on areas exposed to 
sunlight and, in some cases, neurological abnormalities. Some 
XP-B patients present features of Cockayne syndrome, 
including dwarfism, sensorineural deafness, microcephaly, MR, 
pigmentary retinopathy, ataxia, decreased nerve conduction 
velocities. 
Furthermore, defects in ERCC3 are a cause of 
trichothiodystrophy photosensitive, an autosomal recessive 
disease characterized by sulfur-deficient brittle hair and nails, 
ichthyosis, MR, impaired sexual development, abnormal facies 
and cutaneous photosensitivity correlated with a nucleotide 
excision repair (NER) defect.  
 
In order to explore the link between the defective gene and the 
neurological deficits in XP/CS, the expression of ERCC3 
mRNA in developing mice by in situ hybridisation was studied. 
ERCC3 was found to be ubiquitously expressed in cells from all 
regions and all developmental stages, from 9 day post-coitum 
embryo, to 15 day post-natal brain. In post-natal brain, regional 
differences in expression correlated with cell density and there 
was no evidence of cell specific or developmental alterations in 
levels of expression. It is possible that the neurological defects 
apparent in XP-B are likely to arise pleiotypically from the 
participation of ERCC3 in interactions with other elements 
involved in particular aspects of neurodevelopmental control.  
Mutations and/or CNVs affecting ERCC3 have never 
been reported in patients with ASD. 
Hubank and Mayne, 1994 
Oh et al., 2006 
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FAM123C(-) 
de novo 
 
Neurodevelopment 
This gene encodes the family with sequence similarity 123C 
protein, which belongs to the FAM123 family. 
 
High expression in cerebellum. 
Recently, the characterizeation of the Wtx/Amer genes 
(FAM123) has been reported during mouse embryonic 
development. The three members of the family, namely Amer1 
(FAM123A), Amer2 (FAM123B) and Amer3 (FAM123C) are 
expressed in a highly overlapping manner, in particular 
concerning neuroectoderm derivatives, yet they also have 
distinct temporal and tissue-specific signatures. 
Amer genes share to a certain extent expression in neurons of 
both central and peripheral nervous systems, and in many neural 
crest derivatives including sensory cranial ganglia, dorsal 
root ganglia, autonomic ganglia, and branchial arches. This 
spatial and temporal overlap of gene expression patterns may 
suggest that one of the original functions of an AMER ancestor 
protein may have been related to the development of the 
nervous system. 
Recently, a rare small (~450 kb unique sequence) 
recurrent deletion in a previously linked attention-deficit 
hyperactivity disorder (ADHD) locus at 2q21.1 has been 
identified in five unrelated families with developmental 
delay/ID, ADHD, EP and other neurobehavioral 
abnormalities. Moreover, reciprocal duplications have 
been identified in five unrelated families with autism, 
developmental delay, seizures and ADHD. The 
rearranged segment harbors five genes: GPR148, 
FAM123C, ARHGEF4, FAM168B and PLEKHB2.  
 
Patients with germline mutations in AMER1 display, in 
addition to the sclerosing skeletal dysplasia, 
CNS malformations, and learning disabilities, pointing 
toward an important role of AMER1 during neurogenesis. 
Comai et al., 2010 
Dharmadhikari et al., 2012 
Jenkins et al., 2009 
     
FAM168B 
(MANI)(-) 
de novo 
 
Neurodevelopment 
This gene encodes the family with sequence similarity 168, 
member B protein, also known as MANI, myelin-associated 
neurite-outgrowth inhibitor. 
 
Good expression in fetal brain and high expression in 
postnatal CNS, in particular in the cortex. 
The protein MANI (myelin-associated neurite-outgrowth 
inhibitor) has been recently described: it localizes to neural 
membranes, promotes differentiation into catecholaminergic 
neurons, and one of its interacting protein is the cell division 
cycle protein 27 (Cdc27). Furthermore, MANI retards neuronal 
axonal growth as a positive effector of the protein Cdc27 
expression and activity, thus suggesting that the novel MANI-
Cdc27-APC pathway may be an important cascade that prevents 
neurons from extending axons, and providing implications for 
the potential treatment of neurodegenerative diseases. 
Recently, a rare small (~450 kb unique sequence) 
recurrent deletion in a previously linked attention-deficit 
hyperactivity disorder (ADHD) locus at 2q21.1 has been 
identified in five unrelated families with developmental 
delay/ID, ADHD, EP and other neurobehavioral 
abnormalities. Moreover, reciprocal duplications have 
been identified in five unrelated families with autism, 
developmental delay, seizures and ADHD. The 
rearranged segment harbors five genes: GPR148, 
FAM123C, ARHGEF4, FAM168B and PLEKHB2.  
Dharmadhikari et al., 2012 
Mishra et al., 2011 
     
GPR17(-) 
de novo 
 
Neurodevelopment 
This gene encodes the G protein-coupled receptor 17. 
 
Moderate expression in fetal brain and high expression in 
postnatal CNS, in particular in amygdalae, thalamus and 
hypothalamus. 
GPR17 is restricted to oligodendrocyte lineage cells in the CNS 
in a developmentally regulated manner. As development 
progress, GPR17 expression is downregulated and 
oligodendrocyte myelination begins. In vitro, GPR17 
overexpression not only blocks differentiation of neural 
progenitor cells into oligodendrocytes but also inhibits terminal 
differentiation of primary oligodendrocytes precursor cells 
(OPCs).  
In transgenic mice, sustained GPR17 overexpression in 
oligodendrocytes results in myelination arrest and 
oligodendrocyte loss. Conversely, GPR17 deletion accelerates 
OPC maturation in vitro and leads to an early-onset of 
myelination in the developing CNS. Taken together these 
data suggest that GPR17 acts to negatively regulate 
oligodendrocyte differentiation and myelination. 
Mutations and/or CNVs affecting GPR17 have never 
been reported in patients with ASD. 
Chen et al., 2009 
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GPR39(-)  
de novo 
 
Intracellular signaling 
This gene encodes the G protein-coupled receptor 39. 
This receptor mediates its action by association with G 
proteins that activate a phosphatidylinositol-calcium second 
messenger system. It is involved in regulation of body 
weight, gastrointestinal mobility, hormone secretion and cell 
death. Zn2+ acts as an agonist. 
 
Good expression in fetal brain and in postnatal thalamus and 
hypothalamus. 
The effects of Zn2+ on synaptic plasticity and neuronal 
excitability, and the effects of Zn2+ deficiency on learning and 
memory in mice and humans have been reported. Moreover, a 
Zn2+-dependent metabotropic activity in hippocampal CA3 
neurons has been detected, which is probably mediated by 
GPR39 that shows a Zn2+ receptor activity. This activity in brain 
areas rich in synaptic Zn2+ may represent the longsought 
link between dynamic changes in extracellular Zn2+ and 
neuronal metabotropic signaling mediated by this metal.  
Mutations and/or CNVs affecting GPR39 have never 
been reported in patients with ASD. 
Besser et al., 2009 
Cole et al., 2000 
Kodirov et al., 2006 
Lopantsev et al., 2003 
Smart et al., 2004 
     
GPR148(-) 
de novo 
 
Neurodevelopment?  
This gene encodes the G protein-coupled receptor 148, which 
is an orphan receptor. 
 
Expression is restricted to nervous system and testis. 
 
Recently, a rare small (~450 kb unique sequence) 
recurrent deletion in a previously linked attention-deficit 
hyperactivity disorder (ADHD) locus at 2q21.1 has been 
identified in five unrelated families with developmental 
delay/ID, ADHD, EP and other neurobehavioral 
abnormalities. Moreover, reciprocal duplications have 
been identified in five unrelated families with autism, 
developmental delay, seizures and ADHD. The 
rearranged segment harbors five genes: GPR148, 
FAM123C, ARHGEF4, FAM168B and PLEKHB2. 
Dharmadhikari et al., 2012 
     
HS6ST1(-) 
de novo 
 
Heparan sulfate 
biosynthesis 
This gene encodes the heparan sulfate 6-O-sulfotransferase 1, 
which is a member of the heparan sulfate biosynthetic 
enzyme family. This enzyme is a type II integral membrane 
protein and is responsible for 6-O-sulfation of heparan 
sulfate. 
 
Specifically expressed in fetal brain. 
Heparan sulfate (HS) interactions with secreted morphogens 
such as fibroblast growth factors, hedgehogs, and Wnts are 
essential for embryonic development. Formation of biologically 
relevant HS structures is a result of the coordinated action of 
various biosynthetic enzymes, of which HS 6-O-
sulfotransferases (6OST) catalyze the transfer of sulfate groups 
to the 6-O position of glucosamine residues in HS.  
Three 6OST isoforms have been described in the mouse whose 
expression has been mapped during mouse organogenesis. 
6OST transcripts are differentially expressed in several sites 
where heparin-binding growth factors are critical for 
development. In particular, 6OST1 is predominantly transcribed 
in epithelial and neural-derived tissues, 6OST2 is more 
mesenchymal, whereas 6OST3 appears at later stages and in a 
more restricted manner. 
 
It has been reported that mutant mice lacking the heparan 
sulfotransferases Hs2st or Hs6st1 display major axon guidance 
defects at the developing optic chiasm and corpus callosum.  
Mutations and/or CNVs affecting HS6ST1 have never 
been reported in patients with ASD. 
 
The association of autism and other symptoms of mental 
impairment with multiple exostoses in patients carrying 
mutations in HS/HSPG genes has been reported.  
More recently, genetic association has been found 
between autism and the HS3ST5 gene encoding one of 
the HS 3-O sulfotransferases in two large cohorts of 
European ancestry. Furthermore, a genome-wide scan for 
rare CNVs in 996 autism cases has identified four 
independent CNVs in the GPC5/GPC6 gene cluster, 
which encodes the glypican-5 and glypican-6 HSPGs in 
tandem array, on chromosome 13q22. 
Bolton et al.,1995 
Conway et al., 2011 
Ethell and Yamaguchi, 1999  
Hsueh and Sheng 1999  
Inatani et al., 2003  
Irie et al., 2012 
Ishikawa-Brush et al., 1997  
Kantor et al., 2004  
Li et al., 2002  
Matsumoto et al., 2007 
Pinto et al., 2010 
Pratt et al., 2006 
Sedita et al., 2004 
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LYPD1(-) 
de novo 
 
Neurodevelopment 
This gene encodes the LY6/PLAUR domain containing 1 
protein. 
 
High expression in fetal brain and in postnatal CNS. 
A large-scale systematic search for secreted proteins identified 
the gene LYPD1 that is encoded at the antisense DNA strand 
corresponding to the genomic locus of GPR39. 
LYPD1 was found highly expressed in all brain regions tested, 
with the highest levels observed in amygdalae and septum. 
However, the expression in peripheral tissues was large enough 
to be readily detected, with the heart showing the highest 
expression outside the CNS. 
The possible role of LYPD1 in regulation GPR39 expression 
must be still clarified. 
Mutations and/or CNVs affecting LYPD1 have never 
been reported in patients with ASD. 
Clark et al., 2003 
Egerod et al., 2007 
McKee et al., 1997 
      
 
MAP3K2(-) 
de novo 
 
Intracellular signaling: 
MAP kinase and NF-
kappa B signaling 
pathways 
This gene encodes the mitogen-activated protein kinase 
kinase kinase 2, which is a member of serine/threonine 
protein kinase family. This kinase preferentially activates 
other kinases involved in the MAP kinase signaling pathway. 
This kinase has been shown to directly phosphorylate and 
activate Ikappa B kinases, and thus plays a role in NF-kappa 
B signaling pathway. This kinase has also been found to bind 
and activate protein kinase C-related kinase 2, which 
suggests its involvement in a regulated signaling process. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Moderate expression in immune cell types. 
ERK5, the extracellular signal-regulated kinase 5, is highly 
expressed in developing neurons of the CNS and plays a critical 
role in their survival. ERK5 is activated by neurotrophins 
including brain-derived neurotrophic factor (BDNF) and MEK5 
is known to mediate BDNF stimulation of ERK5 in CNS 
neurons. It has been reported in rat cortical neurons that BDNF 
induces a sustained activation of ERK5 and activates Rap1, a 
small GTPase, as well as MAP3K2 (MEKK2), a MEK5 
kinase.  
 
MAP3K2 directly binds to SH2D2A, which is involved in the 
control of T-cell activation.  
Mutations and/or CNVs affecting MAP3K2 have never 
been reported in patients with ASD. 
 
NF-κB is an important gene transcriptional factor that 
mediates cellular responses in inflammation, immunity, 
development, cell proliferation and apoptosis. Elevated 
levels of NF-κB have been reported in autistic patients vs. 
controls. 
Malik et al., 2011 
Naik et al., 2011 
Philippe et al., 2012  
Sun et al., 2001 
Wang et al., 2006 
     
MGAT5(-) 
de novo 
 
Glycoprotein 
oligosaccharide 
biosynthesis 
This gene encodes the mannosyl (alpha-1,6-)-glycoprotein 
beta-1,6-N-acetyl-glucosaminyltransferase, which belongs to 
the glycosyltransferase family. It catalyzes the addition of 
beta-1,6-N-acetylglucosamine to the alpha-linked mannose of 
biantennary N-linked oligosaccharides present on the newly 
synthesized glycoproteins. It is one of the most important 
enzymes involved in the regulation of the biosynthesis of 
glycoprotein oligosaccharides. Alterations of the 
oligosaccharides on cell surface glycoproteins cause 
significant changes in the adhesive or migratory behavior of 
a cell. Increase in the activity of this enzyme has been 
correlated with the progression of invasive malignancies. 
 
Moderate expression in fetal brain and in postnatal temporal 
lobe, amygdalae and thalamus. 
As known, the CNS is rich in glycoconjugates, located on cell 
surface and in extracellular matrix. The products of Golgi UDP-
GlcNAc:N-acetylglucosaminyltransferases (encoded by Mgat1, 
Mgat2, Mgat4 and Mgat5) act sequentially to generate the 
GlcNAc-branched complex-type N-glycans on glycoprotein 
receptors. 
It has been demonstrated in mice that functional alterations of 
these enzymes cause behavioural changes, suggesting in humans 
a possible role in the neurobiology of feelings and behaviours. 
Indeed, Mgat5(-/-) mice are not different from their wild-type 
littermates in physical and neurological assessments, anxiety 
level, startle reactivity and sensorimotor gating. However, they 
displayed a robust decrease in the immobility time in the forced 
swim test and the tail suspension test independent of locomotor 
activity, interpreted as a reduction in depression-like behavior.  
Mutations and/or CNVs affecting MGAT5 have never 
been reported in patients with ASD. 
 
An association between symptoms of depression and a 
SNP near to MGAT5 and NCKAP5 has been recently 
replicated in two independent samples. 
Luciano et al., 2012 
Soleimani et al., 2008 
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NCKAP5(-) 
de novo 
 
Intracellular membrane 
trafficking: regulation of 
actin cytoskeleton 
dynamics 
This gene encodes the NCK-associated protein 5. 
 
Expressed in fetal and adult brain, leukocytes and fetal 
fibroblasts. 
Regulation of actin dynamics through the Nck/N-WASp (neural 
Wiskott-Aldrich syndrome protein)/Arp2/3 pathway is essential 
for organogenesis (including brain development), cell 
invasiveness, T-cell activation, and pathogen infection.  
Mutations and/or CNVs affecting NCKAP5 have never 
been reported in patients with ASD. 
 
A SNP in NCKAP5 has been strongly associated with BD 
in a sample of American individuals of European 
ancestry. Moreover, an association between symptoms of 
depression and a SNP near to MGAT5 and NCKAP5 has 
been recently replicated in two independent samples. 
 
Recessive mutations affecting NCKAP5L have been 
recently identified in an autistic patient.  
Chahrour et al., 2012 
Ditlev et al., 2012 
Luciano et al., 2012 
Smith et al., 2009 
     
PLEKHB2(-) 
de novo 
 
Intracellular signaling 
and trafficking  
This gene encodes the pleckstrin homology domain 
containing, family B (evectins) member 2 protein. 
 
High expression in fetal brain and in postnatal CNS. 
PLEKHB2 (EVT-2) works as a coupling factors between 
extracellular signals and intracellular membrane biosynthesis 
and trafficking. Its pleckstrin homology domain typically binds 
signaling phospholipids that are generated consequent to 
receptor activation.  
 
In mouse studies it has been found that EVT-2 is expressed 
throught fetal and adult brain, except for the white matter where 
EVT-1 shows a specific expression. 
Recently, a rare small (~450 kb unique sequence) 
recurrent deletion in a previously linked attention-deficit 
hyperactivity disorder (ADHD) locus at 2q21.1 has been 
identified in five unrelated families with developmental 
delay/ID, ADHD, EP and other neurobehavioral 
abnormalities. Moreover, reciprocal duplications have 
been identified in five unrelated families with autism, 
developmental delay, seizures and ADHD. The 
rearranged segment harbors five genes: GPR148, 
FAM123C, ARHGEF4, FAM168B and PLEKHB2. 
Dharmadhikari et al., 2012 
Dowler et al., 2000 
Krappa et al., 1999 
      
RAB6C(-) 
de novo 
 
Intracellular membrane 
trafficking: regulation of 
actin cytoskeleton 
dynamics 
This gene encodes the RAB6C protein, which is a small 
GTPase and belongs to the RAS oncogene family. 
 
High expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
Several members of the Rab family small GTPases that are key 
mediators of membrane trafficking, regulate axon-specific 
trafficking events. For example, Rab17 regulates dendritic 
morphogenesis and postsynaptic development in mouse 
hippocampal neurons. Moreover, Rab17 mediates dendrite 
growth and branching and does not regulate axon growth or 
branching.  
Rab4 and Rab5 GTPases are key players in the regulation of 
endocytosis as recently demonstrated in astrocytes, the most 
abundant glial cells in the brain.  
Mutations and/or CNVs affecting RAB6C have never 
been reported in patients with ASD. 
Mori et al., 2012 
Potokar et al., 2012 
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RAB3GAP1(-) 
de novo 
 
Intracellular membrane 
trafficking 
This gene encodes the RAB3 GTPase activating protein, 
catalytic subunit 1, which forms a heterodimer with a non-
catalytic subunit to specifically regulate the activity of 
members of the Rab3 subfamily of small G proteins. This 
protein mediates the hydrolysis of GTP bound Rab3 to the 
GDP bound form.  
 
Moderate expression in fetal brain and good expression in 
postnatal cortex, caudate nucleus, amygdalae, thalamus, and 
corpus callosum. 
Mutations in this gene are associated with Warburg micro 
syndrome, an autosomal recessive disorder characterized by 
severe ID, microcephaly, congenital cataract, microcornea, 
microphthalmia, agenesis, or hypoplasia of the corpus callosum 
and hypogenitalism. 
 
Synaptic vesicles contain several Rab proteins, including four 
Rab3 isoforms: Rab3A, Rab3B, Rab3C, and Rab3D. Rab3 is 
essential for the normal dynamics of neurotransmitter release 
and to maintain the long-term plasticity include long-term 
potentiation in hippocampal mossy-fiber synapses, cerebellar 
parallel-fiber synapses, corticostriatal and corticothalamic 
synapses, and cortico–lateral amygdalae synapses. In particular, 
recently it has been reported that Rab3B is required for long-
term depression of hippocampal inhibitory synapses which may 
contribute to learning and memory, presumably by stabilizing 
circuits established in previous learning processes. 
Mutations and/or CNVs affecting RAB3GAP1 have never 
been reported in patients with ASD. 
Castro-Alamancos and 
Calcagnotto, 1999  
Fourcaudot et al. 2008  
Linden and Ahn, 1999  
Nicoll and Malenka 1995  
Nicoll and Schmitz 2005  
Salin et al., 1996 
Schlüter et al., 2004 
Schlüter et al., 2006 
Spencer and Murphy 2002  
Südhof ,2004 
Tsetsenis et al., 2011 
     
TUBA3D(-) 
de novo 
 
Neurodevelopment: 
organization of 
microtubule cytoskeleton 
This gene encodes the tubulin, alpha 3d protein, which is a 
member of the alpha tubulin family. Tubulin is a major 
component of microtubules, which are composed of alpha- 
and beta-tubulin heterodimers and microtubule-associated 
proteins in the cytoskeleton. Microtubules maintain cellular 
structure, function in intracellular transport, and play a role in 
spindle formation during mitosis. 
 
High expression in fetal brain and in postnatal CNS. 
It has been demonstrated that prenatal exposure to cocain affects 
CNS development altering, for example, cytoskeleton 
organization through a down-regulation of TUBA3D expression. 
Mutations and/or CNVs affecting TUBA3D have never 
been reported in patients with ASD. 
Lee et al., 2009 
     
TUBA3E(-) 
de novo 
 
Neurodevelopment: 
organization of 
microtubule cytoskeleton 
This gene encodes the tubulin, alpha 3e protein, which is a 
member of the alpha tubulin family. Tubulin is a major 
component of microtubules, which are composed of alpha- 
and beta-tubulin heterodimers and microtubule-associated 
proteins in the cytoskeleton. Microtubules maintain cellular 
structure, function in intracellular transport, and play a role in 
spindle formation during mitosis. 
 
High expression in fetal brain and in postnatal CNS. 
By analogy with other members of the same family, TUBA3E 
may be involved in neurodevelopment. 
Mutations and/or CNVs affecting TUBA3E have never 
been reported in patients with ASD. 
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 Patient 52, gain of 1.4 Mb at 7q11.23 (chr7:72726578-74139390) 
 
 
 
BAZ1B(+) 
de novo 
 
Chromatin remodeling  
This gene encodes the bromodomain adjacent to zinc finger 
domain, 1B protein, which is a member of the bromodomain 
protein family. The bromodomain is a structural motif 
characteristic of proteins involved in chromatin-dependent 
regulation of transcription. This gene is deleted in Williams-
Beuren syndrome, a developmental disorder caused by 
deletion of multiple genes at 7q11.23. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in cortex, thalamus and spinal cord. 
High expression in immune cell types. 
BAZ1B (WSTF) is a MAPK-dependent phosphoprotein 
(tyrosine-protein kinase) that plays a central role in chromatin 
remodeling and acts as a transcription regulator. It is involved in 
DNA damage response by phosphorylating 'Tyr-142' of histone 
H2AX (H2AXY142ph). H2AXY142ph plays a central role in 
DNA repair and acts as a mark that distinguishes between 
apoptotic and repair responses to genotoxic stress.  
 
It has been reported that during Xenopus laevis embryonic 
development WSTF is expressed differentially in neural tissue, 
especially during neurulae stages in the eye, in neural crest cells 
and the brain. 
BAZ1B maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
 
Heterozygote (baz1b/-) and homozygote (-/-) mouse 
models show craniofacial abnormalities and cardiac 
malformations but no behavioural anomalies. 
Ashe et al., 2008  
Berg et al., 2007 
Challman et al., 2003 
Cus et al., 2006 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Kirchoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Osborne, 2010 
Oya et al., 2009 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009 
Yoshimura et al., 2009 
     
BCL7B(+) 
de novo 
 
IgE autoantigen 
This gene encodes the B-cell CLL/lymphoma 7B protein, 
which is a member of the BCL7 family including BCL7A, 
BCL7B and BCL7C proteins. BCL7B contains a region that 
is highly similar to the N-terminal segment of BCL7A or 
BCL7C proteins. The BCL7A protein is encoded by the gene 
known to be directly involved in a three-way gene 
translocation in a Burkitt lymphoma cell line. 
 
Low expression in fetal brain and good expression in 
postnatal whole brain, in particular in cortex, cerebellum, 
caudate nucleus, and amygdalae.  
High expression in immune cell types.  
Haploinsufficiency of BCL7B may be the cause of certain 
cardiovascular and musculo-skeletal abnormalities observed in 
WBS. 
Moreover, BCL7B causes an allergic reaction in human as it 
acts as an IgE autoantigen in atopic dermatitis patients with 
severe skin manifestations. The BCL7B atopy-related IgE 
autoantigens have been detected in serum bound to IgE 
antibodies, thus suggesting that intracellular IgE autoantigens 
can become released after tissue damage and may occur as IgE 
immune complexes. Via binding to antigen presenting cells as 
well as to effector cells, IgE autoantigen immune complexes 
may contribute to exacerbation and/or perpetuation of severe 
atopic diseases even in the absence of exogenous allergens. 
BCL7B maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Natter et al., 1998 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
     
 
CLDN3(+) 
de novo 
 
CNS 
immunosurveillance: 
blood-brain barrier 
maturation through 
Wnt/β-catenin pathway  
This gene encodes the claudin 3 protein, which is a member 
of the claudin family. CLDN3 is an integral membrane 
protein and a component of tight junction strands. Tight 
junctions represent one mode of cell-to-cell adhesion in 
epithelial or endothelial cell sheets, forming continuous seals 
around cells and serving as a physical barrier to prevent 
solutes and water from passing freely through the 
paracellular space.  
 
Low expression in fetal brain and in postnatal CNS, except 
for postnatal cerebellum and amygdalae where the expression 
is good. 
CLDN3 is predominantly present in brain endothelial cells 
(ECs), where it plays a specific role in the establishment and 
maintenance of blood-brain barrier (BBB) tight junction 
morphology.  
A major pathway regulating brain development is the canonical 
Wnt/wingless pathway acting via β-catenin (β-cat) stabilization. 
This favors translocation of β-cat to the nucleus, where it binds 
to transcription factors of the lymphoid enhancer factor (Lef)/T 
cell factor (TCF) family, and thus modulates gene 
transcription.  
Endothelial Wnt/β-cat signaling regulates induction and 
maintenance of BBB characteristics during embryonic and 
postnatal development. Endothelial specific stabilization of β-
cat in vivo enhances barrier maturation, whereas inactivation of 
β-cat causes significant down-regulation of claudin3 (Cldn3), 
upregulation of plamalemma vesicle-associated protein, and 
BBB breakdown. 
CLDN3 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Becanovic et al., 2006 
Berg et al., 2007  
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Liebner et al., 2008 
Lincoln et al., 2007 
Moon, 2005 
Nitta et al., 2003 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
Wolburg et al., 2003 
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CLDN4(+) 
de novo 
 
CNS 
immunosurveillance: 
blood-brain barrier 
maturation 
This gene encodes the claudin 4, which is an integral 
membrane protein that belongs to the claudin family. The 
protein is a component of tight junction strands and may play 
a role in internal organ development and function during pre- 
and postnatal life.  
 
Very low expression in fetal brain and in postnatal CNS, 
except for postnatal thalamus where the expression is good. 
CLDN4 is a tight junction protein involved in the blood-brain 
barrier integrity. It has been reported that polymorphisms in 
CLDN4 may act as modulators of the phenotype in murine 
Experimental Autoimmune Encephalomyelitis model, which 
mimics the pathophysiology of multiple sclerosis (MS). 
Indeed, the syntenic region in human (7q11.23) has displayed 
suggestive linkage to MS.  
CLDN4  maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007  
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Haines et al., 1996 
Herguner and Mukaddes, 2006  
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
Wolburg et al., 2003 
     
CLIP2(+) 
de novo 
 
Intracellular trafficking: 
axon growth throught 
microtubule cytoskeleton 
dynamics 
This gene encodes the CAP-GLY domain containing linker 
protein 2, which belongs to the family of cytoplasmic linker 
proteins, which have been proposed to mediate the 
interaction between specific membranous organelles and 
microtubules. This protein was found to associate with both 
microtubules and an organelle called the dendritic lamellar 
body, a membranous organelle predominantly present in 
bulbous dendritic appendages of neurons linked by 
dendrodendritic gap junctions. CLIP2 may operate in the 
control of brain-specific organelle translocations. 
 
High expression in fetal brain and in postnatal CNS. 
CLIP protein enable neuronal polarization by controlling the 
stabilization of microtubules and growth cone dynamics.In 
particular, CLIP2 regulates the cytoskeleton through the 
microtubule network, having a role in cytoskeleton remodeling.  
 
It has been previously reported that mouse models of CLIP2 
exhibited some degree of hippocampal dysfunction as 
evidenced by deficits in contextual fear conditioning and altered 
synaptic plasticity. However, the recently reported Clip2 
hetrozygotes and homozygotes show impaired motor 
coordination on some tasks, but no differences in anxiety 
or amygdalae function, suggesting that CLIP2 may contribute to 
coordination problems in WS but not to the characteristic 
behavioral profile. 
CLIP2 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Hoogenraad et al., 2002, 2004 
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Neukirchen and Bradke, 2011 
Osborne, 2010 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
Vandeweyer et al., 2012 
      
 
 
 
 
EIF4H(+) 
de novo 
 
Translation regulation 
This gene encodes the eukaryotic translation initiation factor 
4H, which functions to stimulate the initiation of protein 
synthesis at the level of mRNA utilization.  
 
Moderate expression in fetal brain and in postnatal CNS. 
High expression in in immune cell types. 
Protein synthesis is a tightly regulated, energy-consuming 
process. The control of mRNA translation into protein is 
fundamentally important for the fine-tuning of gene expression; 
additionally, precise translational control plays a critical role in 
many cellular processes, including development, cellular 
growth, proliferation, differentiation, synaptic plasticity, 
memory, and learning. 
 
Knockout mice deficient in Eif4h have been recently generated. 
These mice display growth retardation with a significant 
reduction of body weight that began from the first week of 
postnatal development. Neuroanatomical profiling results 
revealed a smaller brain volume in null mice compared with 
controls as well as altered brain morphology, where anterior and 
posterior brain regions were differentially affected. The 
inactivation of Eif4h also led to a reduction in both the number 
and complexity of neurons. Behavioral studies revealed severe 
impairments of fear-related associative learning and memory 
formation, thus suggesting that Eif4h might contribute to certain 
deficits associated with Williams-Beuren syndrome. 
EIF4H maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
 
Rare single gene mutations in EIF4E have been 
previously reported in a few autistic patients and their 
unaffected fathers. 
Berg et al., 2007 
Capossela et al., 2012 
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Neves-Pereira et al., 2009 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
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FZD9(+) 
de novo 
 
Intracellular Wnt 
signaling pathway 
This gene encodes the frizzled family receptor 9, which is a  
receptor for Wnt signaling proteins.  
Most of frizzled receptors are coupled to the beta-catenin 
canonical signaling pathway, which leads to the activation of 
disheveled proteins, inhibition of GSK- 3 kinase, nuclear 
accumulation of beta-catenin and activation of Wnt target 
genes. FZD9 may be involved in transduction and 
intercellular transmission of polarity information during 
tissue morphogenesis and/or in differentiated tissues. 
 
Good expression in fetal brain and in postnatal CNS. 
Heterozygote and homozygotes mouse models for FZD9 show 
diminished seizure threshold, abnormal hippocampal structure, 
splenomegaly, thymic atrophy, developing B-cell depletion, 
impaired spatial learning and memory.  
Moreover, it has been demonstrated a role for Fzd9 signaling in 
lymphoid development, particularly at points where B cells 
undergo self-renewal prior to further differentiation.  
FZD9 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007 
Gillberg and Rasmussen, 1994 
Gosch and Pankau, 1994 
Herguner and Mukaddes, 2006  
Kirchhoff et al., 2007 
Klein-Tasman et al., 2009 
Lincoln et al., 2007 
Osborne, 2010 
Qiao et al., 2009 
Ranheim et al., 2005 
Reiss et al., 1985 
Van der Aa et al., 2009  
Zhao et al., 2005 
      
 
 
GTF2I(-)* 
de novo 
 
Transcriptional 
regulation 
This gene encodes the general transcription factor II, which is 
a multifunctional phosphoprotein with roles in transcription 
and signal transduction.  
 
High expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
The GTF2I and GTF2IRD1 paralogs encode two principal 
members of the TFII-I family of transcription factors. In humans 
haploinsufficiency of these two genes are linked to the facial 
dysmorphism and cognitive defects of Williams syndrome. 
 
Homozygous deletion of Gtf2i in mice causes lethality during 
embryonic development with neural tube closure defects and 
exencephaly, whereas heterozygous animals show no gross 
changes in brain structure or development. Furthermore, 
heterozygous animals show no alterations in learning and 
memory, including spatial memory, but show alterations in the 
recognition of novel objects as well as increased social 
interaction with unfamiliar mice, reminiscent of the 
hypersociability observed in WBS patients. 
GTF21 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
 
Two SNPs in GTF2I have recently been associated with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
Makeyev and Bayarsaihan, 2009 
Malenfant et al., 2012 
Osborne, 2010 
Qiao et al., 2009 
Reiss et al., 1985 
Sakurai et al., 2011 
Van der Aa et al., 2009 
     
GTF2IRD1(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the GTF2I repeat domain containing 1  
protein, which contains five GTF2I-like repeats and each 
repeat possesses a potential helix-loop-helix (HLH) motif. It 
functions as a transcription factor or as a positive 
transcriptional regulator under the control of Retinoblastoma 
protein.  
 
Moderate expression in fetal brain and in postnatal CNS. 
The Gtf2ird1 mouse showed several phenotypes that overlap 
with Williams-Beuren syndrome (WBS). Both heterozygous 
and homozygous mice exhibited increased social interaction, 
reduced aggression and anxiety and impaired amygdalae-based 
learning and memory, which correlates with the high sociability, 
lack of social anxiety and disinhibition seen in individuals with 
WBS.  
Their hippocampal function appeared to be intact and they had 
no problems with spatial tasks. Serotonin metabolism was also 
altered in the frontal cortex of these mice, and subsequent 
studies have demonstrated selectively enhanced serotonin 
receptor 1A-mediated responses in layer V pyramidal neurons 
of the pre-frontal cortex, suggesting altered neurophysiology. 
GTF2IRD1 maps within the genomic region involved in 
the Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
Osborne, 2010 
Proulx et al., 2010 
Qiao et al., 2009 
Reiss et al., 1985 
Schneider et al., 2012  
Van der Aa et al., 2009  
Young et al., 2008  
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LAT2(+) 
de novo 
 
T-cell activation 
This gene encodes the linker for activation of T cell family, 
member 2 protein. 
 
Low expression in fetal brain and in postnatal CNS. 
Very high expression in spleen, peripheral blood 
lymphocytes, and germinal centers of lymph nodes. Present 
in B-cells, NK cells and monocytes. 
T cells are essential for the adaptive immune response to 
pathogens. However, dysfunctional T cell activity has been 
implicated in numerous diseases, including the failure of organ 
transplants, allergic reactions, asthma, autoimmune disorders, 
and coronary artery disease.  
T cell responses to pathogens require the induction of the 
primary activating receptor, the T cell receptor (TCR), along 
with other costimulatory and adhesion receptors. Signal 
transduction pathways activated downstream of these receptors 
drive T cell responses required for the immune response and 
disease progression.  
Upon stimulation of the TCR and other receptors, the LAT 
proteins are phosphorylated at several tyrosines residues on their 
cytoplasmic tails. This leads to the binding of SH2 domain-
containing proteins and their associated molecules and the 
formation of large multiprotein complexes. These dynamic and 
highly regulated signaling complexes facilitate the production of 
second messengers, activate downstream pathways, induce actin 
cytoskeleton polymerization, and stimulate the activity of 
multiple transcription factors. Thus, signaling pathways from 
several receptors feed into LATs, which then integrates this 
information and selectively induces pathways critical for T cell 
activation and the adaptive immune response.  
LAT2 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Bartelt and Houtman, 2012 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
     
LIMK1(+) 
de novo 
 
Neurodevelopment: 
axon growth throught 
actin cytoskeleton 
dynamics 
This gene encodes the LIM domain kinase 1 protein. 
LIM domains are highly conserved cysteine-rich structures 
containing 2 zinc fingers. LIMK1 is a serine/threonine kinase 
that regulates actin polymerization via phosphorylation and 
inactivation of the actin binding factor cofilin. This protein is 
ubiquitously expressed during development and plays a role 
in many cellular processes associated with cytoskeletal 
structure. This protein also stimulates axon growth and may 
play a role in brain development.  
 
High expression in fetal brain and in postnatal CNS. 
It has been recently reported a novel interaction between 
LIMK1 and TrkB, which is required for the BDNF induced 
axonal elongation. BDNF induces TrkB dimerization, thus 
leading to LIMK1 dimerization and transphosphorylation 
independent of TrkB kinase activity, which could further 
enhance the activation and stabilization of LIMK1.  
Moreover, activated LIMK1 translocates to membrane fraction 
and phosphorylates its substrate cofilin, thus promoted actin 
polymerization and axonal elongation.  
 
Homozygote mice for LIMK1 show abnormal dendrite spine 
morphology, altered hippocampal function, mild deficit in 
spatial learning and memory. Limk1-null mice show altered 
dendritic spine morphology in pyramidal neurons, a 
phenomenon that has previously been associated with other 
genetic disorders involving ID, such as Down, fragile X and 
Rubinstein–Taybi syndromes. 
LIMK1 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Kaufmann and Moser, 2000 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
Meng et al., 2002 
Osborne, 2010 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
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STX1A(+) 
de novo 
 
Synaptic plasticity 
This gene encodes the syntaxin 1A, which is a member of the 
syntaxin superfamily. Syntaxins are nervous system-specific 
proteins implicated in the docking of synaptic vesicles with 
the presynaptic plasma membrane.  
Syntaxins bind synaptotagmin in a calcium-dependent 
fashion and interact with voltage dependent calcium and 
potassium channels via the C-terminal H3 domain. This gene 
product is a key molecule in ion channel regulation and 
synaptic exocytosis.  
 
Very high expression in fetal brain and postnatal CNS. 
STX1A is part of the SNARE core complex containing 
SNAP25, VAMP2 and STX1A.  
 
Hemizygous deletion of STX1A in mice did not produce any 
obvious behavioral or cognitive phenotype, but mice 
homozygous for a truncated form of STX1A had altered synaptic 
plasticity, related to hippocampal dysfunction. 
STX1A maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
 
SNPs in STX1A have been associated with ASD and HF-
AU. Moreover, in the postmortem anterior cingulate 
gyrus region of autistic patients, STX1A expression was 
found to be significantly lower than that of the control 
group. 
 
SNPs in SNAP25 have been associated to hyperactivity 
phenotype in ASD.  
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Fujiwara et al., 2006 
Ghezzo et al., 2009  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
McRory et al., 2008 
Nakamura. et al. 2008, 2011 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
     
TRIM50(-)* 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the tripartite motif protein 50A, which is 
an E3 ubiquitin-protein ligase. 
 
Good expression in fetal brain and in postnatal cingulate 
cortex, cerebellum, amygdalae and spinal cord. 
Trim50 specifically interacts with E2 ubiquitin-conjugating 
enzymes and autoubiquitinates, showing that it can act as an E3 
ubiquitin ligase.Thus hemizygosity of the TRIM50 E3 ubiquitin 
ligase possibly plays a role in the WBS phenotype as the result 
of accumulation of specific TRIM50 target substrates. 
It is unclear how a defective TRIM50 E3 ligase activity could 
influence some of the clinical manifestations of WBS. The 
specific expression of TRIM50 in stomach, intestine, 
liver and brain suggests a possible involvement of 
TRIM50 haploinsufficiency in the gastrointestinal pathologies 
and/or the cognitive profile of WBS patients. 
TRIM50 maps within the genomic region involved in the 
Williams syndrome (7q11.23 deletion)/7q11.23 
duplication syndrome, which show comorbidity with 
ASD. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Berg et al., 2007 
Challman et al., 2003 
Depienne et al., 2007  
Gillberg and Rasmussen, 1994 
Herguner and Mukaddes, 2006 
Klein-Tasman et al., 2009 
Kirchoff et al., 2007 
Licoln et al., 2007 
Micale et al., 2008 
Qiao et al., 2009 
Reiss et al., 1985 
Van der Aa et al., 2009  
             Patient 53, loss of 11.1 Mb at 2q31.3q32.3 (chr2:181882353-193007633)  
     
FRZB(-) 
de novo 
 
Intracellular Wnt 
signaling 
This gene encodes the frizzled-related protein (SFRP3), 
which is a secreted protein that is involved in the regulation 
of bone development.  
 
Good expression in fetal brain and moderate expression in 
postnatal cerebellum, caudate nucleus, thalamus and spinal 
cord. 
Defects in FRZB are a cause of female-specific osteoarthritis 
susceptibility.  
 
Although FRZB is primarily expressed in the cartilaginous cores 
of the long bone during embryonic and fetal development and in 
the appendicular skeleton, a role in regulating Wnt signaling 
during fetal and postnatal brain development has been proposed.  
Indeed, it has been demonstrated that in postnatal mouse 
cerebral cortex Wnt genes as well as SFRPs (secreted Frizzled-
related proteins) are expressed in gene-specific regional and 
lamina patterns in each of the major subdivisions of the cerebral 
cortex: the olfactory bulb, the hippocampal formation, and the 
neocortex. In particular, FRZB (sFRP3) binds to Wnt3a and acts 
as Wnt-antagonist regulating cell proliferation induced by Wnt 
signaling. 
Recently, epigenetic silencing of FRZB has been detected in 
medulloblastoma sample as well as in other tumors, suggesting 
that SFRP3 functions as a tumor suppressor. For example in 
medulloblastoma, FRZB acts as a melanoma migration and 
invasion suppressor by interfering with Wnt5a signaling.  
Mutations and/or CNVs affecting FRZB have never been 
reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Ëkström et al., 2011 
IMGSAC, 2001 
Rabionet et al., 2004 
Shimogori et al., 2004 
Wawrzak et al., 2007 
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GLS(-) 
de novo 
 
CNS metabolism: 
glutamine catabolism 
This nuclear gene encodes the glutaminase 2 protein, which 
is a mitochondrial phosphate-activated glutaminase that 
catalyzes the hydrolysis of glutamine to stoichiometric 
amounts of glutamate and ammonia. It plays an important 
role in the regulation of glutamine catabolism and promotes 
mitochondrial respiration and increases ATP generation in 
cells by catalyzing the synthesis of glutamate and alpha-
ketoglutarate. In addition, it increases cellular anti-oxidant 
function via NADH and glutathione production and may play 
a role in preventing tumor proliferation. 
 
Very high expression in fetal brain and in postnatal CNS. 
Recent research in ASD has aroused interest in anterior 
cingulate cortex and in the neurometabolite glutamate. Using 
single-voxel proton magnetic resonance spectroscopy in vivo it 
has been demonstrated in anterior cingulate cortex of 8 children 
with ASD a significant elevation of glutamate + glutamine (Glx) 
peak compared to 10 typically developing controls, who were 
well matched for age. The hyperglutamatergic state may reflect 
an imbalance of excitation over inhibition in the brain as 
proposed in recent neurodevelopmental models of ASD. 
Mutations and/or CNVs affecting GLS have never been 
reported in patients with ASD. 
 
Anomalies in glutamate metabolism may be one of the 
causes for ASD development. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Bejjani et al., 2012 
IMGSAC, 2001 
Rabionet et al., 2004 
Shimmura et al., 2011 
     
GULP1(-) 
de novo 
 
Neurodevelopment 
This gene encodes the GULP, engulfment adaptor PTB 
domain containing 1 protein, which is an adapter protein 
necessary for the engulfment of apoptotic cells by 
phagocytes. Several transcript variants, some protein coding 
and some thought not to be protein coding, have been found 
for this gene. 
 
Good expression in fetal brain and moderate expression in 
postnatal CNS, except for cerebellum where the expression is 
low. 
It has been demonstrated that GULP1 is present in human 
hippocampal and neocortical neurons, where it interacts with the 
low-density lipoprotein receptor-related protein 1, LRP1, 
suggesting a potential relevance in Alzheimer's disease (AD). 
Moreover, GULP1 binds to the amyloid-β A4 precursor protein 
(APP). APP and its secreted form, sAPP, contribute to the 
development of neurons in hippocampus, a brain region critical 
for learning and memory.  
GULP1 colocalizes with APP in the Golgi and endoplasmic 
reticulum, and alters trafficking and processing of APP. 
Mutations and/or CNVs affecting GULP1 have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Beyer et al., 2012 
Billnitzer et al., 2012 
IMGSAC, 2001 
Rabionet et al., 2004 
     
HIBCH(-) 
de novo 
 
CNS metabolism: amino 
acid degradation 
This nuclear gene encodes the 3-hydroxyisobutyryl-CoA 
hydrolase protein, which is a mitochondrial enzyme 
responsible for hydrolysis of both HIBYL-CoA and beta-
hydroxypropionyl-CoA. It is involved in L-valine 
catabolism. 
 
Moderate expression in fetal brain and in postnatal caudate 
nucleus, amygdalae, thalamus, corpus callosum, and spinal 
cord. 
Mutations in this gene have been associated with 3-
hyroxyisobutyryl-CoA hydrolase deficiency. 
 
Defects in HIBCH are the cause of HIBCH deficiency, also 
known as deficiency of beta- hydroxyisobutyryl CoA deacylase 
or methacrylic aciduria. The enzyme defect results in 
accumulation of methacrylyl-CoA, a highly reactive compound, 
which readily undergoes addition reactions with free sulfhydryl 
groups. Affected individuals showed delayed development of 
motor skills, hypotonia, initial poor feeding, and a deterioration 
in neurological function during first stages of life. 
 
Recently, it has been reported the identification of six potential 
regulators of synaptic and axonal degeneration in vivo, 
including HIBCH, using mutant Drosophila lines, thus 
suggestimg that pathways not previously linked to synaptic 
formation, such as valine catabolism, may be involved in 
neurodevelopment. 
Mutations and/or CNVs affecting HIBCH have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
IMGSAC, 2001 
Loupatty et al., 2007 
Rabionet et al., 2004 
Wishart et al., 2012 
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INPP1(-) 
de novo 
 
Intracellular 
phosphatidylinositol 
signaling  
This gene encodes the inositol polyphosphate-1-phosphatase 
protein, which is one of the enzymes involved in 
phosphatidylinositol signaling pathway. This enzyme 
removes the phosphate group at position 1 of the inositol ring 
from the polyphosphates inositol 1,4-bisphosphate and 
inositol 1,3,4-trisphophosphate. 
 
Good expression in fetal brain and in postnatal CNS. 
Inositol and phosphatidylinositol phosphates are important 
for numerous cellular processes: neuronal survival, 
differentiation, neuroprotection, and transduction of signals 
from growth factors, neurotransmitters, and G protein 
coupled receptors.  
Mutations and/or CNVs affecting INPP1 have never been 
reported in patients with ASD. 
 
SNPs in genes implicated in phosphatidylinositol 
signaling pathway, suc as INPP1, PIK3CG, and TSC2 
have been previously associated with ASD, suggesting 
that phosphatidylinositol signaling may have a role in 
susceptibility to autism. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Berridge, 1993 
Czech, 2000 
Delmas et al., 2002  
IMGSAC, 2001 
Rabionet et al., 2004 
Serajee et al., 2003 
     
ITGA4(-) 
de novo 
 
Neuroinflammation : 
focal adesion, leukocyte 
transendothelial 
migration 
This gene encodes the integrin, alpha 4 protein, which 
belongs to the integrin alpha chain family of proteins. 
Integrins are heterodimeric integral membrane proteins 
composed of an alpha chain and a beta chain. This gene 
encodes an alpha 4 chain. Unlike other integrin alpha chains, 
alpha 4 neither contains an I-domain, nor undergoes 
disulfide-linked cleavage.  
 
Good expression in fetal brain and in postnatal CNS, in 
particular in thalamus and corpus callosum. 
Very high expression in immune cell types. 
In experimental autoimmune encephalomyelitis, a model for 
multiple sclerosis, it has been recently reported that in vitro 
migration of CD8(+) T lymphocytes across blood-brain barrier-
endothelial cells is dependent on α4 integrin, which is 
considered a mediator of neuroinflammation. 
Mutations and/or CNVs affecting ITGA4 have never been 
reported in patients with ASD. 
 
SNPs in ITGA4 have been associated with ASD. 
Moreover, a positive association was found between one 
of these SNP markers and levels of a serum autoantibody 
directed to brain tissue, which was previously shown to 
be significantly more frequent in autistic patients than in 
age-matched controls, thus suggesting that ITGA4 could 
be involved in a neuroimmune process thought to occur in 
autistic patients. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Conroy et al., 2009 
Correia et al., 2009 
Ifergan et al., 2011 
IMGSAC, 2001 
Rabionet et al., 2004 
     
NAB1(-) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the NGFI-A binding protein 1, which acts 
as a transcriptional repressor for zinc finger transcription 
factors EGR1 and EGR2. 
 
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in cortex, cerebellum, corpus 
callosum and spinal cord. 
The early growth response protein 1, EGR1, is a transcriptional 
switch that regulates a number of diverse gene targets. It is 
strongly expressed in neurons in the adult brain, and its levels 
are altered by neurotransmitter release and neuronal activation. 
It can also exert long-lasting changes in gene expression and 
subsequent protein synthesis that mediate synaptic plasticity. 
EGR1 has been implicated in mediating a variety of behaviors 
that are dysregulated in MDD, including learning and memory, 
fear conditioning, drug addiction, and social interaction.  
 
The early growth response gene 2 (EGR2) is one of the 
susceptibility loci in BD. EGR2 is involved in cognitive 
function, myelination, and signal transduction related to 
neuregulin-ErbB receptor, Bcl-2 family proteins, and brain-
derived neurotrophic factor. SNPs in EGR2 have been 
associated to BD in a Korean sample. 
Mutations and/or CNVs affecting NAB1 have never been 
reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Cole et al., 1989 
IMGSAC, 2001 
Kerman et al., 2012 
Kim et al., 2012 
Knapska and Kaczmarek, 2004  
Malkani et al., 2004  
Rabionet et al., 2004 
Ressler et al., 2002 
Stack et al., 2010 
Valjent et al., 2006  
      
131 
 
Tab. 4.1. Continued. 
NCKAP1(-) 
de novo 
 
Neuronal differentation: 
actin cytoskeleton 
organization  
This gene encodes the NCK-associated protein 1. 
 
Very high expression in fetal brain and in postnatal CNS. 
NCKAP1 (Nap1) is an adaptor protein that is thought to 
modulate actin nucleation by forming a pentameric complex 
with WAVE, PIR121, Abi1/2 and HSPC300. It is selectively 
expressed in the cortical plate region of the developing cortex, 
where neurons terminate their migration and begin their final 
laminar specific differentiation, characterized by the 
elaboration of distinct axonal and dendritic architecture. 
Functional analysis of Nap1 indicate that Nap1-mediated 
cytoskeletal rearrangements in the emerging cortical plate play 
an essential role in cortical neuronal differentiation underlying 
the formation of functional connectivity in cerebral cortex. 
Mutations and/or CNVs affecting NCKAP1 have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Baumgartner et al., 1995  
Bladt et al., 2003 
Bogdan and Klambt, 2003 
Hummel et al., 2000 
IMGSAC, 2001 
Rabionet et al., 2004 
Soto et al., 2002 
Stradal et al., 2004 
Suzuki et al., 2000 
Yokota et al., 2007 
     
NEUROD1(-) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the neurogenic differentiation 1 protein, 
which is a member of the NeuroD family of basic helix-loop-
helix (bHLH) transcription factors. The protein forms 
heterodimers with other bHLH proteins and activates 
transcription of genes that contain a specific DNA sequence 
known as the E-box. It regulates expression of the insulin 
gene, and mutations in this gene result in type II diabetes 
mellitus. 
 
Very high expression in fetal brain and in postnatal CNS. 
 
Mutations and/or CNVs affecting NEUROD1 have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
IMGSAC, 2001 
Rabionet et al., 2004 
     
ORMDL1(-) 
de novo 
 
Neurodevelopment? 
This gene encodes the ORM1-like 1 (S. cerevisiae) protein, 
which is a negative regulator of sphingolipid synthesis. 
 
Expressed in brain. 
By using an antibody specific for the C-terminus the expression 
of ORMDL1 (adoplin-1) has been determined in cultured 
neuronal cells and human brain tissues. Immunohistochemical 
analyses disclosed that adoplin proteins are primarily expressed 
in the neurons of cerebral cortices. Moreover, adoplin is 
localized mainly in the cell bodies and neurites of primary 
cortical neurons, which shows possible role(s) in nerve cells. 
Mutations and/or CNVs affecting ORMDL1 have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Araki et al., 2008 
IMGSAC, 2001 
Rabionet et al., 2004 
     
PDE1A(-) 
de novo 
 
Intracellular cAMP 
signaling 
This gene encodes the phosphodiesterase 1A, calmodulin-
dependent protein. Cyclic nucleotide phosphodiesterases 
(PDEs) play a role in signal transduction by regulating 
intracellular cyclic nucleotide concentrations through 
hydrolysis of cAMP and/or cGMP to their respective 
nucleoside 5-prime monophosphates.  
 
Good expression in fetal brain and in postnatal CNS, in 
particular in amygdalae, corpus callosum, and spinal cord. 
It has been reported that intracranial self-stimulation to the 
murine lateral hypothalamus, a memory improving treatment, 
results in hippocampal changes in gene expression. For 
example, the PDE1A gene is overexpressed, suggesting a role of 
the intracellular calcium signaling in the development and 
improvement of cognitive function, by promoting 
neuroplasticity. 
Mutations and/or CNVs affecting PDE1A have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Huguet et al., 2009 
IMGSAC, 2001 
Rabionet et al., 2004 
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STAT1(-) 
de novo 
 
Modulation of 
neuroinflammation: 
intracellular STAT 
signaling 
This gene encodes the signal transducer and activator of 
transcription 1.91kDa protein, which is a member of the 
STAT protein family. In response to cytokines and growth 
factors, STAT family members are phosphorylated by the 
receptor associated kinases, and then form homo- or 
heterodimers that translocate to the cell nucleus where they 
act as transcription activators. This protein can be activated 
by various ligands including interferon-alpha, interferon-
gamma, EGF, PDGF and IL6. This protein mediates the 
expression of a variety of genes, which is thought to be 
important for cell viability in response to different cell 
stimuli and pathogens. 
 
Moderate expression in fetal brain and in postnatal CNS. 
High expression in immune cell types.  
The strong inflammatory response observed in 
neurodegenerative diseases can depend on the impairment of the 
endogenous control of microglial activation, triggering the 
release of potentially detrimental factors such as cytokines, 
nitric oxide (NO) and superoxide anion (O2
-).  
By studying microglial and mixed glial cell cultures activation 
from neonatal rats after exposure to IFN-gamma and/or IL-1beta 
and TNF-alpha, it has been proposed that IL-1beta modulates 
IFN-gamma-induced production of oxidative molecules through 
cross talk between STAT1 and MAPK pathways, regulating the 
amplitude and duration of microglial activation. Modulation of 
ERK was observed at 30 min, whereas inhibition of pSTAT was 
observed later (at 4 h), indicating that it was an early and 
transient phenomenon. 
 
Mutations in STAT1causes the mendelian susceptibility to 
mycobacterial disease (autosomal dominant, recessive and X-
linled), and the familial candidiasis type 7(autosomal dominant). 
Mutations and/or CNVs affecting STAT1 have never been 
reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
IMGSAC, 2001 
Rabionet et al., 2004 
Tichauer et al., 2007 
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STAT4(-) 
de novo 
 
Modulation of 
neuroinflammation: 
intracellular STAT 
signaling 
This gene encodes the signal transducer and activator of 
transcription 4 protein, which is a member of the STAT 
family of transcription factors. In response to cytokines and 
growth factors, STAT family members are phosphorylated 
by the receptor associated kinases, and then form homo- or 
heterodimers that translocate to the cell nucleus where they 
act as transcription activators. This protein is essential for 
mediating responses to IL12 in lymphocytes, and regulating 
the differentiation of T helper cells.  
 
Low expression in fetal brain and good expression in 
postnatal cortex, amygdalae and thalamus. 
Genetic variations in STAT4 are a cause of susceptibility to 
systemic lupus erythematosus and rheumatoid arthritis. 
 
Inflammatory cytokines are implemented in the pathogenesis of 
experimental autoimmune encephalomyelitis (EAE), an animal 
model of multiple sclerosis. Moreover, the glia maturation 
factor (GMF), a brain protein, induces expression of 
proinflammatory cytokine/chemokine in the central nervous 
system, and GMF-deficient (knockout) mice are relatively 
resistant to EAE development after immunization with 
encephalitogenic MOG peptide. 
The expression evaluation of six murine STAT genes, which are 
known to regulate the cytokine-dependent signal transduction 
pathways in autoimmune inflammation, in the brains and spinal 
cords of wild type and GMF-knockout mice, revealed that the 
expressions of STAT1, STAT2, STAT3, STAT4, STAT5, and 
STAT6 genes were significantly upregulated in the wild type 
mice exhibiting EAE symptoms. Therefore, a significant 
suppression of STATs expression in GMF-knockout mice 
suggests GMF as an upstream effector of JAK/STAT signaling. 
 
In order to identify the molecular mechanisms underlying the 
pathological processes in multiple sclerosis, the gene expression 
profile in non-lesion containing tissue, the so-called normal-
appearing white matter, has been studied. Genes known to be 
involved in anti-inflammatory and protective mechanisms such 
as STAT6, JAK1, IL-4R, IL-10, Chromogranin C and Hif-1alpha 
are consistently upregulated in the multiple sclerosis NAWM, 
and are mainly expressed in oligodendrocytes. On the other 
hand, genes involved in pro-inflammatory mechanisms, such as 
STAT4, IL-1beta and MCSF, were also upregulated but less 
regularly. STAT4 expression was detected predominantly in 
microglia. 
Therefore, the upregulation of genes involved in anti-
inflammatory mechanisms driven by oligodendrocytes may 
protect the CNS environment and thus limit lesion formation, 
whereas the activation of pro-inflammatory mechanisms in 
microglia may favour disease progression.  
Mutations and/or CNVs affecting STAT4 have never been 
reported in patients with ASD. 
 
A previous genomewide screen for autism reported strong 
evidence for linkage to chromosomes 2q (in particular 
2q32), which was subsequently confirmed considering a 
region of 20-30 cM at 2q31q33. 
IMGSAC, 2001 
Rabionet et al., 2004 
Zaheer et al., 2007 
Zeis et al., 2008 
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TMEFF2(-) 
de novo 
 
Neurodevelopment 
This gene encodes thetransmembrane protein with EGF-like 
and two pollistatin-like domains. 
 
High expression in fetal brain and in postnatal CNS, with 
highest level in amygdalae and corpus callosum. 
TMEFF2 is a putative transmembrane protein whose survival 
effect has been measured using primary cultured neurons from 
several regions of fetal rat brain following treatment with a 
recombinant TMEFF2 protein fragment consisting of the 
putative extracellular domain. It has been reported that TMEFF2 
increased survival of neurons from the hippocampus and 
midbrain, but not from the cerebral cortex, indicating that the 
survival effects of TMEFF2 are specific to certain cell types. 
Recombinant TMEFF2 also promoted survival of 
mesencephalic dopaminergic neurons.  
Furthermore, using in situ hybridization analysis it has been 
found that both TMEFF genes are widely expressed in rat brain, 
although they exhibit different patterns of expression, 
suggesting that they have specific roles in the CNS. In 
particular, TMEFF2 is highly expressed in the medial habenular, 
CA2, CA3 and dentate gyrus region of the hippocampus, corpus 
callosum, cerebellar cortex and cranial nerve nuclei (III, IV, 
VII, X, XII).  
Mutations and/or CNVs affecting TMEFF2 have never 
been reported in patients with ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Horie et al., 2000 
IMGSAC, 2001 
Kanemoto et al., 2001  
Rabionet et al., 2004 
     
UBE2E3(-) 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the ubiquitin-conjugating enzyme E2E3. 
Ubiquitination involves at least three classes of enzymes: 
ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating 
enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This 
gene encodes a member of the E2 ubiquitin-conjugating 
enzyme family. 
 
Good expression in fetal brain and moderate expression in 
postnatal CNS. 
Mutations and/or CNVs involving other E3 ligase genes have 
been reported in patients with ASD. 
Mutations and/or CNVs affecting UBE2E3 have never 
been reported in patients with ASD. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Bonati et al., 2007 
Glessner et al., 2009 
IMGSAC, 2001 
Kishino et al., 1997 
Matsuura et al., 1997 
Rabionet et al., 2004 
Sahoo et al., 2006 
Scheuerle and Wilson, 2011 
Smith et al., 2011 
Trillingsgaaard and Østergaard, 
2004 
     
ZNF804A(-) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the zinc finger protein 804A. 
 
High expression in fetal brain, especially in the developing 
hippocampus and the cortex, and good expression in 
postnatal CNS, in particular in adult cerebellum. 
 
A CNV affecting ZNF804A has been recently reported in 
a patient with ASD. 
 
SNP in ZNF804A (rs1344706) has been associated to a 
higher risk to develop BD and SCZ, affecting both brain 
volume and neural connettivity. 
 
A previous genome-wide screen for autism reported 
strong evidence for linkage to chromosomes 2q (in 
particular 2q32), which was subsequently confirmed 
considering a region of 20-30 cM at 2q31q33. 
Griswold et al., 2012 
IMGSAC, 2001 
Rabionet et al., 2004 
Johnson et al, 2009 
Lencz et al., 2010 
O’Donovan et al., 2008 
Owen et al., 2009 
Rabionet et al., 2004 
Talkowski et al., 2012 
Wassink et al., 2012 
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 Patient 57, gain of 3.8 Mb at 5q31.1q31.2 (chr5:133871536-137708167) 
 
 
 
 
CAMLG(+) 
de novo 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the calcium modulating ligand protein.  
The immunosuppressant drug cyclosporin A blocks a 
calcium-dependent signal from the T-cell receptor (TCR) that 
normally leads to T-cell activation. When bound to 
cyclophilin B, cyclosporin A binds and inactivates the key 
signaling intermediate calcineurin. The protein encoded by 
this gene functions similarly to cyclosporin A, binding to 
cyclophilin B and acting downstream of the TCR and 
upstream of calcineurin by causing an influx of calcium. This 
integral membrane protein appears to be a new participant in 
the calcium signal transduction pathway, implicating 
cyclophilin B in calcium signaling, even in the absence of 
cyclosporine. 
 
High expression in fetal brain and in postnatal CNS, in 
particular in caudate nucleus and amygdalae. 
High expression in immune cell types. 
CAMLG was first identified as a cyclophilin B binding protein 
and shown to implicate cyclophilin B in the calcium signal 
transduction pathway in T cell activation.  
CAMLG is reported to be involved in recycling and endocytic 
processing of GABAA receptors. In a cortical culture it has 
been demonstrated that the reduction of CAMLG translated into 
reduced GABAA receptors on the postsynaptic membrane with 
an effect specific to GABAA receptors since glutamate evoked 
current remained unaltered in these neurons.  
CAMLG binds to Tmub1, which is a protein containing a 
ubiquitin-like domain highly expressed in the nervous 
system. These proteins could work in concert to regulate cycling 
of receptors, such as GABA and glutamate receptors, to 
synaptic membranes. 
Mutations and/or CNVs affecting CAMLG have never 
been reported in patients with ASD. 
Bram and Crabtree, 1994 
Yuan et al., 2008 
Zhang et al., 2010 
     
C5orf20 
(DCNP1)(+) 
de novo 
 
T-cell activation, 
regulation of the 
corticotropin-releasing 
hormone in the brain 
This gene encodes the dendritic cell nuclear protein 1. It is 
specifically expressed in dendritic cells (DCs), which are 
potent antigen-presenting cells involved in activating naive T 
cells to initiate antigen-specific immune response. 
 
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in thalamus and hypothalamus. 
Good expression in dendritic cells. 
In situ hybridization experiments have recently found a 
widespread distribution of DCNP1 expression in the human 
brain at both the mRNA and protein levels as well as in the 
microglial cells. Furthermore, DCNP1 is higher expressed in 
neurons of the paraventricular nucleus and supraoptic nucleus in 
patients with depression compared with controls. 
 
DCNP1 may play a role in the pathogenesis of the depressive 
disorder by upregulating the CRH (corticotropin-releasing 
hormone) promoter in the paraventricular nucleus. CRH neurons 
are the driving force for the hypothalamic-pituitary-adrenal axis, 
which is the final common pathway for the stress response and 
also a crucial system in the pathogenesis of depression. 
Mutations and/or CNVs affecting C5orf20 have never 
been reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including 
DCNP1, was previously identified in a genome-wide 
linkage analysis for autism. 
 
DCNP1 has been proposed to be a novel candidate gene 
for major depression and this finding has been recently 
replicated. 
Bosker et al., 2011 
Philippi et al., 2005  
Willis-Owen et al., 2006 
Zhou et al., 2010 
      
 
CDC23(+) 
de novo 
 
Intracellular signaling:  
protein ubiquitination 
pathway 
This gene encodes the cell division cycle 23 homolog (S. 
cerevisiae) protein, which is essential for cell cycle 
progression through the G2/M transition. This protein is a 
component of anaphase-promoting complex (APC), which is 
composed of eight protein subunits and highly conserved in 
eukaryotic cells.  
 
Moderate expression in fetal brain and low expression in 
postnatal CNS. 
High expression in immune cell types. 
CDC23 is a component of the anaphase promoting 
complex/cyclosome (APC/C), a cell cycle-regulated E3 
ubiquitin ligase that controls progression through mitosis and 
the G1 phase of the cell cycle. The APC/C complex acts by 
mediating ubiquitination and subsequent degradation of target 
proteins. In particular, APC catalyzes the formation of cyclin B-
ubiquitin conjugate that is responsible for the ubiquitin-
mediated proteolysis of B-type cyclins. 
 
In Drosophila loss of zygotic expression of cdc23 causes defects 
in the proliferation of brain neuroblasts and results in the 
absence of identified neuronal lineages in the central and 
peripheral nervous systems.  
Mutations and/or CNVs affecting CDC23 have never 
been reported in patients with ASD. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Glessner et al., 2009 
Kishino et al., 1997 
Matsuura et al., 1997 
Zhang et al., 1991 
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CDC25C(+) 
de novo 
 
Intracellular signaling: 
regulation of cell cycle 
progression 
This gene encodes the cell division cycle 25 homolog C (S. 
pombe) protein, is highly conserved during evolution and it 
plays a key role in the regulation of cell division. The 
encoded protein is a tyrosine phosphatase and belongs to the 
Cdc25 phosphatase family. It directs dephosphorylation of 
cyclin B-bound CDC2 and triggers entry into mitosis. It is 
also thought to suppress p53-induced growth arrest. 
 
Moderate expression in fetal brain and low expression in 
postnatal CNS, except for cortex where expression is high. 
High expression in immune cell types. 
CDC25C functions as a dosage-dependent inducer in mitotic 
control, directly dephosphorylating CDK1 and activating its 
kinase activity. 
 
In early animal development, cell proliferation and 
differentiation are tightly linked and coordinated. In Xenopus 
laevis, four isoforms of cdc25 have been identified: cdc25A, 
cdc25B, cdc25C and cdc25D. These isoforms show a specific 
temporal and spatial expression: cdc25A and cdc25C are 
expressed both maternally and zygotically, whereas cdc25B and 
cdc25D are expressed zygotically. Both cdc25A and cdc25C are 
expressed mainly in prospective neural regions, whereas cdc25B 
is expressed preferentially in the CNS, such as the spinal cord 
and the brain. Interestingly, cdc25D is expressed in the 
epidermal ectoderm of the late-neurula embryo, and in the liver 
diverticulum endoderm of the mid-tailbud embryo.  
Mutations and/or CNVs affecting CDC25C have never 
been reported in patients with ASD. 
Nakajo et al., 2011 
     
CXCL14(+) 
de novo 
 
Homeostasis of 
monocyte-derived 
macrophages, 
synaptic plasticity 
mediated by chemokine 
signaling 
This gene encodes the chemokine (C-X-C motif) ligand 14 
protein. It belongs to the cytokine gene family which encode 
secreted proteins involved in immunoregulatory and 
inflammatory processes. The protein encoded by this gene is 
structurally related to the CXC (Cys-X-Cys) subfamily of 
cytokines. It has been implicated that this cytokine is 
involved in the homeostasis of monocyte-derived 
macrophages rather than in inflammation. 
 
Moderate expression in fetal brain and high expression in 
postnatal CNS, except for cerebellum. 
Very low expression in immune cell types. 
CXCL14 is a member of the CXC chemokine family. CXCL14 
possesses chemoattractive activity for activated macrophages, 
immature dendritic cells and natural killer cells. 
CXCL14-deficient mice do not exhibit clear immune system 
abnormalities, suggesting that the function of CXCL14 can be 
compensated for by other chemokines.  
 
It has been recently reported that CXCL14 protein is present in 
a subset of hypothalamic neurons, thus suggesting its 
participation in hypothalamic functions such as control of 
autonomic nervous systems and/or in immune cell recruitment 
via the median eminence. During mouse development, CXCL14 
is not expressed in the nervous system prior to birth. 
Postnatally, CXCL14 is highly expressed in many regions of the 
brain, including the cortex, basal ganglia, septum and 
hippocampus. In particular, in the hippocampal dentate gyrus 
(DG) CXCL14 is expressed by GABAergic interneurons, where 
it inhibits GABAergic transmission to nestin-EGFP-expressing 
neural stem/progenitor cells in the adult DG. In contrast 
CXCL12 enhanced the effects of GABA at these same synapses.  
Moreover, recent evidence revealed that CXCL14 participates in 
glucose metabolism, feeding behaviour-associated neuronal 
circuits, and anti-microbial defense  
Mutations and/or CNVs affecting CXCL14 have never 
been reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including 
CXCL14, was previously identified in a genome-wide 
linkage analysis for autism. 
Banisadr et al., 2011 
Hara and Tanegashima, 2012 
Philippi et al., 2005 
Yamamoto et al., 2011 
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DDX46(+) 
de novo 
 
RNA metabolism 
This gene encodes the DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 46, which is a member of the DEAD box protein 
family. DEAD box proteins are putative RNA helicases 
implicated in a number of cellular processes involving 
alteration of RNA secondary structure, such as translation 
initiation, nuclear and mitochondrial splicing, and ribosome 
and spliceosome assembly. Based on their distribution 
patterns, some members of this family are believed to be 
involved in embryogenesis, spermatogenesis, and cellular 
growth and division. 
 
High expression in fetal brain and moderate expression in 
postnatal CNS. 
High expression in immune cell types. 
The DExD/H-box RNA helicase family is a large protein group 
characterized by the presence of a helicase domain that is highly 
conserved from bacteria to humans. These proteins have been 
shown to play important roles in all aspects of RNA 
metabolism: pre-mRNA splicing, rRNA biogenesis, 
transcription, RNA stability and turnover, RNA export, and 
translation. 
 
It has been recently reported that a mutation in Ddx46 is 
responsible for defects in the digestive organs and brain of the 
zebrafish mutant. Indeed, Ddx46 is specifically expressed in the 
digestive organs and brain of zebrafish and is required for 
premRNA splicing in these organs. 
Mutations and/or CNVs affecting DDX46 have never 
been reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including DDX46, 
was previously identified in a genome-wide linkage 
analysis for autism. 
 
A rare CNV affecting DDX53 has been reported in a 
patient with ASD 
Bleichert and Baserga, 2007 
Hozumi et al., 2012 
Jankowsky, 2011  
Philippi et al., 2005 
Pinto et al., 2010 
Rocak and Linder, 2004  
Silverman et al., 2003 
FAM13B(+) 
de novo 
 
Unknown function 
This gene encodes the family with sequence similarity 13, 
member B protein, which shows an unknown function. 
 
High expression in fetal brain and in postnatal prefrontal 
cortex, amygdalae, and thalamus. 
High expression in immune cell types. 
 
Mutations and/or CNVs affecting FAM13B have never 
been reported in patients with ASD. 
 
     FAM53C(+) 
de novo 
 
Unknown function 
This gene encodes the family with sequence similarity 53, 
member C protein, which shows an unknown function. 
 
Good expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
 
Mutations and/or CNVs affecting FAM53C have never 
been reported in patients with ASD. 
 
     
FBXL21(+) 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the F-box and leucine-rich repeat protein 
21, which is a member of the F-box protein family that is 
characterized by an approximately 40 amino acid motif, the 
F-box. The F-box proteins constitute one of the four subunits 
of ubiquitin protein ligase complex called SCFs (SKP1-
cullin-F-box), which function in phosphorylation-dependent 
ubiquitination.  
 
Moderate expression in fetal brain and in postnatal parietal 
and occipital lobes, cerebellum, amygdalae, and spinal cord. 
The FBXL21 gene encodes an F-box containing protein, which 
is a component of the SCF (SKP1-cullin-F-box) ubiquitin 
protein ligase complex. The SCF complex is involved in the 
phosphorylation-dependent ubiquitination of targeted proteins, 
leading to the degradation of the targeted proteins. The function 
of the F-box protein in the SCF complex is to target specific 
proteins.  
Several neuron specific F-box proteins have been previously 
identified, including FBL2 and Parkin that are involved in 
NMDA receptor degradation and Parkinson’s disease 
respectively. Furthermore, multiple linkage studies implicated 
the long arm of chromosome 5 as harboring susceptibility genes 
for SCZ. 
Mutations and/or CNVs affecting FBXL21 have never 
been reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including 
FBXL21, was previously identified in a genome-wide 
linkage analysis for autism.  
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
 
SNPs in FBXL21 have been associated with SCZ in two 
Irish samples. 
Cardozo and Pagano, 2004 
Chen et al., 2008 
Glessner et al., 2009 
Gurling et al., 2001 
Kishino et al., 1997 
Kato et al., 2005 
Liao et al., 2004 
Matsuura et al., 1997  
Noda et al., 2005 
Paunio et al., 2001 
Philippi et al., 2005 
Sklar et al., 2004 
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H2AFY(+) 
de novo 
 
Chromatin remodeling 
This gene encodes the H2A histone family, member Y. This 
gene encodes a member of the histone H2A family. It 
replaces conventional H2A histones in a subset of 
nucleosomes where it represses transcription and participates 
in stable X chromosome inactivation. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Very high expression in imuune cell types. 
Histones play a central role in transcription regulation, DNA 
repair, DNA replication and chromosomal stability. In 
particular, H2AFY inhibits the binding of transcription factors, 
interferes with the activity of remodeling SWI/SNF complexes, 
and inhibits histone acetylation by EP300 and recruits class I 
HDACs, which induces an hypoacetylated state of chromatin. 
 
It has been recently reported that the dynamic regulator of 
chromatin plasticity H2AFY is specifically overexpressed 
in the blood and frontal cortex of patients with Huntington 
disease compared with controls. This association precedes the 
onset of clinical symptoms, was confirmed in two mouse 
models, and was independently replicated in cross-sectional and 
longitudinal clinical studies. 
Mutations and/or CNVs affecting H2AFY have never 
been reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including H2AFY, 
was previously identified in a genome-wide linkage 
analysis for autism. Nevrtheless, no association was 
found between a few SNPs in H2AFY and ASD. 
Hu et al., 2011 
Philippi et al., 2005, 2007 
     
IL9(+) 
de novo 
 
Cytokine-mediated 
neurodevelopment and 
neuroinflammation  
This gene encodes the interleukin 9, which is a cytokine that 
acts as a regulator of a variety of hematopoietic cells. This 
cytokine stimulates cell proliferation and prevents apoptosis. 
It functions through the interleukin 9 receptor (IL9R), which 
activates different signal transducer and activator (STAT) 
proteins and thus connects this cytokine to various biological 
processes.  
 
Low expression in fetal brain and moderate expression in 
postnatal temporal lobe, prefrontal cortex, cerebellum and 
thalamus. 
Good expression in NK-cells. 
IL9 has been identified as a candidate gene for asthma. Genetic 
studies on a mouse model of asthma demonstrated that this 
cytokine is a determining factor in the pathogenesis of bronchial 
hyperresponsiveness. 
 
In mammals, programmed cell death (PCD) is a central event 
during brain development. Trophic factors have been shown to 
prevent PCD in postmitotic neurons. Similarly, cytokines have 
neurotrophic effects involving regulation of neuronal survival. It 
has been reported that interleukin-9 and its receptor specifically 
control PCD of neurons in the murine newborn neocortex. IL-9 
antiapoptotic action appeared to be time-restricted to early 
postnatal stages as both ligand and receptor transcripts were 
mostly expressed in neocortex between postnatal days 0 and 10. 
This period corresponds to the physiological peak of apoptosis 
for postmitotic neurons in mouse neocortex. IL-9 effects were 
mediated by the activation of the JAK/STAT pathway. Finally, 
IL-9 reduced the expression of the mitochondrial pro-apoptotic 
factor Bax whereas Bcl-2 level was not significantly affected.  
 
Moreover, n the experimental autoimmune encephalomyelitis 
mousel, which is animal model of multiple sclerosis, it has been 
reported that in the CNS IL-9 is produced by several Th cell 
subsets in the presence of IL-4 and that IL-9 receptor complex is 
constitutively expressed by astrocytes. IL-9 induces CCL-20 
production by astrocytes to induce the migration of Th17 cells 
into the CNS, thus sustaining the neuroinflammatory process. 
Mutations and/or CNVs affecting IL9 have never been 
reported in patients with ASD. 
 
Elevated serum levels of a few interleukins have been 
previously reported in autistic patients. 
Fontaine et al., 2008 
Zhou et al., 2011 
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KIF20A(+) 
de novo 
 
Intracellular trafficking: 
retrograde transport from 
Golgi to ER 
This gene encodes the kinesin family member 20A, which 
interacts with guanosine triphosphate (GTP)-bound forms of 
RAB6A and RAB6B and may act as a motor required for the 
retrograde RAB6 regulated transport of Golgi membranes 
and associated vesicles along microtubules. KIF20A has a 
microtubule plus end-directed motility. 
 
Good expression in fetal brain and low expression in 
postnatal CNS. 
Very high expression in eritroid and myeloid cell lineages 
and in dendritic cells. 
KIF20A binds to Rab6B which is preferentially expressed in 
brain, especially in microglial cells, pericytes and Purkinje cells.  
In particular, Rab6B is abundant in SK-N-SH cells that can 
either differentiate into cells with a neuronal phenotype, or in 
cells exhibiting properties common to glial cells.  
Rab6B may also be abundant in human melanocytes. 
The interaction of Rab6B with Rabkinesin-6 (KIF20A) 
suggestes that Rab6B may regulate a transport route through a 
molecular machinery comparable to that of Rab6A, in particular 
a retrograde transport along microtubules from the Golgi 
apparatus to the endoplasmic reticulum. 
Mutations and/or CNVs affecting KIF20A have never 
been reported in patients with ASD. 
Opdam et al., 2000  
Sano et al., 1990 
Shinohara et al., 1997 
     
KLHL3(+) 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the kelch-like 3 (Drosophila) protein, 
which has an N-terminal BTB domain followed by a BACK 
domain and six kelch-like repeats in the C-terminus. These 
kelch-like repeats promote substrate ubiquitination of bound 
proteins via interaction of the BTB domain with the CUL3 
(cullin 3) component of a cullin-RING E3 ubiquitin ligase 
(CRL) complex.  
 
Good expression in fetal brain and in postnatal CNS. 
The ubiquitin-proteasome system plays crucial roles in various 
aspects of neuronal development, such as axon formation, 
elongation, and pruning, and synapse formation and 
elimination.  
The Cullin3 (Cul3)-based ubiquitin E3 ligases use BTB 
domain–containing proteins as substrate adaptors and, recently, 
KLHL20, a protein possessing a BTB domain and six kelch 
repeats, has been identified as such an adaptor. KLHL20 mRNA 
is abundantly expressed in the brain of an embryonic day 14.5 
(E14.5) mouse embryo, implying its role in neural development. 
In the adult mouse brain KLHL20 mRNA is highly expressed in 
the hippocampus, especially in the dentate gyrus, where a 
lifelong neurogenesis occurs. 
By analogy, it is possible that also KLHL3 may be involved in 
neurodevelopment. 
 
Muatations in KLHL3 cause pseudohypoaldosteronism type IID 
(PHA2D); a rare Mendelian syndrome featuring hypertension, 
hyperkalaemia and metabolic acidosis. 
Mutations and/or CNVs affecting KLHL3 have never 
been reported in patients with ASD. 
 
Another member of the same family of proteins, 
KLHL22, maps within the genomic region involved in the 
22q11 microdeletion/microduplication syndrome, which 
shows comorbidity with ASD, SCZ, ADHD and mood 
disorder. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Antshel et al., 2007  
Bucan et al., 2009 
Fine et al., 2005  
Glessner et al., 2009 
Kishino et al., 1997 
Lee et al., 2010 
Lin et al., 2011 
Lo-Castro et al., 2009 
Marshall et al., 2008 
Matsuura et al., 1997  
Mukkades and Herguner, 2007 
Niklasson et al., 2009 
Pinto et al., 2010 
Ramelli et al., 2008 
Segref and Hoppe, 2009  
Szatmari et al., 2007 
Tai and Schuman, 2008 
Vorstman et al., 2006 
Yi and Ehlers, 2007 
 
 
 
    
 
 
 
 
LECT2(+) 
de novo 
 
Neurodevelopment 
This gene encodes the leukocyte cell-derived chemotaxin 2, 
which is a secreted protein that acts as a chemotactic factor to 
neutrophils and stimulates the growth of chondrocytes and 
osteoblasts. A polymorphism in this gene may be associated 
with rheumatoid arthritis. 
 
Moderate expression in fetal brain and in postnatal CNS, 
except for cingulate cortex where the expression is good.  
High expression in fetal and adult liver. No expression has 
been detected in bone marrow.  
Leukocyte cell-derived chemotaxin 2 (LECT2) was first isolated 
as a chemotactic factor from phytohemagglutinin-activated 
human T-cell leukemia SKW-3 cells.  
To elucidate LECT2 functions in brain, the influence of a 
deficiency of LECT2 on the morphology of cultured 
hippocampal neurons during neuronal development was 
investigated, and the expression of neurotrophins (NGF, BDNF, 
and NT-3) and their receptors (TrkA, TrkB, TrkC, and p75NTR) 
in these neurons was examined. It has been reported that the 
extension of axons and dendrites in neurons from LECT2-
knockout mice was shorter than that in neurons from wild-type 
mice during culture and significantly less than that in wild-type 
mice after 4 days in culture. Moreover, neurons from LECT2-
KO mice showed different expression of NGF, BDNF and NT-3 
during culture compared to wild-type mice, suggesting that 
LECT2 regulates the extension of axons and dendrites and the 
expressions of NGF, BDNF and NT-3 during neuronal 
development. 
Mutations and/or CNVs affecting LECT2 have never been 
reported in patients with ASD. 
Koshimizu and Ohtomi, 2010 
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NEUROG1(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the neurogenin 1 protein, which acts as a 
transcriptional regulator. It is involved in the initiation of 
neuronal differentiation, and associates with chromatin to 
enhancer regulatory elements in genes encoding key 
transcriptional regulators of neurogenesis.  
 
Good expression in postnatal thalamus, hypothalamus, 
amygdalae, and cerebellum. 
In mouse beta-catenin/TCF complex appears to directly regulate 
the promoter of neurogenin 1, a gene implicated in cortical 
neuronal differentiation. 
A 1.2 Mb region of chromosome 5q31, including 
NEUROG1, was previously identified in a genome-wide 
linkage analysis for autism.  
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
 
SNPs in NEUROG1 have been previously associated with 
SCZ. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Fanous et al., 2007 
Hirabayashi et al., 2004 
Ma et al., 1999  
Okerlund and Cheyette, 2011 
Philippi et al., 2005, 2007 
Wang et al., 2010  
Zhang et al., 2012 
     
PITX1(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the paired-like homeodomain 1 protein, 
which is a member of the RIEG/PITX homeobox family, i.e., 
the bicoid class of homeodomain proteins. Members of this 
family are involved in organ development and left-right 
asymmetry. This protein acts as a transcriptional regulator 
involved in basal and hormone-regulated activity of 
prolactin.  
 
Moderate expression in fetal brain and in postnatal parietal 
lobe, prefrontal cortex, and hypothalamus. 
PITX1 plays a role in the development of anterior structures, 
and in particular, the brain and facies and in specifying the 
identity or structure of hindlimb. 
 
Defects in PITX1 are a cause of congenital clubfoot (CCF). 
Clubfoot is a congenital limb deformity defined as fixation of 
the foot in cavus, adductus, varus, and equinus (i.e. inclined 
inwards, axially rotated outwards, and pointing downwards) 
with concomitant soft tissue abnormalities. Clubfoot may occur 
in isolation or as part of a syndrome.  
Mutations and/or CNVs affecting PITX1 have never been 
reported in patients with ASD. 
 
A 1.2 Mb region of chromosome 5q31, including PITX1, 
was previously identified in a genome-wide linkage 
analysis for autism. Two SNPs in PITX1 have been 
associated with ASD. 
Philippi et al., 2005, 2007 
      
 
SAR1B(+) 
de novo 
 
Intracellular membrane 
trafficking 
This gene encodes the SAR1 homolog B (S. cerevisiae)  
protein, which is a small GTPase that acts as a homodimer. 
The encoded protein is activated by the guanine nucleotide 
exchange factor PREB and is involved in protein transport 
from the endoplasmic reticulum to the Golgi. This protein is 
part of the COPII coat complex. 
 
Moderate expression in fetal brain and in postnatal prefrontal 
cortex, cerebellum, amygdalae, and thalamus. 
Good expression in immune cell types, in particular in 
dendritic cells, monocytes, and NK-cells. 
SAR1B is involved in transport from the endoplasmic reticulum 
to the Golgi apparatus. 
 
Defects in SAR1B are the cause of chylomicron retention 
disease, also known as Anderson disease, which is an autosomal 
recessive disorder of severe fat malabsorption associated with 
failure to thrive in infancy. Furthermore, defects in SAR1B have 
also been associated with Marinesco-Sjögren syndrome, which 
is a progressive multisystem disease with autosomal recessive 
inheritance characterized by cataracts, MR, and cerebellar 
ataxia.  
Mutations and/or CNVs affecting SAR1B have never been 
reported in patients with ASD. 
Sakai et al., 2008 
      
 
SEC24A(+) 
de novo 
 
Intracellular membrane 
trafficking 
This gene encodes the SEC24 family, member A 
protein, which belongs to a family of proteins that are 
homologous to yeast Sec24. This protein is a component of 
coat protein II (COPII)-coated vesicles that mediate protein 
transport from the endoplasmic reticulum. COPII acts in the 
cytoplasm to promote the transport of secretory, plasma 
membrane, and vacuolar proteins from the endoplasmic 
reticulum to the golgi complex. 
 
Moderate expression in fetal brain and in postnatal cortex, 
and cerebellum. 
Good expression in immune cell types, in particular in 
dendritic cells, NK-cells, and CD4+ T-cells. 
SEC24A interacts with SAR1B to form the COPII complex. 
Mutations and/or CNVs affecting SAR1B have never been 
reported in patients with ASD. 
Wendeler et al., 2007 
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SLC25A48(+) 
de novo 
 
CNS metabolism: 
neuronal energy 
production 
This nuclear gene encodes the solute carrier family 25, 
member 48, which is a mitochondrial protein. 
 
High expression in postnatal whole brain, in particular in 
prefrontal cortex, amygdalae and hypothalamus, and in spinal 
cord. 
SLC25A48 is a member of the solute carrier 
family 25 proteins that function as transporters of a 
large variety of molecules including ATP/ADP and 
amino acids, and localize to the inner mitochondrial membrane.  
In particular, SLC25A48 is highly expressed in the CNS 
including the hypothalamus, pituitary and brainstem and has 
been shown to be important in healthy neurons for energy 
production and to have a role in neuronal signaling.  
Mutations and/or CNVs affecting SLC25A48 have never 
been reported in patients with ASD. 
 
Recently, a genome-wide association study has identified 
SLC25A48 as candidate genes for Parkinson’s disease in 
an Ashkenazi Jewish population. 
Haitina et al., 2006 
Liu et al., 2011 
Palmieri, 2004 
     
SPOCK1(+) 
de novo 
 
Neurogenesis: regulation 
of neuronal migration 
and axonal outgrowth 
This gene encodes the sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan 1 (testican 1), which is the protein 
core of a seminal plasma proteoglycan containing 
chondroitin- and heparan-sulfate chains. The protein's 
function is unknown, although similarity to thyropin-type 
cysteine protease-inhibitors suggests its function may be 
related to protease inhibition. 
 
Very high expression in fetal brain and in postnatal CNS. 
Testican-1 is strongly expressed in the brain and has been 
reported to modulate neuronal attachment and matrix 
metalloproteinase activation.  
During mouse embryonic development SPOCK1 is actively 
expressed at the onset of neurogenesis during periods of neuron 
migration and axonal outgrowth. At a later developmental stage, 
its expression is particularly prevalent within developing 
synaptic fields. In particular, SPOCK1 is most prominently 
expressed in the thalamus, and is upregulated in activated 
astroglial cells of the cerebrum. The purified gene product has 
been shown to inhibit cell attachment and neurite extensions in 
culture. In the peripheral nervous system, SPOCK expression is 
also developmentally regulated particularly in dorsal root 
ganglion neurons. 
 
SPOCK1 has been proposed as a candidate for modulating the 
expression and maintenance of tyrosine hydroxylase (TH) 
content in murine mesencephalic dopamine neurons in vivo. TH 
is the first and rate limiting enzyme in the biosynthesis of 
catecholamine neurotransmitters in the substantia nigra-ventral 
tegmental area and the mesotelencephalic dopamine system is 
implicated in normal and pathological behaviors related to 
motor function, motivation, and learning.  
Mutations and/or CNVs affecting SPOCK1 have never 
been reported in patients with ASD. 
Charbonnier et al., 2000 
Edgell et al., 2004 
Röll et al., 2006 
Vadasz et al., 2007 
     
WNT8A(+) 
de novo 
 
Intracellular Wnt 
signaling pathway 
This gene encodes the wingless-type MMTV integration site 
family, member 8A protein. 
The WNT gene family consists of structurally related genes 
which encode secreted signaling proteins. These proteins 
have been implicated in oncogenesis and in several 
developmental processes, including regulation of cell fate 
and patterning during embryogenesis. This gene is a member 
of the WNT gene family, and may be implicated in 
development of early embryos as well as germ cell tumors. 
 
No expression data are available in UCSC Genome Browser 
(hg19, release February 2009). 
It has been reported in zebrafish that Wnt8 signaling emanating 
from lateral mesendodermal precursors is essential for 
neuroectodermal posteriorization starting from the organizing 
center, located at the midbrain-hindbrain boundary (MHB). 
Indeed, MHB patterns the midbrain and hindbrain primordia of 
the neural plate.  
Wnt8 is required for the initial subdivision of the neuroectoderm 
and graded Wnt8 activity mediates overall neuroectodermal 
posteriorization and thus determines the location of the MHB 
organizer.  
Mutations and/or CNVs affecting WNT8A have never 
been reported in patients with ASD. 
 
Deregulation of Wnt/β-catenin signaling pathway has 
been implicated in the pathogenesis of ASD as well as of 
other neuropsychiatric disorders. 
Chung et al., 2011 
De Ferrari and Moon, 2006 
Okerlund and Cheyette, 2011 
Rhinn et al., 2005, 2009 
Wang et al., 2010  
Zhang et al., 2012 
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 Patient 60, loss of 7.8 Mb at 5p15.33p15.31 (chr5:95243-7859564) 
     
ADCY2(-) 
de novo 
 
Intracellular signaling 
This gene encodes the adenylate cyclase 2 protein, which is a 
member of the family of adenylate cyclases. They are 
membrane-associated enzymes that catalyze the formation of 
the secondary messenger cyclic adenosine monophosphate 
(cAMP). This enzyme is insensitive to Ca(2+)/calmodulin, 
and is stimulated by the G protein beta and gamma subunit 
complex. 
 
High expression in fetal brain and in postnatal CNS, except 
for cerebellum, thalamus and hypothalamus.  
Quite discrete patterns of expression of Ca2+/calmodulin-
insensitive adenylyl cyclase were found in rat brain. Indeed, in 
some areas both species were co-expressed, but in others, little 
overlap was observed. The differential expression of the two 
mRNAs suggests that discrete roles may be fulfilled by the two 
adenylyl cyclases in neural tissues. 
 
Another member of the same family, ADCY1 (a 
Ca2+/calmodulin-sensitive adenylyl cyclase), is involved in 
calcium-signaling that is required for many brain functions, 
such as learning and memory. 
Mutations and/or CNVs affecting ADCY2  have never 
been reported in patients with ASD. 
 
The application of a genome-wide SNP microarray 
approach to a single multiplex consanguineous Pakistani 
family, affected by ID and distal myopathy, allow the 
localization of a single 2.5 Mb homozygosity-by-descent 
(HBD) locus in the region 5p15.32-p15.31, which 
includes ADCY2. 
Khan et al., 2012 
Mons et al., 1993 
Stengel et al., 1992 
Wieczorek et al., 2010 
     
AHRR(-) 
de novo 
 
CNS metabolism: 
hydrocarbon 
detoxification 
This gene encodes the aryl-hydrocarbon receptor repressor, 
which participates in the aryl hydrocarbon receptor (AhR) 
signaling cascade, that mediates dioxin toxicity, and is 
involved in regulation of cell growth and differentiation. It 
functions as a feedback modulator by repressing AhR-
dependent gene expression.  
 
Moderate expression in fetal brain and good expression in 
postnatal whole brain, in particular in amygdalae, thalamus 
and hypothalamus. 
The Aryl hydrocarbon receptor repressor shares structural 
similarities with Aryl hydrocarbon receptor (AhR) and AhR 
nuclear translocator (ARNT). The AhRR is thought to be 
involved in transcriptional control of AhR-regulated genes by 
sequestering ARNT.  
AhRR mRNA expression pattern in untreated C57BL/6 mice 
varies across tissues with high levels in hearts and brains. In 
other tissues, AhRR mRNA expression was low. In contrast to 
wild-type animals, the tissue levels in AhR-/- mice were about 
two to three orders of magnitude lower. Treatment of wild-type 
animals with benzo(a)pyrene resulted in an induced AhRR 
expression in liver, spleen, lung and ovary. No significant 
induction of AhRR mRNA was found in brain and heart tissues, 
which have a constitutively high level of AhRR expression.  
Mutations and/or CNVs affecting AHRR have never been 
reported in patients with ASD. 
Bernshausen et al., 2006 
      
 
CEP72(-) 
de novo 
 
Neurogenesis and 
neuronal migration? 
This gene encodes the centrosomal protein 72kDa, which is a 
member of the leucine-rich-repeat (LRR) superfamily of 
proteins. The protein is localized to the centrosome, a non-
membraneous organelle that functions as the major 
microtubule-organizing center in animal cells. It is involved 
in the recruitment of key centrosomal proteins to the 
centrosome. 
 
Moderate expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
Several centrosomal proteins have been previously involved in 
neurodevelopment. For example, autosomal-recessive primary 
microcephaly (MCPH), a rare congenital disorder characterized 
by ID, reduced brain and head size, is due to mutations in seven 
known loci code for centrosomal proteins, such as CEP135 and 
STIL. Furthermore, CDK5RAP2 and CENPJ have been reported 
expressed in neuroepithelia during prenatal neurogenesis and 
the proteins were found localized to the spindle poles of mitotic 
cells, suggesting that a centrosomal mechanism controls neuron 
number in the developing mammalian brain. 
By analogy, CEP72 may be involved in neurogenesis and 
neuronal migration. 
Mutations and/or CNVs affecting CEP72 have never been 
reported in patients with ASD. 
Bond et al., 2005 
Hussain et al., 2012 
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C5orf38(-) 
de novo 
 
Neurogenesis 
This gene encodes the chromosome 5 open reading frame 38. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Good expression in thalamus. 
An open reading frame coding for an unknown protein, 
C5orf38, is identified in the promoter of IRXA2 on chromosome 
5p. This new gene is composed of four exons and it is orientated 
in a head-to-head manner to IRXA2.  
The expression profile of the gene analysed in 9 different human 
tissues reveals that it is expressed in a coordinated fashion with 
IRXA2. The gene is only found in the human and the 
chimpanzee genome, but not in the mouse or the rat genome, 
which suggests that it is unique for higher primates. As the 
identified bi-directional promoter not being a relic of an ancient 
compact genome, C5orf38 may play an important role in the 
evolution of higher primates in coordination with the IRX genes. 
Mutations and/or CNVs affecting C5orf38 have never 
been reported in patients with ASD. 
Wu et al., 2006 
      
 
 
EXOC3(SEC6)(-) 
de novo 
 
Synaptogenesis: 
intracellulae membrane 
trafficking 
This gene encodes the exocyst complex component 3, which  
is a component of the exocyst complex, a multiple protein 
complex essential for targeting exocytic vesicles to specific 
docking sites on the plasma membrane. Though best 
characterized in yeast, the component proteins and functions 
of exocyst complex have been demonstrated to be highly 
conserved in higher eukaryotes. At least eight components of 
the exocyst complex, including this protein, are found to 
interact with the actin cytoskeletal remodeling and vesicle 
transport machinery. The complex is also essential for the 
biogenesis of epithelial cell surface polarity. 
 
Moderate expression in fetal brain and good expression in 
postnatal CNS, in particular in cortex and cerebellum. 
High expression in immune cell types. 
In a study of developing neurons, Sec6/8 complexes were found 
at the highest levels in regions of the brain undergoing 
synaptogenesis and in regions of cultured neurons where 
synapses will subsequently develop. In contrast, the level of 
Sec6/8 was downregulated in mature synapses. This led to the 
hypothesis that the main function of the Sec6/8 complex is in 
formation of synapses rather than in their function once formed. 
Moreover, it has been demonstrated that the interaction 
between Ral, a member of the Ras-GTPase family,which resides 
on the cytoplasmic side of vesicles, and the Sec6/8 exocyst 
complex, which resides on the inner surface of the plasma 
membrane, could promote the recruitment of synaptic vesicles 
from the reserve pool in the cytoplasm to the plasma membrane 
in response to stimuli like phorbol esters and calcium. 
Mutations and/or CNVs affecting EXOC3 have never 
been reported in patients with ASD. 
Hazuka et al., 1999 
Hsu et al., 1996, 1999 
Polzin et al., 2002 
     
IRX1(-) 
de novo 
 
Neurogenesis 
This gene encodes the iroquois homeobox 1 protein, which is 
a member of the Iroquois homeobox protein family. 
Homeobox genes in this family are involved in pattern 
formation in the embryo.  
 
No expression microarray data available. 
Iroquois homeoproteins are prepatterning factors that positively 
regulate proneural genes and control neurogenesis. In zebrafish 
the Iroquois gene, irx1, homolog has been identified, which is 
also higly homologous to Xenopus Xiro1, Gallus c-Irx1 and 
mouse Irx1. Expression of irx1 was initially detected at the bud 
stage. By 16 h post-fertilization (hpf), irx1 expression was 
exclusively limited to the prospective midbrain and hindbrain.  
Recently, loss of function studies in Xenopus clarified that Irx1 
and Irx3 seem to have a predominant role during regionalization 
of the neural plate. 
Mutations and/or CNVs affecting IRX1 have never been 
reported in patients with ASD. 
Cheng et al., 2001 
Rodríguez-Seguel et al., 2009 
     
IRX2(-) 
de novo 
 
Neurogenesis 
This gene encodes the iroquois homeobox 2 protein, which is 
a member of the Iroquois homeobox gene family. Members 
of this family appear to play multiple roles during pattern 
formation of vertebrate embryos. 
 
No expression microarray data available. 
The Iroquois (Irx) genes encode homeoproteins conserved 
during evolution. Vertebrate genomes contain six Irx genes 
organized in two clusters, IrxA (which harbors Irx1, Irx2 and 
Irx4) and IrxB (which harbors Irx3, Irx5 and Irx6).  
Loss-of-function study of all the early expressed Irx genes 
(Irx1-5) using specific morpholinos in Xenopus revealed that 
the five Irx genes display largely overlapping expression 
patterns and contribute to neural patterning. All Irx genes are 
required for proper formation of posterior forebrain, midbrain, 
hindbrain and, to a lesser an extent, spinal cord.  
Mutations and/or CNVs affecting IRX2 have never been 
reported in patients with ASD. 
Rodríguez-Seguel et al., 2009 
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IRX4(-) 
de novo 
 
Neurogenesis 
This gene encodes the iroquois homeobox 4 protein. 
 
Moderate expression in postnatal parietal lobe, cerebellum, 
thalamus hypothalamus, subtalamic nucleus, and spinal cord.  
High expression in prostate and heart. 
Loss-of-function study of all the early expressed Irx genes 
(Irx1-5) using specific morpholinos in Xenopus revealed that 
the five Irx genes display largely overlapping expression 
patterns and contribute to neural patterning. All Irx genes are 
required for proper formation of posterior forebrain, midbrain, 
hindbrain and, to a lesser an extent, spinal cord. 
Moreover, several findings support a role for IRX4 in heart 
development. 
Mutations and/or CNVs affecting IRX4 have never been 
reported in patients with ASD. 
Garriock et al., 2001 
Rodríguez-Seguel et al., 2009 
      
 
 
 
 
 
LPCAT1(-) 
de novo 
 
CNS homeostasis: lipid 
metabolism 
This gene encodes the lysophosphatidylcholine 
acyltransferase 1 protein, which catalyzes the conversion of 
LPC to phosphatidylcholine (PC) in the remodeling pathway 
of PC biosynthesis. 
 
High expression in fetal brain and in postnatal amygdalae. 
Very high expression in immune cell types. 
Phosphatidylcholine (PC) is the major phospholipid of the 
brain and comprises almost half of vertebrate retinal 
phospholipids. Lyso-PC (LPC) is a bioactive proinflammatory 
lipid generated by the pathological metabolism of PC. 
Accumulation of LPC is associated with a host of diseases, 
including atherosclerosis, myocardial ischemia, 
neurodegeneration, inflammatory diseases, and diabetic 
complications. 
LPCAT1 is a lysophospholipid acyltransferase implicated in the 
anti-inflammatory response by its role in conversion of LPC to 
PC. In addition, the LPCAT1 enzyme also catalyzes the 
synthesis of platelet-activating factor (PAF), another potent 
inflammatory lipid, from lyso-PAF with use of acetyl-CoA as a 
substrate. 
In naive mice constant levels of PAF are produced by microglia 
and astrocytes, thus contributing to the maintenance of 
CNS homeostasis. In the CNS of experimental allergic 
encephalomyelitis (EAE) mice, which mimics multiple 
sclerosis, the blood-brain barrier is broken and inflammatory 
cells, such as T cells and macrophages, infiltrate the CNS. Thus, 
activated microglia and macrophages produce higher amounts 
of LPCAT1/2 and therefore a robust PAF production has been 
observed, contributing to the inflammatory process. 
Mutations and/or CNVs affecting LPCAT1 have never 
been reported in patients with ASD. 
Cheng et al., 2009 
Kihara et al., 2008 
Matsumoto et al., 2007 
Nakanishi et al., 2006 
      
 
 
 
 
 
 
 
 
145 
 
Tab. 4.1. Continued. 
 
 
 
 
 
 
 
NSUN2(-) 
de novo 
 
Translation regulation, 
epigenetic modifications 
This gene encodes the NOP2/Sun domain family, member 2 
protein, which is a methyltransferase that catalyzes the 
methylation of cytosine to 5-methylcytosine (m5C) at 
position 34 of intron-containing tRNA(Leu)(CAA) 
precursors. This modification is necessary to stabilize the 
anticodon-codon pairing and correctly translate the mRNA.  
 
Moderate expression in fetal brain and in postnatal cingulate 
cortex, cerebellum, and globus pallidus. 
High expression in B- and T-cells. 
NSUN2 was the first SUN-domain-containing protein to 
be characterized in vertebrates, and it is strongly conserved 
from bacteria to humans.It functions in spindle assembly during 
mitosis as well as chromosome segregation. 
By studying cortical and cerebellar region dissections from 
whole brains of 3-month-old mice, NSUN2 staining was 
sporadically observed in some cortical and brain-stem neurons 
although the most striking localization was observed in Purkinje 
cells of the cerebellum. 
 
It has been hypothesized that NSUN2 deficiency at critical 
stages during brain development might play a role in 
translational regulation needed for proper synaptic plasticity and 
thus learning and memory.  
Another conceivable disease mechanism might involve 
impaired methylation of hemimethylated DNA, which is 
also one of the targets of NSUN2 activity. It is a well 
established fact that alterations in DNA methylation 
patterns can lead to changes in gene transcription patterns 
and can also promote mutational events. Such epigenetic 
modifications can also cause specific changes in brain 
functions, which is of particular interest with respect to the 
cognitive phenotype. For instance, both the metabotropic 
(GRM1–7) and ionotropic (e.g., NMDA, AMPA, and kainate) 
glutamate-receptor-encoding genes undergo dynamic, 
region-specific, and cell-specific changes in expression 
during the course of brain development. 
Mutations and/or CNVs affecting NSUN2 have never 
been reported in patients with ASD. 
 
The application of a genome-wide SNP microarray 
approach to a single multiplex consanguineous Pakistani 
family, affected by ID and distal myopathy, allow the 
localization of a single 2.5 Mb homozygosity-by-descent 
(HBD) locus in the region 5p15.32–p15.31, which 
includes NSUN2, thus identifying homozygous missense 
changes in NSUN2 coding region which are responsible 
for an autosomal recessive form of ID. 
Interestingly, in addition to ID, NSUN2-mutation-positive 
individuals in the current study display features such as 
poor speech (dysarthria) and broad gait, which have 
previously been associated with cerebellar defects. 
 
Further NSUN2 mutations have been recently identified in 
Kurdish and Iranian ID consanguineous families. 
Abbasi-Moheb et al., 2012 
Akbarian and Huang, 2009  
Hong et al., 2003 
Hussain et al., 2009 
Khan et al., 2012 
Kuss et al., 2011 
Robertson, 2005  
Zhao et al., 2003 
Zschocke et al., 2002 
      
 
 
PDCD6(-) 
de novo 
 
Intracellular signaling for 
cell death 
This gene encodes the programmed cell death 6, a calcium-
binding protein belonging to the penta-EF-hand protein 
family, also known as ALG-2. Calcium binding is important 
for homodimerization and for conformational changes 
required for binding to other protein partners. This gene 
product participates in T cell receptor-, Fas-, and 
glucocorticoid-induced programmed cell death. In mice 
deficient for this gene product, however, apoptosis was not 
blocked suggesting this gene product is functionally 
redundant. 
 
Moderate expression in fetal brain and good expression in 
postnatal amygdalae, thalamus and hypothalamus. 
High expression in immune cell types. 
By using post-mitotic cerebellar neuron cultures it has been 
found that the complex Alix/ALG-2 regulates cell death 
controlling both caspase-dependent and -independent pathways. 
As Alix is a regulator of the endo-lysosomal system, these 
findings suggest a molecular link between the endo-lysosomal 
system and the effectors of the cell death machinery. 
PDCD6 has been previously suggested as autism 
candidate gene by molecular cytogenetic analysis and in 
silico studies. 
Iurov et al., 2010 
Trioulier et al., 2004 
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SDHA(-) 
de novo 
 
CNS metabolism: 
mitochondrial oxidative 
phosphorylation 
This nuclear gene encodes the mitochondrial succinate 
dehydrogenase complex, subunit A, flavoprotein, which is a 
major catalytic subunit of succinate-ubiquinone 
oxidoreductase, a complex of the mitochondrial respiratory 
chain. The complex is composed of four nuclear-encoded 
subunits and is localized in the mitochondrial inner 
membrane.  
 
Low expression in fetal brain and good expression in 
postnatal CNS.  
High expression in immune cell types. 
Mutations in SDHA have been associated with mitochondrial 
complex II deficiency, which shows heterogeneous clinical 
manifestations. Clinical features include psychomotor 
regression in infants, poor growth with lack of speech 
development, severe spastic quadriplegia, dystonia, progressive 
leukoencephalopathy, muscle weakness, exercise intolerance, 
cardiomyopathy. Severe forms are known as Leigh Syndrome, 
a severe disorder characterized by bilaterally symmetrical 
necrotic lesions in subcortical brain regions. 
Mutations and/or CNVs affecting SDHA have never been 
reported in patients with ASD. 
Alston et al., 2012 
Horvath et al., 2006 
     
SLC6A3(-) 
de novo 
 
Trafficking: dopamine 
transport 
This gene encodes the solute carrier family 6 protein, a 
dopamine transporter which is a member of the sodium- and 
chloride-dependent neurotransmitter transporter family.  
It terminates the action of dopamine by its high affinity 
sodium-dependent reuptake into presynaptic terminals. 
 
Low expression in fetal brain and moderate expression in 
postnatal parietal and occipital lobes, prefrontal cortex and 
thalamus. Good expression in amygdalae. 
Dopaminergic circuits are central to many key brain functions, 
i.e., memory, locomotion, reward mechanisms, motivation and 
cognition. Thus, the disturbances in dopaminergic tone are 
implicated in a broad spectrum of neuropsychiatric disorders, 
including ADHD, Parkinson’s disease (PD), SCZ, and diseases 
of addiction.  The 3' UTR of SLC6A3 contains a 40 bp tandem 
repeat, referred to as a variable number tandem repeat or VNTR, 
which can be present in 3 to 11 copies. Variation in the number 
of repeats is associated with several neuropsychiatric disorders. 
Moreover, defects in SLC6A3 are the cause of dystonia-
parkinsonism infantile, which is a neurodegenerative disorder 
characterized by infantile onset of parkinsonism and dystonia. 
Other neurologic features include global developmental delay, 
bradikinesia and pyramidal tract signs. 
 
It has been reportedt that PARK2, a multiprotein E3 ubiquitin 
ligase complex, increases dopamine uptake by enhancing the 
ubiquitination and degradation of misfolded SLC6A3, so as to 
prevent it from interfering with the oligomerization and cell 
surface expression of native SLC6A3. This function of parkin 
would enhance the precision of dopaminergic transmission, 
increase the efficiency of dopamine utilization, and reduce 
dopamine toxicity on neighboring cells. 
VNTR polymorphisms in SLC6A3 have been associated 
with idiopatic epiplepsy, ADHD, PD, addiction disorders. 
Moreover, specific SLC6A3 alleles have been associated 
with more severe social anxiety and tic symptoms in ASD 
patients. 
 
CNVs involving PARK2 have been reported in ASD 
patients. 
Arias-Carrion et al., 2010 
Gadow et al., 2008 
Glessner et al., 2009 
Jiang et al., 2004 
Lafuente et al., 2007 
Scheuerle and Wilson, 2011  
Shohamy and Adcock, 2010  
Shumay et al., 2011 
Swanson et al., 2007 
Vernier et al., 2004 
Volkow et al., 2007 
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SRD5A1(-) 
de novo 
 
CNS metabolism: 
neurosteroid 
byosynthesis 
This gene encodes the steroid-5-alpha-reductase, alpha 
polypeptide 1, which catalyzes the conversion of testosterone 
into the more potent androgen, dihydrotestosterone (DHT). 
 
High expression in fetal brain and in postnatal CNS. 
Allopregnanolone (ALLO) and tetrahydrodeoxycorticosterone 
(THDOC) are potent positive allosteric modulators of GABA 
action at GABAA receptors. ALLO and THDOC are 
synthesized in the brain from progesterone or 
deoxycorticosterone, respectively, by the sequential action of 
two enzymes: 5α-reductase (5α-R) type I and 
3α-hydroxysteroid dehydrogenase (3α-HSD).  
The evaluation of 5α-R type I and 3α-HSD mRNA expression 
level in mouse brain by using in situ hybridization revealed that  
the two enzimes colocalize in cortical, hippocampal, and 
olfactory bulb glutamatergic principal neurons and in some 
output neurons of the amygdalae and thalamus. Moreover, they 
are significantly expressed in principal GABAergic output 
neurons, such as striatal medium spiny, reticular thalamic 
nucleus, and cerebellar Purkinje neurons, thus suggesting that 
ALLO and THDOC, which can be synthesized in principal 
output neurons, modulate GABA action at GABAA receptors, 
either with an autocrine or a paracrine mechanism or by 
reaching GABAA receptor intracellular sites through lateral 
membrane diffusion. 
Mutations and/or CNVs affecting SRD5A1 have never 
been reported in patients with ASD. 
Agis-Balboa et al., 2006 
     
TPPP(-) 
de novo 
 
Neurodevelopment: 
microtubule cytoskeleton 
dynamics 
This gene encodes the tubulin polymerization promoting 
protein, which has a role in maintaining the integrity of the 
microtubule network. 
 
Very high expression in fetal brain and in postnatal CNS. 
Microtubules, which form a major part of the 
cytoskeleton, display many physiological functions in 
eukaryotic cells. The dynamic reorganizing ability and stability 
of microtubular systems show great variability in different 
tissues and at different stages of tissue development.  
TPPP is a recently discovered, brain-specific unstructured 
protein involved in brain function. It is found predominantly in 
oligodendrocytes in normal brain and its physiological function 
seems to be the dynamic stabilization of microtubular 
ultrastructures, as well as the projections of mature 
oligodendrocytes and ciliary structures.  
TPPP has been previously suggested as autism candidate 
gene by molecular cytogenetic analysis and in silico 
studies. 
Colello et al., 2002 
Hlavanda et al., 2002 
Iurov et al., 2010 
Orosz et al., 2008 
Seki et al., 1999 
Skjoerringe et al., 2006 
Tirian et al., 2003 
Zhou et al., 2011 
     
ZDHHC11(-) 
de novo 
 
Intracellular trafficking: 
protein palmitoylation 
This gene encodes the zinc finger, DHHC-type containing 11 
protein. The DHHC domain is required for 
palmitoyltransferase activity. 
 
High expression in fetal brain and in postnatal CNS.  
Protein palmitoylation, a classical and common lipid 
modification, regulates diverse aspects of neuronal protein 
trafficking and function.  
Individual DHHC enzymes, which belong to a family of 
palmitoyltransferases, generate and maintain the specialized 
compartmentalization of substrates in polarized neurons. 
Moreover, protein palmitoylation is implicated in various 
aspects of pathophysiology, including neuronal development 
and synaptic plasticity. 
Mutations and/or CNVs affecting ZDHHC1 have never 
been reported in patients with ASD. 
Fukata and Fukata, 2010 
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 Patient 60, gain of 9.1 Mb at 18p11.32p11.22 (chr18:180229-9281969)  
ADCYAP1(+) 
de novo 
 
Synaptic transmission 
This gene encodes the adenylate cyclase activating 
polypeptide 1 (PACAP) (pituitary), which stimulates 
adenylate cyclase and subsequently increases the cAMP level 
in target cells. Adenylate cyclase activating polypeptide 1 is 
not only a hypophysiotropic hormone, but also functions as a 
neurotransmitter and neuromodulator.  
 
Moderate expression in fetal brain and in postnatal CNS, in 
particular in thalamus.  
The neuropeptide PACAP is an informational molecule released 
from stress-transducing neurons. It exerts post-synaptic effects 
required to complete hypothalamo-pituitary-adrenocortical 
(HPA) and hypothalamo-splanchnico-adrenomedullary (HSA) 
circuits activated by psychogenic and metabolic stressors. 
PACAP-responsive (in cell culture models) and PACAP-
dependent (in vivo) transcriptomic responses in the adrenal 
gland, hypothalamus, and pituitary upon activation of these 
circuits have been identified. Gene products produced in 
response circuits during stress include additional neuropeptides 
and neurotransmitter biosynthetic enzymes and neuroprotective 
factors.  
PACAP is widely expressed throughout the brain and exerts its 
functions through the PACAP-specific receptor (PAC(1)). 
Recent studies reveal that genetic variants of the PACAP and 
PAC(1) genes are associated with mental disorders, and several 
behavioral abnormalities of PACAP knockout mice are reported, 
thus suggesting that PACAP has an important role in the 
regulation of locomotor activity, social behavior, anxiety-like 
behavior and, potentially, working memory. 
Mutations and/or CNVs affecting ADCYAP1 have never 
been reported in patients with ASD. 
 
In a genetic linkage study, fine-scale mapping of a locus 
for severe bipolar mood disorder on chromosome 18p11.3 
suggests that the PACAP gene, which resides at 18p11.32, 
is located close to a BD locus. Recently, genetic 
association studies have also shown that genetic variants 
of the genes encoding PACAP or PAC1 are associated 
with SCZ, MDDand post-traumatic stress disorder.  
Hashimoto et al.,2007, 2010 
Hattori et al., 2012 
Ishiguro et al.,2001 
Koga et al.,2010 
Lohoff et al.,2008 
McInnes et al.,2001 
Ressler et al.,2011  
Stroth et al., 2011 
      
ARHGAP28(+) 
de novo 
 
Intracellular signaling: 
regulation of actin 
cytoskeleton dynamics 
This gene encodes the Rho GTPase activating protein 28. 
 
Good expression in fetal brain and in postnatal thalamus. 
Good expression in immune cell types. 
Very high expression in testis. 
Rho GTPases, RhoA and Cdc42, are involved in neuronal 
morphogenesis, axonal guidance and synaptic plasticity by 
modulating the organization of actin cytoskeleton. 
The same pathway is involved in T-cells activation, migration, 
cell-cell adhesion. 
Mutations or CNVs affecting ARHGAP28 have never 
been reported in patients with ASD.  
 
Point mutations and CNVs affecting TSC1 and TSC2 
have been reported in patients with ASD and Tuberous 
Sclerosis 1 or 2. Both TSC1 and TSC2 proteins activate 
RhoA whereas TSC2 activates CdC42, thus regulating 
cell adhesion and migration. 
Fombonne et al., 1997 
Lewis et al., 2004 
Muzykewicz et al., 2007 
Wiznitzer, 2004 
Wong, 2006 
     
DLGAP1(+) 
de novo 
 
Synaptogenesis and 
synaptic plasticity 
This gene encodes the discs, large (Drosophila) homolog-
associated protein 1. 
 
High expression in fetal brain an in postnatal CNS, in 
particolar in caudate nucleus, thalamus and corpus callosum. 
Very high expression in brain cortex. 
DLGAP1 is a member of the neuronal postsynaptic density 
complex and directly interacts with other members of the 
postsynaptic density such as SHANK1, SHANK2, DLG1, and 
DLG4. 
Mutations and/or CNVs affecting DLGAP1 have never 
been reported in patients with ASD. 
 
Mutations and/or CNVs affecting several genes encoding 
preoteins of the postsynaptic density (e.g., SHANK2, 
SHANK3, DLG1, DLG4) have been reported in autistic 
patients. 
CNVs affecting DLGAP2 have been reported in a few 
autistic patients.  
Berkel et al., 2010, 2012 
Durand et al., 2007 
Feyder et al., 2010 
Leblond et al., 2012 
Marshall et al., 2008 
Moessner et al., 2007 
Peca et al., 2011 
Pinto et al., 2010 
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EPB41L3(+) 
de novo 
 
Neurodevelopment: 
nerve conduction 
This gene encodes the erythrocyte membrane protein band 
4.1-like 3 (4.1B protein). 
 
Very high expression in fetal brain and in postnatal CNS and 
PNS. 
Myelinated axons are organized into specialized domains 
critical to their function in saltatory conduction, i.e., nodes, 
paranodes, juxtaparanodes, and internodes.  
4.1B is expressed by neurons, and at lower levels by Schwann 
cells, which also robustly express 4.1G. Immunofluorescence 
demonstrated that 4.1B is expressed subjacent to the axon 
membrane in all domains except the nodes.  
Mice deficient in 4.1B have preserved paranodes, in contrast to 
the juxtaparanodes, which are substantially affected in both the 
PNS and CNS.  
Mutations and/or CNVs affecting EPB41L3 have never 
been reported in patients with ASD. 
Einheber et al., 2012 
     
LAMA1(+) 
de novo 
 
Neurogenesis 
This gene encodes the laminin, alpha 1protein, which is 
thought to mediate the attachment, migration and 
organization of cells into tissues during embryonic 
development by interacting with other extracellular matrix 
components. 
 
Moderate expression in fetal brain and in postnatal CNS. 
To study the role of this crucial laminin chain during late 
developmental phases and organogenesis, a conditional Laminin 
α1 knockout-mouse model has been created. A strong defect in 
the organization of the adult cerebellum of Lama1(cko) mice 
has been reported. Indeed, the study of the postnatal cerebellum 
of Lama1(cko) animals revealed a disrupted basement 
membrane correlated to an unexpected excessive proliferation 
of granule cell precursors in the external granular layer, thus 
suggesting that Lama1 is essential for the proper cerebellum 
development. 
Mutations and/or CNVs affecting LAMA1 have never 
been reported in patients with ASD. 
 
A SNP in LAMA1 has been recently reported in a patient 
with ASD. 
Anney et al., 2012 
Heng et al., 2011 
      
 
NDUFV2(+) 
de novo 
 
CNS metabolism: 
mitochondrial oxidative 
phosphorylation 
This nuclear gene encodes the mitochondrial NADH 
dehydrogenase (ubiquinone) flavoprotein 2, 24kDa.  
The NADH-ubiquinone oxidoreductase complex (complex I) 
of the mitochondrial respiratory chain catalyzes the transfer 
of electrons from NADH to ubiquinone, and consists of at 
least 43 subunits. The complex is located in the inner 
mitochondrial membrane. This gene encodes the 24 kDa 
subunit of complex I, and is involved in electron transfer.  
 
Low expression in fetal brain and moderate expression in 
postnatal CNS. 
High expression in immune cell types. 
Susceptibility loci for psychosis that includes BD, SCZ, 
psychosis not otherwise specified, and schizoaffective disorder, 
have been mapped at chromosome 18p11. In particular, SNPs in 
the NDUFV2 gene promoter have been associated with BD and 
SCZ in a Japanese cohort. Moreover, NDUFV2 expression 
levels have been found altered in post-mortem brain of 
schizophrenic subjects compared with controls. 
Mutations and/or CNVs affecting NDUFV2 have never 
been reported in patients with ASD. 
Mukherjee et al., 2006 
Nakatani et al., 2006 
Washizuka et al., 2004, 2006 
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PTPRM(+) 
de novo 
 
Intracellular signaling 
This gene encodes the protein tyrosine phosphatase, receptor 
type, M, which is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be signaling 
molecules that regulate a variety of cellular processes 
including cell growth, differentiation, mitotic cycle, and 
oncogenic transformation. This PTP has been shown to 
mediate cell-cell aggregation through the interaction with 
another molecule of this PTP on an adjacent cell. This PTP 
can interact with scaffolding protein RACK1/GNB2L1, 
which may be necessary for the downstream signaling in 
response to cell-cell adhesion. 
 
Good expression in fetal brain and in postnatal CNS, in 
particular in thalamus, hypothalamus, and amygdalae. 
Protein tyrosine phosphatases (PTPs) have emerged as a new 
class of signaling molecules that play important roles in the 
development and function of the CNS. They include both 
tyrosine-specific and dual-specific phosphatases. Based on their 
cellular localization they are also classified as receptor-like or 
intracellular PTP. However, the intracellular mechanisms by 
which these PTPs regulate cellular signaling pathways are not 
well understood.  
 
Recently, candidate blood biomarker genes for mood disorders 
have been identified: five genes are involved in myelination 
(Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes are involved 
in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6 
and Ptprm). All of these genes have prior evidence of 
differential expression in human postmortem brains from mood 
disorder subjects.  
Mutations and/or CNVs affecting PTPRM have never 
been reported in patients with ASD. 
 
A rare CNV affecting PTPRT has been reported in a 
patient with ASD. 
Christian et al., 2008 
Le-Niculescu et al., 2009 
Paul and Lombroso, 2003 
     
RAB12(+) 
de novo 
 
Intracellular membrane 
trafficking 
This gene encodes the RAB12 protein, which is a member of 
the RAS oncogene family of small GTPases. 
 
Moderate expression in fetal brain and in postnatal CNS. 
Plasma membrane receptor proteins play a key role in signal 
transduction and nutrient uptake. After endocytosis, receptor 
proteins are generally delivered to lysosomes for degradation or 
recycled back to the plasma membrane for recycling. 
Transferrin receptor (TfR) is a well-known representative of 
recycling receptor proteins, which are traveled between plasma 
membrane and recycling endosomes. It has been reported that 
the small GTPase Rab12 regulates membrane trafficking of TfR 
from recycling endosomes to lysosomes.  
 
As iron deficiency has been previously linked to cognitive 
impairments, recently the impact of iron deficiency on spatial 
learning and memory has been assessed in neonatal piglets as 
models of human infants. It has been established that neonatal 
iron deficiency leads to cognitive impairment, which may be 
due in part to a reduced iron concentration in the hippocampus. 
Mutations and/or CNVs affecting RAB12 have never been 
reported in patients with ASD. 
 
      
 
 
TGIF1(+) 
de novo 
 
Transcriptional 
regulation 
This gene encodes the TGFB-induced factor homeobox 1, 
which is a member of the three-amino acid loop extension 
(TALE) superclass of atypical homeodomains. TALE 
homeobox proteins are highly conserved transcription 
regulators. This particular homeodomain binds to a 
previously characterized retinoid X receptor responsive 
element from the cellular retinol-binding protein II promoter. 
In addition, TGIF1 is an active transcriptional co-repressor of 
SMAD2 and may participate in the transmission of nuclear 
signals during development and in the adult.  
 
Low expression in fetal brain and in postnatal CNS. 
Good expression in immune cell types, in particular in 
monocytes, B- and T-cells. 
TGIF is an atypical homeo-domain protein. In vitro studies have 
shown that TGIF can repress transcription mediated by either of 
two signaling pathways: TGF-beta and retinoic acid signaling. 
In vivo overexpression of TGIF in the developing chick neural 
tube demonstrated that TGIF plays an important role in 
regulating the expression of genes expressed in specific dorsal-
ventral domains during neural development.  
Moreover, it has been reported that TGIF1 together with 
MEIS2, another TALE family member, regulate the 
transcription of the D(1A) gene, which encodes the predominant 
dopamine receptor in the striatum. The two proteins have 
opposite roles: while MEIS2 activates D(1A) transcription, 
TGIF1 represses the transcription of this gene. 
 
Recently, it has been suggested that TGIF1 may have a role in 
macrophage activation. 
Mutations and/or CNVs affecting TGIF1 have never been 
reported in patients with ASD. 
 
SNPs in TGIF1 have been previously strongly associated 
with psychosis.  
 
Mutations in this gene are associated with 
holoprosencephaly type 4 (HPE-4), which is a structural 
anomaly of the brain associated with MR. HPE is the 
most common structural anomaly of the brain, in which 
the developing forebrain fails to correctly separate into 
right and left hemispheres. Holoprosencephaly is 
genetically heterogeneous and associated with several 
distinct facies and phenotypic variability. 
Chavarría-Siles et al., 2007 
Chen et al., 2003 
Knepper et al., 2006 
Ramsey et al., 2008 
Yang et al., 2000 
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THOC1(+) 
de novo 
 
Transcriptional 
elongation 
This gene encodes the THO complex 1 protein, which is part 
of the TREX (transcription/export) complex, which includes 
TEX1, THO2, ALY, and UAP56. 
 
Expressed ubiquitously. High level in fetal brain and in 
postnatal CNS, in particular in cortex, caudate nucleus, 
corpus callosum, and spinal cord.  
Very high expression in immune cell types. 
 
Mutations and/or CNVs affecting THOC1 have never 
been reported in patients with ASD. 
Matsui and Fukuda, 2011 
Rytych et al., 2012 
      
 
 
USP14(-)* 
de novo 
 
Intracellular signaling: 
protein ubiquitination 
pathway 
This gene encodes the ubiquitin specific peptidase 14 (tRNA-
guanine transglycosylase), which is a member of the 
ubiquitin-specific processing family of proteases that is a 
deubiquitinating enzyme with His and Cys domains. This 
protein is located in the cytoplasm and cleaves the ubiquitin 
moiety from ubiquitin-fused precursors and ubiquitinylated 
proteins.  
 
High expression in fetal brain and in postnatal CNS. 
High expression in immune cell types. 
Recently, it has been reported that homozygous ataxic mice 
(ax(J)) express reduced levels of the deubiquitinating enzyme 
Usp14. They develop severe tremors by 2-3 wk of age, followed 
by hindlimb paralysis, and death by 6-8 wk. While changes in 
the ubiquitin proteasome system often result in the accumulation 
of ubiquitin protein aggregates and neuronal loss, these 
pathological markers are not observed in the ax(J) mice. Instead, 
defects in neurotransmission were observed in both the central 
and peripheral nervous systems of ax(J) mice. These results 
imply that ax(J) nerve terminals are unable to recruit a sufficient 
number of vesicles to keep pace with physiological rates of 
transmitter release.  
Therefore, ubiquitination of synaptic proteins appears to play an 
important role in the normal operation of the neurotransmitter 
release machinery and in regulating the size of pools of synaptic 
vesicles. 
Mutations and/or CNVs affecting USP14 have never been 
reported in patients with ASD. 
 
The protein ubiquitination pathway has been previously 
implicated in ASD. 
Bhattacharyya et al., 2012 
      Patient 62, gain of 1.5 Mb at Xp22.31 (chrX:6551155-8032120)   
 Patient 63, gain of 501 kb at Xp22.31 (chrX:7269569-7820659) 
 
PNPLA4(+) 
 
CNS metabolism: 
lipoprotein metabolism 
This gene encodes the patatin-like phospholipase domain 
containing 4 protein, which is a member of the patatin-like 
family of phospholipases. The encoded enzyme has both 
triacylglycerol lipase and transacylase activities and may be 
involved in adipocyte triglyceride homeostasis. 
 
It is expressed in all tissues examined including the brain: 
low expression in postnatal CNS. 
PNPLA4 has a role in the metabolism of structural 
phospholipids involved in the formation and repair of the 
neuronal membrane. 
Mutations or CNVs affecting PNPLA4 have never been 
reported in patients with ASD.  
 
In syndromic forms of X-linked ichthyosis (XLI), due to 
Xp22.31 microdeletion, it has been recently suggested a 
possible contribution of PNPLA4 deficiency as one of the 
causes of neurological disorders among males, such as 
ADHD, autism and X-linked MR. 
Carrascosa-Romero et al., 2012 
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STS(+) 
STS(-)* 
 
CNS steroid metabolism 
This gene encodes the steroid sulfatase isozyme S, which 
catalyzes the conversion of sulfated steroid precursors to 
estrogens during pregnancy.  
 
Mild expression in fetal brain and high expression in 
postnatal CNS. 
STS mutations are known to cause X-linked ichthyosis, a 
keratinization disorder manifesting with mild erythroderma and 
generalized exfoliation of the skin within a few weeks after 
birth. Affected boys later develop large, polygonal, dark brown 
scales, especially on the neck, extremities, trunk, and buttocks. 
Recently, it has been demonstrated a function for STS in 
sulphate and no-sulfate steroids metabolism in CNS. Indeed, in 
the brain sulphated and non-sulfated steroids can influence the 
function of GABAA and NMDA receptors. 
Furthermore, based on work in mouse models, STS has been 
recently proposed as a novel ADHD candidate. Indeed, STS is 
expressed in regions of the developing brain relevant to ADHD 
pathology. 
STS deletion alone is not sufficient to develop ASD, but if 
the XLI deletion involves also NLGN4X the risk to 
develop ASD is higher. 
 
CNVs (gains) including STS have been reported in ASD 
patients. 
 
Individuals with deletions encompassing STS or 
inactivating STS mutations are at elevated risk of 
developing ADHD. 
Carrascosa-Romero et al., 2012 
Compagnone and Mellon, 2000 
Kent et al., 2008 
Davies et al., 2007  
Li et al., 2010 
Stergiakouli et al., 2011 
Trent et al., 2012 
     §In this table only the genes included in rare CNVs which localize in recurrent genomic regions or in regions previously implicated in ASD and/or in other neuropsychiatric disorders by linkage studies have been analyzed. (-), deleted or disrupted gene due to a rare deletion; (-)*, 
possible disrupted gene due to a rare duplication; (+), duplicated gene due to a rare duplication. The genes already implicated in ASD, due to mutations and/or CNVs, SNPs, or known syndromes which are comorbid with ASD are depicted in red, purple, and dark red, respectively. 
 
      Genes implicated in CNS metabolism. 
      Genes implicated in synaptogenesis and synaptic plasticity. 
      Genes implicated in CNS-IS network.     
      Genes implicated in intracellular signaling and membrane trafficking. 
      Genes implicated in neurogenesis and neurodevelopment. 
      Genes implicated in transcriptional and translational regulation, and chromatin remodeling. 
       
          Genes whose function may be related to the IS development and function, within and outside the CNS. 
 
ADHD, attention deficit hyperactivity disorder; AS, Angelman syndrome; BD, bipolar disorder; BWS, Beckwith-Wiedemann syndrome; CNS, central nervous system; CNV, copy number variation; CSF, cerebrospinal fluid; DD, developmental delay; EP, epilepsy; ER, endoplasmic 
reticulon; GWAS, genome-wide association study; HF-AU, high functioning autism; ID, intellectual disability; IS, immune system; MDD, major depressive disorder; MR, mental retardation; SCZ, schizophrenia; SNP, single nucleotide polymorphism; SRS, Siver-Russell syndrome; 
XLMR, X-linked mental retardation. 
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6.1 Analysis of the identified rare CNVs: implication for genotype-phenotype 
correlation  
The collected ASD cohort was, as expected, clinically heterogeneous, including different 
phenotypic categories ranging from full autism to high-functioning autism (HF-AU), Pervasive 
Developmental Disorder not otherwise specified (PDD-NOS), Asperger syndrome (AS), and 
syndromic autism (S-AU), which were classified according to the DSM-IV international criteria 
[Task Force on DSM-IV, 2000]. In particular, 15% of the patients were diagnosed as S-AU, in 
agreement with previous studies reporting a frequency of 10% of cases of autism in combination 
with facial dysmorphism and/or congenital malformations [Devlin and Scherer, 2012]. In addition, 
epilepsy was diagnosed in only 3.5% of the collected patients, in contrast to the reported frequency 
of 25% [Baird et al., 2006; Tuchman and Rapin, 2002]. 
Through the application of a genome-wide approach, copy number variations (CNVs) were 
determined, both rare (de novo and inherited) and those already reported in healthy controls 
according to the Database of Genomic Variants, which may be implicated in ASD. Specifically, 
55% of the patients were found to be carriers of one or more rare CNV, and, in total, 120 rare 
CNVs were identified, 73 gains (60.8%) and 47 losses (39.2%), confirming that among rare CNVs 
the frequency of gains is higher than that of losses, as previously reported [Levy et al., 2011; 
Marshall et al., 2008; Pinto et al., 2010, Sanders et al., 2011; Sebat et al., 2007; Zhao et al., 2007]. 
Conversely, focusing on the subset of rare de novo CNVs, 60% of these variants are losses, and 
40% are gains, in agreement with published data, which report a higher frequency of losses than 
gains among rare de novo CNVs [Levy et al., 2011; Marshall et al., 2008; Pinto et al., 2010, 
Sanders et al., 2011; Sebat et al., 2007; Zhao et al., 2007].  
Furthermore, since recent studies on several ASD series analyzed by array CGH demonstrated a 
higher frequency of rare de novo CNVs in females than in males [Gilman et al., 2011; Levy et al., 
2011], it has been hypothesized that rearrangements with a more severe effect and a higher 
penetrance are necessary for a female individual to develop ASD, compared to those anomalies 
necessary for the development of the same disease in males. This finding has not been reproduced 
in the cohort reported here, probably due to the small sample size. Indeed, rare de novo CNVs were 
found at the same percentage among female and male patients: 4/23 females (17.4%) and 16/92 
males (17.4%). 
 
In agreement with recently published data, the genotype-phenotype correlation in the present ASD 
series is rather complex [Schaaf et al., 2011]. First, rare CNVs, which may unveil, in part, the 
genetic causes underlying the disease, were found in only 55% of the patients, thus emphasizing 
the need to analyze large cohorts of autistic patients by means of different high-throughput 
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genome-wide approaches (e.g., array CGH, whole-exome sequencing) in order to increase the 
detection rate for these disorders.  
In addition, most patients positive in the array CGH analysis (~76%) were found to be carriers of 
more than one CNV, which were present in different combinations (Fig. 15), thus supporting the 
existence of a genetic model characterized by oligogenic heterozygosity, i.e., the simultaneous 
presence in a single autistic patient of multiple heterozygous quantitative variants/rare mutations, 
both de novo and/or inherited, affecting multiple genes [Pinto et al., 2010; Schaaf et al., 2011]. 
Previous studies of parents and unaffected siblings for the presence of oligogenic events revealed 
that the vast majority of these combinations are unique to the probands [Schaaf et al., 2011], as 
confirmed in the present ASD series by siblings 38–39 (Tab. 3), although some exceptions have 
been reported [Schaaf et al., 2011], suggesting that some of these events are insufficient to cause 
autism alone. It can be speculated that the accumulation of several, if not many, of such inherited 
low-penetrating variants causes a genetic load, which ultimately crosses a given threshold and leads 
to clinical manifestation of the ASD in the respective individuals. 
Therefore, when more rare CNVs are found in a single patient, it is difficult to attribute a “major” 
causative role to one of them, even in case of de novo CNVs, which are generally considered high-
penetrance variants. Indeed, the more severe clinical pictures reported here (i.e., syndromic autism) 
do not always correlate with the finding of rare CNVs, neither with the CNV size nor with the 
presence of de novo CNVs in the subset of patients bearing rare CNVs (Tab. 3). Moreover, it 
cannot be excluded that “common” CNVs may have modulated the behavioural phenotype of the 
reported ASD patients, increasing the complexity of inter-individual genetic and phenotypic 
variability. 
Interestingly, most of the identified rare de novo CNVs map either within genomic regions 
previously implicated in recurrent microrearrangements, which are responsible for some 
microdeletion/microduplication syndromes that are comorbid with ASD (Tab. 3, patients 14, 23, 
27, 29, 50, 52, 62, and 63), or within genomic regions implicated by linkage studies in ASD or in 
other neurologic or neuropsychiatric disorders, such as bipolar and major depressive disorders, 
schizophrenia, and intellectual disability (ID) (Tab. 3, patients 51, 53, 57, and 60). Indeed, the 8.8 
Mb genomic region found deleted in patient 51 at 2q14.3q21.3 includes a small region of 450 kb at 
2q21.1, recurrent deletion of which has been associated with attention deficit hyperactivity 
disorder, ID, epilepsy, and other neurobehavioral abnormalities [Dharmadhikari et al., 2012]. More 
recently, reciprocal duplications have been identified in five unrelated families with autism, 
developmental delay, seizures, and attention deficit hyperactivity disorder [Dharmadhikari et al., 
2012]. The rearranged segment harbors five genes, namely GPR148, FAM123C, ARHGEF4, 
FAM168B, and PLEKHB2, which are deleted in patient 51 (Tabs. 3 and 4.1).  
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Furthermore, in patients 53 and 57, rare large de novo CNVs affecting chromosomal regions 
previously suggested as ASD susceptibility loci by genome-wide linkage analyzes were identified, 
which map to 2q31.3q32.3 and 5q31.1q31.2, respectively (Tab. 3). Finally, both the 7.8 Mb loss at 
5p15.33p15.21 and the 9.1 Mb gain at 18p11.32p11.22 identified in patient 60 have been proposed 
as candidate loci for ID and bipolar disorder, major depressive disorder, and schizophrenia, 
respectively [Hattori et al., 2012; Ishiguro et al., 2001; Kuss et al., 2011; Lohoff et al., 2008; 
McInnes et al., 2001], thus supporting the existence of shared neurological pathways among 
different neuropsychiatric diseases, as previously reported [Bateman and Gull; 2011; Elia et al., 
2011a and b; Jarick et al., 2012; Kirov et al., 2009; Lachman, 2008; Lionel et al., 2011; Shoukier et 
al., 2012; Stefansson et al., 2008; Utine et al., 2012; Vrijenhoek et al., 2008; Walsh et al., 2008; 
Williams et al., 2012].  
Interestingly, in the ASD cohort reported here, the finding of rare de novo CNVs mapping in 
genomic regions responsible for recurrent genomic disorders does not correlate with the presence 
of a syndromic clinical picture in the carrying patients, with the exception of patient 14, who shows 
a mild syndromic phenotype (Tabs. 3 and 4.1). However, there are several possible explanations to 
clarify this discrepancy. Firstly, if the identified de novo CNV is smaller than that reported in 
association with the microdeletion/microduplication syndrome, it may not involve all the causative 
genes, although, conversely, it is possible that the rearrangement also perturbs the expression of 
genes localized outside its range by a position effect (Tab. 3). Furthermore, if the large de novo 
CNV is a duplication, it is difficult to predict the real effect of the rearrangement on the involved 
genes, which may lead to a haploinsufficiency, thus mimicking the effect of a deletion, as well as a 
mild or null perturbation of the gene expression or an increase of the corresponding protein. 
Indeed, Schaaf et al. recently reported the finding of point mutations with a mild effect in 
“syndromic” genes (i.e., missense mutations), such as TSC1, TSC2, PTEN, and CACNA1C, which 
in combination with mutations in other genes may have led to ASD development in a cohort of 
high-functioning autistic patients who do not show any syndromic clinical features [Schaaf et al., 
2011], thus supporting our hypothesis. Therefore, a precise molecular characterization of the 
identified CNVs as well as a quantitative analysis of the gene transcripts is necessary to clarify 
their role in ASD. 
For example, patient 14 carries a duplication of 442 kb at 9q34.3 (Tab. 3), which is included in the 
region responsible for the 9q subtelomeric deletion syndrome (Kleefstra syndrome), and shows a 
mild syndromic clinical picture not yet clearly defined as “Kleefstra”. This syndrome, which is 
characterized by a typical gestalt, microcephaly, hypotonia, ID and, in some cases, ASD/autistic 
traits, is due to the deletion of the EHMT1 gene, encoding a histone-methyltransferase, and, often, 
of the CACNA1B gene, which is located more distally and encodes a voltage-dependent calcium 
channel implicated in neurotransmitter release (Tab. 4.1) [Anderlid et al., 2002; Dawson et al., 
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2002; Iwakoshi et al., 2004; Kleefstra et al., 2005, 2009; McMullan et al., 2009; Sahoo et al., 
2006b]. Although the genomic instability of the chromosome 9q34 region has been well 
documented [Talkowski et al., 2012], often in association with neurodevelopmental disorders, only 
recently were a few autistic patients reported to bear complex deletion-duplication or duplication-
triplication rearrangements involving EHMT1, thus suggesting that increased dosage of EHMT1 
may be responsible for neurodevelopmental impairment and ASD [Yatsenko et al., 2012]. 
However, as both the duplication breakpoints fall within the gene coding sequences in patient 14 
(Fig. 18), it is possible that both EHMT1 and CACNA1B have been disrupted by the 
microrearrangement, thus resulting in gene haploinsufficiency as seen in microdeletion. To confirm 
this hypothesis, the duplication will be molecularly characterized, and any quantitative changes in 
EHMT1 and CACNA1B expression will be evaluated. Furthermore, patient 14 bears another rare 
CNV, inherited from the mother, at Xq22.3, which likely disrupts, differently from what happens in 
the healthy mother, the only copy of the IL1RAPL2 gene, encoding an interleukin receptor (Tabs. 3 
and 4.1). By analogy with the function of another member of the same family, IL1RAPL1, 
IL1RAPL2 is likely involved in presynaptic calcium-dependent neurotransmitter release and 
differentiation of dendritic spines. Since mutations and CNVs affecting IL1RAPL1 have been 
identified in patients with schizophrenia or autism with or without association to X-linked mental 
retardation [Piton et al., 2008], and SNPs in IL1RAPL2 have recently been associated with ASD 
[Kantojarvi et al., 2011], this CNV may play a role in the onset of the disease. 
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Fig 18. (Top) High-resolution array CGH (Agilent Technologies) identified a duplication of 442 kb at 9q34.3 
in patient 14. (Bottom) Schematic view of the region involved in the 9q34.3 subtelomeric deletion syndrome. 
The most interesting genes mapped within this region are depicted in blue, previously reported deletions in 
green [Kleefstra et al., 2009], the duplication identified in patient 14 in red, and the segmental duplications 
on the bottom line. 
 
In patient 23, the de novo deletion of 749 kb at 17q21.31 includes part of the region involved in the 
17q21.31 microdeletion/microduplication syndrome (Tab. 3, Fig. 19). The deletion syndrome is 
characterized by facial dysmorphism, hypotonia, ID, and ASD has been reported in only two 
patients [Betancur et al., 2008; Cooper et al., 2011], whereas this clinical characteristic has been 
demonstrated by several patients with the reciprocal duplication [Grisart et al., 2009]. The minimal 
deleted region spans 424 kb [Koolen et al., 2008; Sharp et al., 2006] and encompasses six genes 
including CRHR1, encoding a G protein-coupled receptor that binds neuropeptides, and MAPT 
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encoding a protein that is involved in the assembly and stability of microtubules (Tab. 4.1). "Gain 
of function" mutations affecting MAPT cause autosomal dominant forms of fronto-temporal 
dementia [D'Souza et al., 1999; Hutton et al., 1998; Rademakers et al., 2004], and common 
variants have been associated with progressive paralysis [Pittman et al., 2005] and Alzheimer’s 
disease [Myers et al., 2005]; therefore defects in this gene have also been suggested as candidates 
for ASD.  
Interestingly, patient 23, who was diagnosed as PDD-NOS in the absence of a syndromic clinical 
picture, bears the deletion of only CRHR1, which is likely disrupted by the rearrangement (Fig. 
19). This finding is in agreement with the recent report of three atypical deletions at 17q21.31 in 
three patients with the clinical signs of 17q21.31 microdeletion syndrome (one of the three patients 
was reported as autistic), which seems to exclude a pathogenetic role of CRHR1 [Cooper et al., 
2011]. Indeed, the critical region for this syndrome has been refined and focused to only three 
genes, MAPT, STH, and KIAA1267, thus supporting the involvement of MAPT in the onset of this 
syndrome, and, likely, in ASD [Cooper et al., 2011]. Although MAPT is not deleted in patient 23, it 
is not possible to exclude its dysregulation due to the identified microrearrangement, which may 
perturb gene expression by a position effect. Similar to the situation described in patient 14, in 
patient 23 the rare de novo CNV at 17q21.31 occurs in combination with a rare inherited CNV at 
17q24, which likely disrupts the gene encoding PRKCA, a calcium-dependent kinase with roles in 
cell adhesion and differentiation, and may have contributed to ASD onset (Tabs. 3 and 4). 
 
Finally, considering the rare inherited variants reported here, as expected, a few CNVs affect 
genomic regions, such as the 15q11.2 and 16p11.2 loci (Tab. 3, patients 25, 38, 39, 55), which are 
involved in recurrent genomic rearrangements that show incomplete penetrance and variable 
expressivity as they have been previously found in autistic patients as well as in healthy parents and 
in controls [Kumar et al., 2008; Marshall et al., 2008; Sempere-Perez et al., 2011; Weiss et al., 
2008]. Interestingly, Nord et al. [Nord et al., 2011] recently described a decrease in the transcripts 
of several genes affected by rare CNVs in a group of autistic probands compared with their 
unaffected transmitting parents and a group of controls, suggesting that transcriptional anomaly 
may explain, at least in part, the phenotypic differences between patients and healthy parents or 
controls. Notably, however, a reduced mRNA level has also been reported in the transmitting 
parent compared with the non-transmitting parent [Nord et al., 2011]. 
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Fig. 19. (Top) High-resolution array CGH (Agilent Technologies) identified a deletion of 749 kb at 17q21.31 
in patient 23. (Bottom) Schematic view of the region involved in the 17q21.31 
microdeletion/microduplication syndrome. The most interesting genes mapped within this region are depicted 
in blue, the recurrent deletion in dark green [Koolen et al., 2008], the duplication identified in patient 23 in 
light green, the reciprocal duplications reported by Grisart et al. in red [Grisart et al., 2009], and the atypical 
deletions reported by Cooper et al. in orange [Cooper et al., 2011]. 
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6.2 Identification of functional networks of genes potentially implicated in ASD 
On the basis of the rare CNV gene content, it is possible to confirm in the present cohort the wide 
genetic heterogeneity associated with ASD. Indeed, the same affected loci were detected in only a 
few unrelated patients (LCLAT1 in patients 7 and 33, and MACROD2 in patients 3, 33, and the 
siblings 40–41), whereas most patients demonstrated specific subsets of rare CNVs in 
combinations characteristic for each patient, thus supporting the genetic complexity of ASD. 
Moreover, most of the selected genes have never been reported in association with ASD, and thus 
they are suggested as new candidate loci (Fig. 17). They can be grouped into six functional 
networks that all contribute to CNS development and maintenance. Convergent pathways of action 
for the vast number of ASD genes proposed so far have been previously reported, most of which 
converge on synaptic function, thus confirming the neurological interpretation of ASD as a 
“synaptopathy” [Zoghbi and Bear, 2012]. Specifically, the selected genes are implicated in (Tabs. 
4 and 4.1, Fig. 17): 
- neurogenesis and neurodevelopment; 
- transcriptional regulation and chromatin remodeling; 
- CNS metabolism; 
- synaptogenesis and synaptic plasticity; 
- intracellular signaling and trafficking; 
- local and systemic immune response. 
Of note, although the schematic subdivision of genes above is proposed, it is clear that all the 
networks are deeply interconnected, and more than one network generally contribute to the same 
final neuronal function. 
 
Neurogenesis and neurodevelopment (the genes affected by de novo CNVs are indicated in bold 
text, Tabs 4 and 4.1) 
Sixty-six of the 276 selected genes contribute to neurogenesis or, more generally, to 
neurodevelopment acting directly on neuronal growth (axon outgrowth and patterning) (e.g., 
ADAMTS9, CFDP1, CSH1, EPB41L5, FMNL1, GH2, CSPG5, DIP2A, and PLD5), neuronal 
migration and organization into tissues (e.g., CEP72, FLNA, LAMA1, LIMK1, NCKAP1, NDE1, 
PCNT, PPP4C, SPOCK1, TUBA3D/3E, TPPP, and TMSB15B), and cell cycle and apoptosis 
regulation (e.g., MPHOSPH9 and AIFM3) (Fig. 20). Most of the CNVs affecting these genes are 
parentally inherited, whereas the de novo variants map to recurrent genomic regions as well as 
regions previously associated with ASD or with other neurodevelopmental disorders by linkage 
studies (Tabs. 3–4.1). Both deletions and duplications were observed, confirming that a decrease in 
neuronal growth and migration, as well as an increase in the same processes, accompanied by 
dysregulation in the spatial organization of the neuronal layers, may result in the same final effect, 
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thus contributing to autism development. 
 
Fig. 20. Schematic view of the functional network of genes implicated in neurogenesis, subdivided on the 
basis of their function (green balls).  
 
For example, the CSPG5 gene (duplicated in patient 3, Tab. 3) encodes neuroglycan C, which is 
specifically expressed in the CNS and promotes neurite outgrowth that is, conversely, inhibited by 
both protein kinase C and phosphatidylinositol 3-kinase, both of which modulate CSPG5 function. 
FMNL1 (deleted in patient 23) encodes a formin-related protein that mediates the induction of 
dendritogenesis and synaptogenesis by neurogenin 3 in mouse hippocampal neurons through a 
direct role in cytoskeleton dynamics. Moreover, both the CSH1 and GH2 genes encode hormones 
of the pituitary GH1/IGF-I axis that play an important role in CNS functions, including those 
associated with neuronal growth, development, and protection. It has been suggested that the 
GH1/IGF axis may play a role in influencing aspects of mood and cognition [Donahue et al., 2006; 
Lodygensky et al., 2008; Zearfoss et al., 2008], and, therefore, it is likely that deletion of both 
CSH1 and GH2 in patient 45 may have played a role in autism development. Of note, the deletion 
detected in patient 45 is maternally inherited, and the mother also shows autistic traits (Tab. 3).  
Finally, LAMA1 encodes the laminin alpha1 protein, which is thought to mediate the attachment, 
migration, and organization of cells into tissues during embryonic development. In the conditional 
laminin α1 knockout mouse, a strong defect in the organization of the adult cerebellum has been 
reported. Indeed, the postnatal cerebellum of these animals revealed a disrupted basement 
membrane correlated to an unexpected excessive proliferation of granule cell precursors in the 
external granular layer, thus suggesting that LAMA1 is essential for proper cerebellum 
development [Heng et al., 2011]. It can be speculated that overexpression of LAMA1 in patient 60 
(Tab. 3), due to a full gene duplication, may have contributed to autism onset by acting on 
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cerebellum organization during embryonic development, thus supporting the fundamental role of 
cerebellum anomalies in ASD as previously reported [Fatemi et al., 2012]. 
It is interesting to note that the shared pathway underlying most of the actions that ultimately give 
rise to neurogenesis and neurodevelopment is the regulation of actin and microtubule cytoskeleton 
dynamics as well as the organization of the centrosome, as confirmed by the identification of 
several genes that modulate these processes whose dysregulation may contribute to ASD 
development. For example, FLNA (potentially disrupted in patient 61, Tab. 3) encodes the filamin 
A protein, which is an actin binding protein that crosslinks actin filaments and links them to 
membrane glycoproteins. FLNA is involved in remodeling the cytoskeleton to affect changes in 
cell shape and migration, and a direct interaction between FLNA and SHANK3 has been recently 
reported in mouse brain extracts [Lian et al., 2012]. Moreover, LIMK1 (duplicated in patient 52, 
Tab. 3) encodes the LIM domain kinase 1 protein, which is a serine/threonine kinase that regulates 
actin polymerization via phosphorylation and inactivation of the actin binding factor cofilin. 
LIMK1 stimulates axon growth and binds to TrkB, which is required for BDNF-induced axonal 
elongation. In Limk1-null mice, abnormal dendrite spine morphology as well as altered 
hippocampal function and mild deficits in spatial learning and memory have been reported 
[Osborne, 2010].  
The deletion of NCKAP1 seen in patient 53 may have resulted in an impairment of functional 
connectivity in the cerebral cortex (Tab. 3). NCKAP1 is an adaptor protein that is thought to 
modulate actin nucleation. It is selectively expressed in the cortical plate region of the developing 
cortex, where neurons terminate their migration and begin their final laminar-specific 
differentiation, characterized by the elaboration of distinct axonal and dendritic architecture 
[Yokota et al., 2007]. Similarly, overexpression of SPOCK1 in patient 57 due to a full gene 
duplication (Tab. 3) may have abnormally modulated neuronal attachment and matrix 
metalloproteinase activation during neurodevelopment. During mouse embryonic development, 
SPOCK1 is actively expressed at the onset of neurogenesis during periods of neuronal migration 
and axonal outgrowth. At a later developmental stage, its expression is particularly prevalent within 
developing synaptic fields. In particular, SPOCK1 is most prominently expressed in the thalamus 
and is upregulated in activated astroglial cells of the cerebrum [Charbonnier et al., 2000; Edgell et 
al., 2004; Röll et al., 2006; Vadasz et al., 2007].  
Both the TPPP and TUBA3D/3E genes encode proteins with a role in microtubule cytoskeleton 
organization. Indeed, the tubulin polymerization-promoting protein (TPPP) has a brain-specific role 
in the dynamic stabilization of microtubular ultrastructures as well as in the projections of mature 
oligodendrocytes and ciliary structures, whereas the tubulins alpha 3d and 3e are major components 
of microtubules. Thus, possible defects in microtubule assembly and organization due to TPPP and 
TUBA3D/3E deletions, identified in patients 60 and 51, respectively (Tab. 3), may be implicated 
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in ASD. 
Finally, four of the collected genes encode proteins that are integral components of the centrosome 
structure, a non-membranous organelle that functions as the major microtubule-organizing centre in 
animal cells, with clear roles in centrosome organization. Specifically, PCNT (potentially disrupted 
in patient 28, Tab. 3), an integral component of the filamentous matrix of the centrosome, is 
involved in the initial establishment of organized microtubule arrays in both mitosis and meiosis; 
NDE1 (duplicated in patient 30) interacts with other centrosome components as part of a 
multiprotein complex that regulates dynein function; PPP4C (duplicated in patients 25, 38, and 39) 
acts in many processes, such as microtubule organization at centrosomes, maturation of 
spliceosomal snRNPs, apoptosis, DNA repair, tumour necrosis factor (TNF)-alpha signaling, 
regulation of histone acetylation, DNA damage checkpoint signaling, NF-kappa-B activation, and 
cell migration; and CEP72 (deleted in patient 60) is involved in the recruitment of key centrosomal 
proteins to the centrosome. A few centrosomal proteins have been previously involved in 
neurodevelopment: mutations in the coding genes (e.g., CEP135, STIL, CDK5RAP2, and CENPJ) 
cause autosomal-recessive congenital disorders characterized by intellectual disability and reduced 
brain and head size, suggesting that a centrosomal mechanism controls neuron numbers in the 
developing mammalian brain [Bond et al., 2005; Hussain et al., 2012]. Therefore, it is likely that 
anomaly in centrosomal protein may also contribute to ASD onset. 
 
Transcriptional and translational regulation and chromatin remodeling (the genes affected by de 
novo CNVs are indicated in bold, Tabs. 4 and 4.1) 
Fifty-one of the 276 selected genes have reported functions correlated with neuronal nuclear 
activities, such as DNA replication, repair, transcriptional regulation, and chromatin remodeling, as 
well as with protein synthesis, which contribute to overall neurodevelopment (Fig. 21). Similar to 
the findings reported for the subset of genes involved in neurogenesis, both losses and gains were 
observed. Moreover, all the de novo CNVs, except for one detected in patient 24, map to recurrent 
genomic regions as well as to regions previously associated with ASD or with other 
neurodevelopmental disorders by linkage studies (Tabs. 3–4.1).  
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Fig. 21. Schematic view of the network of genes implicated in transcriptional and translational regulation, 
and in chromatin remodeling, subdivided on the basis of their function (light pink balls). 
 
The largest functional category is that of transcriptional regulation, where the encoded proteins 
may act both as activators and repressors of transcription, playing a role, in most cases, in early 
embryonic development and thus regulating the differential expression of genes involved in 
neurodevelopment in a time-dependent manner. In particular, RFX3 deletion is the only de novo 
variant that does not map to a recurrent genomic region (patient 24, Tab. 3). RFX3 is a 
transcriptional activator that acts as a transcription factor required for ciliogenesis. In mouse, it is 
strongly expressed in the ciliated ependymal cells of the subcommissural organ, choroid plexuses, 
and ventricular walls during embryonic and postnatal development [Benadiba et al., 2012; El-Zein 
et al., 2009], thus supporting a similar role in humans.  
In addition to the well known genes implicated in transcriptional regulation and already associated 
with ASD, such as GTF1 and GTF2IRD1 at 7q11.23 (patient 52, Tab. 3), NDN at 15q11q13 
(patient 29), and GSC2, MED15 and TBX1 at 22q11.21 (patient 27), other genes may be suggested 
as ASD candidate genes after careful analysis. For example, GLI2 encodes a member of the GLI 
family of zinc finger proteins that is thought to play a role during embryogenesis. In fact, in mouse 
embryo, GLI2 plays an essential role in the establishment of dorsoventral polarity and in thalamic 
development acting downstream of Sonic hedgehog (Shh) signaling [Haddad-Tovolli et al., 2012; 
Matise et al., 1998; Takanaga et al., 2009].  
Furthermore, TGIF1, which is duplicated in patient 60 along with THOC1 (Tab. 3), encodes the 
TGFB-induced factor homeobox 1 protein, a member of the highly conserved TALE homeobox 
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protein family of transcription regulators. In vivo overexpression of TGIF in the developing chick 
neural tube demonstrated that TGIF plays an important role in regulating the expression of genes 
expressed in specific dorsal-ventral domains during neural development [Knepper et al., 2006]. 
Interestingly, NAB1, which is deleted in patient 53 along with NEUROG1 and ZNF804A (Tab. 3), 
encodes NGFI-A binding protein 1, which acts as a transcriptional repressor for zinc finger 
transcription factors EGR1 and EGR2. Both EGR1 and EGR2 have previously been implicated in 
mood disorders, such as major depressive disorder and bipolar disorder, respectively [Kerman et 
al., 2012; Kim et al., 2012]. Indeed, EGR1 is strongly expressed in neurons in the adult brain, 
where it can exert long-lasting changes in gene expression and subsequent protein synthesis that 
mediate synaptic plasticity, whereas EGR2 is involved in cognitive function, myelination, and 
signal transduction related to neuregulin-ErbB receptor, Bcl-2 family proteins, and brain-derived 
neurotrophic factor [Cole et al., 1989; Knapska and Kaczmarek, 2004; Malkani et al., 2004; 
Ressler et al., 2002; Valjent et al., 2006]. Dysregulation of EGR1/2 due to NAB1 
haploinsufficiency may be speculated to contribute to ASD development. 
Finally, NEUROG1, which is duplicated along with PITX1 in patient 57 (Tab. 3), encodes 
neurogenin 1, which acts as a transcriptional regulator. It is involved in the initiation of cortical 
neuronal differentiation and associates with chromatin at enhancer regulatory elements in genes 
encoding key transcriptional regulators of neurogenesis. Interestingly, SNPs in NEUROG1 have 
previously been associated with schizophrenia, whereas SNPs in PITX1 have been associated with 
ASD [Fanous et al., 2007; Philippi et al., 2007]. PITX1 encodes the paired-like homeodomain 1 
protein, which plays a role in the development of anterior structures, in particular the brain and 
facies, and in specifying the identity or structure of hindlimbs [Philippi et al., 2007]. 
Interestingly, on the basis of the identified genes, anomalies in all the steps of neuronal nuclear 
activity may potentially be correlated with ASD pathology. Indeed, at least two genes are 
implicated in DNA replication, namely CDC45 (duplicated in patient 27, Tab. 3), which encodes a 
protein necessary for the early steps of DNA replication in eukaryotes and is highly expressed 
during neurogenesis in cortical ventricular and subventricular zones, and RNASEH2B (deleted in 
patient 34), whose encoded protein specifically degrades the RNA of RNA:DNA hybrids. Of note, 
mutations affecting RNASEH2B cause Aicardi-Goutières syndrome type 2 (autosomal recessive 
and, rarely, autosomal dominant inheritance), which is characterized by brain malformations and 
cognitive dysfunction [Crow and Livingston, 2008]; thus, anomaly in this gene is also suggested in 
ASD development.  
In addition, DNA repair must also be considered an essential process for proper neurogenesis. 
Indeed, the ERCC3 protein, whose corresponding gene demonstrated heterozygous deletion in 
patient 51 (Tab. 3), was found to be ubiquitously expressed in developing mouse brain from 9-day 
post-coitum embryo to 15-day postnatal brain, suggesting that defects may arise from ERCC3 
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interactions with other elements involved in particular aspects of neurodevelopmental control 
[Hubank and Mayne, 1994]. Moreover, mutations in ERCC3 cause recessive forms of xeroderma 
pigmentosum group B combined with Cockayne syndrome (XP/CS), characterized by anomalies in 
skin pigmentation and, sometimes, neurological features such as microcephaly, intellectual 
disability, pigmentary retinopathy, ataxia, and decreased nerve conduction velocities [Oh et al., 
2006].  
Once mRNA has been transcribed, the translational process must begin, and specific proteins are 
required to form the initiation complex for translation. Rare mutations and balanced chromosomal 
abnormalities affecting EIF4E, encoding translation initiation factor 4E, have previously been 
reported in a small group of autistic boys and their unaffected fathers [Neves-Pereira et al., 2009]. 
Thus, the findings of rare CNVs involving EIF4H (fully duplicated in patient 52, Tab. 3) and 
EIF2S3 (possibly disrupted in patient 1) seem to confirm a role of fine regulators of the 
translational process in ASD (Tabs. 3–4.1). The control of mRNA translation into protein is, in 
fact, fundamentally important for the fine tuning of gene expression; additionally, precise 
translational control plays a critical role in many cellular processes, including development, cellular 
growth, proliferation, differentiation, synaptic plasticity, memory, and learning. Knockout mice 
deficient in Eif4h demonstrated a smaller brain volume compared with controls, altered brain 
morphology, and a reduction in both the number and complexity of neurons. Behavioural studies 
revealed severe impairments of fear-related associative learning and memory formation, thus 
suggesting that Eif4h, which in humans maps to 7q11.23, may contribute to certain deficits 
associated with Williams-Beuren syndrome [Capossela et al., 2012].  
Similarly, when necessary translation must be finely repressed, one of the best-known genes 
encoding a protein that plays such a role is CYFIP1 at 15q11.2, which is both deleted and 
duplicated in the reported cohort (patients 29, 50, and 55, Tab. 3). This gene encodes the 
cytoplasmic FMR1-interacting protein 1, which is a component of the CYFIP1-EIF4E-FMR1 
complex that binds to the mRNA cap and mediates translational repression, thus promoting the 
translational repression activity of FMR1 in brain. 
However, the complex process of transcription may also be regulated by the action of non-coding 
RNAs as well as by DNA epigenetic modifications also known as chromatin remodeling. As the 
evolution of the human brain has resulted in the emergence of higher-order cognitive abilities such 
as reasoning, planning, and social awareness, it is likely that in addition to larger brain size with 
greater complexity and capacity, a concomitant expansion of novel functional components and 
regulatory systems evolved [Barry and Mattick, 2012]. Recently, it has been suggested that RNA-
directed epigenetic mechanisms have mediated human development and have contributed to brain 
plasticity, leading to the collateral emergence of psychiatric fragilities and conditions [Barry and 
Mattick, 2012]. In agreement with this hypothesis, ASD may be at least in part the result of 
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aberrant microRNA biogenesis, due to aberrations affecting, for example, DGCR8 (duplicated in 
patient 27, Tab. 3), which encodes a subunit of the microprocessor complex that mediates the 
biogenesis of microRNAs from the primary microRNA transcript and plays a fundamental role in 
transcriptional regulation in the prefrontal cortex of developing mice [Schofield et al., 2011]. 
Similarly, defects in chromatin remodeling may contribute to ASD (e.g., BAZ1B, EHMT1, 
JMJD2A, JMJD2C, SMARCC1, and SMYD3), as confirmed by patients with Kleefstra/reciprocal 
duplication syndromes (patient 14, Tab. 3) [Kleefstra et al., 2005, 2009; Talkowski et al., 2012], 
both of which are comorbid with ASD and caused by aberrant EHMT1 gene dosages leading to 
anomalies in histone methylation. Indeed, EHMT1 functions as a histone-lysine N-
methyltransferase, whereas JMJD2A (deleted in patient 2, Tab. 3) and JMJD2C (possibly disrupted 
in siblings 38–39, Tab. 3), are histone-lysine demethylases. Of note, a SNP in JMJD2C has been 
previously associated with ASD in Finnish samples [Kantojärvi et al., 2010]. 
Moreover, during neural development, a switch from a stem/progenitor to a post-mitotic chromatin 
remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult 
state. Therefore, anomalies in chromatin remodeling may have contributed to ASD in the reported 
cohort. For example, SMARCC1, which belongs to the neural progenitors-specific chromatin 
remodeling complex (npBAF complex) and to the neuron-specific chromatin remodeling complex 
(nBAF complex), participates in this process, displaying helicase and ATPase activities (possibly 
disrupted in patient 3, Tab. 3). In mouse embryonic stem cells, Smarcc1 is necessary for 
heterochromatin formation and chromatin compaction during differentiation and plays important 
roles in facilitating mESC differentiation by coupling gene repression with global and local 
changes in chromatin structure [Marei et al., 2012; Schaniel et al., 2009]. Finally, BAZ1B maps to 
7q11.23 (duplicated in patient 52, Tab. 3) and is deleted in the Williams-Beuren syndrome. It 
encodes a member of the bromodomain protein family, a MAPK-dependent phosphoprotein 
(tyrosine-protein kinase) that plays a central role in chromatin remodeling. Indeed, it is involved in 
DNA damage response by phosphorylating Tyr-142 of histone H2AX (H2AXY142ph). 
H2AXY142ph plays a central role in DNA repair and acts as a mark that distinguishes between 
apoptotic and repair responses to genotoxic stress [Cus et al., 2006; Oya et al., 2009]. Of note, 
heterozygote (Baz1b/-) and homozygote (-/-) mouse models show craniofacial abnormalities and 
cardiac malformations but no behavioural anomalies [Osborne, 2010]. 
 
Synaptogenesis and synaptic plasticity (the genes affected by de novo CNVs are indicated in bold, 
Tabs. 4 and 4.1) 
Twenty-nine of the 276 selected genes are directly implicated in synaptogenesis and synaptic 
function and plasticity. In agreement with reported data that consider ASD as a synaptopathy 
[Zoghbi and Bear, 2012], most of the genes previously implicated in ASD (genes depicted in red in 
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Tabs. 4 and 4.1) belong to this network and can be classified as either of the following: 
1) genes localized pre-synaptically, which are involved in the docking of the synaptic vesicles onto 
the presynaptic membrane, vesicle recycling, membrane depolarization, and, consequently, 
neurotransmitter release; 
2) genes localized post-synaptically, which encode either structural proteins that form the 
scaffolding complex known as postsynaptic density, adhesion molecules, or different types of 
neurotransmitter receptors such as glutamate, GABA, acetylcholine, and secretin receptors as well 
as synaptic signaling modulators (Fig. 22). 
 
Fig. 22. Schematic view of the subsequent steps involved in synaptic function. 
 
In observing a synapse from the presynaptic point of view, several known genes have been found 
to be affected by both de novo and inherited CNVs, such as CACNA1B (potentially disrupted in 
patient 14, Tab. 3) and CACNA1C (potentially disrupted in patients 38–39), which both encode 
voltage-dependent calcium channels responsible for intracellular Ca
2+
 influx that modulates 
neurotransmitter release. Additionally, IL1RAPL2 (potentially disrupted in patient 14) may play a 
similar role. It encodes a member of the interleukin 1 receptor family that interacts with the 
neuronal calcium sensor 1 protein, thus playing a role in the downregulation of voltage-dependent 
calcium channel activity and in calcium-dependent exocytosis in excitatory synapses [Valnegri et 
al., 2011].  
In addition, genes encoding proteins implicated in docking of synaptic vesicles to the membrane, 
such as DOC2A (duplicated in patients 25, 38, 39, Tab. 3), STX1A (duplicated in patient 52), and 
SNAP29 (duplicated in patient 27), were detected. STX1A binds synaptotagmin in a calcium-
dependent fashion and interacts with voltage-dependent calcium and potassium channels, thus 
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regulating calcium-dependent synaptic exocytosis. Furthermore, STX1A is part of the SNARE core 
complex, which also contains SNAP25 [Ghezzo et al., 2009]. SNAP29 forms a complex with 
SNAP23, SNAP25, and STX1A and acts as a negative modulator for neurotransmitter release, 
probably by slowing recycling of the SNARE-based fusion machinery and synaptic vesicle 
turnover [Pan et al., 2005; Su et al., 2001]. Moreover, DOC2A binds to STXBP1, the syntaxin 
(STX) binding protein 1, thus regulating the STXBP1-STX interaction, which is essential for the 
activity of the synaptic vesicle fusion machinery [Mochida et al., 1998]. All the genes encoding 
these proteins map to recurrent genomic regions previously implicated in genomic disorders that 
are comorbid with ASD (Tabs. 3-4.1) [Betancur, 2011] as well as in other neuropsychiatric 
disorders, such as attention deficit hyperactivity disorder, intellectual disability, and schizophrenia, 
confirming the existence of functional networks of genes whose dysregulation is the shared 
pathological base for the development of this class of diseases.  
Interestingly, the large de novo deletion detected in patient 60 at 5p15.33p15.31 (Tab. 3) involves, 
among others, the EXOC3 gene, also known as SEC6, which has not been previously suggested as 
an ASD candidate gene. This gene encodes the exocyst complex component 3, which is a 
component of the exocyst complex, a multiple-protein complex essential for targeting exocytic 
vesicles to specific docking sites on the plasma membrane. In a study of developing neurons, 
Sec6/8 complexes were found at the highest levels in regions of the brain undergoing 
synaptogenesis and in regions of cultured neurons where synapses will subsequently develop. By 
contrast, the level of Sec6/8 was downregulated in mature synapses [Hazuka et al., 1999; Hsu et 
al., 1996, 1999], leading to the hypothesis that the main function of the Sec6/8 complex is in the 
formation of synapses rather than in their function once formed. 
Furthermore, two ASD candidate genes emerged from the present study, the VAT1 and ADCYAP1 
genes (deleted in patient 25 and duplicated in patient 60, respectively, Tab.3). VAT1 is an 
abundant integral membrane protein of cholinergic synaptic vesicles and is thought to be involved 
in vesicular transport. In the CNS which uses acetylcholine as a neurotransmitter, is known to have 
a variety of neuromodulatory effects upon plasticity, arousal, and reward. Indeed, acetylcholine 
plays an important role in sustaining attention, learning, and short-term memory, and functional 
studies implicate the cholinergic system in the development of autism on the basis of neuronal 
nicotinic acetylcholine receptor losses in cerebral and cerebellar cortex and in the thalamus of 
autistic brains [Ray et al., 2005; Suzuki et al., 2011]. 
ADCYAP1 encodes adenylate cyclase activating polypeptide 1 (PACAP), which stimulates 
adenylate cyclase and subsequently increases the cAMP level in target cells. The neuropeptide 
PACAP is a molecule released from stress-transducing neurons. It exerts postsynaptic effects 
required to complete hypothalamo-pituitary-adrenocortical (HPA) and hypothalamo-splanchnico-
adrenomedullary (HSA) circuits activated by psychogenic and metabolic stressors. PACAP is 
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widely expressed throughout the brain and exerts its functions through the PACAP-specific 
receptor PAC(1). Recent studies reveal that genetic variants of the PACAP and PAC(1) genes are 
associated with mental disorders, and several behavioural abnormalities of PACAP knockout mice 
have been reported, thus suggesting that PACAP has an important role in the regulation of 
locomotor activity, social behaviour, anxiety-like behaviour, and, potentially, working memory 
[Hattori et al., 2012; Stroth et al., 2011]. 
Among genes encoding structural proteins that function post-synaptically as transmembrane or 
scaffolding proteins, most have been reported previously, such as NLGN4X (potentially disrupted 
in patient 35, Tab. 3), DLGAP2 (duplicated in patient 59), and DLG2 (deleted in patient 26). 
Conversely, to the best of our knowledge, this study is the first to report a rare de novo CNV 
affecting DLGAP1, which was fully duplicated in patient 60 (Tab. 3). Additionally, DLGAP1 
works at the postsynaptic density; therefore stoichiometric imbalances in the protein dosage may 
produce defects in scaffold formation, as previously suggested for SHANK3 [Toro et al., 2010]. 
Many transmembrane proteins encoded by this network of genes are actually neurotransmitter 
receptors, most of which have already been implicated in ASD. Specifically, CNVs affecting genes 
for glutamate receptors GRID2 (deleted in patient 42, Tab. 3) and GRM7 (potentially disrupted in 
patient 44) and receptors of GABA (GABRA5/B3/G3, duplicated in patient 29), acetylcholine 
(CHRNA7, duplicated in patient 25), and secretin (SCTR, duplicated in patient 10) have been 
identified.  
Moreover, some interesting genes have been identified that modulate synaptic plasticity. First, 
CAMLG, which is duplicated in patient 57 (Tab. 3), encodes a calcium modulating ligand protein 
that has been reported to be involved in recycling and endocytic processing of GABAA receptors. 
Indeed, in neuronal cortical cultures it has been demonstrated that a reduction of CAMLG 
translated to reduced GABAA receptors on the postsynaptic membrane with an effect specific to 
GABAA receptors, since glutamate-evoked current remained unaltered in these neurons [Yuan et 
al., 2008; Zhang et al., 2010]. Moreover, GABA signaling seems also to be modulated by the 
protein encoded by the DBI gene, which is fully duplicated in patient 10 (Tab. 3). This gene 
encodes the diazepam binding inhibitor, a GABA receptor modulator, which is able to displace 
diazepam from the benzodiazepine (BZD) recognition site located on the GABA type A receptor. It 
is possible that this protein acts as a neuropeptide to modulate the action of the GABA receptor 
located in brain synapses. Recently, a CNV involving loss of DBI was described in an autistic 
patient, and SNPs in DBI have been associated with anxiety and panic attacks [Griswold et al., 
2012; Thoeringer et al., 2007]. Furthermore, functional studies reported reduced numbers of 
GABA and benzodiazepine receptors in autistic brain, particularly in posterior cingulate cortex 
[Oblak et al., 2011].  
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Finally, the CA4 gene, which is fully duplicated in patient 16 as a result of a de novo duplication 
(Tab. 3), can be considered a good candidate for ASD development. It encodes carbonic anhydrase 
IV, which belongs to a large family of zinc metalloenzymes that catalyze the reversible hydration 
of carbon dioxide. These enzymes are indirectly implicated in regulation of excitatory synaptic 
transmission, because the curtailment of extracellular alkaline shifts by extracellular carbonic 
anhydrases was shown to limit postsynaptic NMDA receptor activation during synchronous neural 
activity [Tong et al., 2000]. To date, defects in CA4 have only been associated with retinitis 
pigmentosa type 17. However, rare single-gene mutations affecting CA6, another member of the 
same family, have been reported in a few autistic patients [Bucan et al., 2009]. 
 
CNS metabolism and homeostasis (the genes affected by de novo CNVs are indicated in bold, 
Tabs. 4 and 4.1) 
Twenty-seven of the 276 selected genes play roles essential for proper neuronal metabolism, 
coding for genes involved in amino acid catabolism (e.g., ACMSD, BCHDHA, GLDC, GLS, 
HIBCH, PRODH, and QPRT); neurotransmitter and neuropeptide maturation and degradation (e.g., 
COMT, PREP, and SULT1A3); glycolysis, Krebs cycle, and mitochondrial metabolism (e.g., 
ALDOA, ME3, NDUFV2, SDHA, SLC25A48, and TXNRD2); and biosynthesis of heparan sulfate 
molecules, phospholipids and lipoproteins (ABCD4, HS6ST1, LCLAT1, LPCAT1, and NDST2) 
(Tabs. 4 and 4.1, Fig. 23).  
 
Fig. 23. Schematic view of the principal reactions implicated in CNS metabolism that are potentially 
dysregulated in the present ASD cohort.  
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Among the subset of genes that encode anabolic enzymes, those implicated in heparan sulfate (HS) 
biosynthesis appear as very interesting new ASD candidates on the basis of previous studies that 
report, for example, autism in patients with multiple exostoses due to mutations in HS genes 
[Bolton et al.,1995; Ishikawa-Brush et al., 1997; Li et al., 2002]. Both these genes, namely 
HS6ST1 and NDST2, are affected by de novo deletions (Tab. 3, patients 36 and 51, respectively) 
and encode sulfotransferase proteins, which are necessary for processing glucosamine and heparin 
polymers. Indeed, roles of HS in neural development have been well established using animal 
models that carry mutations in genes encoding enzymes involved in HS synthesis, thus revealing 
that HS is necessary for the specification of certain brain structures, such as the cerebellum and the 
olfactory bulbs, cortical neurogenesis, and a variety of axon path-finding processes [Conway et al., 
2011; Irie et al., 2012]. Moreover, several pieces of evidence suggest a role for HS in synaptic 
function as well as in higher cognitive function. For example, in adult neurons, HS is enriched in 
synapses, especially in the postsynaptic membrane of dendritic spines [Ethell and Yamaguchi, 
1999]. Thus, it may be speculated that the anomalies in HS genes identified in the two patients 
reported here may have played a role in ASD.  
Another interesting gene appears to be LPCAT1, which is included in a large de novo deletion 
identified in patient 60 (Tab. 3). It encodes the lysophosphatidylcholine acyltransferase 1 protein, 
which plays important roles in phospholipid metabolism and modulation of inflammation. Indeed, 
LPCAT1 catalyzes the conversion of lysophosphatidylcholine (LPC) to phosphatidylcholine (PC), 
which is the major phospholipid of the brain. Since LPC is a bioactive pro-inflammatory lipid 
whose accumulation is associated with atherosclerosis, myocardial ischemia, neurodegeneration, 
and inflammatory diseases, LPCAT1 is implicated in the anti-inflammatory response by its role in 
the conversion of LPC to PC. In addition, the LPCAT1 enzyme catalyzes the synthesis of platelet-
activating factor (PAF), a potent inflammatory lipid, from lyso-PAF [Cheng et al., 2009; 
Matsumoto et al., 2007; Nakanishi et al., 2006]. In naïve mice, constant levels of PAF are produced 
by microglia and astrocytes, thus contributing to the maintenance of CNS homeostasis. Conversely, 
in the CNS of experimental allergic encephalomyelitis mice, which mimic multiple sclerosis, the 
blood-brain barrier is broken. Inflammatory cells, such as T cells and macrophages, infiltrate the 
CNS, and higher amounts of LPCAT1/2 and therefore of PAF are produced by the activated 
microglia and macrophages, contributing to the inflammatory process [Kihara et al., 2008]. 
 
Of note, other genes involved in CNS metabolism show implications in inflammation and strong 
relationships with immune cells, confirming that the role of the immune system is essential for 
correct CNS homeostasis. For example, PREP, which was found deleted in patient 18 due to a de 
novo CNV, encodes a prolyl endopeptidase protein that has been reported to be involved in the 
maturation and degradation of peptide hormones and neuropeptides. Several neuropeptides 
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associated with learning, memory, and neurodegenerative disorders have been proposed as the 
substrates for PREP, suggesting a possible role for PREP in these processes. Indeed, Prep knockout 
mice demonstrate decreased synaptic spine density in the hippocampus, reduced hippocampal long-
term potentiation, and impaired hippocampal-mediated learning and memory, thus revealing a 
possible role for PREP in mediating hippocampal plasticity and spatial memory formation 
[D’Agostino et al., 2012].  
More interestingly, PREP directly binds TAC1, tachykinin precursor 1, thus participating in its 
maturation. Tachykinins (substance P, neurokinin A and B) are active neuropeptides that have been 
recognized as key mediators of neuro-immune interactions in neuroinflammation and some 
autoimmune diseases [Veres et al., 2009]. They are found throughout the CNS, with evidence for 
both neuronal and glial cells as being sources of them, and traditionally show well-defined 
functions as neurotransmitters modulating glutamatergic excitatory synaptic transmission. 
Furthermore, tachykinins may have a role in augmenting the immune functions of CNS glial cells 
resulting in the progression and duration of damaging inflammation within the CNS, which has 
already been observed in autistic brains. Indeed, elevated serum levels of neurokinin A have been 
recently reported in some autistic children compared to controls. Interestingly, levels of neurokinin 
A correlated to the severity of autism and to serum levels of anti-ribosomal P protein antibodies, 
thus supporting the pathogenic role of neurokinin A and its possible link to autoimmunity in autism 
[Mostafa and Al-Ayadhi, 2011]. Thus, it is a likely hypothesis that altered PREP levels within the 
CNS may interfere with tachykinin metabolism and the subsequent response to inflammatory 
stimuli, thus playing a role in ASD. 
Finally, among the subset of genes that encode enzymes acting in amino acid catabolism, two are 
specifically involved in tryptophan catabolism, namely ACMSD, deleted in patient 51, and QPRT, 
duplicated in patients 25, 38, and 39 (Tab. 3). ACMSD is the aminocarboxymuconate 
semialdehyde decarboxylase that converts alpha-amino-beta-carboxy-muconate-epsilon-
semialdehyde to a benign catabolite, thus preventing the accumulation of quinolinate, whereas 
QPRT is the quinolinate phosphoribosyltransferase that converts quinolic acid to nicotinic acid 
ribonucleotide and carbon dioxide (Fig. 24) [Schwarcz et al., 2012]. Therefore, these enzymes are 
both implicated in limiting the cerebral levels of quinolate, which acts as a neuroactive compound, 
as well as other intermediates in tryptophan degradation, such as kynurenic acid and 3-
hydroxykynurenine (Fig. 24). In particular, quinolinate is able to induce a neuronal excitotoxin due 
to its role as a NMDA receptor agonist. 
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Fig. 24. The kynurenine pathway of tryptophan degradation in mammals [Schwarcz et al., 2012]. 
 
The synthesis of these metabolites is regulated by an enzymatic cascade known as the kynurenine 
pathway, which is tightly controlled by the immune system. Indeed, as shown in Fig. 25, the two 
branches of the pathway are performed normally by non-neuronal cells, such as astrocytes and 
other glial cells, which metabolize tryptophan and intermediate metabolites from the blood vessels, 
thus producing quinolate (microglia) and kynurenic acid (astrocytes) [Schwarcz et al., 2012]. 
Under normal conditions, in the periphery, the degradation of tryptophan and the subsequent 
formation of circulating kynurenines is normally regulated by steroid hormones, cytokines, and 
growth factors. Brain uptake of these kynurenines determines kynurenine pathway flux in the brain. 
Conversely, inflammatory conditions stimulate the kynurenine pathway both in the periphery and 
in the brain. Therefore, increased influx of brain-permeable metabolites leads to an excess of 
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kynurenines in the brain parenchyma. Furthermore, infiltrating cytokines stimulate the kynurenine 
pathway in activated microglial cells and blood-borne cells within the brain [Schwarcz et al., 
2012]. 
 
Fig. 25. Segregation of the two kynurenine pathway branches in the brain [Schwarcz et al., 2012]. 
 
It has been reported that dysregulation of this pathway, resulting in hyper- or hypofunction of 
active metabolites, is associated with neurodegenerative and other neurological disorders, such as 
Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease, as well as with psychiatric 
diseases, such as depression and schizophrenia. In this context, one possible explanation for ASD 
pathogenesis is the modern theory of immunoexcitotoxicity, that is, an excessive stimulation of 
glutamatergic synapses mediated by increased levels of neuroactive compounds produced by 
microglial cells, as hypothesized in a few patients reported here. Indeed, chronic microglial 
activation has been reported in autistic brains, which results in an outpouring of neurotoxic levels 
of the excitotoxins glutamate and quinolinic acid. Careful control of brain glutamate levels is 
essential to brain pathway development, and excesses can result in arrest of neural migration, as 
well as in dendritic and synaptic loss. In addition, certain cytokines, such as TNF-alpha, can, via 
their receptors, interact with glutamate receptors to enhance the neurotoxic reaction [Schwarcz et 
al., 2012]. 
 
Intracellular signaling and trafficking (the genes affected by de novo CNVs are indicated in bold, 
Tabs. 4 and 4.1) 
Eighty-one of the 276 selected genes belong to a functional network implicated in intracellular 
signaling and trafficking, which acts in response to external signals that are first represented by 
synaptic neurotransmission. Of note, the present ASD cohort is enriched in rare CNVs affecting 
genes that act in this functional network, which, as expected, includes a few pathways already 
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suggested to be implicated in ASD pathogenesis: such as, the remodeling of actin cytoskeleton 
[Blanchoin et al., 2000; Linseman and Loucks, 2008], which is deeply interconnected with the 
Wnt/β-catenin signaling pathway [Okerlund and Cheyette, 2011; Rosso et al., 2005; Salinas and Zou, 
2008; Salinas et al., 199], the MAPK/ERK signaling pathway that ultimately regulates the mTOR 
pathway [Tavazoie et al., 2005; Wang et al., 2012], and the protein ubiquitination pathway [Ehlers, 
2003; Glessner et al., 2009; Peça and Feng, 2012; Philpot et al., 2010] (Fig. 26). 
However, most of the selected genes are new candidates, as they have not previously been 
associated with ASD (Tabs. 4 and 4.1). 
 
Fig. 26. Schematic view of the pathways (blue and light blue satellites) that act in concert to mediate the 
intracellular signaling processes. 
 
One of the most important types of information that is transmitted through the synapse is related to 
the regulation of the morphology of the dendritic spines. It is mediated by the GTPase Rho family 
of proteins, such as RhoA/B, CdC42, and Rac1, whose role in ASD is well known. In addition, 
GTPase activity is regulated by different GEF (guanine nucleotide exchange factor), GDI (GDP 
dissociation inhibitor), and GAP (GTP-activating) proteins. Actin cytoskeleton remodeling is 
involved in neuronal morphogenesis, axonal guidance, and synaptic plasticity, and, pre-
synaptically, it is necessary to mediate the docking of synaptic vesicles to the plasma membrane 
and subsequent neurotransmitter release. RhoGEFs have been previously implicated in human 
genetic disorders. For example, mutations in ARHGEF6 have been associated with X-linked 
nonsyndromic mental retardation [Kutsche et al., 2000], and aberrant EphB/Ephexin5 signaling 
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during the development of synapses has been linked to the abnormal cognitive function that 
possibly occurs in ASD [Margolis et al., 2010]. 
Thus, it may be hypothesized that anomalies in ARHGAP26 (potentially disrupted in patient 21, 
Tab. 3), ARHGAP28 (duplicated in patient 60), ARHGEF4 (deleted in patient 51), and 
ARHGEF10 (duplicated in patient 59) may be implicated in the neurobehavioral disorders 
described in the affected patients. Recently, a rare small recurrent deletion in a region previously 
linked attention deficit hyperactivity disorder at 2q21.1, including ARHGEF4, has been identified 
in five unrelated families with developmental delay, intellectual disability, attention deficit 
hyperactivity disorder, and epilepsy and other neurobehavioral abnormalities, whereas the 
reciprocal duplications have been identified in five unrelated families with autism [Dharmadhikari 
et al., 2012]. 
Another GEF protein, DOCK8, was recently found to be deleted in two unrelated autistic patients 
who carry a 9p24 terminal deletion also including the KANK1 gene [Lerer et al., 2005]. This 
finding is confirmed by the two rare duplications detected in patient 33, which potentially disrupt 
both the DOCK8 and KANK1 genes (Tab. 3). In particular, KANK1 functions in cytoskeleton 
formation in a RhoA-dependent manner by regulating actin polymerization, and recently it has 
been demonstrated that nucleo-cytoplasmic shuttling of human KANK protein accompanies 
intracellular translocation of beta-catenin and, therefore, beta-catenin-dependent transcription 
[Wang et al., 2006]. In addition, CFL2 (duplicated in patient 17) encodes the cofilin 2 protein, 
which plays a role in the direct regulation of actin filament dynamics. 
Interestingly, two genes encoding members of the Ras-like small GTPases that have not been 
previously associated with ASD were found to be affected by rare CNVs in the present cohort, 
namely RALB (deleted in patient 10, Tab. 3) and RAB6C (deleted in patient 51). RalA and RalB 
regulate a wide variety of cellular processes, including transcription, translation, cytoskeletal 
organization, membrane trafficking, cytokinesis, cell migration, cell proliferation, and cell survival. 
Recently, the involvement of RalA/B in projection neuron migration from the ventricular zone to 
the neocortical plate during mouse brain development has been demonstrated [Jossin and Cooper, 
2011]. Moreover, several members of the Rab family small GTPases are key mediators of 
membrane trafficking and regulate axon-specific trafficking events. For example, Rab17 regulates 
dendritic morphogenesis and postsynaptic development in mouse hippocampal neurons [Mori et 
al., 2012], whereas Rab4 and Rab5 are key players in the regulation of endocytosis, as recently 
demonstrated in astrocytes, the most abundant glial cells in the brain [Potokar et al., 2012]. By 
analogy, it is likely that Rab6 may also be implicated in neurodevelopment. 
Of note, all the genes involved in actin cytoskeleton remodeling show a high expression in immune 
cell types, as they are also involved in the maturation of dendritic cells, T cell activation, migration, 
and cell-cell adhesion, as well as formation of immunological synapses (Tabs. 4 and 4.1). Thus, it 
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is possible that a dysregulation of this pathway due to genetic defects may impact not only 
neurological but also immune system development.  
Interestingly, a small percentage of genes encode proteins that play a role in the organization of the 
microtubules at the kinetochore (B9D2 and CLASP1) as well as motor proteins required for the 
transport of organelles along the microtubules (KIF2A and KIF22), whose encoding genes may be 
suggested as new ASD candidate loci. In particular, the kinesin proteins are microtubule-dependent 
molecular motors that transport organelles within cells, an essential process for axonal growth and 
elongation, and move chromosomes during cell division. 
 
Wnt signaling is a key pathway that helps to organize development of the nervous system. It 
influences cell proliferation, cell fate, and cell migration in the developing nervous system, as well 
as axon guidance, dendrite development, and synapse formation. Given this wide range of roles, 
dysregulation of Wnt signaling could have any number of deleterious effects on neural 
development and thereby contribute in many different ways to the pathogenesis of 
neurodevelopmental disorders. Some major psychiatric disorders, including schizophrenia, bipolar 
disorder, and ASD, are, indeed, coming to be understood as involving subtle dysregulation of 
nervous system development, particularly of synapse formation and maintenance [Okerlund and 
Cheyette, 2011]. As shown in Fig. 27, a few genes, among those selected, participate in Wnt 
signaling and therefore may be new ASD candidates. 
 
 
Fig. 27. Canonical (β-catenin-dependent signal, left) and non-canonical (β-catenin-independent signal, right) 
Wnt signaling pathways [Okerlund and Cheyette, 2011]. The new suggested ASD candidate genes are circled 
in red. 
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For example, DVL3 (duplicated in patient 48, Tab. 3), the dishevelled (dsh) homolog 3 protein, is a 
member of a multi-gene family that shares strong similarity with the Drosophila dishevelled gene. 
DVL activation leads to its binding of AXIN, phosphorylation, and inhibition of glycogen synthase 
kinase-3β (GSK3β), and the regulation of several downstream targets, including β-catenin (Fig. 27) 
[Gao and Chen, 2010]. WNT8A (duplicated in patient 57) and FRZB (deleted in patient 53) encode 
secreted molecules that specifically bind receptor proteins, such as FZD9 (duplicated in patient 
52), thus activating the signaling cascade. Finally, EN1 (duplicated in patient 10) encodes a 
transcription factor with a well known role in CNS development, and together with β-catenin 
regulates transcription of β-catenin target genes in neuronal cells [Alves dos Santos and Smidt, 
2011], whereas CAMK2G (deleted in patient 36) is the only identified gene with a specific role in 
non-canonical Wnt signaling.  
Furthermore, it is known that the Ras/Raf/ERK1/2 signaling pathway (Fig. 28) plays important 
roles in the genesis of neural progenitors and in learning and memory, as well as death-promoting 
apoptotic roles in neural cells. Upregulation of this pathway has been observed in the brains of 
autistic subjects and mouse models [Yang et al., 2011, 2012; Zou et al., 2011]. In addition, rare 
single missense mutations affecting MAPK3 have been reported in a few HF-AU patients [Schaaf 
et al., 2011]. 
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Fig. 28. Synaptic ERK1/2 signaling pathway [Wang et al., 2012]. The new suggested ASD candidate genes 
are circled in red. The AMPA (orange), NMDA (red), and mGlu (green) receptors are indicated at the 
postsynaptic membrane. 
 
ERK1 (duplicated in patients 25, 38, and 39, Tab. 3), ERK8 (deleted in patient 37), and MAP3K2 
(deleted in patient 51) have been found to be affected by rare CNVs in the present ASD series, and 
therefore they may be potentially implicated in ASD (Fig. 28). Interestingly, myelin basic protein, 
encoded by MBP (potentially disrupted in patient 42), which is a major constituent of the myelin 
sheath of oligodendrocytes and Schwann cells in the nervous system, is also related to the ERK 
signaling pathway. Indeed, MBP directly interacts with ERK1 and ERK2, and in vitro assays 
indicated a direct interaction between ERK8 and MBP (Fig. 28) [Abe et al., 2002].  
Finally, due first of all to the well known implications of mutations affecting UBE3A in ASD 
pathogenesis, dysregulation of the ubiquitination pathway, which regulates the levels of synapse 
proteins and their turnover, has been previously implicated in ASD [Ehlers, 2003; Glessner et al., 
2009; Peça and Feng, 2012; Philpot et al., 2010]. The finding of many genes encoding proteins that 
function in this pathway seems to confirm this observation. As shown in Fig. 29, the ubiquitin 
ligase UBE3A (duplicated in patient 29), which belongs to the E3 ubiquitin ligase family, works as 
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a single enzyme, directly binding the target protein as well as an ubiquitin conjugating enzyme 
(E2), whereas the SCF E3 ubiquitin ligase works as a complex. 
 
 
Fig. 29. E3 ubiquitin ligases. (a) UBE3A-type E3 ubiquitin ligase, which acts as a single protein; (B) SCF 
(Skp, Cullin, F-box containing complex) E3 ubiquitin ligase, which acts as a multiprotein complex. 
 
Among the selected genes, TRIM50 (potentially disrupted in patient 52, Tab. 3) encodes an E3 
ubiquitin ligase; UBE2E3 (deleted in patient 53) encodes a conjugating enzyme belonging to the 
family of E3 ubiquitin ligases; and KLHL22 (duplicated in patient 27), KLHL3 (duplicated in 
patient 57), and FBXL21 (duplicated in patient 57) encode proteins of the SCF E3 ubiquitin ligase 
family. In particular, KLHL22 and KLHL3 are substrate adaptors for the ubiquitin ligase, whereas 
FBX22 is a specific F-box protein whose role is to target specific proteins. Furthermore, two of the 
selected genes, USP9Y (potentially disrupted in patient 19) and USP14 (potentially disrupted in 
patient 60), code for peptidases that cleave the ubiquitin residues in order to recycle the proteins, 
thus contributing to protein turnover. 
 
CNS development and homeostasis mediate by the immune system, immunosurveillance and 
modulation of inflammation (in bold are indicated the genes affected by de novo CNVs, Tabs. 4 
and 4.1). 
In agreement with published data, the CNV gene content analysis in the present ASD cohort has 
revealed deep interconnections between all the identified functional networks of genes and the 
immune system, thus supporting the hypothesis that ASD may be the result of defects in both the 
CNS and the immune system (Tabs. 4 and 4.1) [Onore et al., 2012]. In addition, 19 of the 276 
selected genes have been classified as genes encoding proteins which specifically play a role in 
mediating the cross-talk between the CNS and the immune system (Fig. 30). 
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Over the years several theories have been proposed to explain immune dysfunctions in ASD, 
howevere some questions are still unresolved: 
- is there a strong genetic basis in patients with ASD, which may result in immune dysregulation? 
- what role do viral or bacterial infections as well as maternal antibodies against foetus brain 
epitopes play in the CNS development during pregnancy or in the early months/years of life? 
- why markers of chronic inflammation have been found in a subset of autistic patients? Is this 
phenomenon the consequence of genetic alterations, or is an abnormal response to non-genetic 
stimuli? 
 
Fig. 30. Schematic view of the functional network of genes which are implicated in the cross-talk between 
the CNS and the IS. CNS, central nervous system; IS, immune system. 
 
A few CNVs have been identified in the present ASD cohort whose gene content analysis might be 
of some help in answering to the above questions. First, a few genes are involved in 
neurodevelopment and CNS homeostasis, thus confirming that aberrations in immune genes may 
alter not only the immune response but also neurodevelopment, and that these events may have a 
genetic bases. For example, MARCO (duplicated in patient 10, Tab.3) is involved in microglial 
maturation, IL-9 (duplicated in patient 57) is implicated in regulation of programmed cell death in 
developing brain, CXCL14 (duplicated in patient 57) is involved in post-natal regulation of 
GABAergic transmission in specific areas of the brain, and TSPAN5 (possibly disrupted in patient 
6) encodes the tetraspanin 5, that mediates signal transduction events which play a role in the 
regulation of cell development, activation, growth and motility.  
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One of the first TSPAN5 interacting proteins is NOTCH2, that is involved in differentiation and 
synapse formation. Expression studies of autistic and matched control brains reported increased 
transcript levels of many immune system related genes such as NOTCH2. However, these 
expression patterns appear to be more associated with the late recovery phase of autoimmune brain 
disorders, than with the innate immune response characteristic of neurodegenerative diseases 
[Garbett et al., 2008]. Interestingly, rare single gene mutations affecting TSPAN7, another member 
of the tetraspanin family, have been reported in a few autistic patients [Piton et al., 2011]. 
 
Other genes of interest are implicated in CNS immunosurveillance, which is first mediated by the 
integrity of blood brain barrier, or in modulation of pro-inflammatory pathways. For example, in 
patient 55 the duplication of the SELE and SELEL genes has been identified (Tab. 3). These genes 
encode E-selectin and L-selectin, respectively, which are two members of the selectin family of 
proteins. E protein is generally found in cytokine-stimulated endothelial cells and is thought to be 
responsible for the accumulation of blood leukocytes at sites of inflammation by mediating the 
adhesion of cells to the vascular lining. P-selectin is expressed on the endothelium of the blood–
CNS barrier and soluble L-selectin has been found in cerebrospinal fluid. Moreover, both P and L-
selectin play important roles in the entry of circulating T-lymphocytes into the CNS. Therefore, it 
has been hypothesized that molecules not expressed in the brain may alter CNS function. 
Diminished expression of P-selectin has been associated with delayed neutrophil transmigration in 
neonatal rats [Engelhardt and Ransohoff , 2005; Onore et al., 2012]. Thus, decreased expression of 
P-selectin in individuals early in life may contribute to delayed leukocyte transmigration and 
increased susceptibility to infection, which may in turn damage neural tissues during CNS 
development. A decreased serum level of P- and L-selectin has been recently observed in a group 
of autistic subjects vs. controls, confirming a previous finding in a cohort of HF-AU patients, thus 
indicating an involvement of hypoactivity of T-lymphocytes in the pathophysiology of ASD [Iwata 
et al., 2008; Onore et al., 2012]. Similarly, it may be speculated that hyperactivity of T-
lymphocytes, mediated by increased dosage of selectins, could contribute to ASD. 
Conversely, the potential overexpression of the CLDN3, CLDN4 (duplicated in patient 52), and 
CLDN5 (duplicated in patient 27) genes, which encode integral membrane proteins with a role in 
maintaining the integrity of the blood brain barrier, may play a role in CNS homeostasis as well as 
in protecting the CNS against infections [Nitta et al., 2003; Wolburg et al., 2003]. In addition, 
patient 52 was found to carry the duplication of the LAT2 gene (Tab. 3), which encodes the linker 
for activation of T cell family, member 2. T cell responses to pathogens require the induction of the 
primary activating receptor, the T cell receptor (TCR), along with other costimulatory and adhesion 
receptors. Signal transduction pathways activated downstream of these receptors drive T cell 
responses required for the immune response and disease progression. One of this pathways is the 
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LAT signaling pathway which has the role to integrate the information and selectively induces 
pathways critical for T cell activation and the adaptive immune response [Bartelt and Houtman, 
2012]. To date, it is not possible to predict if an up-regulation of the LAT signaling, possible due to 
the LAT2 gene duplication, may have produced a T-cell hyper-responsiveness in patient 53; 
however, this hypothesis can not be excluded. 
Similarly, other pathways, which are known to modulate inflammation, may be predicted to be 
dysregulated in a subset of the ASD patients reported here. The STAT1 and STAT4 genes are 
found deleted in patient 53 (Tab. 3), and both encode proteins with a pro-inflammatory role. In 
response to cytokines and growth factors, STAT family members are phosphorylated by the 
receptor associated kinases, and then form homo- or heterodimers that translocate to the cell 
nucleus where they act as transcription activators. In particular, STAT1 mediates the expression of 
a variety of genes, which is thought to be important for cell viability in response to different cell 
stimuli and pathogens. It has been proposed that the strong inflammatory response observed in 
neurodegenerative diseases may depend on the impairment of the endogenous control of microglial 
activation, and that the cross-talk between STAT1 and MAPK pathways may regulate the 
amplitude and duration of microglial activation [Zaheer et al., 2007].  
Moreover, patient 53 bears the deletion of the ITGA4 gene, which encodes an integral membrane 
protein that mediates the migration of T lymphocytes across blood-brain barrier-endothelial cells, 
and therefore it is considered a mediator of neuroinflammation [Ifergan et al., 2011]. Interestingly, 
SNPs in ITGA4 have been previously associated with ASD [Correia et al., 2009]. Furthermore, a 
positive association was found between one of these SNP markers and levels of a serum 
autoantibody directed to brain tissue, which was previously shown to be significantly more 
frequent in autistic patients than in age-matched controls, thus suggesting that ITGA4 could be 
involved in a neuroimmune process thought to occur in autistic patients [Correia et al., 2009]. 
Previous data reported elevated levels of NF-κB in autistic patients vs. controls [Malik et al., 2011; 
Naik et al., 2011]. NF-κB is an important gene transcriptional factor that mediates cellular 
responses in inflammation, immunity, development, cell proliferation and apoptosis. The IKBKG 
gene (duplicated in patient 61, Tab.3) encodes the inhibitor of kappa light polypeptide, which is the 
regulatory subunit of the inhibitor of kappaB kinase (IKK) complex, which, in turn, activates NF-
kappaB resulting in activation of genes involved in inflammation, immunity, cell survival, and 
other pathways. Recently, it has been reported that brain abnormalities correlate with additional 
copies of the IKBKG gene [Ramocki et al., 2009, 2010]. Indeed, IKBKG overexpression causes 
impaired NF-κB signaling in skin fibroblasts derived from patients with white matter anomalies, 
thus further supporting the role of NF-κB signaling in astroglial cells for normal myelin formation 
of the CNS [Philippe et al., 2012]. Similarly, it is possible that an excessive induction of NF-κB, 
due to IKBKG gene duplication, may be involved in ASD pathogenesis. 
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Of note, most of the reported genes are affected by de novo large CNVs, thus their role in ASD 
pathogenesis must be interpreted in the context of a genomic disorder. However, the collected data 
support the hypothesis of the existence of a genetic basis, likely wide heterogeneous, that might 
explain, almost in part, the immune dysfunction observed in ASD patients. In addition, it is 
important to stress the idea that the genetic causes must be researched not only in anomalies 
affecting genes with a clear role in immunity but also in genes implicated in functional pathways 
which ultimately lead to CNS development, which also show high expression in immune cell types 
and, thus, may contribute to immune system development as well. 
Nevertheless, further studies are necessary to replicate the hypothesized genetic aetiology of a part 
of immune system dysfunctions in ASD, although it will be more likely to replicate the implication 
of recurrent pathways rather than of recurrent genes, as already confirmed for the plethora of genes 
implicated in neurodevelopment. In addition, in order to validate genomic data the challenge will 
be to correlate in each patient the single genetic lesion with specific aberrations of the immune 
system. 
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